Science.gov

Sample records for darbepoetin alfa results

  1. Population pharmacokinetics of darbepoetin alfa in healthy subjects

    PubMed Central

    Agoram, Balaji; Sutjandra, Liviawati; Sullivan, John T

    2007-01-01

    Aim To develop and evaluate a population pharmacokinetic (PK) model of the long-acting erythropoiesis-stimulating protein, darbepoetin alfa in healthy subjects. Methods PK profiles were obtained from 140 healthy subjects receiving single intravenous and/or single or multiple subcutaneous doses of darbepoetin alfa (0.75–8.0 µg kg−1, or either 80 or 500 µg). Data were analysed by a nonlinear mixed-effects modelling approach using NONMEM software. Influential covariates were identified by covariate analysis emphasizing parameter estimates and their confidence intervals, rather than stepwise hypothesis testing. The model was evaluated by comparing simulated profiles (obtained using the covariate model) to the observed profiles in a test dataset. Results The population PK model, including first-order absorption, two-compartment disposition and first-order elimination, provided a good description of data. Modelling indicated that for a 70-kg human, the observed nearly twofold disproportionate dose–exposure relationship at the 8.0 µg kg−1-dose relative to the 0.75 µg kg−1-dose may reflect changing relative bioavailability, which increased from ∼48% at 0.75 µg kg−1 to 78% at 8.0 µg kg−1. The covariate analysis showed that increasing body weight may be related to increasing clearance and central compartment volume, and that the absorption rate constant decreased with increasing age. The full covariate model performed adequately in a fixed-effects prediction test against an external dataset. Conclusion The developed population PK model describes the inter- and intraindividual variability in darbepoetin alfa PK. The model is a suitable tool for predicting the PK response of darbepoetin alfa using clinically untested dosing regimens. PMID:16939525

  2. An overview of the pharmacokinetic disposition of darbepoetin alfa.

    PubMed

    Zamboni, William C; Stewart, Clinton E

    2002-09-01

    Darbepoetin alfa is a new erythropoiesis-stimulating protein that has five carbohydrate chains compared with three in recombinant human erythropoietin (r-HuEPO, epoetin alfa). Owing to its increased carbohydrate content, the terminal half-life of darbepoetin alfa is 2-3-fold greater than that of r-HuEPO in patients with chronic kidney disease or cancer. This pharmacokinetic property may allow for less frequent administration of darbepoetin alfa compared with r-HuEPO. Although several regimens are still being tested, a predictable increase was observed in serum concentrations of darbepoetin alfa and no clinically relevant accumulation was seen with once-weekly administration for up to 48 weeks. Preliminary data in patients with cancer suggest that concurrent chemotherapy may influence the pharmacokinetics of darbepoetin alfa. Therefore, the timing of dosing relative to chemotherapy may be important. Darbepoetin alfa, through its potential for less frequent dosing, offers a more convenient treatment option than r-HuEPO for patients with anemia secondary to cancer or kidney disease.

  3. Darbepoetin alfa for anemia with myelodysplastic syndrome.

    PubMed

    Seastone, David J; Gerds, Aaron T

    2015-04-01

    The myelodysplastic syndromes are characterized by refractory cytopenias that lead to symptomatic anemia, bleeding, and increased risk for infections. For almost two decades, the use of darbepoetin and other erythropoietin stimulating agents to treat symptomatic anemia in lower-risk myelodysplastic syndromes has been a standard of care. This practice is supported by numerous Phase I/II studies and one Phase III study demonstrating the benefit of using erythropoietin stimulating agents alone, or in combination with granulocyte colony stimulating factor, for treatment of symptomatic anemia with the goal of decreasing red blood cell transfusion requirements. This review summarizes the published experience regarding the use of erythropoietin stimulating agents, with a special focus on darbepoetin, in patients with myelodysplastic syndrome and symptomatic anemia.

  4. Darbepoetin alfa 300 or 500 μg once every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia.

    PubMed

    Auerbach, Michael; Silberstein, Peter T; Webb, R Timothy; Averyanova, Svetlana; Ciuleanu, Tudor-Eliade; Shao, James; Bridges, Kenneth

    2010-09-01

    This study evaluated efficacy and safety of darbepoetin alfa administered every 3 weeks (Q3W) at fixed doses of 300 or 500 μg with or without intravenous (IV) iron in treating anemia in patients receiving multicycle chemotherapy. This Phase 2, double-blind, 2 × 2 factorial study randomized patients to one of four treatment arms; darbepoetin alfa 300 μg (n = 62), darbepoetin alfa 300 μg plus IV iron (n = 60), darbepoetin alfa 500 μg (n = 60), or darbepoetin alfa 500 μg plus IV iron (n = 60). Patients had nonmyeloid malignancies, hemoglobin levels ≤10 g dL(-1), and no iron deficiency. Primary endpoint was achievement of target hemoglobin (≥11 g dL(-1)). Secondary endpoints included incidence of transfusions and change in Functional Assessment of Cancer Therapy Fatigue (FACT-F) score from baseline to end of study. Safety was evaluated by incidence of adverse events. No evidence of a statistically significant interaction between darbepoetin alfa dose received and IV iron usage was observed, therefore, results are provided separately comparing darbepoetin alfa doses and comparing IV iron usage groups. Similar proportions of patients receiving darbepoetin alfa 300 or 500 μg achieved target hemoglobin (75 and 78%, respectively); Kaplan-Meier median time to target hemoglobin was 10 and 8 weeks, respectively. More patients receiving IV iron (82%) than not receiving IV iron (72%) achieved hemoglobin target. Adverse events profiles were similar for darbepoetin alfa treatment groups. Transient anaphylactoid reactions were reported in two patients receiving IV iron. Darbepoetin alfa at 300 μg Q3W and 500 μg Q3W showed similar benefit, while added IV iron improved treatment response in these patients.

  5. Switch from epoetin to darbepoetin alfa in hemodialysis: dose equivalence and hemoglobin stability

    PubMed Central

    Arrieta, Javier; Moina, Iñigo; Molina, José; Gallardo, Isabel; Muñiz, María Luisa; Robledo, Carmen; García, Oscar; Vidaur, Fernando; Muñoz, Rosa Inés; Iribar, Izaskun; Aguirre, Román; Maza, Antonio

    2014-01-01

    Aim The objective of the study reported here was to describe dose equivalence and hemoglobin (Hb) stability in a cohort of unselected hemodialysis patients who were switched simultaneously from epoetin alfa to darbepoetin alfa. Methods This was a multicenter, observational, retrospective study in patients aged ≥18 years who switched from intravenous (IV) epoetin alfa to IV darbepoetin alfa in October 2007 (Month 0) and continued on hemodialysis for at least 24 months. The dose was adjusted to maintain Hb within 1.0 g/dL of baseline. Results We included 125 patients (59.7% male, mean [standard deviation (SD)] age 70.4 [13.4] years). No significant changes were observed in Hb levels (mean [SD] 11.9 [1.3] g/dL, 12.0 [1.5], 12.0 [1.5], and 12.0 [1.7] at Months −12, 0, 12 and 24, respectively, P=0.409). After conversion, the erythropoiesis-stimulating agent (ESA) dose decreased significantly (P<0.0001), with an annual mean of 174.7 (88.7) international units (IU)/kg/week for epoetin versus 95.7 (43.4) (first year) and 91.4 (42.7) IU/kg/week (second year) for darbepoetin (65% and 64% reduction, respectively). The ESA resistance index decreased from 15.1 (8.5) IU/kg/week/g/dL with epoetin to 8.1 (3.9) (first year) and 7.9 (4.0) (second year) with darbepoetin (P<0.0001). The conversion rate was 354:1 in patients requiring high (>200 IU/kg/week) doses of epoetin and 291:1 in patients requiring low doses. Conclusion In patients on hemodialysis receiving ESAs, conversion from epoetin alfa to darbepoetin alfa was associated with an approximate and persistent reduction of 65% of the required dose. To maintain Hb stability, a conversion rate of 300:1 seems to be appropriate for most patients receiving low doses of epoetin alfa (≤200 IU/kg/week), while 350:1 would be better for patients receiving higher doses. PMID:25336984

  6. Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial

    PubMed Central

    Carrera, Fernando; Lok, Charmaine E.; de Francisco, Angel; Locatelli, Francesco; Mann, Johannes F.E.; Canaud, Bernard; Kerr, Peter G.; Macdougall, Iain C.; Besarab, Anatole; Villa, Giuseppe; Kazes, Isabelle; Van Vlem, Bruno; Jolly, Shivinder; Beyer, Ulrich; Dougherty, Frank C.

    2010-01-01

    Background. Several studies with erythropoiesis-stimulating agents claim that maintenance therapy of renal anaemia may be possible at extended dosing intervals; however, few studies were randomized, results varied, and comparisons between agents were absent. We report results of a multi-national, randomized, prospective trial comparing haemoglobin maintenance with methoxy polyethylene glycol-epoetin beta and darbepoetin alfa administered once monthly. Methods. Haemodialysis patients (n = 490) on stable once-weekly intravenous darbepoetin alfa were randomized to methoxy polyethylene glycol-epoetin beta once monthly or darbepoetin alfa every 2 weeks for 26 weeks, with dose adjustment for individual haemoglobin target (11–13 g/dL; maximum decrease from baseline 1 g/dL). Subsequently, patients entered a second 26-week period of once-monthly methoxy polyethylene glycol-epoetin beta and darbepoetin alfa. The primary endpoint was the proportion of patients who maintained average haemoglobin ≥10.5 g/dL, with a decrease from baseline ≤1 g/dL, in Weeks 50–53; the secondary endpoint was dose change over time. The trial is registered at www.ClinicalTrials.gov, number NCT00394953. Results. Baseline characteristics were similar between groups. One hundred and fifty-seven of 245 patients treated with methoxy polyethylene glycol-epoetin beta and 99 of 245 patients with darbepoetin alfa met the response definition (64.1% and 40.4%; P < 0.0001). Doses increased by 6.8% with methoxy polyethylene glycol-epoetin beta and 58.8% with darbepoetin alfa during once-monthly treatment. Death rates were equal between treatments (5.7%). Most common adverse events included hypertension, procedural hypotension, nasopharyngitis and muscle spasms, with no differences between groups. Conclusions. Methoxy polyethylene glycol-epoetin beta maintained target haemoglobin more successfully than darbepoetin alfa at once-monthly dosing intervals despite dose increases with darbepoetin alfa

  7. Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF)

    PubMed Central

    McMurray, John J.V.; Anand, Inder S.; Diaz, Rafael; Maggioni, Aldo P.; O'Connor, Christopher; Pfeffer, Marc A.; Solomon, Scott D.; Tendera, Michal; van Veldhuisen, Dirk J.; Albizem, Moetaz; Cheng, Sunfa; Scarlata, Debra; Swedberg, Karl; Young, James B.; Amuchastegui, M.; Belziti, C.; Bluguermann, J.; Caccavo, M.; Cartasegna, L.; Colque, R.; Cuneo, C.; Fernandez, A.; Gabito, A.; Goicochea, R.; Gonzalez, M.; Gorosito, V.; Grinfeld, L.; Hominal, M.; Kevorkian, R.; Litvak Bruno, M.; Llanos, J.; Mackinnon, I.; Manuale, O.; Marzetti, E.; Nul, D.; Perna, E.; Riccitelli, M.; Sanchez, A.; Santos, D.; Schygiel, P.; Toblli, J.; Vogel, D.; Aggarwal, A.; Amerena, J.; De Looze, F.; Fletcher, P.; Hare, D.; Ireland, M.; Krum, H.; Lattimore, J.; Marwick, T.; Sindone, A.; Thompson, P.; Waites, J.; Altenberger, J.; Ebner, C.; Lenz, K.; Pacher, R.; Poelzl, G.; Charlier, F.; de Ceuninck, M.; De Keulenaer, G.; Dendale, P.; Maréchal, P.; Mullens, W.; Thoeng, J.; Vanderheyden, M.; Vanhaecke, J.; Weytjens, C.; Wollaert, B.; Albuquerque, D.; Almeida, D.; Aspe y Rosas, J.; Bocchi, E.; Bordignon, S.; Clausell, N.; Kaiser, S.; Leaes, P.; Martins Alves, S.; Montera, M.; Moura, L.; Pereira de Castro, R.; Rassi, S.; Reis, A.; Saraiva, J.; Simões, M.; Souza Neto, J.; Teixeira, M.; Benov, H.; Chompalova, B.; Donova, T.; Georgiev, P.; Gotchev, D.; Goudev, A.; Grigorov, M.; Guenova, D.; Hergeldjieva, V.; Ivanov, D.; Kostova, E.; Manolova, A.; Marchev, S.; Nikolov, F.; Popov, A.; Raev, D.; Tzekova, M.; Czarnecki, W.; Giannetti, N.; Haddad, H.; Heath, J.; Huynh, T.; Lepage, S.; Liu, P.; Lonn, E.; Ma, P.; Manyari, D.; Moe, G.; Parker, J.; Pesant, Y.; Rajda, M.; Ricci, J.; Roth, S.; Sestier, F.; Sluzar, V.; Sussex, B.; Vizel, S.; Antezana, G.; Bugueno, C.; Castro, P.; Conejeros, C.; Manriquez, L.; Martinez, D.; Potthoff, S.; Stockins, B.; Vukasovic, J.; Gregor, P.; Herold, M.; Jerabek, O.; Jirmar, R.; Kuchar, R.; Linhart, A.; Podzemska, B.; Soucek, M.; Spac, J.; Spacek, R.; Vodnansky, P.; Bronnum-Schou, J.; Clemmensen, K.; Egstrup, K.; Jensen, G.; Kjoller-Hansen, L.; Kober, L.; Markenvard, J.; Rokkedal, J.; Skagen, K.; Torp-Pedersen, C.; Tuxen, C.; Videbak, L.; Laks, T.; Vahula, V.; Harjola, V.; Kettunen, R.; Kotila, M.; Bauer, F.; Cohen Solal, A.; Coisne, D.; Davy, J.; De Groote, P.; Dos Santos, P.; Funck, F.; Galinier, M.; Gibelin, P.; Isnard, R.; Neuder, Y.; Roul, G.; Sabatier, R.; Trochu, J.; Anker, S.; Denny, S.; Dreykluft, T.; Flesch, M.; Genth-Zotz, S.; Hambrecht, R.; Hein, J.; Jeserich, M.; John, M.; Kreider-Stempfle, H.; Laufs, U.; Muellerleile, K.; Natour, M.; Sandri, M.; Schäufele, T.; von Hodenberg, E.; Weyland, K.; Winkelmann, B.; Tse, H.; Yan, B.; Barsi, B.; Csikasz, J.; Dezsi, C.; Edes, I.; Forster, T.; Karpati, P.; Kerekes, C.; Kis, E.; Kosa, I.; Lupkovics, G.; Nagy, A.; Preda, I.; Ronaszeki, A.; Tomcsanyi, J.; Zamolyi, K.; Agarwal, D.; Bahl, V.; Bordoloi, A.; Chockalingam, K.; Chopda, M.; Chopra, V.; Dugal, J.; Ghaisas, N.; Ghosh, S.; Grant, P.; Hiremath, S.; Iyengar, S.; Jagadeesa Subramania, B.; Jain, P.; Joshi, A.; Khan, A.; Mullasari, A.; Naik, S.; Oomman, A.; Pai, V.; Pareppally Gopal, R.; Parikh, K.; Patel, T.; Prakash, V.; Sastry, B.; Sathe, S.; Sinha, N.; Srikanthan, V.; Subburamakrishnan, P.; Thacker, H.; Wander, G.; Admon, D.; Katz, A.; Klainman, E.; Lewis, B.; Marmor, A.; Moriel, M.; Mosseri, M.; Shotan, A.; Weinstein, J.; Zimlichman, R.; Agostoni, P.; Albanese, M.; Alunni, G.; Bini, R.; Boccanelli, A.; Bolognese, L.; Campana, C.; Carbonieri, E.; Carpino, C.; Checco, L.; Cosmi, F.; D'Angelo, G.; De Cristofaro, M.; Floresta, A.; Fucili, A.; Galvani, M.; Ivleva, A.; Marra, S.; Musca, G.; Peccerillo, N.; Perrone Filardi, P.; Picchio, E.; Russo, T.; Scelsi, L.; Senni, M.; Tavazzi, L.; Erglis, A.; Jasinkevica, I.; Kakurina, N.; Veze, I.; Volans, E.; Bagdonas, A.; Berukstis, E.; Celutkiene, J.; Dambrauskaite, A.; Jarasuniene, D.; Luksiene, D.; Rudys, A.; Sakalyte, G.; Sliaziene, S.; Aguilar-Romero, R.; Cardona-Muñoz, E.; Castro-Jimenez, J.; Chavez-Herrera, J.; Chuquiure Valenzuela, E.; De la Pena, G.; Herrera, E.; Leiva-Pons, J.; Lopez Alvarado, A.; Mendez Machado, G.; Ramos-Lopez, G.; Basart, D.; Buijs, E.; Cornel, J.; de Leeuw, M.; Dijkgraaf, R.; Dunselman, P.; Freericks, M.; Hamraoui, K.; Lenderlink, T.; Linssen, G.; Lodewick, P.; Lodewijks, C.; Lok, D.; Nierop, P.; Ronner, E.; Somsen, A.; van Dantzig, J.; van der Burgh, P.; van Kempen, L.; van Vlies, B.; Voors, A.; Wardeh, A.; Willems, F.; Dickstein, K.; Gundersen, T.; Hole, T.; Thalamus, J.; Westheim, A.; Dabrowski, M.; Gorski, J.; Korewicki, J.; Kuc, K.; Miekus, P.; Musial, W.; Niegowska, J.; Piotrowski, W.; Podolec, P.; Polonski, L.; Ponikowski, P.; Rynkiewicz, A.; Szelemej, R.; Trusz-Gluza, M.; Ujda, M.; Wojciechowski, D; Wysokinski, A.; Camacho, A.; Fonseca, C.; Monteiro, P.; Apetrei, E.; Bruckner, I.; Carasca, E.; Coman, I.; Datcu, M.; Dragulescu, S.; Ionescu, P.; Iordachescu-Petica, D.; Manitiu, I.; Popa, V.; Pop-Moldovan, A.; Radoi, M.; Stamate, S.; Tomescu, M.; Vita, I.; Aroutiounov, G.; Ballyuzek, M.; Bart, B.; Churina, S.; Glezer, M.; Goloshchekin, B.; Ivleva, A.; Kobalava, Z.; Kostenko, V.; Lopatin, Y.; Martynov, A.; Orlov, V.; Semernin, E.; Shogenov, Z.; Sidorenko, B.; Skvortsov, A.; Storzhakov, G.; Sulimov, V.; Talibov, O.; Tereshenko, S.; Tsyrline, V.; Zadionchenko, V.; Zateyshchikov, D.; Dzupina, A.; Hranai, M.; Kmec, J.; Micko, K.; Murin, J.; Pella, D.; Sojka, G.; Spisak, V.; Vahala, P.; Vinanska, D.; Badat, A.; Bayat, J.; Dawood, S.; Delport, E.; Ellis, G.; Garda, R.; Klug, E.; Mabin, T.; Naidoo, D.; Pretorius, M.; Ranjith, N.; Van Zyl, L.; Weich, H.; Anguita, M.; Berrazueta, J.; Bruguera i Cortada, J.; de Teresa, E.; Gómez Sánchez, M.; González Juanatey, J.; Gonzalez-Maqueda, I.; Jordana, R.; Lupon, J.; Manzano, L.; Pascual Figal, D.; Pulpón, L.; Recio, J.; Ridocci Soriano, F.; Rodríguez Lambert, J.; Roig Minguell, E.; Roig Minguell, E.; Romero, J.; Valdovinos, P.; Klintberg, L.; Kronvall, T.; Lycksell, M.; Morner, S.; Rydberg, E.; Swedberg, K.; Timberg, I.; Wikstrom, G.; Moccetti, T.4; Ashok, J.; Banerjee, P.; Carr-White, G.; Cleland, J.; Connolly, E.; Francis, M.; Greenbaum, R.; Kadr, H.; Lindsay, S.; McMurray, J.; Megarry, S.; Memon, A.; Murdoch, D.; Senior, R.; Squire, I.; Tan, L.; Witte, K.; Adams, K.; Adamson, P.; Adler, A.; Altschul, L.; Altschuller, A.; Amirani, H.; Anand, I.; Andreou, C.; Ansari, M.; Antonishen, M.; Banchs, H.; Banerjee, S.; Banish, D.; Bank, A.; Barbagelata, A.; Barnard, D.; Bellinger, R.; Benn, A.; Berk, M.; Berry, B.; Bethala, V.; Bilazarian, S.; Bisognano, J.; Bleyer, F.; Blum, M.; Boehmer, J.; Bouchard, A.; Boyle, A.; Bozkurt, B.; Brown, C.; Burlew, B.; Burnham, K.; Butler, J.; Call, J.; Cambier, P.; Cappola, T.; Carlson, R.; Chandler, B.; Chandra, R.; Chandraratna, P.; Chernick, R.; Colan, D.; Colfer, H.; Colucci, W.; Connelly, T.; Costantini, O.; Dadkhah, S.; Dauber, I.; Davis, J.; Davis, S.; Denning, S.; Drazner, M.; Dunlap, S.; Egbujiobi, L.; Elkayam, U.; Elliott, J.; El-Shahawy, M.; Essandoh, L.; Ewald, G.; Fang, J.; Farhoud, H.; Felker, G.; Fernandez, J.; Festin, R.; Fishbein, G.; Florea, V.; Flores, E.; Floro, J.; Gabris, M.; Garg, M.; Gatewood, R.; Geller, M.; Ghali, J.; Ghumman, W.; Gibbs, G.; Gillespie, E.; Gilmore, R.; Gogia, H.; Goldberg, L.; Gradus-Pizlo, I.; Grainger, T.; Gudmundsson, G.; Gunawardena, D.; Gupta, D.; Hack, T.; Hall, S.; Hamroff, G.; Hankins, S.; Hanna, M.; Hargrove, J.; Haught, W.; Hauptman, P.; Hazelrigg, M.; Herzog, C.; Heywood, J.; Hill, T.; Hilton, T.; Hirsch, H.; Hunter, J.; Ibrahim, H.; Imburgia, M.; Iteld, B.; Jackson, B.; Jaffrani, N.; Jain, D.; Jain, A.; James, M.; Jimenez, J.; Johnson, E.; Kale, P.; Kaneshige, A.; Kapadia, S.; Karia, D.; Karlsberg, R.; Katholi, R.; Kerut, E.; Khoury, W.; Kipperman, R.; Klapholz, M.; Kosinski, E.; Kozinn, M.; Kraus, D.; Krueger, S.; Krum, H.; Kumar, S.; Lader, E.; Lee, C.; Levy, W.; Lewis, E.; Light-McGroary, K.; Loh, I.; Lombardi, W.; Machado, C.; Maislos, F.; Mancini, D.; Markus, T.; Mather, P.; McCants, K.; McGrew, F.; McLaurin, B.; McMillan, E.; McNamara, D.; Meyer, T.; Meymandi, S.; Miller, A.; Minami, E.; Modi, M.; Mody, F.; Mohanty, P.; Moscoso, R.; Moskowitz, R.; Moustafa, M.; Mullen, M.; Naz, T.; Noonan, T.; O'Brien, T.; Oellerich, W.; Oren, R.; Pamboukian, S.; Pereira, N.; Pitt, W.; Porter, C.; Prabhu, S.; Promisloff, S.; Ratkovec, R.; Richardson, R.; Ross, A.; Saleh, N.; Saltzberg, M.; Sarkar, S.; Schmedtje, J.; Schneider, R.; Schuyler, G.; Shanes, J.; Sharma, A.; Siegel, C.; Siegel, R.; Silber, D.; Singh, V.; Singh, N.; Singh, J.; Sklar, J.; Small, R.; Smith, A.; Smith, E.; Smith, E.; Smull, D.; Sotolongo, R.; Staniloae, C.; Stapleton, D.; Steele, P.; Stehlik, J.; Stein, M.; Tang, W.; Thadani, U.; Torre-Amoine, G.; Trichon, B.; Tsai, C.; Tummala, R.; Van Bakel, A.; Vicari, R.; Vijay, N.; Vijayaraghavan, K.; Vittorio, T.; Vossler, M.; Wagoner, L.; Wallis, D.; Ward, N.; Widmer, M.; Wight, J.; Wilkins, C.; Williams, C.; Williams, G.; Winchester, M.; Winkel, E.; Wittmer, B.; Wood, D.; Wormer, D.; Wright, R.; Xu, Z.; Yasin, M.; Zolty, R.

    2013-01-01

    Aims This report describes the baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF) which is testing the hypothesis that anaemia correction with darbepoetin alfa will reduce the composite endpoint of death from any cause or hospital admission for worsening heart failure, and improve other outcomes. Methods and results Key demographic, clinical, and laboratory findings, along with baseline treatment, are reported and compared with those of patients in other recent clinical trials in heart failure. Compared with other recent trials, RED-HF enrolled more elderly [mean age 70 (SD 11.4) years], female (41%), and black (9%) patients. RED-HF patients more often had diabetes (46%) and renal impairment (72% had an estimated glomerular filtration rate <60 mL/min/1.73 m2). Patients in RED-HF had heart failure of longer duration [5.3 (5.4) years], worse NYHA class (35% II, 63% III, and 2% IV), and more signs of congestion. Mean EF was 30% (6.8%). RED-HF patients were well treated at randomization, and pharmacological therapy at baseline was broadly similar to that of other recent trials, taking account of study-specific inclusion/exclusion criteria. Median (interquartile range) haemoglobin at baseline was 112 (106–117) g/L. Conclusion The anaemic patients enrolled in RED-HF were older, moderately to markedly symptomatic, and had extensive co-morbidity. PMID:23329651

  8. Darbepoetin alfa (Aranesp) improves recognition memory in adult rats that have sustained bilateral ventral hippocampal lesions as neonates or young adults.

    PubMed

    Hori, S E; Powell, K J; Robertson, G S

    2007-01-05

    Recognition memory was assessed in adult rats that received bilateral injections of saline (sham lesions) or ibotenic acid (lesioned) in the ventral hippocampus as neonates (postnatal day 7, PD7) or young adult (42 days of age, PD42) using the Novel Object Recognition Test (NORT). Normal or sham-lesioned rats were able to distinguish novel from familiar objects over a 0.5 and 2 h delay between the sample and choice phases. Adult rats (PD70) lesioned as neonates performed progressively worse than sham-lesioned animals at delays of 0.5 and 2 h. A single injection of darbepoetin alfa (500 or 5000 U/kg, i.p.), given 1 h before the sample phase restored performance 0.5 or 2 h later in the choice phase to same levels as sham-lesioned rats. Adults lesioned on PD42 displayed deficits in NORT performance with a 2 h delay between the choice and sample phases that were completely reversed by administration of darbepoetin alfa (5000 U/kg, i.p.) 1 h before the sample phase. These results suggest that darbepoetin alfa may have utility in treating memory deficits associated with brain dysfunction related to developmental disorders such as schizophrenia.

  9. Peginesatide for Maintenance Treatment of Anemia in Hemodialysis and Nondialysis Patients Previously Treated with Darbepoetin Alfa

    PubMed Central

    Roger, Simon D.; Martin, Edouard; Runyan, Grant; O’Neil, Janet; Qiu, Ping; Locatelli, Francesco

    2013-01-01

    Summary Background and objectives Peginesatide (Omontys) is a novel, synthetic, PEGylated, peptide-based erythropoiesis-stimulating agent (ESA) that is designed to specifically stimulate the erythropoietin receptor. This study evaluated maintenance of hemoglobin levels in patients after conversion from darbepoetin alfa to once-monthly peginesatide. Design, setting, participants, & measurements This open-label, multicenter study included 101 CKD patients, 52 of whom were receiving dialysis. The duration of the study was 24 weeks. The primary endpoint was the mean change in hemoglobin from baseline to the evaluation period (weeks 19–24). The study was conducted during the period from September 22, 2008 to December 24, 2009. Results The mean change among hemodialysis patients was –0.42 g/dl (95% confidence interval, –0.65 to –0.19) and the mean change among CKD nondialysis patients was 0.49 g/dl (95% confidence interval, 0.26–0.71). The percentages of patients who maintained hemoglobin levels within ±1.0 g/dl of baseline values were as follows: 80.0% for hemodialysis and 68.1% for nondialysis, and73.3% for hemodialysis and 68.1% for nondialysis within the target range of 10.0–12.0 g/dl. Few patients received red blood cell transfusions (hemodialysis, 5.8%; nondialysis, 2.0%). Seventy-nine patients experienced adverse events, the majority of which were mild or moderate in severity. There were 40 serious adverse events and 2 deaths reported. Conclusions In this study, once-monthly peginesatide resulted in a slight decrease in mean hemoglobin levels in individuals on hemodialysis and a small increase in individuals with CKD who were not on dialysis. PMID:23243269

  10. Darbepoetin-alfa and intravenous iron administration after autologous hematopoietic stem cell transplantation: a prospective multicenter randomized trial.

    PubMed

    Beguin, Yves; Maertens, Johan; De Prijck, Bernard; Schots, Rik; Seidel, Laurence; Bonnet, Christophe; Hafraoui, Kaoutar; Willems, Evelyne; Vanstraelen, Gaetan; Servais, Sophie; Jaspers, Aurélie; Fillet, Georges; Baron, Frederic

    2013-12-01

    We conducted a randomized study analyzing the impact of darbepoetin alfa (DA) administration with or without intravenous (i.v.) iron on erythroid recovery after autologous hematopoietic cell transplantation (HCT). Patients were randomized between no DA (Arm 1), DA 300 μg every 2 weeks starting on Day 28 after HCT (Arm 2), or DA plus i.v. iron 200 mg on Days 28, 42, and 56 (Arm 3). The proportion achieving complete hemoglobin (Hb) response within 18 weeks (primary end point) was 21% in Arm 1 (n = 24), 79% in Arm 2 (n = 25), and 100% in Arm 3 (n = 23; P < 0.0001). Erythropoietic response was shown to be significantly higher in Arm 3 (n = 46) than in Arm 2 (n = 50; P = 0.008), resulting in lower DA use, reduced drug costs, and improved quality of life scores, but the effect on transfusions was not significant. In multivariate analysis, DA administration (P < 0.0001), i.v. iron administration (P = 0.0010), high baseline Hb (P < 0.0001), and low baseline creatinine (P = 0.0458) were independently associated with faster achievement of complete Hb response. In conclusion, DA is highly effective to ensure full erythroid reconstitution after autologous HCT when started on Day 28 post-transplant. I.v. iron sucrose further improves erythroid recovery.

  11. Antibody-mediated pure red cell aplasia (PRCA) on switching from darbepoetin alfa to epoetin beta: what are the implications?

    PubMed Central

    Assunção, José; Vinhas, José

    2008-01-01

    We report the development of antibody-mediated pure red cell aplasia (PRCA) in a 63-year-old man with end-stage renal disease following a switch from darbepoetin alfa to epoetin beta. Haemoglobin levels began to decrease 6 months after the switch. Increasing the epoetin beta dose produced no response and regular blood transfusions were required; PRCA was confirmed and epoetin beta was discontinued. The patient responded positively to immunosuppression; after 2 months on prednisone and cyclophosphamide, haemoglobin levels stabilized and no further transfusions were required. This case highlights the difficulty in establishing a cause-effect relationship where more than one erythropoiesis-stimulating agent is involved. PMID:25983889

  12. Antibody-mediated pure red cell aplasia (PRCA) on switching from darbepoetin alfa to epoetin beta: what are the implications?

    PubMed

    Assunção, José; Vinhas, José

    2008-08-01

    We report the development of antibody-mediated pure red cell aplasia (PRCA) in a 63-year-old man with end-stage renal disease following a switch from darbepoetin alfa to epoetin beta. Haemoglobin levels began to decrease 6 months after the switch. Increasing the epoetin beta dose produced no response and regular blood transfusions were required; PRCA was confirmed and epoetin beta was discontinued. The patient responded positively to immunosuppression; after 2 months on prednisone and cyclophosphamide, haemoglobin levels stabilized and no further transfusions were required. This case highlights the difficulty in establishing a cause-effect relationship where more than one erythropoiesis-stimulating agent is involved.

  13. Impact of Switching From Darbepoetin Alfa to Epoetin Beta Pegol on Iron Utilization and Blood Pressure in Peritoneal Dialysis Patients.

    PubMed

    Washida, Naoki; Inoue, Shuji; Kasai, Takahiro; Shinozuka, Keisuke; Hosoya, Koji; Morimoto, Kohkichi; Wakino, Shu; Hayashi, Koichi; Itoh, Hiroshi

    2015-10-01

    New erythropoiesis-stimulating agents with a longer half-life have been developed for the treatment of anemia in patients with end-stage renal disease. This study evaluated the efficacy of darbepoetin alfa (DA) and long-acting epoetin beta pegol (continuous erythropoietin receptor activator, CERA) in patients on peritoneal dialysis (PD). Twenty-nine patients who had undergone PD for at least 6 months and were iron replacement-naïve and negative for inflammatory parameters were enrolled. Hemoglobin (Hgb) levels and blood pressure were evaluated before and after switching from DA to CERA. Percent transferrin saturation (TSAT), serum ferritin levels and blood pressure were also assessed. Twenty-eight patients were subject to the analysis, excluding one patient with a decrease in Hgb by ≥10%. Switching from DA to CERA did not alter Hgb levels. The doses of DA and CERA after 12 month treatment of each agent were 118.48 ± 79.63 and 89.88 ± 47.50 μg/4 weeks, respectively (conversion ratio, 1:0.76). The CERA dose administered during the final 6 months was abated, compared with that given during the initial 6 months (P = 0.035). The frequency of CERA injection over a 12-month period was less than that of DA (10.0 ± 3.0 vs. 16.4 ± 5.0, P < 0.01). The conversion from DA to CERA did not alter TSAT, but decreased serum ferritin levels (from 202.69 ± 132.57 to 150.15 ± 110.07 ng/mL, P = 0.012) and systolic blood pressure (from 133.8 ± 17.3 to 129.5 ± 11.3 mm Hg, P = 0.024). In PD patients, lower doses and less frequent injection of CERA are sufficient to maintain Hgb at levels similar to those achieved by DA therapy, with improved iron utilization and reduced blood pressure.

  14. Darbepoetin Alfa Injection

    MedlinePlus

    ... with the grey cover and that the yellow plastic sleeve has not been pulled over the needle. ... to your pharmacist or contact your local garbage/recycling department to learn about take-back programs in ...

  15. Clinical trials update from the European Society of Cardiology heart failure meeting: TNT subgroup analysis, darbepoetin alfa, FERRIC-HF and KW-3902.

    PubMed

    Coletta, Alison P; Tin, Lwin; Loh, P Huan; Clark, Andrew L; Cleland, John G F

    2006-08-01

    This article provides information and a commentary on trials relevant to the pathophysiology, prevention and treatment of heart failure, presented at the European Society of Cardiology heart failure meeting held in June 2006. All reports should be considered as preliminary data, as analyses may change in the final publication. In a sub-group analysis of the TNT study, intensive treatment with high-dose atorvastatin significantly reduced hospitalisations for heart failure in patients with stable coronary heart disease, compared with low-dose atorvastatin; this benefit was most evident in patients with a history of heart failure at baseline. In a combined analysis of two studies of darbepoetin alfa, which included 475 patients, treatment increased and maintained haemoglobin levels and produced non-significant improvements in symptoms and morbidity in anaemic heart failure patients compared to placebo. In the FERRIC-HF study (n=35), intravenous iron sucrose therapy improved exercise capacity and symptom status in iron-deficient heart failure patients. In a combined analysis of two studies (n=186), the adenosine A(1) receptor antagonist KW-3902 showed diuretic properties and appeared to enhance response to loop diuretics in heart failure patients hospitalised with fluid overload.

  16. The ALFA ZOA Deep Survey: First Results

    NASA Astrophysics Data System (ADS)

    McIntyre, T. P.; Henning, P. A.; Minchin, R. F.; Momjian, E.; Butcher, Z.

    2015-07-01

    The Arecibo L-band Feed Array Zone of Avoidance (ALFA ZOA) Deep Survey is the deepest and most sensitive blind H i survey undertaken in the ZOA. ALFA ZOA Deep will cover about 300 square degrees of sky behind the Galactic Plane in both the inner (30^\\circ ≤slant l≤slant 75^\\circ ;b≤slant | 2^\\circ | ) and outer (175^\\circ ≤slant l≤slant 207^\\circ ;-2^\\circ ≤slant b≤slant +1^\\circ ) Galaxy, using the Arecibo Radio Telescope. First results from the survey have found 61 galaxies within a 15 square degree area centered on l=192^\\circ and b = -2°. The survey reached its expected sensitivity of rms = 1 mJy at 9 km s-1 channel resolution, and is shown to be complete above integrated flux, FHi = 0.5 Jy km s-1. The positional accuracy of the survey is 28″ and detections are found out to a recessional velocity of nearly 19,000 km s-1. The survey confirms the extent of the Orion and Abell 539 clusters behind the plane of the Milky Way and discovers expansive voids, at 10,000 and 18,000 km s-1. Twenty-six detections (43%) have a counterpart in the literature, but only two of these have known redshifts. Counterparts are 20% less common beyond vhel = 10,000 km s-1 and 33% less common at extinctions higher than AB = 3.5 mag. The ALFA ZOA Deep survey is able to probe large scale structure beyond redshifts that even the most modern wide-angle surveys have been able to detect in the ZOA at any wavelength.

  17. Preschool Assessment of Preterm Infants Treated With Darbepoetin and Erythropoietin

    PubMed Central

    Cannon, Daniel C.; Phillips, John; Caprihan, Arvind; Patel, Shrena; Winter, Sarah; Steffen, Michael; Yeo, Ronald A.; Campbell, Richard; Wiedmeier, Susan; Baker, Shawna; Gonzales, Sean; Lowe, Jean

    2016-01-01

    BACKGROUND: We previously reported improved neurodevelopmental outcomes at 2 years among infants treated with the erythropoiesis-stimulating agents (ESAs) darbepoetin alfa (darbepoetin) or erythropoietin. Here we characterize 4-year outcomes. METHODS: Former preterm infants randomly assigned to receive darbepoetin (10 μg/kg, once per week), erythropoietin (400 U/kg, 3 times/week), or placebo through 35 weeks’ postconceptual age were evaluated at 3.5 to 4 years of age. For comparison, healthy children formerly delivered full term (term controls [TCs]) were also recruited. All participants were assessed by using measures of full-scale IQ (FSIQ) and general language from the Wechsler Preschool and Primary Scale of Intelligence, Third Edition, and an overall measure of executive function, on the basis of tests evaluating inhibitory control and spatial working memory. Rates of neurodevelopmental impairment were compared across groups. RESULTS: Multivariate analysis of variance compared children randomly assigned to ESAs (n = 39), placebo (n =14), and TCs (n = 24). FSIQ and performance IQ were significantly higher in the ESA group than in the placebo group (FSIQ: 91.1 ± 17.5 vs 79.2 ± 18.5, P = .036; performance IQ: 93.0 ± 17.0 vs 79.5 ± 19.5, P = .018). Follow-up analyses revealed that the children receiving ESAs performed better than those who received placebo on executive function tasks. The ESA group’s performance was below that of TCs, but the results did not reach significance on executive function. The incidence of neurodevelopmental impairment was greater in the placebo group than in the ESA group. CONCLUSIONS: ESA-treated infants had better cognitive outcomes and less developmental impairment at 3.5 to 4 years of age compared with placebo-treated infants. ESAs show promise in improving long-term cognitive outcomes of infants born prematurely. PMID:26908704

  18. Antioxidant and antiapoptotic effects of darbepoetin-α against traumatic brain injury in rats

    PubMed Central

    Kertmen, Hayri; Yilmaz, Erdal Resit; Kanat, Mehmet Ali; Arikok, Ata Türker; Ergüder, Berrin Imge; Hasturk, Askin Esen; Ergil, Julide; Sekerci, Zeki

    2015-01-01

    Introduction In this study, we tried to determine whether darbepoetin-α would protect the brain from oxidative stress and apoptosis in a rat traumatic brain injury model. Material and methods The animals were randomized into four groups; group 1 (sham), group 2 (trauma), group 3 (darbepoetin α), group 4 (methylprednisolone). In the sham group only the skin incision was performed. In all the other groups, a moderate traumatic brain injury modelwas applied. Results Following trauma both glutathione peroxidase, superoxide dismutase levels decreased (p < 0.001 for both); darbepoetin-α increased the activity of both antioxidant enzymes (p = 0.001 and p < 0.001 respectively). Trauma caused significant elevation in the nitric oxide synthetase and xanthine oxidase levels (p < 0.001 for both). Administration of darbepoetin-α significantly decreased the levels of nitric oxide synthetase and xanthine oxidase (p < 0.001 for both). Also, trauma caused significant elevation in the nitric oxide levels (p < 0.001); darbepoetin-α administration caused statistically significant reduction in the nitric oxide levels (p < 0.001). On the other hand, malondialdehyde levels were increased following trauma (p < 0.001), and darbepoetin α significantly reduced the malondialdehyde levels (p < 0.001). Due to the elevated apoptotic activity following the injury, caspase-3 activity increased significantly. Darbepoetin-α treatment significantly inhibited apoptosis by lowering the caspase-3 activity (p < 0.001). In the darbepoetin group, histopathological score was lower than the trauma group (p = 0.016). Conclusions In this study, darbepoetin-α was shown to be at least as effective as methylprednisolone in protecting brain from oxidative stress, lipid peroxidation and apoptosis. PMID:26528358

  19. Epoetin alfa improves survival after chemoradiation for Stage III esophageal cancer: Final results of a prospective observational study

    SciTech Connect

    Rades, Dirk . E-mail: Rades.Dirk@gmx.net; Tribius, Silke; Yekebas, Emre F.; Bahrehmand, Roia; Wildfang, Ingeborg; Kilic, Ergin; Muellerleile, Ulrich; Gross, Eberhard; Schild, Steven E.; Alberti, Winfried

    2006-06-01

    Purpose: This prospective, nonrandomized study evaluates the effectiveness of epoetin alfa to maintain the hemoglobin levels at 12 to14 g/dL (optimal range for tumor oxygenation) during chemoradiation for Stage III esophageal cancer and its impact on overall survival (OS), metastatic-free survival (MFS), and locoregional control (LC). Methods and Materials: Ninety-six patients were included. Forty-two patients received epoetin alfa (150 IU/kg, 3 times a week) during radiotherapy, which was started at hemoglobin less than 13 g/dL and stopped at 14 g/dL or higher. Hemoglobin levels were measured weekly during RT. Results: Both groups were balanced for age, sex, performance status, tumor length/location, histology, grading, T-stage/N-stage, chemotherapy, treatment schedule, and hemoglobin before RT. Median change of hemoglobin was +0.3 g/dL/wk with epoetin alfa and -0.5 g/dL/wk without epoetin alfa. At least 60% of hemoglobin levels were 12 to 14 g/dL in 64% and 17% of the patients, respectively (p < 0.001). Patients who received epoetin alfa had better OS (32% vs. 8% at 2 years, p = 0.009) and LC (67% vs. 15% at 2 years, p = 0.001). MFS was not significantly different (42% vs. 18% at 2 years, p = 0.09). Conclusions: The findings suggest that epoetin alfa when used to maintain the hemoglobin levels at 12 to 14 g/dL can improve OS and LC of Stage III esophageal cancer patients.

  20. Dornase Alfa

    MedlinePlus

    ... and to improve lung function in patients with cystic fibrosis. It breaks down the thick secretions in the ... your doctor.Dornase alfa is used to treat cystic fibrosis but does not cure it. Continue to use ...

  1. Long-term efficacy and safety results of taliglucerase alfa up to 36 months in adult treatment-naïve patients with Gaucher disease.

    PubMed

    Zimran, Ari; Durán, Gloria; Mehta, Atul; Giraldo, Pilar; Rosenbaum, Hanna; Giona, Fiorina; Amato, Dominick J; Petakov, Milan; Muñoz, Eduardo Terreros; Solorio-Meza, Sergio Eduardo; Cooper, Peter A; Varughese, Sheeba; Chertkoff, Raul; Brill-Almon, Einat

    2016-07-01

    Taliglucerase alfa is an intravenous enzyme replacement therapy approved for treatment of type 1 Gaucher disease (GD), and is the first available plant cell-expressed recombinant therapeutic protein. Herein, we report long-term safety and efficacy results of taliglucerase alfa in treatment-naïve adult patients with GD. Patients were randomized to receive taliglucerase alfa 30 or 60 U/kg every other week, and 23 patients completed 36 months of treatment. Taliglucerase alfa (30 U/kg; 60 U/kg, respectively) resulted in mean decreases in spleen volume (50.1%; 64.6%) and liver volume (25.6%; 24.4%) with mean increases in hemoglobin concentration (16.0%; 35.8%) and platelet count (45.7%; 114.0%), and mean decreases in chitotriosidase activity (71.5%; 82.2%). All treatment-related adverse events were mild to moderate in intensity and transient. The most common adverse events were nasopharyngitis, arthralgia, upper respiratory tract infection, headache, pain in extremity, and hypertension. These 36-month results of taliglucerase alfa in treatment-naïve adult patients with GD demonstrate continued improvement in disease parameters with no new safety concerns. These findings extend the taliglucerase alfa clinical safety and efficacy dataset. www.clinicaltrials.gov identifier NCT00705939. Am. J. Hematol. 91:656-660, 2016. © 2016 Wiley Periodicals, Inc.

  2. Long‐term efficacy and safety results of taliglucerase alfa up to 36 months in adult treatment‐naïve patients with Gaucher disease

    PubMed Central

    Durán, Gloria; Mehta, Atul; Giraldo, Pilar; Rosenbaum, Hanna; Giona, Fiorina; Amato, Dominick J.; Petakov, Milan; Muñoz, Eduardo Terreros; Solorio‐Meza, Sergio Eduardo; Cooper, Peter A.; Varughese, Sheeba; Chertkoff, Raul; Brill‐Almon, Einat

    2016-01-01

    Taliglucerase alfa is an intravenous enzyme replacement therapy approved for treatment of type 1 Gaucher disease (GD), and is the first available plant cell–expressed recombinant therapeutic protein. Herein, we report long‐term safety and efficacy results of taliglucerase alfa in treatment‐naïve adult patients with GD. Patients were randomized to receive taliglucerase alfa 30 or 60 U/kg every other week, and 23 patients completed 36 months of treatment. Taliglucerase alfa (30 U/kg; 60 U/kg, respectively) resulted in mean decreases in spleen volume (50.1%; 64.6%) and liver volume (25.6%; 24.4%) with mean increases in hemoglobin concentration (16.0%; 35.8%) and platelet count (45.7%; 114.0%), and mean decreases in chitotriosidase activity (71.5%; 82.2%). All treatment‐related adverse events were mild to moderate in intensity and transient. The most common adverse events were nasopharyngitis, arthralgia, upper respiratory tract infection, headache, pain in extremity, and hypertension. These 36‐month results of taliglucerase alfa in treatment‐naïve adult patients with GD demonstrate continued improvement in disease parameters with no new safety concerns. These findings extend the taliglucerase alfa clinical safety and efficacy dataset. www.clinicaltrials.gov identifier NCT00705939. Am. J. Hematol. 91:656–660, 2016. © 2016 Wiley Periodicals, Inc. PMID:27174694

  3. Evaluation of results obtained with corifollitropin alfa after poor ovarian response in previous cycle using recombinant follicular stimulating hormone in the long-term protocol

    PubMed Central

    Salgueiro, Lister L.; Rolim, Juliana R.; Moura, Bernardo R. L.; Machado, Suelen P. P.; Haddad, Carolina

    2016-01-01

    Objective This study evaluated the use of Corifollitropin alfa in patients with previous poor response to recombinant follicle stimulating hormone in long-term protocols using gonadotropin-releasing hormone. Methods Twenty-seven poor responders to previous treatment with the long term protocol using the recombinant follicle stimulating hormone (Group 1) were selected and then submitted to a second attempt using the same long term protocol with Corifollitropin alfa instead of the recombinant follicle stimulating hormone (Group 2). Ovarian down-regulation was achieved using subcutaneous administration of Leuprolide Acetate. Ovarian stimulation was performed with recombinant follicle stimulating hormone until the administration of human chorionic gonadotropin, followed by follicular aspiration (Group 1). Group 2 was submitted to this same protocol using Corifollitropin alfa instead of recombinant follicle stimulating hormone. Results There were significant differences in the number of aspirated oocytes, percentage of mature oocytes, amount of injected oocytes and transferred embryos - with all of these parameters being increased in the Corifollitropin alfa group. In addition, the rates of pregnancy and ongoing pregnancy were also significantly higher in the Corifollitropin alfa group. Conclusion The present study demonstrated that the use of Corifollitropin alfa in the long-term protocol could be a highly effective alternative for patients with poor ovarian response, who were unsuccessful in a previous treatment with In Vitro Fertilization - Intracytoplasmic Sperm Injection. PMID:27584604

  4. Enzyme replacement therapy with taliglucerase alfa: 36-month safety and efficacy results in adult patients with Gaucher disease previously treated with imiglucerase.

    PubMed

    Pastores, Gregory M; Shankar, Suma P; Petakov, Milan; Giraldo, Pilar; Rosenbaum, Hanna; Amato, Dominick J; Szer, Jeffrey; Chertkoff, Raul; Brill-Almon, Einat; Zimran, Ari

    2016-07-01

    Taliglucerase alfa is the first available plant cell-expressed human recombinant therapeutic protein. It is indicated for treatment of patients with type 1 Gaucher disease (GD) in adult and pediatric patients in several countries. Study PB-06-002 examined the safety and efficacy of taliglucerase alfa for 9 months in patients who previously received imiglucerase. The results of adult patients from Study PB-06-002 who continued receiving taliglucerase alfa in extension Study PB-06-003 for up to 36 months are reported here. Eighteen patients received at least one dose of taliglucerase alfa in Study PB-06-003; 10 patients completed 36 total months of therapy, and four patients who transitioned to commercial drug completed 30-33 months of treatment. In patients who completed 36 total months of treatment, mean percent (±standard error) changes from baseline/time of switch to taliglucerase alfa to 36 months were as follows: hemoglobin concentration, -1.0% (±1.9%; n = 10); platelet count, +9.3% (±9.8%; n = 10); spleen volume measured in multiples of normal (MN), -19.8% (±9.9%; n = 7); liver volume measured in MN, +0.9% (±5.4%; n = 8); chitotriosidase activity, -51.5% (±8.1%; n = 10); and CCL18 concentration, -36.5 (±8.0%; n = 10). Four patients developed antidrug antibodies, including one with evidence of neutralizing activity in vitro. All treatment-related adverse events were mild or moderate and transient. The 36-month results of switching from imiglucerase to taliglucerase alfa treatment in adults with GD provide further data on the clinical safety and efficacy of taliglucerase alfa beyond the initial 9 months of the original study. www.clinicaltrials.gov identifier NCT00705939. Am. J. Hematol. 91:661-665, 2016. © 2016 Wiley Periodicals, Inc.

  5. Elosulfase alfa: first global approval.

    PubMed

    Sanford, Mark; Lo, Jin Han

    2014-04-01

    Elosulfase alfa (Vimizim™) is a recombinant form of N-acetylgalactosamine-6-sulfatase (GALNS) that was developed by BioMarin Pharmaceutical Inc. as an enzyme replacement therapy for patients with mucopolysaccharidosis type IVA (MPS IVA), also known as Morquio A syndrome. Patients with MPS IVA have a GALNS deficiency, which results in serious musculoskeletal, cardiorespiratory and other system disturbances. Elosulfase alfa was approved by the US FDA on 14 February 2014 for the treatment of MPS IVA. The European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) has recently recommended that elosulfase alfa be approved for use in the EU in the same indication. Within the last year, the manufacturer has also filed applications for approval for the use of elosulfase alfa in MPS IVA in Brazil, Australia, Canada and Mexico. This article summarizes the milestones in the development of elosulfase alfa leading to its first global approval in MPS IVA.

  6. Delayed administration of darbepoetin or erythropoietin protects against ischemic acute renal injury and failure.

    PubMed

    Johnson, D W; Pat, B; Vesey, D A; Guan, Z; Endre, Z; Gobe, G C

    2006-05-01

    Administration of human recombinant erythropoietin (EPO) at time of acute ischemic renal injury (IRI) inhibits apoptosis, enhances tubular epithelial regeneration, and promotes renal functional recovery. The present study aimed to determine whether darbepoetin-alfa (DPO) exhibits comparable renoprotection to that afforded by EPO, whether pro or antiapoptotic Bcl-2 proteins are involved, and whether delayed administration of EPO or DPO 6 h following IRI ameliorates renal dysfunction. The model of IRI involved bilateral renal artery occlusion for 45 min in rats (N = 4 per group), followed by reperfusion for 1-7 days. Controls were sham-operated. Rats were treated at time of ischemia or sham operation (T0), or post-treated (6 h after the onset of reperfusion, T6) with EPO (5000 IU/kg), DPO (25 mug/kg), or appropriate vehicle by intraperitoneal injection. Renal function, structure, and immunohistochemistry for Bcl-2, Bcl-XL, and Bax were analyzed. DPO or EPO at T0 significantly abrogated renal dysfunction in IRI animals (serum creatinine for IRI 0.17 +/- 0.05 mmol/l vs DPO-IRI 0.08 +/- 0.03 mmol/l vs EPO-IRI 0.04 +/- 0.01 mmol/l, P = 0.01). Delayed administration of DPO or EPO (T6) also significantly abrogated subsequent renal dysfunction (serum creatinine for IRI 0.17 +/- 0.05 mmol/l vs DPO-IRI 0.06 +/- 0.01 mmol/l vs EPO-IRI 0.03 +/- 0.03 mmol/l, P = 0.01). There was also significantly decreased tissue injury (apoptosis, P < 0.05), decreased proapoptotic Bax, and increased regenerative capacity, especially in the outer stripe of the outer medulla, with DPO or EPO at T0 or T6. These results reaffirm the potential clinical application of DPO and EPO as novel renoprotective agents for patients at risk of ischemic acute renal failure or after having sustained an ischemic renal insult.

  7. Enzyme replacement therapy with taliglucerase alfa: 36‐month safety and efficacy results in adult patients with Gaucher disease previously treated with imiglucerase

    PubMed Central

    Shankar, Suma P.; Petakov, Milan; Giraldo, Pilar; Rosenbaum, Hanna; Amato, Dominick J.; Szer, Jeffrey; Chertkoff, Raul; Brill‐Almon, Einat; Zimran, Ari

    2016-01-01

    Taliglucerase alfa is the first available plant cell‐expressed human recombinant therapeutic protein. It is indicated for treatment of patients with type 1 Gaucher disease (GD) in adult and pediatric patients in several countries. Study PB‐06‐002 examined the safety and efficacy of taliglucerase alfa for 9 months in patients who previously received imiglucerase. The results of adult patients from Study PB‐06‐002 who continued receiving taliglucerase alfa in extension Study PB‐06‐003 for up to 36 months are reported here. Eighteen patients received at least one dose of taliglucerase alfa in Study PB‐06‐003; 10 patients completed 36 total months of therapy, and four patients who transitioned to commercial drug completed 30–33 months of treatment. In patients who completed 36 total months of treatment, mean percent (±standard error) changes from baseline/time of switch to taliglucerase alfa to 36 months were as follows: hemoglobin concentration, −1.0% (±1.9%; n = 10); platelet count, +9.3% (±9.8%; n = 10); spleen volume measured in multiples of normal (MN), −19.8% (±9.9%; n = 7); liver volume measured in MN, +0.9% (±5.4%; n = 8); chitotriosidase activity, −51.5% (±8.1%; n = 10); and CCL18 concentration, −36.5 (±8.0%; n = 10). Four patients developed antidrug antibodies, including one with evidence of neutralizing activity in vitro. All treatment‐related adverse events were mild or moderate and transient. The 36‐month results of switching from imiglucerase to taliglucerase alfa treatment in adults with GD provide further data on the clinical safety and efficacy of taliglucerase alfa beyond the initial 9 months of the original study. www.clinicaltrials.gov identifier NCT00705939. Am. J. Hematol. 91:661–665, 2016. © 2016 Wiley Periodicals, Inc. PMID:27102949

  8. Long-term efficacy and safety results of taliglucerase alfa through 5years in adult treatment-naïve patients with Gaucher disease.

    PubMed

    Zimran, Ari; Durán, Gloria; Giraldo, Pilar; Rosenbaum, Hanna; Giona, Fiorina; Petakov, Milan; Terreros Muñoz, Eduardo; Solorio-Meza, Sergio Eduardo; Cooper, Peter A; Varughese, Sheeba; Alon, Sari; Chertkoff, Raul

    2016-07-18

    Taliglucerase alfa, the first available plant cell-expressed recombinant therapeutic protein, is an enzyme replacement therapy approved for Gaucher disease (GD). PB-06-001, a pivotal phase 3, multicenter, randomized, double-blind, parallel-dose study investigated taliglucerase alfa 30 or 60U/kg every other week through 9months in treatment-naïve adults with GD; 30-month extension study PB-06-003 followed. Patients completing PB-06-001 and PB-06-003 could continue treatment in PB-06-007. Nineteen patients enrolled in PB-06-007 (30U/kg, n=8; 60U/kg, n=9; dose adjusted, n=2); 17 completed 5 total years of treatment. In these 3 groups, respectively, taliglucerase alfa resulted in mean decreases in spleen volume (-8.7, -6.9, -12.4 multiples of normal), liver volume (-0.6, -0.4, -0.5 multiples of normal), chitotriosidase activity (-83.1%, -93.4%, -87.9%), and chemokine (CC motif) ligand 18 concentration (-66.7%, -83.3%, -78.9%), as well as mean increases in hemoglobin concentration (+2.1, +2.1, +1.8mg/dL) and platelet count (+31,871, +106,800, +34,000/mm(3)). The most common adverse events were nasopharyngitis and arthralgia. Most adverse events were mild/moderate; no serious adverse events were considered treatment-related. These results demonstrate continued improvement of disease parameters during 5years of taliglucerase alfa therapy in 17 treatment-naive patients with no new safety concerns, extending the taliglucerase alfa clinical efficacy and safety dataset. This study was registered at www.clinicaltrials.gov as NCT01422187.

  9. Management of anaemia in oncohaematological patients treated with biosimilar epoetin alfa: results of an Italian observational, retrospective study

    PubMed Central

    Rosti, Giovanni; Petrini, Mario; Bosi, Alberto; Galieni, Piero; Bernardi, Daniele; Giglio, Gianfranco; Dorotea, Laura; Falini, Brunangelo; Scelzi, Elvira; Veltri, Enzo; Castelli, Roberto; Longagnani, Chiara; Raggi, Tommaso; Simonetti, Federico

    2016-01-01

    Background: Many patients with solid tumours or nonmyeloid haematopoietic tumours develop symptomatic anaemia, which has a major impact on quality of life (QoL). The efficacy of erythropoiesis-stimulating agents (ESAs) in improving QoL and reducing blood transfusions has been widely demonstrated. Binocrit® (biosimilar epoetin alfa) is an ESA indicated in the European Union for treating chemotherapy-induced anaemia. The aim of this study was to investigate the effect of Binocrit® on haemoglobin (Hb) levels in anaemic cancer patients in Italian clinical practice. Methods: The ANEMONE study was a national, longitudinal, retrospective, multicentre observational study. Patients had to be 18 years or older, with a solid tumour or non-Hodgkin’s lymphoma, Hodgkin’s disease or multiple myeloma, receiving chemotherapy, and treated with Binocrit® to manage chemotherapy-induced anaemia. The primary outcomes were the proportion of patients with a Hb increase ⩾1 g/dl during the first 4 weeks and with a Hb increase ⩾2 g/dl during the first 12 weeks. Results: A total of 245 patients were enrolled and 215 patients were evaluable for statistical analysis. In the first 4 weeks, 49.3% of patients showed an increase in Hb of ⩾1 g/dl: 45.5% in patients with solid tumours and 52.1% in patients with haematological malignancies. In the first 12 weeks, 51.6% of patients showed an increase in Hb of ⩾2 g/dl (48.4% solid tumours, 54.2% haematological diseases). Treatment with Binocrit® was well tolerated. Conclusions: These results confirm the effectiveness and safety of Binocrit® for chemotherapy-induced anaemia in routine practice in patients with solid tumours, lymphoma and myeloma. PMID:28203295

  10. Pegylated Interferon Alfa-2a Monotherapy Results in Suppression of HIV Type 1 Replication and Decreased Cell-Associated HIV DNA Integration

    PubMed Central

    Azzoni, Livio; Foulkes, Andrea S.; Papasavvas, Emmanouil; Mexas, Angela M.; Lynn, Kenneth M.; Mounzer, Karam; Tebas, Pablo; Jacobson, Jeffrey M.; Frank, Ian; Busch, Michael P.; Deeks, Steven G.; Carrington, Mary; O'Doherty, Una; Kostman, Jay; Montaner, Luis J.

    2013-01-01

    Background. Antiretroviral therapy (ART)–mediated immune reconstitution fails to restore the capacity of the immune system to spontaneously control human immunodeficiency virus (HIV) replication. Methods. A total of 23 HIV type 1 (HIV-1)–infected, virologically suppressed subjects receiving ART (CD4+ T-cell count, >450 cells/μL) were randomly assigned to have 180 μg/week (for arm A) or 90 μg/week (for arm B) of pegylated (Peg) interferon alfa-2a added to their current ART regimen. After 5 weeks, ART was interrupted, and Peg–interferon alfa-2a was continued for up to 12 weeks (the primary end point), with an option to continue to 24 weeks. End points included virologic failure (viral load, ≥400 copies/mL) and adverse events. Residual viral load and HIV-1 DNA integration were also assessed. Results. At week 12 of Peg–interferon alfa-2a monotherapy, viral suppression was observed in 9 of 20 subjects (45%), a significantly greater proportion than expected (arm A, P = .0088; arm B, P = .0010; combined arms, P < .0001). Over 24 weeks, both arms had lower proportions of subjects who had viral load, compared with the proportion of subjects in a historical control group (arm A, P = .0046; arm B, P = .0011). Subjects who had a sustained viral load of <400 copies/mL had decreased levels of integrated HIV DNA (P = .0313) but increased residual viral loads (P = .0078), compared with subjects who experienced end-point failure. Conclusions. Peg–interferon alfa-2a immunotherapy resulted in control of HIV replication and decreased HIV-1 integration, supporting a role for immunomediated approaches in HIV suppression and/or eradication. Clinical Trials Registration. NCT00594880. PMID:23105144

  11. Tongue hyperpigmentation resulting from peginterferon alfa-2b and ribavirin treatment in a patient with chronic hepatitis C.

    PubMed

    Ghosh, Souvik; Duseja, Ajay; Dhiman, Radha Krishan; Chawla, Yogesh Kumar

    2012-03-01

    Hepatitis C virus (HCV) infection has been associated with several cutaneous diseases such as lichen planus, porphyria cutanea tarda, chronic pruritus, and cutaneous necrotizing vasculitis (Doutre, Arch Dermatol 135:1401-1403, 1999). The antiviral treatment for chronic HCV with interferon alfa (INF) or peginterferon alfa (PEG-INF) combined with rivabirin also leads to many skin side effects including injection site reaction, generalized skin rashes, pruritus, dry skin, alopecia, and exacerbation of autoimmune processes, particularly psoriasis, lichen planus or vitiligo (Dalekos et al., Eur J Gastroenterol Hepatol 10:933-939, 1998; Sookoian et al., Arch Dermatol 135:1000-1000, 1999). There are case reports of tongue hyperpigmentation during combination therapy of PEG IFN and RBV in chronic hepatitis C both in dark-skined as well as Caucasian. We report the first case of tongue hyperpigmentation associated with PEG-INF-2b plus ribavirin administration in a non-Caucasian patient with genotype 4.

  12. Safety and efficacy results of switch from imiglucerase to velaglucerase alfa treatment in patients with type 1 Gaucher disease.

    PubMed

    Elstein, Deborah; Mehta, Atul; Hughes, Derralynn A; Giraldo, Pilar; Charrow, Joel; Smith, Laurie; Shankar, Suma P; Hangartner, Thomas N; Kunes, Yune; Wang, Nan; Crombez, Eric; Zimran, Ari

    2015-07-01

    Gaucher disease (GD) is a lysosomal storage disorder; symptomatic patients with type 1 GD need long-term disease-specific therapy of which the standard of care has been enzyme replacement therapy (ERT). Thirty-eight of 40 patients (aged 9-71 years) clinically stable on ERT with imiglucerase, safely switched to a comparable dose of velaglucerase alfa (units/kg) during TKT034, a 12-month, open-label clinical study, and for 10-50 months in an extension study. The most common adverse events (AEs) judged to be drug-related in the extension were fatigue and bone pain. No drug-related serious AEs were reported. No AEs led to study withdrawal. At 24 months from baseline (baseline being TKT034 week 0), patients had generally stable hemoglobin, platelet, spleen, liver, and bone density parameters. Nevertheless, dose adjustment based on the achievement of therapeutic goals was permitted, and 10 patients, including seven patients who had platelet counts <100 × 10(9) /L at baseline, were given at least one 15 U/kg-dose increase during the extension. Trends indicative of improvement in platelet count and spleen volume, and decreasing levels of GD biomarkers, chitotriosidase and CCL18, were observed. Immunogenicity was seen in one patient positive for anti-imiglucerase antibodies at baseline. This patient tested positive for anti-velaglucerase alfa antibodies in TKT034, with low antibody concentrations, and throughout the extension study; however, the patient continued to receive velaglucerase alfa without clinical deterioration. In conclusion, clinically stable patients can be switched from imiglucerase to velaglucerase alfa ERT and maintain or achieve good therapeutic outcomes.

  13. Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial.

    PubMed

    Strothotte, S; Strigl-Pill, N; Grunert, B; Kornblum, C; Eger, K; Wessig, C; Deschauer, M; Breunig, F; Glocker, F X; Vielhaber, S; Brejova, A; Hilz, M; Reiners, K; Müller-Felber, W; Mengel, E; Spranger, M; Schoser, Benedikt

    2010-01-01

    Late-onset glycogen storage disease type 2 (GSD2)/Pompe disease is a progressive multi-system disease evoked by a deficiency of lysosomal acid alpha-glucosidase (GAA) activity. GSD2 is characterized by respiratory and skeletal muscle weakness and atrophy, resulting in functional disability and reduced life span. Since 2006 alglucosidase alfa has been licensed as a treatment in all types of GSD2/Pompe disease. We here present an open-label, investigator-initiated observational study of alglucosidase alfa enzyme replacement therapy (ERT) in 44 late-onset GSD2 patients with various stages of disease severity. Alglucosidase alfa was given i.v. at the standard dose of 20 mg/kg every other week. Assessments included serial arm function tests (AFT), Walton Gardner Medwin scale (WGMS), timed 10-m walk tests, four-stair climb tests, modified Gowers' maneuvers, 6-min walk tests, MRC sum score, forced vital capacities (FVC), creatine kinase (CK) levels and SF-36 self-reporting questionnaires. All tests were performed at baseline and every 3 months for 12 months of ERT. We found significant changes from baseline in the modified Gowers' test, the CK levels and the 6-min walk test (341 +/- 149.49 m, median 342.25 m at baseline; 393 +/- 156.98 m; median 411.50 m at endpoint; p = 0.026), while all other tests were unchanged. ERT over 12 months revealed minor allergic reactions in 10% of the patients. No serious adverse events occurred. None of the patients died or required de novo ventilation. Our clinical outcome data imply stabilization of neuromuscular deficits over 1 year with mild functional improvement.

  14. Low-Dose Treatment with Erythropoiesis-Stimulating Agents and Cardiovascular Geometry in Chronic Kidney Disease: Is Darbepoetin-α More Effective than Expected?

    PubMed

    Di Lullo, Luca; Floccari, Fulvio; Granata, Antonio; Malaguti, Moreno

    2012-02-01

    INTRODUCTION: Chronic kidney disease (CKD) is a widespread invalidating condition, leading to erythropoietin deficiency and decreased cardiovascular performance. Darbepoetin-α and epoetin-α are extensively used to correct renal anemia. The aim of this study was to evaluate cardiological outcomes in two groups of CKD patients treated with erythropoiesis-stimulating agents (ESA: 20 μg darbepoetin-α weekly vs. 2,000 IU epoetin-α thrice weekly) with an unconventional 1:300 conversion ratio. METHODS: The study was designed as a single center, retrospective, observational study. One hundred stage IV CKD patients were selected. Hemoglobin (Hb), hematocrit, C-reactive protein, pro-brain natriuretic peptide (BNP) and basal echocardiograms were monitored every 3 months. RESULTS: Darbepoetin-α was significantly more effective in increasing Hb levels after 3 (p < 0.0001), 6 (p < 0.0001), 9 (p < 0.01) and 12 months (p < 0.01) compared to epoetin-α. The optimal Hb target level (11 g/dl < Hb < 12 g/dl) was completely reached after 1 year of treatment with darbepoetin-α and in 70% of the patients treated with epoetin-α (p < 0.01). Cardiovascular performance (left ventricular end-diastolic volume, ejection fraction and pro-BNP) was significantly improved after darbepoetin-α treatment at the 6- and 12-month follow-ups compared to epoetin-α. Discussion: Despite the limitations of a retrospective observational study, these results encourage nephrologists to test the 1:300 darbepoetin/epoetin conversion ratio in 'easy' patients, and aggressive protocols for the treatment of anemia in CKD patients are avoided. Darbepoetin-α appeared effective in anemia correction, improving cardiovascular performance in a significantly higher proportion than epoetin. At low doses, on the other hand, it has to be borne in mind that a treatment regimen with only one submaximal administration per week may increase patient compliance and adherence to therapy, explaining in part the observed

  15. Low-Dose Treatment with Erythropoiesis-Stimulating Agents and Cardiovascular Geometry in Chronic Kidney Disease: Is Darbepoetin-α More Effective than Expected?

    PubMed Central

    Di Lullo, Luca; Floccari, Fulvio; Granata, Antonio; Malaguti, Moreno

    2012-01-01

    Introduction Chronic kidney disease (CKD) is a widespread invalidating condition, leading to erythropoietin deficiency and decreased cardiovascular performance. Darbepoetin-α and epoetin-α are extensively used to correct renal anemia. The aim of this study was to evaluate cardiological outcomes in two groups of CKD patients treated with erythropoiesis-stimulating agents (ESA: 20 μg darbepoetin-α weekly vs. 2,000 IU epoetin-α thrice weekly) with an unconventional 1:300 conversion ratio. Methods The study was designed as a single center, retrospective, observational study. One hundred stage IV CKD patients were selected. Hemoglobin (Hb), hematocrit, C-reactive protein, pro-brain natriuretic peptide (BNP) and basal echocardiograms were monitored every 3 months. Results Darbepoetin-α was significantly more effective in increasing Hb levels after 3 (p < 0.0001), 6 (p < 0.0001), 9 (p < 0.01) and 12 months (p < 0.01) compared to epoetin-α. The optimal Hb target level (11 g/dl < Hb < 12 g/dl) was completely reached after 1 year of treatment with darbepoetin-α and in 70% of the patients treated with epoetin-α (p < 0.01). Cardiovascular performance (left ventricular end-diastolic volume, ejection fraction and pro-BNP) was significantly improved after darbepoetin-α treatment at the 6- and 12-month follow-ups compared to epoetin-α. Discussion: Despite the limitations of a retrospective observational study, these results encourage nephrologists to test the 1:300 darbepoetin/epoetin conversion ratio in ‘easy’ patients, and aggressive protocols for the treatment of anemia in CKD patients are avoided. Darbepoetin-α appeared effective in anemia correction, improving cardiovascular performance in a significantly higher proportion than epoetin. At low doses, on the other hand, it has to be borne in mind that a treatment regimen with only one submaximal administration per week may increase patient compliance and adherence to therapy, explaining in part the observed

  16. Epoetin Alfa Injection

    MedlinePlus

    ... surgery to decrease the chance that blood transfusions (transfer of one person's blood to another person's body) ... wheezing difficulty breathing or swallowing hoarseness lack of energy dizziness fainting Epoetin alfa injection may cause other ...

  17. A Pharmacoeconomic Analysis of In-Hospital Costs Resulting from Reintubation in Preterm Infants Treated with Lucinactant, Beractant, or Poractant Alfa

    PubMed Central

    Guardia, Carlos G.; Moya, Fernando R.; Sinha, Sunil; Simmons, Phillip D.; Segal, Robert; Greenspan, Jay S.

    2012-01-01

    OBJECTIVES Reintubation and subsequent mechanical ventilation (MV) in preterm infants after surfactant replacement therapy are associated with excess morbidity and mortality and likely increase in-hospital costs. Specific surfactant therapy selection for prevention of respiratory distress syndrome (RDS) in preterm infants receiving conventional MV may impact not only clinical outcomes but also pharmacoeconomic outcomes. METHODS We conducted a pharmacoeconomic analysis of the impact of surfactant selection and reintubation and subsequent MV of preterm infants on health care resource utilization. Rates of reintubation and duration of MV after reintubation were determined from 1546 preterm infants enrolled in two surfactant trials comparing lucinactant to beractant and poractant alfa. Hospital costs were obtained from a 2010 US database from 1564 preterm infants with RDS, with a direct cost of $2637 per day for MV in the neonatal intensive care unit. Cost of reintubation by study and treatment was estimated as the incidence of reintubation multiplied by days on MV therapy after reintubation multiplied by cost per day for direct MV costs, standardized per 100 surfactant-treated infants. RESULTS There were no differences between studies or treatment groups in the overall extubation rate. Average MV duration following reintubation was similar between groups in both trials; however, reintubation rates were significantly lower (p<0 05) for infants treated with lucinactant than for those receiving beractant or poractant alfa. The observed differences in reintubation rates resulted in a projected cost saving of $160,013 to $252,203 per 100 infants treated with lucinactant versus animal-derived surfactants. CONCLUSIONS In this analysis, higher reintubation rates following successful extubation in preterm infants receiving animal-derived surfactant preparations significantly increased estimated in-hospital costs, primarily due to excess costs associated with MV. This analysis

  18. Drotrecogin alfa Eli Lilly.

    PubMed

    de Jonge, E

    2002-04-01

    Drotrecogin alfa (Xigris, recombinant activated protein C) is an anticoagulant developed and launched by Eli Lilly & Co for the treatment of sepsis [333781], [339372], [430133], [436271]. The FDA and the EMEA accepted the brand name Xigris for drotrecogin alfa in June 2001. This trade name had been proposed by Lilly in place of the previous brand name, Zovant, which was deemed unacceptable by the EMEA due to concerns that the name could be confused with hospital-based drugs [412512]. Filings for sepsis were made in the US, EU and Australia in February 2001 [398514], [447870] and in March 2001, the US FDA assigned drotrecogin alfa Priority Review status [403435]. The FDA extended the action date from July 27 to October 27, 2001 for completion of its review of the biologics license application (BLA) for drotrecogin alfa to assess further supplementary data submitted by Lilly [412512]. At the October 16, 2001 meeting (postponed from September 12), the FDA Advisory Committee on Anti-Infective Drugs split 10 to 10 over whether to recommend approval [425873], [425940]. In late October 2001, Lilly received an approvable letter from the FDA for the treatment of severe sepsis. Approval was contingent upon successful negotiation of labeling, agreement on post-approval clinical trials, and successful completion of manufacturing inspections [427301]. In November 2001, the FDA approved drotrecogin alfa for the reduction of mortality in adult patients with severe sepsis who have a high risk of death [430133]; the product was launched onto the US market days later [436271]. Following the FDA committee's split decision in October 2001, Credit Suisse First Boston, which expected mid-2002 approval but with restrictive labeling, revised its predictions from $1.265 billion in 2004 sharply downwards to $543 million [425929].

  19. The efficacy of darbepoetin alpha in hemodialysis patients resistant to human recombinant erythropoietin (rHuEpo).

    PubMed

    Hejaili, Fayez

    2009-07-01

    Darbepoetin due to longer half life is convenient and effective for long term. This study was done to assess the efficacy of darbepoetin in the treatment of patients on high doses of erythropoietin (EPO) and to compare its efficacy in patients resistant and responsive to EPO. This is a prospective, controlled open label study assessing the efficacy of darbepoetin in 55 hemodialysis patients on high dose EPO and comparing its efficacy in the patients who were "EPO -resistant" (group 1, n= 28) and in those who were "EPO-responsive" (group 2, n= 27). The initial conversion ratio was 380 mcg darbepoetin: 1 U EPO/ week and the dose of darbepoetin was adjusted thereafter at fortnightly intervals with the aim of achieving and maintaining the hemoglobin level between 11-12 g/dL. The patients were followed up for 12 weeks following the introduction of darbepoetin. The impact of gender, baseline PTH, age, Kt/V, duration on dialysis, initial EPO dose on the response to darbepoetin was investigated. Continuous variables were compared using two tailed t-test and non-parametric by Fisher exact test. Overall darbepoetin was effective with 85.5 % of the patients responding and 21.8 % of the patients' able to maintain their hemoglobin with once fortnightly dose by the end of the study. Mean darbepoetin dose and the mean EPO to darbepoetin conversion ratio on completion of the study were 58.2 (42.4) mcg/week (0.983 (0.87) mcg/kg/week) and 384:1 respectively. Hemoglobin levels in groups 1 improved from 9.8 +/- 0.9 g/dL to 12.0 +/- 1.4 g/dL (0.0001) and 2 were and maintained it in group 2 at 11.9 +/- 1.3 g/dL (P= 0.79). The doses of darbepoetin required in groups 1 and 2 were similar (54.3 +/- 33 and 53.9 +/- 47 mcg/week (P= 0.97) respectively and 0.89 +/- 0.6 and 0.98 +/- 1.0 mcg/kg/week (P= 0.8). 22 (78.6 %) of the EPO resistant patients responded to darbepoetin. In conclusion conversion from high dose EPO to darbepoetin proved successful even in patients who were resistant to EPO

  20. Performance of a Predictive Model for Long-Term Hemoglobin Response to Darbepoetin and Iron Administration in a Large Cohort of Hemodialysis Patients.

    PubMed

    Barbieri, Carlo; Bolzoni, Elena; Mari, Flavio; Cattinelli, Isabella; Bellocchio, Francesco; Martin, José D; Amato, Claudia; Stopper, Andrea; Gatti, Emanuele; Macdougall, Iain C; Stuard, Stefano; Canaud, Bernard

    2016-01-01

    Anemia management, based on erythropoiesis stimulating agents (ESA) and iron supplementation, has become an increasingly challenging problem in hemodialysis patients. Maintaining hemodialysis patients within narrow hemoglobin targets, preventing cycling outside target, and reducing ESA dosing to prevent adverse outcomes requires considerable attention from caregivers. Anticipation of the long-term response (i.e. at 3 months) to the ESA/iron therapy would be of fundamental importance for planning a successful treatment strategy. To this end, we developed a predictive model designed to support decision-making regarding anemia management in hemodialysis (HD) patients treated in center. An Artificial Neural Network (ANN) algorithm for predicting hemoglobin concentrations three months into the future was developed and evaluated in a retrospective study on a sample population of 1558 HD patients treated with intravenous (IV) darbepoetin alfa, and IV iron (sucrose or gluconate). Model inputs were the last 90 days of patients' medical history and the subsequent 90 days of darbepoetin/iron prescription. Our model was able to predict individual variation of hemoglobin concentration 3 months in the future with a Mean Absolute Error (MAE) of 0.75 g/dL. Error analysis showed a narrow Gaussian distribution centered in 0 g/dL; a root cause analysis identified intercurrent and/or unpredictable events associated with hospitalization, blood transfusion, and laboratory error or misreported hemoglobin values as the main reasons for large discrepancy between predicted versus observed hemoglobin values. Our ANN predictive model offers a simple and reliable tool applicable in daily clinical practice for predicting the long-term response to ESA/iron therapy of HD patients.

  1. ALFA: an automated line fitting algorithm

    NASA Astrophysics Data System (ADS)

    Wesson, R.

    2016-03-01

    I present the automated line fitting algorithm, ALFA, a new code which can fit emission line spectra of arbitrary wavelength coverage and resolution, fully automatically. In contrast to traditional emission line fitting methods which require the identification of spectral features suspected to be emission lines, ALFA instead uses a list of lines which are expected to be present to construct a synthetic spectrum. The parameters used to construct the synthetic spectrum are optimized by means of a genetic algorithm. Uncertainties are estimated using the noise structure of the residuals. An emission line spectrum containing several hundred lines can be fitted in a few seconds using a single processor of a typical contemporary desktop or laptop PC. I show that the results are in excellent agreement with those measured manually for a number of spectra. Where discrepancies exist, the manually measured fluxes are found to be less accurate than those returned by ALFA. Together with the code NEAT, ALFA provides a powerful way to rapidly extract physical information from observations, an increasingly vital function in the era of highly multiplexed spectroscopy. The two codes can deliver a reliable and comprehensive analysis of very large data sets in a few hours with little or no user interaction.

  2. Asfotase alfa therapy for children with hypophosphatasia

    PubMed Central

    Madson, Katherine L.; Phillips, Dawn; Reeves, Amy L.; McAlister, William H.; Yakimoski, Amy; Mack, Karen E.; Hamilton, Kim; Kagan, Kori; Fujita, Kenji P.; Thompson, David D.; Moseley, Scott; Odrljin, Tatjana; Rockman-Greenberg, Cheryl

    2016-01-01

    Background. Hypophosphatasia (HPP) is caused by loss-of-function mutation(s) of the gene that encodes the tissue-nonspecific isoenzyme of alkaline phosphatase (TNSALP). Consequently, cell-surface deficiency of TNSALP phosphohydrolase activity leads to extracellular accumulation of inorganic pyrophosphate, a natural substrate of TNSALP and inhibitor of mineralization. Children with HPP can manifest rickets, skeletal pain, deformity, fracture, muscle weakness, and premature deciduous tooth loss. Asfotase alfa is a recombinant, bone-targeted, human TNSALP injected s.c. to treat HPP. In 2012, we detailed the 1-year efficacy of asfotase alfa therapy for the life-threatening perinatal and infantile forms of HPP. Methods. Here, we evaluated the efficacy and safety of asfotase alfa treatment administered to children 6–12 years of age at baseline who were substantially impaired by HPP. Two radiographic scales quantitated HPP skeletal disease, including comparisons to serial radiographs from similarly affected historical control patients. Results. Twelve children receiving treatment were studied for 5 years. The 6-month primary endpoint was met, showing significant radiographic improvement. Additional significant improvements included patient growth, strength, motor function, agility, and quality of life, which for most patients meant achieving normal values for age- and sex-matched peers that were sustained at 5 years of treatment. For most, pain and disability resolved. Mild to moderate injection-site reactions were common and were sometimes associated with lipohypertrophy. Low anti–asfotase alfa antibody titers were noted in all patients. No evidence emerged for clinically important ectopic calcification or treatment resistance. Conclusions. Asfotase alfa enzyme replacement therapy has substantial and sustained efficacy with a good safety profile for children suffering from HPP. Trial Registration. ClinicalTrials.gov NCT00952484 (https://clinicaltrials.gov/ct2/show

  3. Asfotase alfa therapy for children with hypophosphatasia.

    PubMed

    Whyte, Michael P; Madson, Katherine L; Phillips, Dawn; Reeves, Amy L; McAlister, William H; Yakimoski, Amy; Mack, Karen E; Hamilton, Kim; Kagan, Kori; Fujita, Kenji P; Thompson, David D; Moseley, Scott; Odrljin, Tatjana; Rockman-Greenberg, Cheryl

    2016-06-16

    Background. Hypophosphatasia (HPP) is caused by loss-of-function mutation(s) of the gene that encodes the tissue-nonspecific isoenzyme of alkaline phosphatase (TNSALP). Consequently, cell-surface deficiency of TNSALP phosphohydrolase activity leads to extracellular accumulation of inorganic pyrophosphate, a natural substrate of TNSALP and inhibitor of mineralization. Children with HPP can manifest rickets, skeletal pain, deformity, fracture, muscle weakness, and premature deciduous tooth loss. Asfotase alfa is a recombinant, bone-targeted, human TNSALP injected s.c. to treat HPP. In 2012, we detailed the 1-year efficacy of asfotase alfa therapy for the life-threatening perinatal and infantile forms of HPP. Methods. Here, we evaluated the efficacy and safety of asfotase alfa treatment administered to children 6-12 years of age at baseline who were substantially impaired by HPP. Two radiographic scales quantitated HPP skeletal disease, including comparisons to serial radiographs from similarly affected historical control patients. Results. Twelve children receiving treatment were studied for 5 years. The 6-month primary endpoint was met, showing significant radiographic improvement. Additional significant improvements included patient growth, strength, motor function, agility, and quality of life, which for most patients meant achieving normal values for age- and sex-matched peers that were sustained at 5 years of treatment. For most, pain and disability resolved. Mild to moderate injection-site reactions were common and were sometimes associated with lipohypertrophy. Low anti-asfotase alfa antibody titers were noted in all patients. No evidence emerged for clinically important ectopic calcification or treatment resistance. Conclusions. Asfotase alfa enzyme replacement therapy has substantial and sustained efficacy with a good safety profile for children suffering from HPP. Trial Registration. ClinicalTrials.gov NCT00952484 (https://clinicaltrials.gov/ct2/show

  4. Darbepoetin-α prevents progressive left ventricular dysfunction and remodeling in nonanemic dogs with heart failure

    PubMed Central

    Rastogi, Sharad; Imai, Makoto; Sharov, Victor G.; Mishra, Sudhish; Sabbah, Hani N.

    2008-01-01

    In anemic patients with heart failure (HF), erythropoietin-type drugs can elicit clinical improvement. This study examined the effects of chronic monotherapy with darbepoetin-α (DARB) on left ventricular (LV) function and remodeling in nonanemic dogs with advanced HF. HF [LV ejection fraction (EF) ∼25%] was produced in 14 dogs by intracoronary microembolizations. Dogs were randomized to once a week subcutaneous injection of DARB (1.0 μg/kg, n = 7) or to no therapy (HF, n = 7). All procedures were performed during cardiac catheterization under general anesthesia and under sterile conditions. LV end-diastolic volume (EDV), end-systolic volume (ESV), and EF were measured before the initiation of therapy and at the end of 3 mo of therapy. mRNA and protein expression of caspase-3, hypoxia inducible factor-1α, and the bone marrow-derived stem cell marker c-Kit were determined in LV tissue. In HF dogs, EDV and ESV increased and EF decreased after 3 mo of followup. Treatment with DARB prevented the increase in EDV, decreased ESV, and increased EF. DARB therapy also normalized the expression of HIF-1α and active caspase-3 and enhanced the expression of c-Kit. We conclude that chronic monotherapy with DARB prevents progressive LV dysfunction and dilation in nonanemic dogs with advanced HF. These results suggest that DARB elicits beneficial effects in HF that are independent of the presence of anemia. PMID:18952719

  5. Enhanced antitumor reactivity of tumor-sensitized T cells by interferon alfa

    SciTech Connect

    Vander Woude, D.L.; Wagner, P.D.; Shu, S.; Chang, A.E. )

    1991-03-01

    Tumor-draining lymph node cells from mice bearing the methylcholanthrene-induced MCA 106 tumors can be sensitized in vitro to acquire antitumor reactivity. We examined the effect of interferon alfa on the function of cells that underwent in vitro sensitization in adoptive immunotherapy. Interferon alfa increased the antitumor reactivity of in vitro sensitized cells in the treatment of MCA 106 pulmonary metastases. This effect was evident in irradiated mice, indicating that a host response to the interferon alfa was not required. Interferon alfa treatment increased class I major histocompatibility complex antigen expression on tumor cells and increased their susceptibility to lysis by in vitro sensitized cells. These results suggest that interferon alfa enhancement of adoptive immunotherapy was mediated by its effect on tumor cells. Interferon alfa may be a useful adjunct to the adoptive immunotherapy of human cancer.

  6. Biosimilar epoetin alfa increases haemoglobin levels and brings cognitive and socio-relational benefits to elderly transfusion-dependent multiple myeloma patients: results from a pilot study.

    PubMed

    Castelli, Roberto; Sciara, Simona; Lambertenghi Deliliers, Giorgio; Pantaleo, Giuseppe

    2017-05-01

    Anaemia is a complication reported in up to 70% of the multiple myeloma patients (MM), with remarkable clinical, cognitive and socio-relational consequences. Anaemia relates to the course of MM, normalizing in patients during remission and reappearing in relapsing/non-responding patients. In a pilot study with 31 patients with MM and transfusion-dependent anaemia, we evaluated the effects of Binocrit (biosimilar epoetin alfa) on transfusions, haemoglobin levels, mental status (mini-mental state evaluation) and the patients' social-relational functioning and quality of life (QoL). Within a 12-week interval, patients received 40.000 U Binocrit once a week. Binocrit significantly decreased the incidence of transfusion, regardless of the patients' transfusion history, and significantly increased haemoglobin levels (before-and-after-treatment median haemoglobin values = 8.20 vs. 9.40 g/dl, respectively; Wilcoxon Z test, p < .001). A comparatively greater increment in haemoglobin levels among patients who responded to first vs. additional lines of chemotherapy was also observed. Importantly, we additionally found moderate-to-strong positive associations between increments in haemoglobin levels and corresponding increments both in psychological well-being and QoL (FACT-An scores) and the patients' cognitive status (mini-mental state evaluation scores). After statistically controlling for possible concurrent benefits of anti-myeloma therapy, increments in haemoglobin levels clearly predicted both increments in socio-relational FACT-An scores (Spearman's rho = 0.60, p < .001) and in cognitive functioning scores (Spearman's rho = 0.49, p < .006). Binocrit thus appears as an effective, well-tolerated agent for the management of myeloma anaemia, whose documented benefits include amelioration of anaemia, reduction in transfusion, and improvements in the patients' social-relational functioning and cognitive well-being.

  7. Impact of severe haemophilia A on patients' health status: results from the guardian(™) 1 clinical trial of turoctocog alfa (NovoEight(®) ).

    PubMed

    Ozelo, M; Chowdary, P; Regnault, A; Busk, A K

    2015-07-01

    Haemophilia and its treatment interfere with patients' life and may affect adherence to treatment. This study explored the impact of severe haemophilia A on patients' health status, especially in young adults (YA), using data from guardian(™) 1, a multinational, open-label, non-controlled phase 3 trial investigating safety and efficacy of turoctocog alfa (NovoEight(®) ) in previously treated patients aged 12 years and older with severe haemophilia A (FVIII ≤ 1%). Health status was assessed using the EuroQoL-5 dimensions (EQ-5D-3L), covering 5 dimensions of health (mobility, self-care, usual activities, pain/discomfort and anxiety/depression), and a visual analogue scale (VAS) measuring self-rated overall health status. EQ-5D was administered pretreatment (screening/baseline) and posttreatment (end-of-trial). Baseline responses to the EQ-5D dimensions and VAS were described overall and by age and compared to reference values from UK general population. Guardian(™) 1 included 150 patients (16 adolescents, 83 YA aged 16-29 and 51 adults aged 30+). All five dimensions of patients' health status were impacted at baseline. The percentage of haemophilia patients reporting problems was consistently significantly greater than age-matched general population reference values. Likewise, for all age groups mean baseline EQ-5D VAS score was significantly lower for haemophilia patients (YA: 78.0) than for the general population (YA aged 18-29: 87.3). The health status of patients with severe haemophilia A entering guardian(™) 1 was markedly poorer than that of the general population, particularly regarding mobility and pain. YA patients reported better health status than older patients, but considerably lower than that of the general YA population.

  8. Detection of recombinant epoetin and darbepoetin alpha after subcutaneous administration in the horse.

    PubMed

    Lasne, Françoise; Popot, Marie-Agnes; Varlet-Marie, Emmanuelle; Martin, Laurent; Martin, Jean-Antoine; Bonnaire, Yves; Audran, Michel; de Ceaurriz, Jacques

    2005-01-01

    A direct detection method for anti-doping control of recombinant human erythropoietin (rHuEPO) abuse in racehorses is proposed. This method involves screening of plasma (or serum) by an enzyme-linked immunosorbent assay specific for human EPO and confirmation in urine samples by characterization of the urinary EPO isoelectric profile. This method was tested on horses that were administered epoetin alpha (rHuEPO) and the hyper-glycosylated form of this drug (darbepoetin alpha).

  9. ALFA: Automated Line Fitting Algorithm

    NASA Astrophysics Data System (ADS)

    Wesson, R.

    2015-12-01

    ALFA fits emission line spectra of arbitrary wavelength coverage and resolution, fully automatically. It uses a catalog of lines which may be present to construct synthetic spectra, the parameters of which are then optimized by means of a genetic algorithm. Uncertainties are estimated using the noise structure of the residuals. An emission line spectrum containing several hundred lines can be fitted in a few seconds using a single processor of a typical contemporary desktop or laptop PC. Data cubes in FITS format can be analysed using multiple processors, and an analysis of tens of thousands of deep spectra obtained with instruments such as MUSE will take a few hours.

  10. Asfotase Alfa Treatment Improves Survival for Perinatal and Infantile Hypophosphatasia

    PubMed Central

    Rockman-Greenberg, Cheryl; Ozono, Keiichi; Riese, Richard; Moseley, Scott; Melian, Agustin; Thompson, David D.; Bishop, Nicholas; Hofmann, Christine

    2016-01-01

    Context: Hypophosphatasia (HPP) is an inborn error of metabolism that, in its most severe perinatal and infantile forms, results in 50–100% mortality, typically from respiratory complications. Objectives: Our objective was to better understand the effect of treatment with asfotase alfa, a first-in-class enzyme replacement therapy, on mortality in neonates and infants with severe HPP. Design/Setting: Data from patients with the perinatal and infantile forms of HPP in two ongoing, multicenter, multinational, open-label, phase 2 interventional studies of asfotase alfa treatment were compared with data from similar patients from a retrospective natural history study. Patients: Thirty-seven treated patients (median treatment duration, 2.7 years) and 48 historical controls of similar chronological age and HPP characteristics. Interventions: Treated patients received asfotase alfa as sc injections either 1 mg/kg six times per week or 2 mg/kg thrice weekly. Main Outcome Measures: Survival, skeletal health quantified radiographically on treatment, and ventilatory status were the main outcome measures for this study. Results: Asfotase alfa was associated with improved survival in treated patients vs historical controls: 95% vs 42% at age 1 year and 84% vs 27% at age 5 years, respectively (P < .0001, Kaplan-Meier log-rank test). Whereas 5% (1/20) of the historical controls who required ventilatory assistance survived, 76% (16/21) of the ventilated and treated patients survived, among whom 75% (12/16) were weaned from ventilatory support. This better respiratory outcome accompanied radiographic improvements in skeletal mineralization and health. Conclusions: Asfotase alfa mineralizes the HPP skeleton, including the ribs, and improves respiratory function and survival in life-threatening perinatal and infantile HPP. PMID:26529632

  11. Evaluating the transport layer of the ALFA framework for the Intel® Xeon Phi™ Coprocessor

    NASA Astrophysics Data System (ADS)

    Santogidis, Aram; Hirstius, Andreas; Lalis, Spyros

    2015-12-01

    The ALFA framework supports the software development of major High Energy Physics experiments. As part of our research effort to optimize the transport layer of ALFA, we focus on profiling its data transfer performance for inter-node communication on the Intel Xeon Phi Coprocessor. In this article we present the collected performance measurements with the related analysis of the results. The optimization opportunities that are discovered, help us to formulate the future plans of enabling high performance data transfer for ALFA on the Intel Xeon Phi architecture.

  12. Elosulfase Alfa: a review of its use in patients with mucopolysaccharidosis type IVA (Morquio A syndrome).

    PubMed

    Lyseng-Williamson, Katherine A

    2014-10-01

    Elosulfase alfa (Vimizim(®)) is a recombinant form of the human lysosomal enzyme N-acetylgalactosamine-6-sulfatase (GALNS) that is lacking in patients with mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome). It is the first, and currently only, disease-specific treatment option for this very rare, progressively degenerative, autosomal-recessive lysosomal storage disorder. Enzyme replacement therapy with elosulfase alfa aims to restore GALNS activity, thereby preventing the accumulation of keratan sulfate (KS) and chondroitin-6-sulfate in lysosomal compartments of cells that results in the clinical manifestations of MPS IVA. In clinical trials in children and adults with MPS IVA, intravenous elosulfase alfa 2 mg/kg/week provided significant and sustained improvements in urinary levels of KS (a pharmacodynamic biomarker for the disease). In the key placebo-controlled, 24-week, phase 3 trial in patients with MPS IVA aged ≥5 years, elosulfase alfa 2 mg/kg/week significantly improved endurance [least squares mean placebo-adjusted change from baseline in 6-min walk test distance 22.5 m (95 % CI 4.0-40.9)]. Infusion-associated reactions, the primary tolerability issue associated with elosulfase alfa, are generally mild to moderate in severity, self-limiting, and manageable. In the absence of a cure, GALNS enzyme replacement therapy with elosulfase alfa is an important achievement in the treatment of MPS IVA.

  13. Agalsidase alfa: a review of its use in the management of Fabry disease.

    PubMed

    Keating, Gillian M

    2012-10-01

    The enzyme replacement therapy agalsidase alfa (Replagal®) has an amino acid sequence identical to that of native α-galactosidase A; intravenous agalsidase alfa 0.2 mg/kg every other week is indicated for the long-term treatment of patients with confirmed Fabry disease. This article reviews the efficacy and tolerability of agalsidase alfa in patients with Fabry disease, as well as summarizing its pharmacologic properties. Agalsidase alfa had beneficial effects in adult men with Fabry disease, according to the results of two randomized, double-blind, placebo-controlled, 6-month trials (n = 15 and 26). For example, left ventricular mass index was reduced to a significantly greater extent with agalsidase alfa than with placebo. Although the change in myocardial globotriaosylceramide content (primary endpoint in one study) did not significantly differ between agalsidase alfa and placebo recipients, the change in the Brief Pain Inventory (BPI) 'pain at its worst' score (reflecting neuropathic pain while without pain medications; primary endpoint in the second study) was improved to a significantly greater extent with agalsidase alfa than with placebo. In addition, the change in creatinine clearance, but not inulin clearance, significantly favored agalsidase alfa versus placebo recipients. Abnormalities in functional cerebral blood flow and cerebrovascular responses were also reversed with agalsidase alfa therapy. In extensions of these placebo-controlled trials, the reduction in left ventricular mass and improvements in BPI pain scores were maintained after longer-term agalsidase alfa therapy. The significant decline in estimated glomerular filtration rate (eGFR) seen after 48 months' agalsidase alfa treatment was mainly driven by a marked decline in eGFR seen in four patients with stage 3 chronic kidney disease at baseline (although the progression of decline appeared slower than that seen in historic controls); renal function appeared stable in patients with

  14. Taliglucerase alfa: an enzyme replacement therapy using plant cell expression technology.

    PubMed

    Grabowski, Gregory A; Golembo, Myriam; Shaaltiel, Yoseph

    2014-05-01

    Gaucher disease (GD) is a rare, genetic lysosomal storage disorder caused by functional defects of acid β-glucosidase that results in multiple organ dysfunction. Glycosylation of recombinant acid human β-glucosidase and exposure of terminal mannose residues are critical to the success of enzyme replacement therapy (ERT) for the treatment of visceral and hematologic manifestations in GD. Three commercially available ERT products for treatment of GD type 1 (GD1) include imiglucerase, velaglucerase alfa, and taliglucerase alfa. Imiglucerase and velaglucerase alfa are produced in different mammalian cell systems and require production glycosylation modifications to expose terminal α-mannose residues, which are needed for mannose receptor-mediated uptake by target macrophages. Such modifications add to production costs. Taliglucerase alfa is a plant cell-expressed acid β-glucosidase approved in the United States and other countries for ERT in adults with GD1. A plant-based expression system, using carrot root cell cultures, was developed for production of taliglucerase alfa and does not require additional processing for postproduction glycosidic modifications. Clinical trials have demonstrated that taliglucerase alfa is efficacious, with a well-established safety profile in adult, ERT-naïve patients with symptomatic GD1, and for such patients previously treated with imiglucerase. These included significant improvements in organomegaly and hematologic parameters as early as 6months, and maintenance of achieved therapeutic values in previously treated patients. Ongoing clinical trials will further characterize the long-term efficacy and safety of taliglucerase alfa in more diverse patient populations, and may help to guide clinical decisions for achieving optimal outcomes for patients with GD1.

  15. Thermophysical and mechanical characterization of clay bricks reinforced by alfa or straw fibers

    NASA Astrophysics Data System (ADS)

    Elhamdouni, Y.; Khabbazi, A.; Benayad, C.; Mounir, S.; Dadi, A.

    2017-03-01

    This work is part of the valuation of local materials such as clay (earth), alfa fiber and straw fiber. The goal is to use these materials as bricks in rural construction. These materials are abundant, natural, and renewable. The objective of this work is to study the thermal and mechanical behavior of a new material by mixing clay (chosen as the binder) with different mass percentages of alfa fiber (0.5%, 1%, 2%, 3%, 4%), and to compare these results with those of materials often used in the construction of individual houses in rural Morocco (clay + straw). The results obtained prove to us that using straw fibers can reduce the thermal conductivity compared to alfa fiber, which allows to have energy savings of 2% to 7%. By against, alfa fibers can improve the mechanical behavior of clay-based materials when compared to the clay + straw material (an increase of 8% to 17% in the tractive resistance by bending and 6% to 18% for compression resistance). These results also specify the optimal usage conditions of these fibers (alfa and straw) in the clay bricks.

  16. Role of elosulfase alfa in mucopolysaccharidosis IVA.

    PubMed

    Regier, Debra S; Tanpaiboon, Pranoot

    2016-01-01

    Mucopolysaccharidosis type IVA (MPS IVA or Morquio A) is an autosomal recessive lysosomal storage disease which results in a striking skeletal phenotype, but does not negatively impact the intellect of the patient. MPS IVA has a phenotypic continuum that ranges from a severe and rapidly progressing form to a slowly progressive form. The clinical diagnosis is often made in the preschool years based on abnormal bone findings on physical examination and dysplasia on radiographic imaging. Supportive care has been the mainstay in caring for patients. Orthopedic physicians often form the core of the care team due to the early and severe skeletal abnormalities; however, systemic disease is common and requires aggressive monitoring and management. Interdisciplinary care teams often consist of medical geneticists, cardiologists, pulmonary specialists, gastroenterologists, otolaryngologists, audiologists, and ophthalmologists. With the US Food and Drug Administration's approval of elosulfase alfa, patients >5 years of age now have access to this medication from the time of diagnosis. The clinical trial with once weekly intravenous dosing (2.0 mg/kg per week) showed improvement in the 6-minute walk test. The composite end point analysis to evaluate the combining changes from baseline in 6-minute walk test, 3-minute stair climb test, and respiratory function showed that at a dose of 2.0 mg/kg per week, subjects performed better when compared to placebo. This indication was clinically meaningful in the treatment group. The treatment was generally well tolerated, and the uncommon infusion reactions responded well to traditional enzyme replacement therapy infusion reaction management algorithms. Currently, clinical trials are underway to determine the efficacy and safety in MPS IVA patients <5 years of age.

  17. Role of elosulfase alfa in mucopolysaccharidosis IVA

    PubMed Central

    Regier, Debra S; Tanpaiboon, Pranoot

    2016-01-01

    Mucopolysaccharidosis type IVA (MPS IVA or Morquio A) is an autosomal recessive lysosomal storage disease which results in a striking skeletal phenotype, but does not negatively impact the intellect of the patient. MPS IVA has a phenotypic continuum that ranges from a severe and rapidly progressing form to a slowly progressive form. The clinical diagnosis is often made in the preschool years based on abnormal bone findings on physical examination and dysplasia on radiographic imaging. Supportive care has been the mainstay in caring for patients. Orthopedic physicians often form the core of the care team due to the early and severe skeletal abnormalities; however, systemic disease is common and requires aggressive monitoring and management. Interdisciplinary care teams often consist of medical geneticists, cardiologists, pulmonary specialists, gastroenterologists, otolaryngologists, audiologists, and ophthalmologists. With the US Food and Drug Administration’s approval of elosulfase alfa, patients >5 years of age now have access to this medication from the time of diagnosis. The clinical trial with once weekly intravenous dosing (2.0 mg/kg per week) showed improvement in the 6-minute walk test. The composite end point analysis to evaluate the combining changes from baseline in 6-minute walk test, 3-minute stair climb test, and respiratory function showed that at a dose of 2.0 mg/kg per week, subjects performed better when compared to placebo. This indication was clinically meaningful in the treatment group. The treatment was generally well tolerated, and the uncommon infusion reactions responded well to traditional enzyme replacement therapy infusion reaction management algorithms. Currently, clinical trials are underway to determine the efficacy and safety in MPS IVA patients <5 years of age. PMID:27366102

  18. Treatment of basal cell carcinoma of the nasal pyramid with intralesional interferon alfa-2b.

    PubMed

    Fernández-Vozmediano, José Manuel; Armario-Hita, José Carlos

    2010-04-01

    For patients with basal cell carcinoma (BCC) in whom surgical intervention is not optimal, local treatment with interferon alfa-2b is an alternative. In this study, patients with BCC of the nasal pyramid were treated with intralesional interferon alfa-2b (five million international units three times per week) for four to eight weeks. Cutaneous biopsies were performed before and after treatment for histologic examination. Twelve patients, primarily with the infiltrative histologic form (80%), were treated. Complete clinical and histologic regression was confirmed in all cases, and the aesthetic results were excellent. After four years' follow-up, no tumor persistence was observed in any patient. The most frequent adverse events were transient, mild-to-moderate flu-like symptoms in 95% of patients and asymptomatic leukopenia or neutropenia in 25%. These results suggest that intralesional interferon alfa-2b is a safe and effective nonsurgical alternative approach to treat BCC of the nasal pyramid.

  19. Nutritional and inflammatory status influence darbepoetin dose in pre-dialysis elderly patients.

    PubMed

    Neves, P L; Morgado, E; Faísca, M; Carrasqueira, H; Baptista, A; Silva, A P

    2006-01-01

    Anaemia is a common finding in elderly patients particularly in those with chronic kidney disease. Effective correction of anaemia improves survival and quality of life. The association between anaemia and a poor nutritional status as well as the presence of inflammation has already been documented. The aim of our study was to assess the impact of the nutritional and inflammatory status on darbepoetin dose requirements of elderly patients followed in a "Chronic Kidney Disease" outpatient clinic. We included 71 elderly patients (age>or=65 years) in a "Chronic Kidney Disease" outpatient clinic. Creatinine Clearance (CrCl) was estimated according to the Cockroft-Gault equation. Nutritional status was evaluated by biochemical and anthropometric parameters. Tumour Necrosis Factor-alpha (TNF-alpha), Interleukin-6 (IL-6) and high sensitivity C-reactive protein (hs-CRP) were used as biomarkers of inflammation. Our patients (56% males) with a mean age of 76.2+/-6.6 years were followed for 33.1+/-43.6 months. Mean eCrCl was 13.5+/-7.2 ml/mn/1.73 m2. All patients were under supplemental iron therapy and 74.7% needed darbepoietin (0.762+/-0.6 (microg/kg/week) to correct anaemia. Among the several variables regressed on darbepoietin dose, in a multiple regression model, only Hb, IL-6 and TNF-alpha levels and SGA score predicted the need for higher doses of darbepoietin. (r=0.677; r2=0.459). In Conclusion, in our pre-dialysis elderly patients, markers of a poor nutritional status (SGA and albumin) and inflammation (IL-6 and TNF-alpha) independently predicted the use of higher doses of darbepoietin to correct anaemia.

  20. Pathophysiology of hypophosphatasia and the potential role of asfotase alfa

    PubMed Central

    Orimo, Hideo

    2016-01-01

    Hypophosphatasia (HPP) is an inherited systemic bone disease that is characterized by bone hypomineralization. HPP is classified into six forms according to the age of onset and severity as perinatal (lethal), perinatal benign, infantile, childhood, adult, and odontohypophosphatasia. The causative gene of the disease is the ALPL gene that encodes tissue-nonspecific alkaline phosphatase (TNAP). TNAP is expressed ubiquitously, and its physiological role is apparent in bone mineralization. A defect in bone mineralization can manifest in several ways, including rickets or osteomalacia in HPP patients. Patients with severe forms suffer from respiratory failure because of hypoplastic chest, which is the main cause of death. They sometimes present with seizures due to a defect in vitamin B6 metabolism resulting from the lack of alkaline phosphatase activity in neuronal cells, which is also lethal. Patients with a mild form of the disease exhibit rickets or osteomalacia and a functional defect of exercise. Odontohypophosphatasia shows only dental manifestations. To date, 302 mutations in the ALPL gene have been reported, mainly single-nucleotide substitutions, and the relationships between phenotype and genotype have been partially elucidated. An established treatment for HPP was not available until the recent development of enzyme replacement therapy. The first successful enzyme replacement therapy in model mice using a modified human TNAP protein (asfotase alfa) was reported in 2008, and subsequently success in patients with severe form of the disease was reported in 2012. In 2015, asfotase alfa was approved in Japan in July, followed by in the EU and Canada in August, and then by the US Food and Drug Administration in the USA in October. It is expected that therapy with asfotase alfa will drastically change treatments and prognosis of HPP. PMID:27274262

  1. Successful Within-patient Dose Escalation of Olipudase Alfa in Acid Sphingomyelinase Deficiency

    PubMed Central

    Wasserstein, Melissa P.; Jones, Simon A.; Soran, Handrean; Diaz, George A.; Lippa, Natalie; Thurberg, Beth L.; Culm-Merdek, Kerry; Shamiyeh, Elias; Inguilizian, Haig; Cox, Gerald F.; Puga, Ana Cristina

    2015-01-01

    Background Olipudase alfa, a recombinant human acid sphingomyelinase (rhASM), is an investigational enzyme replacement therapy (ERT) for patients with ASM deficiency [ASMD; Niemann-Pick Disease (NPD) A and B]. This open-label phase 1b study assessed the safety and tolerability of olipudase alfa using within-patient dose escalation to gradually debulk accumulated sphingomyelin and mitigate the rapid production of metabolites, which can be toxic. Secondary objectives were pharmacokinetics, pharmacodynamics, and exploratory efficacy. Methods Five adults with nonneuronopathic ASMD (NPD B) received escalating doses (0.1 to 3.0 mg/kg) of olipudase alfa intravenously every 2 weeks for 26 weeks. Results All patients successfully reached 3.0 mg/kg without serious or severe adverse events. One patient repeated a dose (2.0 mg/kg) and another had a temporary dose reduction (1.0 to 0.6 mg/kg). Most adverse events (97%) were mild and all resolved without sequelae. The most common adverse events were headache, arthralgia, nausea and abdominal pain. Two patients experienced single acute phase reactions. No patient developed hypersensitivity or anti-olipudase alfa antibodies. The mean circulating half-life of olipudase alfa ranged from 20.9 to 23.4 hours across doses without accumulation. Ceramide, a sphingomyelin catabolite, rose transiently in plasma after each dose, but decreased over time. Reductions in sphingomyelin storage, spleen and liver volumes, and serum chitotriosidase activity, as well as improvements in infiltrative lung disease, lipid profiles, platelet counts, and quality of life assessments, were observed. Conclusions This study provides proof-of-concept for the safety and efficacy of within-patient dose escalation of olipudase alfa in patients with nonneuronopathic ASMD. PMID:26049896

  2. Interferon Alfa Versus Interferon Alfa Plus Cytarabine Combination Therapy for Chronic Myeloid Leukemia: A Meta-Analysis of Randomized Controlled Trials

    PubMed Central

    Chen, Rui; Ma, Bin; Yang, Kehu; Tian, Jinhui; Liu, Yali; Zhao, Li

    2011-01-01

    Objective This article compares the effect of interferon alfa plus cytarabine (IFN-alfa + Ara-C) versus IFN-alfa alone on the chronic phase of chronic myelogenous leukemia. Methods Electronic searches were performed in the Cochrane Central Register of Controlled Trials, PubMed, EMBASE, Chinese Biomedical Database, China Journal Full-text Database, and Chinese Scientific Journals Database. The languages were limited to Chinese and English. Randomized controlled trials were selected by 2 investigators. Analyses were performed using RevMan 5.0 software. Results A total of 3139 patients in 4 studies met the inclusion criteria. In those patients, complete hematologic response and cytogenetic responses showed significant improvements in favor of IFN-alfa + Ara-C, with complete hematologic response relative risk (RR) of 1.15 (95% CI, 1.09–1.21), complete cytogenetic response RR of 1.87 (95% CI, 1.47–2.38), partial cytogenetic response RR of 1.48 (95% CI, 1.25–1.75), and major cytogenetic response RR of 1.61 (95% CI, 1.42–1.83), respectively. The overall 3-year survival rate in the IFN-alfa + Ara-C group was 86% compared with 79% in the IFN-alfa group (RR = 1.09; 95% CI, 1.03–1.14). In the other 2 studies, 5-year overall survival was 69% compared with 63%, respectively (RR = 1.08; 95% CI, 1.01–1.15). However, IFN-alfa and Ara-C involved higher risk of hematologic toxicity, gastrointestinal adverse events, and severe mucositis compared with IFN-alfa monotherapy (RR = 2.63 [95% CI, 1.94–3.56); RR = 3.38 [95% CI, 2.28–5.00], and RR = 8.84 [95% CI, 3.82–20.46], respectively). Weight loss and skin rash were also observed more frequently in the combination treatment group (RR = 2.00 [95% CI, 1.47–2.73) and RR = 3.75 [95% CI, 2.13–6.59], respectively). Conclusions In patients with chronic myelogenous leukemia in the chronic phase, the combination of IFN-alfa + Ara-C demonstrated improved complete hematologic response, superior cytogenetic responses, and

  3. Epoetin alfa (Eprex) and quality of life.

    PubMed

    Littlewood, Tim

    2005-01-01

    Several recently published clinical trials in anaemic patients with cancer provide convincing evidence that the quality of life of such patients is considerably impaired and that a significant improvement in quality of life can be achieved if their anaemia is corrected by treatment with recombinant erythropoietin (epoetin alfa, Eprex). Findings of some of the major studies are summarised in this issue. These summaries have been prepared to make the findings more accessible to busy clinicians who may not have time to read longer reports in specialist journals but who need to understand the important clinical implications of this research.

  4. A multicenter open-label treatment protocol (HGT-GCB-058) of velaglucerase alfa enzyme replacement therapy in patients with Gaucher disease type 1: safety and tolerability

    PubMed Central

    Pastores, Gregory M.; Rosenbloom, Barry; Weinreb, Neal; Goker-Alpan, Ozlem; Grabowski, Gregory; Cohn, Gabriel M.; Zahrieh, David

    2014-01-01

    Purpose: To evaluate the safety of velaglucerase alfa in patients with type 1 Gaucher disease who received velaglucerase alfa in the US treatment protocol HGT-GCB-058 (ClinicalTrials.gov identifier NCT00954460) during a global supply shortage of imiglucerase. Methods: This multicenter open-label treatment protocol enrolled patients who were either treatment naïve or had been receiving imiglucerase. Patients received intravenous velaglucerase alfa every other week at a dose of 60 U/kg (treatment naïve) or 15–60 U/kg (previously treated). Results: A total of 211 (including six treatment-naïve) patients were enrolled. Among the 205 previously treated patients, 35 (17.1%) experienced an adverse event considered related to study drug. Among the six treatment-naïve patients, one had an adverse event considered related to study drug. Infusion-related adverse events occurred in 28 (13.3%) of the 211 patients and usually occurred during the first three infusions. De novo, nonneutralizing, anti–velaglucerase alfa antibodies developed during treatment in one (<1.0%) previously treated patient and none of the treatment-naïve patients. Conclusion: The currently observed safety profile was consistent with those previously reported for imiglucerase and velaglucerase alfa phase III clinical trials. These results support the safety of initiating treatment with velaglucerase alfa or transitioning patients from imiglucerase therapy to velaglucerase alfa therapy. PMID:24263462

  5. Velaglucerase alfa (VPRIV) enzyme replacement therapy in patients with Gaucher disease: Long-term data from phase III clinical trials.

    PubMed

    Hughes, Derralynn A; Gonzalez, Derlis E; Lukina, Elena A; Mehta, Atul; Kabra, Madhulika; Elstein, Deborah; Kisinovsky, Isaac; Giraldo, Pilar; Bavdekar, Ashish; Hangartner, Thomas N; Wang, Nan; Crombez, Eric; Zimran, Ari

    2015-07-01

    Type 1 Gaucher disease is an inherited lysosomal enzyme deficiency with variable age of symptom onset. Common presenting signs include thrombocytopenia, anemia, hepatosplenomegaly, bone abnormalities, and, additionally in children, growth failure. Fifty-seven patients aged 3-62 years at the baseline of two phase III trials for velaglucerase alfa treatment were enrolled in the single extension study. In the extension, they received every-other-week velaglucerase alfa intravenous infusions for 1.2-4.8 years at 60 U/kg, although 10 patients experienced dose reduction. No patient experienced a drug-related serious adverse event or withdrew due to an adverse event. One patient died following a convulsion that was reported as unrelated to the study drug. Only one patient tested positive for anti-velaglucerase alfa antibodies. Combining the experience of the initial phase III trials and the extension study, significant improvements were observed in the first 24 months from baseline in hematology variables, organ volumes, plasma biomarkers, and, in adults, the lumbar spine bone mineral density Z-score. Improvements were maintained over longer-term treatment. Velaglucerase alfa had a good long-term safety and tolerability profile, and patients continued to respond clinically, which is consistent with the results of the extension study to the phase I/II trial of velaglucerase alfa. EudraCT number 2008-001965-27; www.clinicaltrials.gov identifier NCT00635427.

  6. Velaglucerase alfa (VPRIV) enzyme replacement therapy in patients with Gaucher disease: Long-term data from phase III clinical trials

    PubMed Central

    Hughes, Derralynn A; Gonzalez, Derlis E; Lukina, Elena A; Mehta, Atul; Kabra, Madhulika; Elstein, Deborah; Kisinovsky, Isaac; Giraldo, Pilar; Bavdekar, Ashish; Hangartner, Thomas N; Wang, Nan; Crombez, Eric; Zimran, Ari

    2015-01-01

    Type 1 Gaucher disease is an inherited lysosomal enzyme deficiency with variable age of symptom onset. Common presenting signs include thrombocytopenia, anemia, hepatosplenomegaly, bone abnormalities, and, additionally in children, growth failure. Fifty-seven patients aged 3–62 years at the baseline of two phase III trials for velaglucerase alfa treatment were enrolled in the single extension study. In the extension, they received every-other-week velaglucerase alfa intravenous infusions for 1.2–4.8 years at 60 U/kg, although 10 patients experienced dose reduction. No patient experienced a drug-related serious adverse event or withdrew due to an adverse event. One patient died following a convulsion that was reported as unrelated to the study drug. Only one patient tested positive for anti-velaglucerase alfa antibodies. Combining the experience of the initial phase III trials and the extension study, significant improvements were observed in the first 24 months from baseline in hematology variables, organ volumes, plasma biomarkers, and, in adults, the lumbar spine bone mineral density Z-score. Improvements were maintained over longer-term treatment. Velaglucerase alfa had a good long-term safety and tolerability profile, and patients continued to respond clinically, which is consistent with the results of the extension study to the phase I/II trial of velaglucerase alfa. EudraCT number 2008-001965-27; http://www.clinicaltrials.gov identifier NCT00635427. Am. J. Hematol. 90:584–591, 2015. © 2015 Wiley Periodicals, Inc. PMID:25801797

  7. Taliglucerase alfa in Gaucher disease: Description of a Brazilian experience.

    PubMed

    Cravo, R; Rotman, V; Oliveira, P M N; Defendi, H G T; Conceição, D A; Xavier, J R; Chertkoff, R; Noronha, T G; Maia, M L S

    2017-01-16

    We evaluated retrospectively, efficacy and safety of taliglucerase alfa for Gaucher disease in a Brazilian population. Thirteen patients were included for efficacy analysis only one of them naïve to enzyme replacement therapy. All the parameters evaluated remained stable throughout treatment (mean duration 3,5years). Only three patients (out of 35) had to discontinue treatment due to a serious adverse event. In conclusion, treatment with taliglucerase alfa was found to be safe and efficient.

  8. Cost-effectiveness analysis of treatment with peginterferon-alfa-2a versus peginterferon-alfa-2b for patients with chronic hepatitis C under the public payer perspective in Brazil

    PubMed Central

    2013-01-01

    guidelines for Health Technology Assessment (HTA). Results Analysis showed that peginterferon-alfa-2a is a dominant therapy compared to peginterferon-alfa-2b for genotype 1 ($Brz 4,345 savings and 0.10 LY/0.25 QALY gains) as well for genotype 2/3 ($Brz 8,001 savings and 0.16 LY/0.39 QALY gains). Projections indicated that for each 1000 patients treated with peginterferon-alfa-2a instead of peginterferon-alfa-2b, the amount of resources saved would be of $Brz 4.3 million for genotypes 2/3 and up to $Brz 8 million for genotype 1. Conclusion These findings suggest that treatment with peginterferon-alfa-2a is more effective and less costly when compared to peginterferon-alfa-2b under SUS perspective in Brazil. PMID:24103591

  9. Ovulation induction with minimal dose of follitropin alfa: a case series study

    PubMed Central

    2011-01-01

    Background Gonadotropins are used in ovulation induction (OI) for patients with anovulatory infertility. Pharmacologic OI is associated with risks of ovarian hyperstimulation syndrome and multiple pregnancy. Treatment protocols that minimize these risks by promoting monofollicular development are required. A starting dose of 37.5 IU/day follitropin alfa has been used in OI, particularly among women at high risk of multifollicular development and multiple pregnancy. A retrospective case series study was performed to evaluate rates of monofollicular development and singleton pregnancy following standard treatment with 37.5 IU/day follitropin alfa. Methods Spanish centers that had performed at least five OI cycles during 2008 using 37.5 IU/day follitropin alfa as a starting dose were invited to participate. Data could be provided from any cycle performed in 2008 (up to a maximum of 12 consecutive cycles per site). Case report forms were collected during April-November 2009 and reviewed centrally. Descriptive statistics were obtained from all cases, and follicular development and clinical pregnancy rates assessed. Potential associations of age and body mass index with follicular development and clinical pregnancy were assessed using univariate correlation analyses. Results Thirty centers provided data on 316 cycles of OI using a starting dose of 37.5 IU/day follitropin alfa. Polycystic ovary syndrome was the cause of anovulatory infertility in 217 (68.7%) cases. Follitropin alfa at 37.5 IU/day was sufficient to achieve ovarian stimulation in 230 (72.8%) cycles. A single follicle ≥16 mm in diameter developed in 193 cycles (61.1%; 95% confidence interval [CI] 55.7-66.4%). Seventy-eight women (24.7%; 95% CI 19.9-29.5%) became pregnant: 94.9% singleton and 5.1% twin pregnancies. Fourteen started cycles (4.4%) were cancelled, mainly due to poor response. Univariate correlation analyses detected weak associations. Conclusions Monofollicular growth rate was comparable with

  10. Prospective surveillance study of haemophilia A patients switching from moroctocog alfa or other factor VIII products to moroctocog alfa albumin-free cell culture (AF-CC) in usual care settings.

    PubMed

    Parra Lopez, Rafael; Nemes, Laszlo; Jimenez-Yuste, Victor; Rusen, Luminita; Cid, Ana R; Charnigo, Robert J; Baumann, James A; Smith, Lynne; Korth-Bradley, Joan M; Rendo, Pablo

    2015-10-01

    This prospective, open-label, postauthorisation safety surveillance study assessed clinically significant inhibitor development in patients with severe haemophilia A transitioning from moroctocog alfa or other factor VIII (FVIII) replacement products to reformulated moroctocog alfa (AF-CC). Males aged ≥ 12 years with severe haemophilia A (FVIII:C) < 1 IU/dl), > 150 exposure days (EDs) to recombinant or plasma-derived FVIII products, and no detectable inhibitor at screening were enrolled. Primary end point was the incidence of clinically significant FVIII inhibitor development. Secondary end points included annualised bleeding rate (ABR), less-than-expected therapeutic effect (LETE), and FVIII recovery. Patients were assigned to one of two cohorts based on whether they were transitioning to moroctocog alfa (AF-CC) from moroctocog alfa (cohort 1; n=146) or from another recombinant or plasma-derived FVIII product (cohort 2; n=62). Mean number of EDs on study was 94 (range, 1-139). Six positive FVIII inhibitor results, as determined by local laboratories, were reported in four patients; none were confirmed by a central laboratory, no inhibitor-related clinical manifestations were reported, and all anti-FVIII antibody assays were negative. Median ABRs were 23.4 and 3.4 in patients categorised at baseline as following on-demand and prophylactic regimens, respectively; 86.5% of bleeding episodes resolved after one infusion. LETE incidence was 0.06% and 0.19% in the on-demand and prophylaxis settings, respectively. FVIII recovery remained constant throughout the study. No new safety concerns were identified. This study found no increased risk of clinically significant FVIII inhibitor development in patients transitioning from moroctocog alfa or other FVIII replacement products to moroctocog alfa (AF-CC).

  11. The safety profile of drotrecogin alfa (activated)

    PubMed Central

    Fumagalli, Roberto; Mignini, Mariano A

    2007-01-01

    Continued safety assessment is essential for any newly approved therapy. Drotrecogin alfa (activated; DrotAA), which is approved for use in severe sepsis, has undergone clinical trials with corresponding safety analyses since 1995. However, the only comprehensive review of all trials is that reported in 2003 by Bernard and coworkers. This is an important review that focuses on the safety profile of DrotAA in all published studies (six randomized clinical trials and five national registry studies) and in previously unpublished data. DrotAA treatment is associated with an increased risk for bleeding (which in general is manageable). Nevertheless, the available evidence shows that any adverse effects of DrotAA are outweighed by its benefits in patients with severe sepsis who are at high risk for death. So far, more than 9,000 patients have been enrolled in clinical trials involving DrotAA, providing a valuable safety database. It is of note that although DrotAA does increase the risk of bleeding, this has not been associated with an overall increase in the rate of all severe adverse events. PMID:18269693

  12. Human factors engineering and design validation for the redesigned follitropin alfa pen injection device

    PubMed Central

    Mahony, Mary C; Patterson, Patricia; Hayward, Brooke; North, Robert; Green, Dawne

    2015-01-01

    Objectives: To demonstrate, using human factors engineering (HFE), that a redesigned, pre-filled, ready-to-use, pre-asembled follitropin alfa pen can be used to administer prescribed follitropin alfa doses safely and accurately. Methods: A failure modes and effects analysis identified hazards and harms potentially caused by use errors; risk-control measures were implemented to ensure acceptable device use risk management. Participants were women with infertility, their significant others, and fertility nurse (FN) professionals. Preliminary testing included ‘Instructions for Use’ (IFU) and pre-validation studies. Validation studies used simulated injections in a representative use environment; participants received prior training on pen use. Results: User performance in preliminary testing led to IFU revisions and a change to outer needle cap design to mitigate needle stick potential. In the first validation study (49 users, 343 simulated injections), in the FN group, one observed critical use error resulted in a device design modification and another in an IFU change. A second validation study tested the mitigation strategies; previously reported use errors were not repeated. Conclusions: Through an iterative process involving a series of studies, modifications were made to the pen design and IFU. Simulated-use testing demonstrated that the redesigned pen can be used to administer follitropin alfa effectively and safely. PMID:25895897

  13. XM17 Follitropin Alfa (Ovaleap(®)): A Review in Reproductive Endocrine Disorders.

    PubMed

    Hoy, Sheridan M

    2016-08-01

    The subcutaneous recombinant human follicle-stimulating hormone XM17 follitropin alfa (Ovaleap(®)) is approved in the EU as a biosimilar of follitropin alfa (Gonal-f(®)) for use in all indications for which the reference product is approved, including as a multifollicular stimulant in women undergoing superovulation for assisted reproductive technology (ART) treatment. In a nonblind, phase I study in healthy female volunteers, the pharmacokinetic profile of XM17 follitropin alfa was bioequivalent to that of reference follitropin alfa following single dosing. Moreover, in a multinational, phase III study, the efficacy of XM17 follitropin alfa as a multifollicular stimulant was equivalent to that of reference follitropin alfa in terms of the number of retrieved oocytes (primary endpoint) in women undergoing controlled ovarian stimulation for ART treatment. There were no clinically relevant differences in oocyte quality between XM17 follitropin alfa and reference follitropin alfa, with biochemical, clinical and ongoing pregnancy rates and take-home baby rates not significantly differing between the treatment groups. XM17 follitropin alfa was generally well tolerated in this patient population, with its tolerability profile generally similar to that of reference follitropin alfa and with no new unexpected tolerability concerns identified. Thus, XM17 follitropin alfa is an effective treatment option in patients requiring follitropin alfa therapy for various reproductive endocrine disorders, providing a useful alternative to reference follitropin alfa.

  14. Efficacy of Alfa EEG wave biofeedback in the management of anxiety

    PubMed Central

    Bhat, Pookala

    2010-01-01

    Background: Biofeedback is a technique in which people are trained to improve their health by learning to control certain internal bodily processes that normally occur involuntarily. Various studies in the past have shown usefulness of Alfa electroencephalographic (EEG) biofeedback in the alleviation of anxiety symptoms. Though most of the psychiatric centers in the armed forces have this facility, not much work has been done in our setup to assess its efficacy in the management of anxiety. Hence this study was undertaken. Materials and Methods: This study was carried out in a multispecialty Command Hospital by enrolling 100 patients with psychiatric diagnosis from both inpatient and outpatient services. The anxiety level was assessed clinically and by using Hamilton Anxiety Scale and Taylor's Manifest Anxiety Scale. One group of 50 patients was treated with Alfa EEG biofeedback sessions only, 5 times in a week for 8 weeks, along with specific pharmacotherapy. The other group was treated with appropriate dose of anxiolytics. The anxiety level was reassessed after 4 weeks and 8 weeks. Results: The response was better for mixed anxiety and depressive disorder with pharmacotherapy than with the biofeedback, but female patients showed better response with EEG biofeedback. Conclusion: In the short term, Alfa EEG biofeedback therapy is almost as efficacious as pharmacological intervention in the management of anxiety symptoms, and relatively more useful in females. PMID:22174533

  15. Charging properties of cassiterite (alfa-SnO2) surfaces

    SciTech Connect

    Rosenqvist, Jorgen K; Machesky, Michael L.; Vlcek, L.; Cummings, Peter T; Wesolowski, David J

    2009-01-01

    The acid-base properties of cassiterite (alfa-SnO2) surfaces at 10 50 C were studied using potentiometric titrations of powder suspensions in aqueous NaCl and RbCl media. The proton sorption isotherms exhibited common intersection points in the pH-range 4.0 to 4.5 at all conditions and the magnitude of charging was similar but not identical in NaCl and RbCl. The hydrogen bonding configuration at the oxide-water interface, obtained from classical Molecular Dynamics (MD) simulations, was analyzed in detail and the results were explicitly incorporated in calculations of protonation constants for the reactive surface sites using the revised MUSIC model. The calculations indicated that the terminal SnOH2 group is more acidic than the bridging Sn2OH group, with protonation constants (log KH) of 3.60 and 5.13 at 25 C, respectively. This is contrary to the situation on the isostructural alfa-TiO2 (rutile), apparently due to the difference in electronegativity between Ti and Sn. MD simulations and speciation calculations indicated considerable differences in the speciation of Na+ and Rb+, despite the similarities in overall charging. Adsorbed sodium ions are almost exclusively found in bidentate surface complexes, while adsorbed rubidium ions form comparable amounts of bidentate and tetradentate complexes. Also, the distribution of adsorbed Na+ between the different complexes shows a considerable dependence on surface charge density (pH), while the distribution of adsorbed Rb+ is almost independent of pH. A Surface Complexation Model (SCM) capable of accurately describing both the measured surface charge and the MD predicted speciation of adsorbed Na+/Rb+ was formulated. According to the SCM, the deprotonated terminal group (SnOH-0.40) and the protonated bridging group (Sn2OH+0.36) dominate the surface speciation over the entire pH-range (2.7 10), illustrating the ability of positively and negatively charged surface groups to coexist. Complexation of the medium cations

  16. Final Results of the Sunbelt Melanoma Trial: A Multi-Institutional Prospective Randomized Phase III Study Evaluating the Role of Adjuvant High-Dose Interferon Alfa-2b and Completion Lymph Node Dissection for Patients Staged by Sentinel Lymph Node Biopsy

    PubMed Central

    Egger, Michael E.; Edwards, Michael J.; Ross, Merrick I.; Reintgen, Douglas S.; Noyes, R. Dirk; Martin, Robert C.G.; Goydos, James S.; Beitsch, Peter D.; Urist, Marshall M.; Ariyan, Stephan; Sussman, Jeffrey J.; Davidson, B. Scott; Gershenwald, Jeffrey E.; Hagendoorn, Lee J.; Stromberg, Arnold J.; Scoggins, Charles R.

    2016-01-01

    Purpose The Sunbelt Melanoma Trial is a prospective randomized trial evaluating the role of high-dose interferon alfa-2b therapy (HDI) or completion lymph node dissection (CLND) for patients with melanoma staged by sentinel lymph node (SLN) biopsy. Patients and Methods Patients were eligible if they were age 18 to 70 years with primary cutaneous melanoma ≥ 1.0 mm Breslow thickness and underwent SLN biopsy. In Protocol A, patients with a single tumor-positive lymph node after SLN biopsy underwent CLND and were randomly assigned to observation versus HDI. In Protocol B, patients with tumor-negative SLN by standard histopathology and immunohistochemistry underwent molecular staging by reverse transcriptase polymerase chain reaction (RT-PCR). Patients positive by RT-PCR were randomly assigned to observation versus CLND versus CLND+HDI. Primary end points were disease-free survival (DFS) and overall survival (OS). Results In the Protocol A intention-to-treat analysis, there were no significant differences in DFS (hazard ratio, 0.82; P = .45) or OS (hazard ratio, 1.10; P = .68) for patients randomly assigned to HDI versus observation. In the Protocol B intention-to-treat analysis, there were no significant differences in overall DFS (P = .069) or OS (P = .77) across the three randomized treatment arms. Similarly, efficacy analysis (excluding patients who did not receive the assigned treatment) did not demonstrate significant differences in DFS or OS in Protocol A or Protocol B. Median follow-up time was 71 months. Conclusion No survival benefit for adjuvant HDI in patients with a single positive SLN was found. Among patients with tumor-negative SLN by conventional pathology but with melanoma detected in the SLN by RT-PCR, there was no OS benefit for CLND or CLND+HDI. PMID:26858331

  17. Accurate Learning with Few Atlases (ALFA): an algorithm for MRI neonatal brain extraction and comparison with 11 publicly available methods

    NASA Astrophysics Data System (ADS)

    Serag, Ahmed; Blesa, Manuel; Moore, Emma J.; Pataky, Rozalia; Sparrow, Sarah A.; Wilkinson, A. G.; MacNaught, Gillian; Semple, Scott I.; Boardman, James P.

    2016-03-01

    Accurate whole-brain segmentation, or brain extraction, of magnetic resonance imaging (MRI) is a critical first step in most neuroimage analysis pipelines. The majority of brain extraction algorithms have been developed and evaluated for adult data and their validity for neonatal brain extraction, which presents age-specific challenges for this task, has not been established. We developed a novel method for brain extraction of multi-modal neonatal brain MR images, named ALFA (Accurate Learning with Few Atlases). The method uses a new sparsity-based atlas selection strategy that requires a very limited number of atlases ‘uniformly’ distributed in the low-dimensional data space, combined with a machine learning based label fusion technique. The performance of the method for brain extraction from multi-modal data of 50 newborns is evaluated and compared with results obtained using eleven publicly available brain extraction methods. ALFA outperformed the eleven compared methods providing robust and accurate brain extraction results across different modalities. As ALFA can learn from partially labelled datasets, it can be used to segment large-scale datasets efficiently. ALFA could also be applied to other imaging modalities and other stages across the life course.

  18. Accurate Learning with Few Atlases (ALFA): an algorithm for MRI neonatal brain extraction and comparison with 11 publicly available methods.

    PubMed

    Serag, Ahmed; Blesa, Manuel; Moore, Emma J; Pataky, Rozalia; Sparrow, Sarah A; Wilkinson, A G; Macnaught, Gillian; Semple, Scott I; Boardman, James P

    2016-03-24

    Accurate whole-brain segmentation, or brain extraction, of magnetic resonance imaging (MRI) is a critical first step in most neuroimage analysis pipelines. The majority of brain extraction algorithms have been developed and evaluated for adult data and their validity for neonatal brain extraction, which presents age-specific challenges for this task, has not been established. We developed a novel method for brain extraction of multi-modal neonatal brain MR images, named ALFA (Accurate Learning with Few Atlases). The method uses a new sparsity-based atlas selection strategy that requires a very limited number of atlases 'uniformly' distributed in the low-dimensional data space, combined with a machine learning based label fusion technique. The performance of the method for brain extraction from multi-modal data of 50 newborns is evaluated and compared with results obtained using eleven publicly available brain extraction methods. ALFA outperformed the eleven compared methods providing robust and accurate brain extraction results across different modalities. As ALFA can learn from partially labelled datasets, it can be used to segment large-scale datasets efficiently. ALFA could also be applied to other imaging modalities and other stages across the life course.

  19. Nitric oxide synthase mediates the ability of darbepoetin alpha to improve the cognitive performance of STOP null mice.

    PubMed

    Kajitani, Kosuke; Thorne, Michael; Samson, Michel; Robertson, George S

    2010-07-01

    STOP (stable tubule only polypeptide) null mice display neurochemical and behavioral abnormalities that resemble several well-recognized features of schizophrenia. Recent evidence suggests that the hematopoietic growth factor erythropoietin improves the cognitive performance of schizophrenics. The mechanism, however, by which erythropoietin is able to improve the cognition of schizophrenics is unclear. To address this question, we first determined whether acute administration of the erythropoietin analog known as darbepoetin alpha (D. alpha) improved performance deficits of STOP null mice in the novel objective recognition task (NORT). NORT performance of STOP null mice, but not wild-type littermates, was enhanced 3 h after a single injection of D. alpha (25 microg/kg, i.p.). Improved NORT performance was accompanied by elevated NADPH diaphorase staining in the ventral hippocampus as well as medial and cortical aspects of the amygdala, indicative of increased nitric oxide synthase (NOS) activity in these structures. NOS generates the intracellular messenger nitric oxide (NO) implicated in learning and memory. In keeping with this hypothesis, D. alpha significantly increased NO metabolite levels (nitrate and nitrite, NOx) in the hippocampus of both wild-type and STOP null mice. The NOS inhibitor, N (G)-nitro-L- arginine methyl ester (L-NAME; 25 mg/kg, i.p.), completely reversed the increase in hippocampal NOx levels produced by D. alpha. Moreover, L-NAME also inhibited the ability of D. alpha to improve the NORT performance of STOP null mice. Taken together, these observations suggest D. alpha enhances the NORT performance of STOP null mice by increasing production of NO.

  20. A novel approach using a minimal number of injections during the IVF/ICSI cycle: Luteal half-dose depot GnRH agonist following corifollitropin alfa versus the corifollitropin alfa with a GnRH-antagonist cycle

    PubMed Central

    Haydardedeoğlu, Bülent; Kılıçdağ, Esra Bulgan

    2016-01-01

    Objective Corifollitropin alfa is a good choice for assisted reproductive technology (ART) cycles because fewer injections are needed than with other agents. In this retrospective cohort, we analyzed luteal injected half-dose depot gonadotropin hormone-releasing hormone (GnRH) agonist cycles in women who received corifollitropin alfa and those who underwent a conventional corifollitropin alfa cycle with a GnRH antagonist. Material and Methods In this retrospective cohort, we analyzed luteal injected half-dose depot GnRH agonist cycles in women who received corifollitropin alfa and those who underwent a conventional corifollitropin alfa cycle with a GnRH antagonist at the Division of Reproductive Endocrinology and IVF Unit, Obstetrics and Gynecology Department, Başkent University School of Medicine, Adana, Turkey, from March 2014 to August 2015. The patient’s baseline characteristics were similar between the two groups. Forty-five patients underwent the long protocol, in which a half-dose of depot GnRH agonist was administered on day 21 of the preceding cycle. Forty-nine patients underwent the GnRH-antagonist protocol. Corifollitropin alfa was administered on the menstrual cycle day 3. Results The mean ages of the two groups were similar (32.77±5.55 vs. 34.2±4.51 years [“for the long- and antagonist-protocol groups, respectively”]). The total number of retrieved oocytes, the fertilization rate, and the number of transferred embryos were similar between the two groups. The only significant difference between the two protocols was the number of injections during the controlled ovarian stimulation (COH) cycle, which included the depot-agonist injection in the long-protocol group (4.46±1.64 vs. 5.71±2.51, p=0.006). The clinical pregnancy and implantation rates were similar in the two protocols (16/45 [35.6%] vs. 16/49 [32.7%] for the intention to treat and 32.5±6.82% vs. 36.25±8.58%, respectively). Conclusion Our results show that ART cycles could be

  1. Characterization of IXINITY® (Trenonacog Alfa), a Recombinant Factor IX with Primary Sequence Corresponding to the Threonine-148 Polymorph

    PubMed Central

    Monroe, Dougald M.; Jenny, Richard J.; Van Cott, Kevin E.; Saward, Laura L.

    2016-01-01

    The goal of these studies was to extensively characterize the first recombinant FIX therapeutic corresponding to the threonine-148 (Thr-148) polymorph, IXINITY (trenonacog alfa [coagulation factor IX (recombinant)]). Gel electrophoresis, circular dichroism, and gel filtration were used to determine purity and confirm structure. Chromatographic and mass spectrometry techniques were used to identify and quantify posttranslational modifications. Activity was assessed as the ability to activate factor X (FX) both with and without factor VIIIa (FVIIIa) and in a standard clotting assay. All results were consistent across multiple lots. Trenonacog alfa migrated as a single band on Coomassie-stained gels; activity assays were normal and showed <0.002 IU of activated factor IX (FIXa) per IU of FIX. The molecule has >97%  γ-carboxylation and underwent the appropriate structural change upon binding calcium ions. Trenonacog alfa was activated normally with factor XIa (FXIa); once activated it bound to FVIIIa and FXa. When activated to FIXa, it was inhibited efficiently by antithrombin. Glycosylation patterns were similar to plasma-derived FIX with sialic acid content consistent with the literature reports of good pharmacokinetic performance. These studies have shown that trenonacog alfa is a highly pure product with a primary sequence and posttranslational modifications consistent with the common Thr-148 polymorphism of plasma-derived FIX. PMID:26997955

  2. ALFA: The new ALICE-FAIR software framework

    NASA Astrophysics Data System (ADS)

    Al-Turany, M.; Buncic, P.; Hristov, P.; Kollegger, T.; Kouzinopoulos, C.; Lebedev, A.; Lindenstruth, V.; Manafov, A.; Richter, M.; Rybalchenko, A.; Vande Vyvre, P.; Winckler, N.

    2015-12-01

    The commonalities between the ALICE and FAIR experiments and their computing requirements led to the development of large parts of a common software framework in an experiment independent way. The FairRoot project has already shown the feasibility of such an approach for the FAIR experiments and extending it beyond FAIR to experiments at other facilities[1, 2]. The ALFA framework is a joint development between ALICE Online- Offline (O2) and FairRoot teams. ALFA is designed as a flexible, elastic system, which balances reliability and ease of development with performance using multi-processing and multithreading. A message- based approach has been adopted; such an approach will support the use of the software on different hardware platforms, including heterogeneous systems. Each process in ALFA assumes limited communication and reliance on other processes. Such a design will add horizontal scaling (multiple processes) to vertical scaling provided by multiple threads to meet computing and throughput demands. ALFA does not dictate any application protocols. Potentially, any content-based processor or any source can change the application protocol. The framework supports different serialization standards for data exchange between different hardware and software languages.

  3. Agalsidase alfa and kidney dysfunction in Fabry disease.

    PubMed

    West, Michael; Nicholls, Kathy; Mehta, Atul; Clarke, Joe T R; Steiner, Robert; Beck, Michael; Barshop, Bruce A; Rhead, William; Mensah, Robert; Ries, Markus; Schiffmann, Raphael

    2009-05-01

    In male patients with Fabry disease, an X-linked disorder of glycosphingolipid metabolism caused by deficient activity of the lysosomal enzyme alpha-galactosidase A, kidney dysfunction becomes apparent by the third decade of life and invariably progresses to ESRD without treatment. Here, we summarize the effects of agalsidase alfa on kidney function from three prospective, randomized, placebo-controlled trials and their open-label extension studies involving 108 adult male patients. The mean baseline GFR among 54 nonhyperfiltrating patients (measured GFR <135 ml/min per 1.73 m(2)) treated with placebo was 85.4 +/- 29.6 ml/min per 1.73 m(2); during 6 mo of placebo, the mean annualized rate of change in GFR was -7.0 +/- 32.9 ml/min per 1.73 m(2). Among 85 nonhyperfiltrating patients treated with agalsidase alfa, the annualized rate of change was -2.9 +/- 8.7 ml/min per 1.73 m(2). Treatment with agalsidase alfa did not affect proteinuria. Multivariate analysis revealed that GFR and proteinuria category (< 1 or > or = 1 g/d) at baseline significantly predicted the rate of decline of GFR during treatment. This summary represents the largest group of male patients who had Fabry disease and for whom the effects of enzyme replacement therapy on kidney function have been studied. These data suggest that agalsidase alfa may stabilize kidney function in these patients.

  4. Astronaut Scott Carpenter practices in the ALFA trainer at Langley

    NASA Technical Reports Server (NTRS)

    1962-01-01

    Project Mercury Astronaut M. Scott Carpenter practices in the Air Lubricated Free Attitude (ALFA) trainer located at NASA's Manned Spacecraft Center at Langley AFB, Virginia. This trainer allows the astronaut to see the image of the earth's surface at his feet while manually controlling the spacecraft.

  5. Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial

    PubMed Central

    Bielack, Stefan S.; Smeland, Sigbjørn; Whelan, Jeremy S.; Marina, Neyssa; Jovic, Gordana; Hook, Jane M.; Krailo, Mark D.; Gebhardt, Mark; Pápai, Zsuzsanna; Meyer, James; Nadel, Helen; Randall, R. Lor; Deffenbaugh, Claudia; Nagarajan, Rajaram; Brennan, Bernadette; Letson, G. Douglas; Teot, Lisa A.; Goorin, Allen; Baumhoer, Daniel; Kager, Leo; Werner, Mathias; Lau, Ching C.; Sundby Hall, Kirsten; Gelderblom, Hans; Meyers, Paul; Gorlick, Richard; Windhager, Reinhard; Helmke, Knut; Eriksson, Mikael; Hoogerbrugge, Peter M.; Schomberg, Paula; Tunn, Per-Ulf; Kühne, Thomas; Jürgens, Heribert; van den Berg, Henk; Böhling, Tom; Picton, Susan; Renard, Marleen; Reichardt, Peter; Gerss, Joachim; Butterfass-Bahloul, Trude; Morris, Carol; Hogendoorn, Pancras C.W.; Seddon, Beatrice; Calaminus, Gabriele; Michelagnoli, Maria; Dhooge, Catharina; Sydes, Matthew R.; Bernstein, Mark

    2015-01-01

    Purpose EURAMOS-1, an international randomized controlled trial, investigated maintenance therapy with pegylated interferon alfa-2b (IFN-α-2b) in patients whose osteosarcoma showed good histologic response (good response) to induction chemotherapy. Patients and Methods At diagnosis, patients age ≤ 40 years with resectable high-grade osteosarcoma were registered. Eligibility after surgery for good response random assignment included ≥ two cycles of preoperative MAP (methotrexate, doxorubicin, and cisplatin), macroscopically complete surgery of primary tumor, < 10% viable tumor, and no disease progression. These patients were randomly assigned to four additional cycles MAP with or without IFN-α-2b (0.5 to 1.0 μg/kg per week subcutaneously, after chemotherapy until 2 years postregistration). Outcome measures were event-free survival (EFS; primary) and overall survival and toxicity (secondary). Results Good response was reported in 1,041 of 2,260 registered patients; 716 consented to random assignment (MAP, n = 359; MAP plus IFN-α-2b, n = 357), with baseline characteristics balanced by arm. A total of 271 of 357 started IFN-α-2b; 105 stopped early, and 38 continued to receive treatment at data freeze. Refusal and toxicity were the main reasons for never starting IFN-α-2b and for stopping prematurely, respectively. Median IFN-α-2b duration, if started, was 67 weeks. A total of 133 of 268 patients who started IFN-α-2b and provided toxicity information reported grade ≥ 3 toxicity during IFN-α-2b treatment. With median follow-up of 44 months, 3-year EFS for all 716 randomly assigned patients was 76% (95% CI, 72% to 79%); 174 EFS events were reported (MAP, n = 93; MAP plus IFN-α-2b, n = 81). Hazard ratio was 0.83 (95% CI, 0.61 to 1.12; P = .214) from an adjusted Cox model. Conclusion At the preplanned analysis time, MAP plus IFN-α-2b was not statistically different from MAP alone. A considerable proportion of patients never started IFN-α-2b or stopped

  6. Taliglucerase alfa leads to favorable bone marrow responses in patients with type I Gaucher disease.

    PubMed

    van Dussen, L; Zimran, A; Akkerman, E M; Aerts, J M F G; Petakov, M; Elstein, D; Rosenbaum, H; Aviezer, D; Brill-Almon, E; Chertkoff, R; Maas, M; Hollak, C E M

    2013-03-01

    Taliglucerase alfa (Protalix Biotherapeutics, Israel) is a carrot-cell-expressed recombinant human beta-glucocerebrosidase recently approved in the United States for the treatment of type 1 Gaucher disease (GD). As bone disease is one of the most debilitating features of GD, quantification of bone marrow involvement is important for monitoring the response to treatment. Therefore, bone marrow fat fraction (Ff) measured by quantitative chemical shift imaging (QCSI) was included as exploratory parameter to evaluate bone marrow response in treatment naïve GD patients participating in a double-blind, randomized phase III study. Eight GD patients with intact spleens were treated with 30 or 60U/kg biweekly. Ff results were compared to outcomes in 15 untreated Dutch GD patients with a follow-up interval of 1year. Five taliglucerase alfa treated patients had a Ff below the threshold that relates to complication risk (<0.23) at baseline (median (n=8) 0.19, range 0.11-0.35). Ff significantly increased compared to baseline (p=0.012) and compared to untreated patients (p=0.005), already after 1year of follow-up with further improvement up to 36months. In four patients with the lowest Ff, the higher dose resulted in increases above 0.23 within 1year. All patients had sustained improvements in all other parameters. There was no influence of antibodies on response parameters. Treatment with taliglucerase alfa results in significant increases in lumbar spine fat fractions, which indicates clearance of Gaucher cells from the bone marrow.

  7. Effectiveness of corifollitropin alfa used for ovarian stimulation of poor responder patients

    PubMed Central

    Selman, Helmy; Rinaldi, Leonardo

    2016-01-01

    Purpose To evaluate the efficiency and efficacy of corifollitropin alfa (follicle-stimulating hormone–carboxy terminal peptide) in the treatment of poor responder patients. Methods A total of 85 poor responder patients with a mean age 40.2±3.9 years entered our assisted fertilization program. The patients were prospectively randomized into two groups based on the ovarian stimulation regimen used: group A (study group) (n=42) received clomiphene citrate and corifollitropin alfa for the first 7 days of stimulation followed by recombinant follicle stimulating hormone (rFSH) in a gonadotropin-releasing hormone antagonist protocol, and group B (control group) (n=43) received clomiphene citrate and a daily injection of rFSH in a gonadotropin-releasing hormone antagonist protocol. We analyzed the stimulation outcome, the number of retrieved oocytes, cleaving embryos, and pregnancy and implantation rates as well. Results Comparable results were observed between the two groups in terms of demographic data, stimulation outcome, and the number of canceled cycles. There were no differences evident between groups A and B with respect to the number of retrieved oocytes (3.0±0.8 and 2.7±0.7, respectively) and the number of cleaving embryos (1.8±0.6 and 1.7±0.7, respectively). Higher, though not statistically significant, differences were observed in favor of group A compared to group B in terms of pregnancy rate per cycle (19% and 16.3%, respectively), pregnancy rate per transfer (21.6% and 17.9%, respectively), and implantation rate (14.7% and 13.4%, respectively). Also, miscarriage rate was similar between patients treated with corifollitropin alfa and those treated with daily rFSH injection (12.5% and 14.2%, respectively). Conclusion The results show that ovarian stimulation with corifollitropin alfa appears to be as efficacious and efficient as daily injection rFSH regimen to treat patients with poor ovarian response. PMID:27799826

  8. Environmental Variability at Site Alfa during the Broadband-87 Exercise

    DTIC Science & Technology

    1989-08-01

    temporally sampled XBT data set was taken aboard Lynch during tlie exercise for the purpose of assessing the effects of internal wave activity and...Variability at Site Alfa during tine Broadband-87 Exercise 6. Author(s). Paul J. Bucca and Roger W. Meredith 5. Funding Numbers. Program Element No...Directorate IMaval Ocean Research and Development Activity Stennis Space Center, Mississippi 39529-5004 8. Performing Organization Report Number

  9. Physico-chemical properties and thermal stability of microcrystalline cellulose isolated from Alfa fibres.

    PubMed

    Trache, Djalal; Donnot, André; Khimeche, Kamel; Benelmir, Riad; Brosse, Nicolas

    2014-04-15

    In this study, microcrystalline cellulose (Alfa-MCC) was extracted from Alfa fibres using acid hydrolysis method. The molecular weight of the cellulose samples was determined by gel permeation chromatography. The crystallinities were studied by means of X-ray diffraction and solid state cross polarization magic angle spinning (13)C nuclear magnetic resonance spectroscopy, revealing that Alfa-MCC was more crystalline than the native cellulose isolated from Alfa fibres. The morphology of the celluloses was investigated using scanning electron microscopy, showing a compact structure and a rough surface. Furthermore, a good thermal stability was shown for Alfa-MCC. Based on these analyses, Alfa-MCC showed tremendous potential use as composites reinforcing agent, foods stabilizer and pharmaceutical additive.

  10. C.E.R.A. once every 4 weeks corrects anaemia and maintains haemoglobin in patients with chronic kidney disease not on dialysis

    PubMed Central

    Locatelli, Francesco; Woitas, Rainer P.; Laville, Maurice; Tobe, Sheldon W.; Provenzano, Robert; Golper, Thomas A.; Ruangkanchanasetr, Prajej; Lee, Ho Yung; Wu, Kwan-Dun; Nowicki, Michal; Ladanyi, Agnes; Martínez-Castelao, Alberto; Beyer, Ulrich; Dougherty, Frank C.

    2011-01-01

    Background. No previous randomized controlled studies have been reported examining de novo, once every 4 weeks (Q4W) administration of erythropoiesis-stimulating agents in chronic kidney disease (CKD) patients. We report results from a randomized multinational study that compared continuous erythropoietin receptor activator (C.E.R.A.) Q4W with darbepoetin alfa once weekly (QW) or every 2 weeks (Q2W) for the correction of anaemia in non-dialysis CKD patients. Methods. Patients were randomized (1:1) to receive either 1.2 μg/kg C.E.R.A. Q4W or darbepoetin alfa QW/Q2W during a 20-week correction period and an 8-week evaluation period. Two primary end points were assessed: the haemoglobin (Hb) response rate and the change in average Hb concentration between baseline and evaluation. Results. The Hb response rate for C.E.R.A. was 94.1%, significantly higher than the protocol-specified 60% response rate [95% confidence interval (CI): 89.1, 97.3; P < 0.0001] and comparable with darbepoetin alfa (93.5%; 95% CI: 88.4, 96.8; P < 0.0001). C.E.R.A. Q4W was non-inferior to darbepoetin alfa QW/Q2W, with similar mean Hb changes from baseline of 1.62 g/dL and 1.66 g/dL, respectively. Patients receiving C.E.R.A. showed a steady rise in Hb, with fewer patients above the target range during the first 8 weeks compared with darbepoetin alfa [39 patients (25.8%) versus 72 patients (47.7%); P < 0.0001]. Adverse event rates were comparable between the treatment groups. Conclusion. C.E.R.A. Q4W successfully corrects anaemia and maintains stable Hb levels within the recommended target range in non-dialysis CKD patients. PMID:21505096

  11. ARECIBO PULSAR SURVEY USING ALFA: PROBING RADIO PULSAR INTERMITTENCY AND TRANSIENTS

    SciTech Connect

    Deneva, J. S.; Cordes, J. M.; McLaughlin, M. A.; Lorimer, D. R.; Edel, S.; Kondratiev, V. I.; Nice, D. J.; Crawford, F.; Bhat, N. D. R.; Camilo, F.; Champion, D. J.; Freire, P. C. C.; Hessels, J. W. T.; Jenet, F. A.; Kasian, L.; Kaspi, V. M.; Lazarus, P.; Stairs, I. H.; Kramer, M.; Ransom, S. M.

    2009-10-01

    We present radio transient search algorithms, results, and statistics from the ongoing Arecibo Pulsar ALFA (PALFA) survey of the Galactic plane. We have discovered seven objects through a search for isolated dispersed pulses. All of these objects are Galactic and have measured periods between 0.4 and 4.7 s. One of the new discoveries has a duty cycle of 0.01%, smaller than that of any other radio pulsar. We discuss the impact of selection effects on the detectability and classification of intermittent sources, and compare the efficiencies of periodicity and single-pulse (SP) searches for various pulsar classes. For some cases we find that the apparent intermittency is likely to be caused by off-axis detection or a short time window that selects only a few bright pulses and favors detection with our SP algorithm. In other cases, the intermittency appears to be intrinsic to the source. No transients were found with DMs large enough to require that they originate from sources outside our Galaxy. Accounting for the on-axis gain of the ALFA system, as well as the low gain but large solid-angle coverage of far-out sidelobes, we use the results of the survey so far to place limits on the amplitudes and event rates of transients of arbitrary origin.

  12. Macroscale production of crystalline interferon alfa-2b in microgravity on STS-52

    NASA Astrophysics Data System (ADS)

    Nagabhushan, Tattanahalli L.; Reichert, Paul; Long, Marianna M.; DeLucas, Lawrence J.; Bugg, Charles E.

    1995-01-01

    Macroscale crystallization of zinc interferon alfa-2b was achieved on STS-52 in October 1992 in the Protein Crystallization Facility. Conditions for crystallization were established by adapting a microscale vapor diffusion method to a macroscale temperature induction method. A series of earth based pilot experiments established conditions to reproducibly crystallize zinc interferon alfa-2b in high yield and under cleanroom conditions. As a control for the STS-52 mission, a ground experiment was run simultaneously and in the same configuration as the flight experiment. Greater than 95% of the available protein crystallized in both the ground and flight experiments. Using a battery of physical, biochemical and biological characterization assays, demonstrated that sample processing, polysulfone bottle confinement and the conditions used for crystallization did not have a negative effect on protein integrity. Redissolved crystals from the flight and ground experiments showed full biological activity in a cytopathic effect inhibition assay as compared to an interferon control standard. Morphometric analysis comparing the overall length and width of the derived crystals showed a 2.4 fold increase in the length and width of the space grown crystals as compared to earth grown crystals. Space grown crystals have remained a stable free flowing suspension for over 2 years. Based on these results, further experiments are envisioned to investigate macroscale crystallization of biologically active macromolecules in microgravity.

  13. The oxidation of methionine-54 of epoetinum alfa does not affect molecular structure or stability, but does decrease biological activity.

    PubMed

    Labrenz, Steven R; Calmann, Melissa A; Heavner, George A; Tolman, Glen

    2008-01-01

    Erythropoietin therapy is used to treat severe anemia in renal failure and chemotherapy patients. One of these therapies based on recombinant human erythropoietin is marketed under the trade name of EPREX and utilizes epoetinum alfa as the active pharmaceutical ingredient. The effect of oxidation of methionine-54 on the structure and stability of the erythropoietin molecule has not been directly tested. We have observed partial and full chemical oxidation of methionine-54 to methionine-54 sulfoxide, accomplished using tert-Butylhydroperoxide and hydrogen peroxide, respectively. A blue shift in the fluorescence center of spectral mass wavelength was observed as a linear response to the level of methionine sulfoxide in the epoetinum alfa molecule, presumably arising from a local change in the environment near tryptophan-51, as supported by potassium iodide quenching studies. Circular dichroism studies demonstrated no change in the folded structure of the molecule with methionine oxidation. The thermal unfolding profiles of partial and completely oxidized epoetinum alfa overlap, with a T(m) of 49.5 degrees C across all levels of methionine sulfoxide content. When the protein was tested for activity, a decrease in biological activity was observed, correlating with methionine sulfoxide levels. An allosteric effect between Met54, Trp51, and residues involved in receptor binding is proposed. These results indicate that methionine oxidation has no effect on the folded structure and global thermodynamic stability of the recombinant human erythropoietin molecule. Oxidation can affect potency, but only at levels significantly in excess of those seen in EPREX.

  14. Safety and efficacy of velaglucerase alfa in Gaucher disease type 1 patients previously treated with imiglucerase

    PubMed Central

    Zimran, Ari; Pastores, Gregory M.; Tylki-Szymanska, Anna; Hughes, Derralynn A.; Elstein, Deborah; Mardach, Rebecca; Eng, Christine; Smith, Laurie; Heisel-Kurth, Margaret; Charrow, Joel; Harmatz, Paul; Fernhoff, Paul; Rhead, William; Longo, Nicola; Giraldo, Pilar; Ruiz, Juan A.; Zahrieh, David; Crombez, Eric; Grabowski, Gregory A.

    2013-01-01

    Velaglucerase alfa is a glucocerebrosidase produced by gene activation technology in a human fibroblast cell line (HT-1080), and is indicated as an enzyme replacement therapy (ERT) for the treatment of Gaucher disease type 1 (GD1). This multicenter, open-label, 12-month study examined the safety and efficacy of velaglucerase alfa in patients with GD1 previously receiving imiglucerase. Eligible patients, ≥2 years old and clinically stable on imiglucerase therapy, were switched to velaglucerase alfa at a dose equal to their prior imiglucerase dose. Infusion durations were 1 hour every other week. Forty patients received velaglucerase alfa (18 male, 22 female; four previously splenectomized; age range 9–71 years). Velaglucerase alfa was generally well tolerated with most adverse events (AEs) of mild or moderate severity. The three most frequently reported AEs were headache (12 of 40 patients), arthralgia (nine of 40 patients), and nasopharyngitis (eight of 40 patients). No patients developed antibodies to velaglucerase alfa. There was one serious AE considered treatment-related: a Grade 2 anaphylactoid reaction within 30 minutes of the first infusion. The patient withdrew; this was the only AE-related withdrawal. Hemoglobin concentrations, platelet counts, and spleen and liver volumes remained stable through 12 months. In conclusion, adult and pediatric patients with GD1, previously treated with imiglucerase, successfully transitioned to velaglucerase alfa, which was generally well tolerated and demonstrated efficacy over 12-months’ treatment consistent with that observed in the velaglucerase alfa Phase 3 clinical trial program. PMID:23339116

  15. Peginterferon alfa-2a for AIDS-associated Kaposi sarcoma: experience with 10 patients.

    PubMed

    Rokx, Casper; van der Ende, Marchina E; Verbon, Annelies; Rijnders, Bart J A

    2013-11-01

    In this observational cohort study, 10 patients with extensive or treatment-refractory AIDS-associated Kaposi sarcoma were treated with peginterferon alfa-2a. Tumor responses were observed in 9 patients with a median progression-free survival of 645 days. Peginterferon alfa-2a could be an effective therapy for extensive or treatment-resistant Kaposi sarcoma.

  16. Morbidity, mortality and quality of life in the ageing haemodialysis population: results from the ELDERLY study

    PubMed Central

    Dschietzig, Wilfried; Leimenstoll, Gerd; Rob, Peter M.; Kuhlmann, Martin K.; Pommer, Wolfgang; Fraass, Uwe; Ritz, Eberhard; Schwenger, Vedat

    2016-01-01

    Background The physical–functional and social–emotional health as well as survival of the elderly (≥75 years of age) haemodialysis patient is commonly thought to be poor. In a prospective, multicentre, non-interventional, observational study, the morbidity, mortality and quality of life (QoL) in this patient group were examined and compared with a younger cohort. Methods In 92 German dialysis centres, 2507 prevalent patients 19–98 years of age on haemodialysis for a median of 19.2 months were included in a drug monitoring study of darbepoetin alfa. To examine outcome and QoL parameters, 24 months of follow-up data in the age cohorts <75 and ≥75 years were analysed. Treatment parameters, adverse and intercurrent events, hospitalizations, morbidity and mortality were assessed. QoL was evaluated by means of the 47-item Functional Assessment of Chronic Illness Therapy–Anaemia score (FACT-An, version 4). Results The 2-year mortality rate was 34.7% for the older cohort and 15.8% for the younger cohort. The mortality rate for the haemodialysed elderly patients was 6.2% higher in absolute value compared with the age-matched background population. A powerful predictor of survival was the baseline FACT-An score and a close correlation with the 20-item anaemia subscale (AnS) was demonstrated. While the social QoL in the elderly patients was more stable than in the younger cohort (leading to equivalent values at the end of the study period), a pronounced deterioration of physical and functional status was observed. The median number of all-cause hospital days per patient-year was 12.3 for the elderly cohort and 8.9 for the younger patient population. The overall 24-month hospitalization rate was only marginally higher in the elderly cohort (34.0 versus 33.3%). Conclusions In this observational study, the mortality rate of elderly haemodialysis patients was not exceedingly high compared with the age-matched background population. Furthermore, the hospitalization

  17. Arecibo Pulsar Survey Using ALFA. I. Survey Strategy and First Discoveries

    NASA Astrophysics Data System (ADS)

    Cordes, J. M.; Freire, P. C. C.; Lorimer, D. R.; Camilo, F.; Champion, D. J.; Nice, D. J.; Ramachandran, R.; Hessels, J. W. T.; Vlemmings, W.; van Leeuwen, J.; Ransom, S. M.; Bhat, N. D. R.; Arzoumanian, Z.; McLaughlin, M. A.; Kaspi, V. M.; Kasian, L.; Deneva, J. S.; Reid, B.; Chatterjee, S.; Han, J. L.; Backer, D. C.; Stairs, I. H.; Deshpande, A. A.; Faucher-Giguère, C.-A.

    2006-01-01

    We report results from the initial stage of a long-term pulsar survey of the Galactic plane using the Arecibo L-band Feed Array (ALFA), a seven-beam receiver operating at 1.4 GHz with 0.3 GHz bandwidth, and fast-dump digital spectrometers. The search targets low Galactic latitudes, |b|<~5deg, in the accessible longitude ranges 32deg<~l<~77deg and 168deg<~l<~214deg. The instrumentation, data processing, initial survey observations, sensitivity, and database management are described. Data discussed here were collected over a 100 MHz passband centered on 1.42 GHz using a spectrometer that recorded 256 channels every 64 μs. Analysis of the data with their full time and frequency resolutions is ongoing. Here we report the results of a preliminary, low-resolution analysis for which the data were decimated to speed up the processing. We have detected 29 previously known pulsars and discovered 11 new ones. One of these, PSR J1928+1746, with a period of 69 ms and a relatively low characteristic age of 82 kyr, is a plausible candidate for association with the unidentified EGRET source 3EG J1928+1733. Another, PSR J1906+07, is a nonrecycled pulsar in a relativistic binary with an orbital period of 3.98 hr. In parallel with the periodicity analysis, we also search the data for isolated dispersed pulses. This technique has resulted in the discovery of PSR J0628+09, an extremely sporadic radio emitter with a spin period of 1.2 s. Simulations we have carried out indicate that ~1000 new pulsars will be found in our ALFA survey. In addition to providing a large sample for use in population analyses and for probing the magnetoionic interstellar medium, the survey maximizes the chances of finding rapidly spinning millisecond pulsars and pulsars in compact binary systems. Our search algorithms exploit the multiple data streams from ALFA to discriminate between radio frequency interference and celestial signals, including pulsars and possibly new classes of transient radio sources.

  18. Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients(◆)

    PubMed Central

    Nelson, David R.; Zeuzem, Stefan; Andreone, Pietro; Ferenci, Peter; Herring, Robert; Jensen, Donald M.; Marcellin, Patrick; Pockros, Paul J.; Rodríguez-Torres, Maribel; Rossaro, Lorenzo; Rustgi, Vinod K.; Sepe, Thomas; Sulkowski, Mark; Thomason, Isaac R.; Yoshida, Eric M.; Chan, Anna; Hill, George

    2013-01-01

    Introduction Balapiravir (R1626, RG1626) is the prodrug of a nucleoside analogue inhibitor of the hepatitis C virus (HCV) RNA-dependent RNA polymerase (R1479, RG1479). This phase 2, double-blind international trial evaluated the optimal treatment regimen of balapiravir plus peginterferon alfa-2a (40KD)/ribavirin. Material and methods Treatment-naive genotype 1 patients (N = 516) were randomized to one of seven treatment groups in which they received balapiravir 500, 1,000, or 1,500 mg twice daily, peginterferon alfa-2a (40KD) 180 or 90 μg/week and ribavirin 1,000/1,200 mg/day or peginterferon alfa-2a (40KD)/ribavirin. The planned treatment duration with balapiravir was reduced from 24 to 12 weeks due to safety concerns. Results The percentage of patients with undetectable HCV RNA was consistently higher in all balapiravir groups from week 2 to 12. However, high rates of dose modifications and discontinuations of one/all study drugs compromised the efficacy assessment and resulted in similar sustained virological response rates in the balapiravir groups (range 32-50%) and the peginterferon alfa-2a (40KD)/ribavirin group (43%). Balapiravir was discontinued for safety reasons in 28-36% of patients (most often for lymphopenia) and the percentage of patients with serious adverse events (especially hematological, infection, ocular events) was dose related. Serious hematological adverse events (particularly neutropenia, lymphopenia) were more common in balapiravir recipients. Two deaths in the balapiravir/peginterferon alfa-2a/ribavirin combination groups were considered possibly related to study medication. Conclusion Further development of balapiravir for the treatment of chronic hepatitis C has been halted because of the unacceptable benefit to risk ratio revealed in this study (www.ClinicalTrials.gov NCT 00517439). PMID:22166557

  19. Fast radio burst discovered in the Arecibo pulsar ALFA survey

    SciTech Connect

    Spitler, L. G.; Freire, P. C. C.; Lazarus, P.; Lee, K. J.; Cordes, J. M.; Chatterjee, S.; Wharton, R. S.; Brazier, A.; Hessels, J. W. T.; Lorimer, D. R.; McLaughlin, M. A.; Crawford, F.; Deneva, J. S.; Kaspi, V. M.; Karako-Argaman, C.; Allen, B.; Bogdanov, S.; Camilo, F.; Jenet, F. A.; Knispel, B.; and others

    2014-08-01

    Recent work has exploited pulsar survey data to identify temporally isolated, millisecond-duration radio bursts with large dispersion measures (DMs). These bursts have been interpreted as arising from a population of extragalactic sources, in which case they would provide unprecedented opportunities for probing the intergalactic medium; they may also be linked to new source classes. Until now, however, all so-called fast radio bursts (FRBs) have been detected with the Parkes radio telescope and its 13-beam receiver, casting some concern about the astrophysical nature of these signals. Here we present FRB 121102, the first FRB discovery from a geographic location other than Parkes. FRB 121102 was found in the Galactic anti-center region in the 1.4 GHz Pulsar Arecibo L-band Feed Array (ALFA) survey with the Arecibo Observatory with a DM = 557.4 ± 2.0 pc cm{sup –3}, pulse width of 3.0 ± 0.5 ms, and no evidence of interstellar scattering. The observed delay of the signal arrival time with frequency agrees precisely with the expectation of dispersion through an ionized medium. Despite its low Galactic latitude (b = –0.°2), the burst has three times the maximum Galactic DM expected along this particular line of sight, suggesting an extragalactic origin. A peculiar aspect of the signal is an inverted spectrum; we interpret this as a consequence of being detected in a sidelobe of the ALFA receiver. FRB 121102's brightness, duration, and the inferred event rate are all consistent with the properties of the previously detected Parkes bursts.

  20. Clearance of Hepatic Sphingomyelin by Olipudase Alfa Is Associated With Improvement in Lipid Profiles in Acid Sphingomyelinase Deficiency

    PubMed Central

    Wasserstein, Melissa P.; Jones, Simon A.; Schiano, Thomas D.; Cox, Gerald F.; Puga, Ana Cristina

    2016-01-01

    Acid sphingomyelinase deficiency (ASMD; Niemann-Pick disease type A and B) is a lysosomal storage disorder characterized by abnormal intracellular sphingomyelin (SM) accumulation. Prominent liver involvement results in hepatomegaly, fibrosis/cirrhosis, abnormal liver chemistries, and a proatherogenic lipid profile. Olipudase alfa (recombinant human ASM) is in clinical development as an investigational enzyme replacement therapy for the non-neurological manifestations of ASMD. In a phase 1b study conducted to evaluate the safety and tolerability of within-patient dose escalation with olipudase alfa, measurement of SM levels in liver biopsies was used as a pharmacodynamic biomarker of substrate burden. Five adult patients with non neuronopathic ASMD received escalating doses of olipudase alfa every 2 weeks for 26 weeks. Liver biopsies obtained at baseline and 26 weeks after treatment were evaluated for SM storage by histomorphometric analysis, biochemistry, and electron microscopy. Biopsies were also assessed for inflammation and fibrosis, and for the association of SM levels with liver volume, liver function tests, and lipid profiles. At baseline, SM storage present in Kupffer cells and hepatocytes ranged from 9.8% to 53.8% of the microscopic field. After 26 weeks of treatment, statistically significant reductions in SM (P<0.0001) measured by morphometry were seen in 4 patients with evaluable liver biopsies. The 26-week biopsy of the fifth patient was insufficient for morphometric quantitation. Posttreatment SM levels ranged from 1.2% to 9.5% of the microscopic field, corresponding to an 84% to 92% relative reduction from baseline. Improvements in liver volume, liver function tests, and lipid profiles were also observed. This study illustrates the utility of SM assessment by liver biopsy as a pharmacodynamic biomarker of disease burden in these patients. PMID:27340749

  1. Safety and clinical activity of elosulfase alfa in pediatric patients with Morquio A syndrome (mucopolysaccharidosis IVA) less than 5 y

    PubMed Central

    Jones, Simon A.; Bialer, Martin; Parini, Rossella; Martin, Ken; Wang, Hui; Yang, Ke; Shaywitz, Adam J.; Harmatz, Paul

    2015-01-01

    Background: Previous studies have shown that elosulfase alfa has a favorable efficacy/safety profile in Morquio A patients aged ≥5 y. This study evaluated safety and impact on urine keratan sulfate (uKS) levels and growth velocity in younger patients. Methods: Fifteen Morquio A patients aged <5 y received elosulfase alfa 2.0 mg/kg/week for 52 wk during the primary treatment phase of a phase II, open-label, multinational study. Primary endpoint was safety and tolerability; secondary endpoints were change in uKS and growth velocity over 52 wk. Results: All 15 patients completed the primary treatment phase. Six of 743 infusions (0.8%) administered led to adverse events (AEs) requiring infusion interruption and medical intervention. Eleven patients (73.3%) had ≥1 study drug-related AE, mostly infusion-associated reactions. Mean z-score growth rate per year numerically improved from −0.6 at baseline to −0.4 at week 52. Comparison to untreated subjects of similar age in the Morquio A Clinical Assessment Program study showed a smaller decrease in height z-scores for treated than for untreated patients. Mean percent change from baseline in uKS was −30.2% at 2 wk and −43.5% at 52 wk. Conclusion: Early intervention with elosulfase alfa is well-tolerated and produces a decrease in uKS and a trend toward improvement in growth. PMID:26331768

  2. Impact of elosulfase alfa in patients with morquio A syndrome who have limited ambulation: An open‐label, phase 2 study

    PubMed Central

    Mengel, Eugen; Geberhiwot, Tarekegn; Muschol, Nicole; Hendriksz, Christian J.; Burton, Barbara K.; Jameson, Elisabeth; Berger, Kenneth I.; Jester, Andrea; Treadwell, Marsha; Sisic, Zlatko; Decker, Celeste

    2016-01-01

    Efficacy and safety of elosulfase alfa enzyme replacement therapy (ERT) were assessed in an open‐label, phase 2, multi‐national study in Morquio A patients aged ≥5 years unable to walk ≥30 meters in the 6‐min walk test. Patients received elosulfase alfa 2.0 mg/kg/week intravenously for 48 weeks. Efficacy measures were functional dexterity, pinch/grip strength, mobility in a modified timed 25‐foot walk, pain, quality of life, respiratory function, and urine keratan sulfate (KS). Safety/tolerability was also assessed. Fifteen patients received elosulfase alfa, three patients discontinued ERT due to adverse events (two were grade 3 drug‐related adverse events, the other was not drug‐related), and two patients missed >20% of planned infusions; 10 completed treatment through 48 weeks and received ≥80% of planned infusions (Modified Per Protocol [MPP] population). The study population had more advanced disease than that enrolled in other trials. From baseline to week 48, MPP data showed biochemical efficacy (urine KS decreased 52.4%). The remaining efficacy results were highly variable due to challenges in test execution because of severe skeletal and joint abnormalities, small sample sizes, and clinical heterogeneity among patients. Eight patients showed improvements in one or more outcome measures; several patients indicated improvements not captured by the study assessments (e.g., increased energy, functional ability). The nature of adverse events was similar to other elosulfase alfa studies. This study illustrates the considerable challenges in objectively measuring impact of ERT in very disabled Morquio A patients and highlights the need to examine results on an individual basis. © 2016 The Authors. American Journal of Medical Genetics Part A Published by Wiley Periodicals, Inc. PMID:27774754

  3. Impact of elosulfase alfa in patients with morquio A syndrome who have limited ambulation: An open-label, phase 2 study.

    PubMed

    Harmatz, Paul R; Mengel, Eugen; Geberhiwot, Tarekegn; Muschol, Nicole; Hendriksz, Christian J; Burton, Barbara K; Jameson, Elisabeth; Berger, Kenneth I; Jester, Andrea; Treadwell, Marsha; Sisic, Zlatko; Decker, Celeste

    2017-02-01

    Efficacy and safety of elosulfase alfa enzyme replacement therapy (ERT) were assessed in an open-label, phase 2, multi-national study in Morquio A patients aged ≥5 years unable to walk ≥30 meters in the 6-min walk test. Patients received elosulfase alfa 2.0 mg/kg/week intravenously for 48 weeks. Efficacy measures were functional dexterity, pinch/grip strength, mobility in a modified timed 25-foot walk, pain, quality of life, respiratory function, and urine keratan sulfate (KS). Safety/tolerability was also assessed. Fifteen patients received elosulfase alfa, three patients discontinued ERT due to adverse events (two were grade 3 drug-related adverse events, the other was not drug-related), and two patients missed >20% of planned infusions; 10 completed treatment through 48 weeks and received ≥80% of planned infusions (Modified Per Protocol [MPP] population). The study population had more advanced disease than that enrolled in other trials. From baseline to week 48, MPP data showed biochemical efficacy (urine KS decreased 52.4%). The remaining efficacy results were highly variable due to challenges in test execution because of severe skeletal and joint abnormalities, small sample sizes, and clinical heterogeneity among patients. Eight patients showed improvements in one or more outcome measures; several patients indicated improvements not captured by the study assessments (e.g., increased energy, functional ability). The nature of adverse events was similar to other elosulfase alfa studies. This study illustrates the considerable challenges in objectively measuring impact of ERT in very disabled Morquio A patients and highlights the need to examine results on an individual basis. © 2016 The Authors. American Journal of Medical Genetics Part A Published by Wiley Periodicals, Inc.

  4. Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease.

    PubMed

    Zimran, Ari; Brill-Almon, Einat; Chertkoff, Raul; Petakov, Milan; Blanco-Favela, Francisco; Muñoz, Eduardo Terreros; Solorio-Meza, Sergio E; Amato, Dominick; Duran, Gloria; Giona, Fiorina; Heitner, Rene; Rosenbaum, Hanna; Giraldo, Pilar; Mehta, Atul; Park, Glen; Phillips, Mici; Elstein, Deborah; Altarescu, Gheona; Szleifer, Mali; Hashmueli, Sharon; Aviezer, David

    2011-11-24

    Taliglucerase alfa (Protalix Biotherapeutics, Carmiel, Israel) is a novel plant cell-derived recombinant human β-glucocerebrosidase for Gaucher disease. A phase 3, double-blind, randomized, parallel-group, comparison-dose (30 vs 60 U/kg body weight/infusion) multinational clinical trial was undertaken. Institutional review board approvals were received. A 9-month, 20-infusion trial used inclusion/exclusion criteria in treatment-naive adult patients with splenomegaly and thrombocytopenia. Safety end points were drug-related adverse events: Ab formation and hypersensitivity reactions. Primary efficacy end point was reduction in splenic volume measured by magnetic resonance imaging. Secondary end points were: changes in hemoglobin, hepatic volume, and platelet counts. Exploratory parameters included biomarkers and bone imaging. Twenty-nine patients (11 centers) completed the protocol. There were no serious adverse events; drug-related adverse events were mild/moderate and transient. Two patients (6%) developed non-neutralizing IgG Abs; 2 other patients (6%) developed hypersensitivity reactions. Statistically significant spleen reduction was achieved at 9 months: 26.9% (95% confidence interval [CI]: -31.9, -21.8) in the 30-unit dose group and 38.0% (95% CI: -43.4, -32.8) in the 60-unit dose group (both P < .0001); and in all secondary efficacy end point measures, except platelet counts at the lower dose. These results support safety and efficacy of taliglucerase alfa for Gaucher disease.

  5. Home infusion program for Fabry disease: experience with agalsidase alfa in Argentina.

    PubMed

    Kisinovsky, Isaac; Cáceres, Guillermo; Coronel, Cristina; Reisin, Ricardo

    2013-01-01

    Fabry disease is an X-linked lysosomal storage disorder caused by inherited deficiency of the enzyme a-galactosidase A. Enzyme replacement treatment using agalsidase alfa significantly reduces pain, improves cardiac function and quality of life, and slows renal deterioration. Nevertheless, it is a life-long treatment which requires regular intravenous infusions and entails a great burden for patients. Our objective was to evaluate retrospectively the safety and tolerability of the home infusion of agalsidase alfa in patients with Fabry disease in Argentina. We evaluated all the patients with Fabry disease who received home infusion with agalsidase alfa 0.2 mg/kg between January 2005 and June 2011. The program included 87 patients; 51 males (mean age: 30 years) and 36 females (mean age: 34 years). A total of 5229 infusions (mean: 59 per patient; range: 1-150) were administered. A total of 5 adverse reactions were seen in 5 patients (5.7% of patients and 0.9% of the total number of infusions). All were mild in severity and resolved by reducing the rate of infusion and by using antihistaminics. All these 5 patients were positive for IgG antibodies, but none of them presented IgE antibodies and none suffered an anaphylactic shock. In our group 18 patients were switched from agalsidase beta to agalsidase alfa without complications. Home infusion with agalsidase alfa is safe, well tolerated and is associated to high compliance.

  6. Impact of epoetin alfa on left ventricular structure, function, and pressure volume relations as assessed by cardiac magnetic resonance: the heart failure preserved ejection fraction (HFPEF) anemia trial.

    PubMed

    Green, Philip; Babu, Benson A; Teruya, Sergio; Helmke, Stephen; Prince, Martin; Maurer, Mathew S

    2013-01-01

    Anemia, a common comorbidity in older adults with heart failure and a preserved ejection fraction (HFPEF), is associated with worse outcomes. The authors quantified the effect of anemia treatment on left ventricular (LV) structure and function as measured by cardiac magnetic resonance (CMR) imaging. A prospective, randomized single-blind clinical trial (NCT NCT00286182) comparing the safety and efficacy of epoetin alfa vs placebo for 24 weeks in which a subgroup (n=22) had cardiac magnetic resonance imaging (MRI) at baseline and after 3 and 6 months to evaluate changes in cardiac structure and function. Pressure volume (PV) indices were derived from MRI measures of ventricular volume coupled with sphygmomanometer-measured pressure and Doppler estimates of filling pressure. The end-systolic and end-diastolic PV relations and the area between them as a function of end-diastolic pressure, the isovolumic PV area (PVAiso), were calculated. Patients (75±10 years, 64% women) with HFPEF (EF=63%±15%) with an average hemoglobin of 10.3±1.1 gm/dL were treated with epoetin alfa using a dose-adjusted algorithm that increased hemoglobin compared with placebo (P<.0001). As compared with baseline, there were no significant changes in end-diastolic (-7±8 mL vs -3±8 mL, P=.81) or end-systolic (-0.4±2 mL vs -0.7±5 mL, P=.96) volumes at 6-month follow-up between epoetin alfa compared with placebo. LV function as measured based on EF (-1.5%±1.6% vs -2.6%±3.3%, P=.91) and pressure volume indices (PVAiso-EDP at 30 mm Hg, -5071±4308 vs -1662±4140, P=.58) did not differ between epoetin alfa and placebo. Administration of epoetin alfa to older adult patients with HFPEF resulted in a significant increase in hemoglobin, without evident change in LV structure, function, or pressure volume relationships as measured quantitatively using CMR imaging.

  7. A Phase 3, multicenter, open-label, switchover trial to assess the safety and efficacy of taliglucerase alfa, a plant cell-expressed recombinant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease previously treated with imiglucerase.

    PubMed

    Pastores, Gregory M; Petakov, Milan; Giraldo, Pilar; Rosenbaum, Hanna; Szer, Jeffrey; Deegan, Patrick B; Amato, Dominick J; Mengel, Eugen; Tan, Ee Shien; Chertkoff, Raul; Brill-Almon, Einat; Zimran, Ari

    2014-12-01

    Taliglucerase alfa is a β-glucosidase enzyme replacement therapy (ERT) approved in the US and other countries for the treatment of Gaucher disease (GD) in adults and is approved in pediatric and adult patients in Australia and Canada. It is the first approved plant cell-expressed recombinant human protein. A Phase 3, multicenter, open-label, 9-month study assessed safety and efficacy of switching to taliglucerase alfa in adult and pediatric patients with GD treated with imiglucerase for at least the previous 2years. Patients with stable disease were offered taliglucerase alfa treatment using the same dose (9-60U/kg body weight) and regimen of administration (every 2weeks) as imiglucerase. This report summarizes results from 26 adult and 5 pediatric patients who participated in the trial. Disease parameters (spleen and liver volumes, hemoglobin concentration, platelet count, and biomarker levels) remained stable through 9months of treatment in adults and children following the switch from imiglucerase. All treatment-related adverse events were mild or moderate in severity and transient in nature. Exploratory parameters of linear growth and development showed positive outcomes in pediatric patients. These findings provide evidence of the efficacy and safety profile of taliglucerase alfa as an ERT for GD in patients previously treated with imiglucerase. This trial was registered at www.clinicaltrials.gov as # NCT00712348.

  8. Biological activity of EDQM CRS for Interferon alfa-2a and Interferon alfa-2b - assessment in two in vitro bioassays.

    PubMed

    Silva, M M C G; Gaines-Das, R E; Jones, C; Robinson, C J

    2007-12-01

    The European Directorate for the Quality of Medicines (EDQM) supplies Chemical Reference Substances (CRS) for Interferon (IFN) alfa-2a (CRS I0320300) and for IFN alfa-2b (CRS I0320301) for specified physicochemical tests. However, no information is provided as to their biological activity. In contrast, the World Health Organization (WHO) provides the 2nd International Standards (IS) for IFN alfa-2a (code 95/650) and for IFN alfa-2b (code 95/566), with activity defined in International Units (IU) for calibration of biological activity of preparations of IFN. We have compared the EDQM CRSs with the WHO ISs in two bioassay systems, one measuring the anti-proliferative activity in the Daudi cell line and the other measuring a reporter gene activation in an A549 cell line. In each of these assay systems, the CRSs gave dose - response relations, which were similar to those for the WHO ISs. Estimates of relative activity for each CRS, in terms of the respective IS, showed specific biological activity for the CRSs of the same order as the nominal specific activity for the ISs. However, the estimates of relative activity were not consistent between the two assays systems, emphasizing the need for calibration within each system, if the CRS were to be used as a working standard for bioassays. For structure-activity studies, both physicochemical and biological activity characterisation are required for the same biopharmaceutical preparation. CRS I0320300 and CRS I0320301 may prove useful as working standards for some bioassay systems.

  9. The Synchrony and Diachrony of Bosnian-Croatian-Serbian Adjectival Long-Form Allomorphy (ALFA)

    ERIC Educational Resources Information Center

    Pennington, James Joshua

    2010-01-01

    In Bosnian-Croatian-Serbian (BCS), the gentive (G) and dative/locative (DL) cases exhibit adjectival long-form allomorphy (ALFA). The genitive -"og" -"oga" and the DL -"om" -"ome" -"omu" stand in free variation, inasmuch as when one form is substituted for another the truth value of an utterance…

  10. Interferon alfa-2b and ribavirin: new indication. In children: more risks than in adults.

    PubMed

    2007-04-01

    (1) There is a far lower seroprevalence of hepatitis C virus (HCV) infection in children and adolescents (0.2% to 0.4%) than in adults. In childhood, the principal route of infection is mother-child transmission during pregnancy, while in adolescence transmission is mainly through certain at-risk behaviour (piercing, tattooing and drug injection). In adults with HCV infection, the standard treatment is a combination of peginterferon alfa and ribavirin. (2) 125 children aged 3 to 16 years were treated for 48 weeks in two non comparative trials. HCV RNA was undetectable in plasma in 46% of children six months after treatment cessation (36% for genotype 1 infection, 81% for other genotypes), a proportion similar to that generally seen in adults. It is not known whether the interferon alfa-2b + ribavirin combination slows the progression of histological lesions or prevents clinical complications of HCV infection. (3) Psychological disorders, particularly depression and suicidal tendencies, are the main adverse effects of treatment, especially in children. Growth retardation can also occur, mainly due to gastrointestinal disorders linked to interferon alfa-2b (loss of appetite, nausea and vomiting, diarrhoea). Catch-up growth appears to occur during the six months after treatment cessation. (4) The combination of interferon alfa-2b and ribavirin appears to have similar virological efficacy in children to that seen in adults. Adverse effects, especially those of a psychological nature, remain frequent.

  11. Antithrombin alfa in hereditary antithrombin deficient patients: A phase 3 study of prophylactic intravenous administration in high risk situations.

    PubMed

    Tiede, Andreas; Tait, R Campbell; Shaffer, Don W; Baudo, Francesco; Boneu, Bernard; Dempfle, Carl Erik; Horellou, Marie Helene; Klamroth, Robert; Lazarchick, John; Mumford, Andrew D; Schulman, Sam; Shiach, Caroline; Bonfiglio, Laura J; Frieling, Johan T M; Conard, Jacqueline; von Depka, Mario

    2008-03-01

    During surgery and childbirth, patients with hereditary antithrombin (AT) deficiency are at high risk for thrombosis, and heparin prophylaxis may not be sufficiently efficacious. In these patients, exogenous AT may be used in association with heparin. A recombinant human AT (generic name: antithrombin alfa) has been developed. This multi-center study assessed the efficacy and safety of prophylactic intravenous administration of antithrombin alfa to hereditary AT deficient patients in high risk situations, including elective surgery, childbirth, or cesarean section. Antithrombin alfa was administered prior to and during the high risk period for restoration and maintenance of AT activity at 100% of normal. Heparin, low-molecular-weight heparin, and/or vitamin K antagonists were used according to standard of care. The primary efficacy endpoint was the incidence of acute deep vein thrombosis (DVT) from baseline up to day 30 post dosing as assessed by independent central review of duplex ultrasonograms and/or venograms. Safety was assessed based on adverse events (AEs) and laboratory evaluations. Five surgical and nine obstetrical hereditary AT deficiency patients received antithrombin alfa for a mean period of seven days. No clinically overt DVT occurred. Central review of ultrasonograms identified signs of acute DVT in two out of 13 evaluable patients. No antithrombin alfa-related AEs were reported. No patient developed anti-antithrombin alfa antibodies. In conclusion, this study suggests that antithrombin alfa is a safe and effective alternative to human plasma-derived AT for treating hereditary AT deficiency patients at high risk for thromboembolic events.

  12. Safety and efficacy of two dose levels of taliglucerase alfa in pediatric patients with Gaucher disease.

    PubMed

    Zimran, Ari; Gonzalez-Rodriguez, Derlis Emilio; Abrahamov, Aya; Elstein, Deborah; Paz, Alona; Brill-Almon, Einat; Chertkoff, Raul

    2015-01-01

    Taliglucerase alfa is a plant cell-expressed beta-glucocerebrosidase approved in the United States, Israel, Australia, Canada, and other countries for enzyme replacement therapy in adults with Type 1 Gaucher disease (GD), for treatment of pediatric patients in the United States, Australia, and Canada, and for the hematologic manifestations of Type 3 GD in pediatric patients in Canada. This multicenter, randomized, double-blind, parallel-dose, 12-month study assessed efficacy and safety of taliglucerase alfa in pediatric patients with GD. Eleven children were randomized to taliglucerase alfa 30U/kg (n=6) or 60U/kg (n=5) per infusion every other week. From baseline to month 12, the following changes were noted in the taliglucerase alfa 30-U/kg and 60-U/kg dose groups, respectively: median hemoglobin concentrations increased by 12.2% and 14.2%; the interquartile ranges of median percent change in hemoglobin levels from baseline were 20.6 and 10.4, respectively; mean spleen volume decreased from 22.2 to 14.0 multiples of normal (MN) and from 29.4 to 12.9 MN; mean liver volume decreased from 1.8 to 1.5 MN and from 2.2 to 1.7 MN; platelet counts increased by 30.9% and 73.7%; and chitotriosidase activity was reduced by 58.5% and 66.1%. Nearly all adverse events were mild/moderate, unrelated to treatment, and transient. One patient presented with treatment-related gastroenteritis reported as a serious adverse event due to the need for hospitalization for rehydration. No patient discontinued. These data suggest that taliglucerase alfa has the potential to be a therapeutic treatment option for children with GD. This study was registered at www.clinicaltrials.gov as NCT01132690.

  13. Darbepoietin-alfa has comparable erythropoietic stimulatory effects to recombinant erythropoietin whilst preserving the bone marrow microenvironment.

    PubMed

    Dewamitta, Sita R; Russell, Megan R; Nandurkar, Harshal; Walkley, Carl R

    2013-05-01

    Erythropoiesis stimulating agents are widely used for the treatment of anemia. Recently, we reported erythroid expansion with impaired B lymphopoiesis and loss of trabecular bone in C57BL/6 mice following ten days of treatment with low-dose short acting recombinant human erythropoietin. We have assessed erythropoietin against longer-acting darbepoietin-alfa at a comparable erythroid stimulatory dosage regime. Darbepoietin-alfa and erythropoietin induced similar in vivo erythropoietic expansion. Both agents induced an expansion of the colony-forming unit-erythroid populations. However, unlike erythropoietin, darbepoietin-alfa did not impair bone marrow B lymphopoiesis. Strikingly the bone loss observed with erythropoietin was not apparent following darbepoietin-alfa treatment. This analysis demonstrates that whilst darbepoietin-alfa has similar in vivo erythropoietic potency to erythropoietin, it preserves the bone marrow microenvironment. Thus erythropoietin and darbepoietin-alfa manifest different action showing that erythropoiesis stimulating agents have differential non-erythroid effects dependent on their duration of action.

  14. Use of drotrecogin alfa in necrotizing fasciitis: a case report and pharmacologic review.

    PubMed

    Bland, Christopher M; Frizzi, James D; Reyes, Angel

    2008-01-01

    Necrotizing fasciitis (NF) is a devastating subset of necrotizing soft tissue infections that requires prompt diagnosis and treatment. Although often occurring in patients with impaired host defense mechanisms (diabetes mellitus, systemic immunosuppression, malignancy, etc.), NF may also present in the immunocompetent following a cutaneous lesion or break. Patients with NF often progress to a systemic inflammatory response syndrome or multiorgan system failure that demands advanced critical care practices. We present a case of NF in an immunocompetent patient and the subsequent use of drotrecogin alfa (Xigris). A review of the pharmacologic treatment of streptococcal NF is included. The addition of drotrecogin alfa to operative debridement and penicillin G/clindamycin therapy may be a useful adjunct in the treatment of necrotizing fasciitis due to group A streptococcus.

  15. Myelodysplastic Syndromes

    MedlinePlus

    ... as fatigue and to prevent bleeding and infections. Blood transfusions Blood transfusions can be used to replace red blood cells, ... darbepoetin alfa (Aranesp), can reduce the need for blood transfusions by increasing red blood cells. Others may help ...

  16. Results.

    ERIC Educational Resources Information Center

    Zemsky, Robert; Shaman, Susan; Shapiro, Daniel B.

    2001-01-01

    Describes the Collegiate Results Instrument (CRI), which measures a range of collegiate outcomes for alumni 6 years after graduation. The CRI was designed to target alumni from institutions across market segments and assess their values, abilities, work skills, occupations, and pursuit of lifelong learning. (EV)

  17. Alglucosidase alfa enzyme replacement therapy as a therapeutic approach for glycogen storage disease type III.

    PubMed

    Sun, Baodong; Fredrickson, Keri; Austin, Stephanie; Tolun, Adviye A; Thurberg, Beth L; Kraus, William E; Bali, Deeksha; Chen, Yuan-Tsong; Kishnani, Priya S

    2013-02-01

    We investigated the feasibility of using recombinant human acid-α glucosidase (rhGAA, Alglucosidase alfa), an FDA approved therapy for Pompe disease, as a treatment approach for glycogen storage disease type III (GSD III). An in vitro disease model was established by isolating primary myoblasts from skeletal muscle biopsies of patients with GSD IIIa. We demonstrated that rhGAA significantly reduced glycogen levels in the two GSD IIIa patients' muscle cells (by 17% and 48%, respectively) suggesting that rhGAA could be a novel therapy for GSD III. This conclusion needs to be confirmed in other in vivo models.

  18. Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial

    PubMed Central

    Gore, Martin E; Griffin, Clare L; Hancock, Barry; Patel, Poulam M; Pyle, Lynda; Aitchison, Michael; James, Nicholas; Oliver, Roderick TD; Mardiak, Jozef; Hussain, Tahera; Sylvester, Richard; Parmar, Mahesh KB; Royston, Patrick; Mulders, Peter FA

    2010-01-01

    Summary Background In metastatic renal cell carcinoma combinations of interferon alfa-2a, interleukin-2, and fluorouracil produce higher response rates and longer progression-free survival than do single agents. We aimed to compare overall survival in patients receiving combination treatment or interferon alfa-2a. Methods RE04/30012 was an open-label randomised trial undertaken in 50 centres across eight countries. 1006 treatment-naive patients diagnosed with advanced metastatic renal cell carcinoma were randomly allocated (1 to 1) by minimisation to receive interferon alfa-2a alone or combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil. Treatment was not masked. The primary endpoint was overall survival. Treatment groups were compared with a non-stratified log-rank test. Analysis was by intention to treat. This study is registered, number ISRCTN 46518965. Findings 502 patients were randomly assigned to receive interferon alfa-2a and 504 to receive combined treatment. Median follow-up was 37·2 months (24·8–52·3). Median overall survival was 18·8 months (17·0–23·2) for patients receiving interferon alfa-2a versus 18·6 months (16·5–20·6) for those receiving combination therapy. Overall survival did not differ between the two groups (hazard ratio 1·05 [95% CI 0·90–1·21], p=0·55; absolute difference 0·3% (−5·1 to 5·6) at 1 year and 2·7% (−8·2 to 2·9) at 3 years). Serious adverse events were reported in 113 (23%) patients receiving interferon alfa-2a and 131 (26%) of those receiving combined treatment. Interpretation Although combination therapy does not improve overall or progression-free survival compared with interferon alfa-2a alone, immunotherapy might still have a role because it can produce remissions that are of clinically relevant length in some patients. Identification of patients who will benefit from immunotherapy is crucial. Funding UK Medical Research Council. PMID:20153039

  19. Drotrecogin alfa (activated)...a sad final fizzle to a roller-coaster party.

    PubMed

    Angus, Derek C

    2012-02-06

    Following the failure of PROWESS-SHOCK to demonstrate efficacy, Eli Lilly and Company withdrew drotrecogin alfa (activated) from the worldwide market. Drotrecogin was initially approved after the original trial, PROWESS, was stopped early for overwhelming efficacy. These events prompt consideration of both the initial approval decision and the later decision to withdraw. It is regrettable that the initial decision was made largely on a single trial that was stopped early. However, the decision to approve was within the bounds of normal regulatory practice and was made by many approval bodies around the world. Furthermore, the overall withdrawal rate of approved drugs remains very low. The decision to withdraw was a voluntary decision by Eli Lilly and Company and likely reflected key business considerations. Drotrecogin does have important biologic effects, and it is probable that we do not know how best to select patients who would benefit. Overall, there may still be a small advantage to drotrecogin alfa, even used non-selectively, but the costs of determining such an effect with adequate certainty are likely prohibitive, and the point is now moot. In the future, we should consider ways to make clinical trials easier and quicker so that more information can be available in a timely manner when considering regulatory approval. At the same time, more sophisticated selection of patients seems key if we are to most wisely test agents designed to manipulate the septic host response.

  20. Novel treatment options for lysosomal acid lipase deficiency: critical appraisal of sebelipase alfa

    PubMed Central

    Su, Kim; Donaldson, Emma; Sharma, Reena

    2016-01-01

    Lysosomal acid lipase deficiency (LAL-D) is a rare disorder of cholesterol metabolism with an autosomal recessive mode of inheritance. The absence or deficiency of the LAL enzyme gives rise to pathological accumulation of cholesterol esters in various tissues. A severe LAL-D phenotype manifesting in infancy is associated with adrenal calcification and liver and gastrointestinal involvement with characteristic early mortality. LAL-D presenting in childhood and adulthood is associated with hepatomegaly, liver fibrosis, cirrhosis, and premature atherosclerosis. There are currently no curative pharmacological treatments for this life-threatening condition. Supportive management with lipid-modifying agents does not ameliorate disease progression. Hematopoietic stem cell transplantation as a curative measure in infantile disease has mixed success and is associated with inherent risks and complications. Sebelipase alfa (Kanuma) is a recombinant human LAL protein and the first enzyme replacement therapy for the treatment of LAL-D. Clinical trials have been undertaken in infants with rapidly progressive LAL-D and in children and adults with later-onset LAL-D. Initial data have shown significant survival benefits in the infant group and improvements in biochemical parameters in the latter. Sebelipase alfa has received marketing authorization in the United States and Europe as long-term therapy for all affected individuals. The availability of enzyme replacement therapy for this rare and progressive disorder warrants greater recognition and awareness by physicians. PMID:27799810

  1. A first-year dornase alfa treatment impact on clinical parameters of patients with cystic fibrosis: the Brazilian cystic fibrosis multicenter study

    PubMed Central

    Rozov, Tatiana; Silva, Fernando Antônio A. e; Santana, Maria Angélica; Adde, Fabíola Villac; Mendes, Rita Heloisa

    2013-01-01

    OBJECTIVE: To describe the clinical impact of the first year treatment with dornase alfa, according to age groups, in a cohort of Brazilian Cystic Fibrosis (CF) patients. METHODS: The data on 152 eligible patients, from 16 CF reference centers, that answered the medical questionnaires and performed laboratory tests at baseline (T0), and at six (T2) and 12 (T4) months after dornase alfa initiation, were analyzed. Three age groups were assessed: six to 11, 12 to 13, and >14 years. Pulmonary tests, airway microbiology, emergency room visits, hospitalizations, emergency and routine treatments were evaluated. Student's t-test, chi-square test and analysis of variance were used when appropriated. RESULTS: Routine treatments were based on respiratory physical therapy, regular exercises, pancreatic enzymes, vitamins, bronchodilators, corticosteroids, and antibiotics. In the six months prior the study (T0 phase), hospitalizations for pulmonary exacerbations occurred in 38.0, 10.0 and 61.4% in the three age groups, respectively. After one year of intervention, there was a significant reduction in the number of emergency room visits in the six to 11 years group. There were no significant changes in forced expiratory volume in one second (VEF1), in forced vital capacity (FVC), in oxygen saturation (SpO2), and in Tiffenau index for all age groups. A significant improvement in Shwachman-Kulczychi score was observed in the older group. In the last six months of therapy, chronic or intermittent colonization by P. aeruginosa was detected in 75.0, 71.4 and 62.5% of the studied groups, respectively, while S. aureus colonization was identified in 68.6, 66.6 and 41.9% of the cases. CONCLUSIONS: The treatment with dornase alfa promoted the maintenance of pulmonary function parameters and was associated with a significant reduction of emergency room visits due to pulmonary exacerbations in the six to 11 years age group, with better clinical scores in the >14 age group, one year after the

  2. Home infusion of intravenous velaglucerase alfa: Experience from pooled clinical studies in 104 patients with type 1 Gaucher disease.

    PubMed

    Elstein, Deborah; Burrow, T Andrew; Charrow, Joel; Giraldo, Pilar; Mehta, Atul; Pastores, Gregory M; Lee, Hak-Myung; Mellgard, Björn; Zimran, Ari

    The introduction of a home therapy option during clinical trials of velaglucerase alfa in patients with type 1 Gaucher disease marked the first time that home infusions have been permitted during a clinical trial for an investigational drug for Gaucher disease. Home infusions were an available option in 4 open-label velaglucerase alfa clinical studies to eligible patients who received their initial infusions at a clinic. Patients who participated in the home therapy option and received at least 10% of their infusions at home (n=100) received a range of 11.6%-100% of their scheduled infusions at home (median 87.5%), excluding infusions received at the clinic during protocol-mandated visits. The length of time over which individual patients received home therapy ranged from 13days to 4.56years (median 0.57years). During the time that home therapy was available, 2904 of 3572 (81.3%) infusions were administered at home. Ten patients experienced 62 infusion-related adverse events (IRAEs) during 38 home infusions, with malaise, pain, hypertension, fatigue, and headache being reported most frequently. No notable differences were found between the type and severity of IRAEs experienced at home and those experienced at the clinic. Home infusions administered by trained and qualified medical personnel were successfully introduced into the velaglucerase alfa clinical development program, and fewer than 10% of patients experienced IRAEs in the home setting. Local labeling and practice guidelines should be consulted for administration of velaglucerase alfa infusions at home.

  3. HCV quasispecies evolution during treatment with interferon alfa-2b and ribavirin in two children coinfected with HCV and HIV-1.

    PubMed

    Quesnel-Vallières, Mathieu; Lemay, Mireille; Lapointe, Normand; Martin, Steven R; Soudeyns, Hugo

    2008-10-01

    Two children who acquired hepatitis C virus (HCV) and human immunodeficiency virus type 1 (HIV-1) infection by mother-to-child transmission were monitored during interferon alfa-2b and ribavirin treatment. In Patient C1, CD4(+) T cell counts were within normal range and HIV-1 viral load was undetectable. HCV viral load declined slightly following treatment initiation while novel variants rapidly emerged, indicative of quasispecies diversification. In Patient C2, CD4(+) T cell counts were low and HIV-1 replication was not fully controlled by antiretroviral therapy. HCV viral load rose during treatment and a striking conservation of the variant spectrum was observed. In both cases, there was no decline in quasispecies complexity following treatment initiation and sustained virological response was not achieved. These results suggest that reduction in quasispecies complexity, which is observed in adult responders following interferon treatment, may be mechanistically unrelated with evolution of the variant profile and/or selective pressure exerted on HCV.

  4. Prospective randomized multicenter adjuvant dermatologic cooperative oncology group trial of low-dose interferon alfa-2b with or without a modified high-dose interferon alfa-2b induction phase in patients with lymph node-negative melanoma.

    PubMed

    Hauschild, Axel; Weichenthal, Michael; Rass, Knuth; Linse, Ruthild; Ulrich, Jens; Stadler, Rudolf; Volkenandt, Matthias; Grabbe, Stephan; Proske, Ulrike; Schadendorf, Dirk; Brockmeyer, Norbert; Vogt, Thomas; Rompel, Rainer; Kaufmann, Roland; Kaatz, Martin; Näher, Helmut; Mohr, Peter; Eigentler, Thomas; Livingstone, Elisabeth; Garbe, Claus

    2009-07-20

    PURPOSE Interferon alfa (IFN-alpha) has shown clinical efficacy in the adjuvant treatment of patients with high-risk melanoma in several clinical trials, but optimal dosing and duration of treatment are still under discussion. It has been argued that in high-dose IFN-alpha (HDI), the intravenous (IV) induction phase might be critical for the clinical benefit of the regimen. PATIENTS AND METHODS In an attempt to investigate the potential role of a modified high-dose induction phase, lymph node-negative patients with resected primary malignant melanoma of more than 1.5-mm tumor thickness were included in this prospective randomized multicenter Dermatologic Cooperative Oncology Group trial. Six hundred seventy-four patients were randomly assigned to receive 4 weeks of a modified HDI scheme. This schedule consisted of 5 times weekly 10 MU/m(2) IFN-alpha-2b IV for 2 weeks and 5 times weekly 10 MU/m(2) IFN-alpha-2b administered subcutaneously (SC) for another 2 weeks followed by 23 months of low-dose IFN-alpha-2b (LDI) 3 MU SC three times a week (arm A). LDI 3 MU three times a week was given for 24 months in arm B. Results Of 650 assessable patients, there were 92 relapses among the 321 patients receiving high-dose induction as compared with 95 relapses among the 329 patients receiving LDI only. Five-year relapse-free survival rates were 68.0% (arm A) and 67.1% (arm B), respectively. Likewise, melanoma-related fatalities were similar between both groups, resulting in 5-year overall survival rates of 80.2% (arm A) and 82.9% (arm B). CONCLUSION The addition of a 4-week modified HDI induction phase to a 2-year low-dose adjuvant IFN-alpha-2b treatment schedule did not improve the clinical outcome.

  5. [Topical interferon alfa-2b for primary treatment of conjunctiva-cornea intraepithelial neoplasia].

    PubMed

    Pérez de Arcelus, M; Aranguren, M; Andonegui, J

    2012-01-01

    We describe two cases of conjunctival-cornea intraepithelial neoplasia (CIN), treated with topical IFN alfa 2b. The traditional treatment for CIN is surgical excision usually with adjunctive cryotherapy. However, residual tumour may remain, which can lead to recurrence rates of more than 50%. 5-Fluorouracil, mitomicyn C and interferon α 2b are new pharmacological agents that have proved their efficacy in the treatment of CIN. As side effects are common, we present IFN α 2b as a single therapeutic agent as an effective and optimal treatment for presumed recurrent corneal and conjunctival intraepithelial neoplasia. It offers the benefits of topical therapy and avoids the risks of surgical or other interventions - specifically, ocular surface toxicity, cicatricial conjunctival changes, and limbal stem cell deficiency.

  6. Interferon alfa-2b in the management of recurrent conjunctival papillomatosis.

    PubMed

    Singh, Manpreet; Gautam, Natasha; Gupta, Adit; Kaur, Manpreet

    2016-10-01

    A 2-year-old boy presented with a recurrent strawberry-like reddish mass arising from the left caruncular region for 8 months. An incisional biopsy was performed elsewhere 2 months earlier, followed by an increase in size of mass, significant epiphora, and intermittent bleeding. On examination, exuberant exophytic gelatinous mass with multifocal origin was observed arising from inferior forniceal conjunctiva and caruncle. Clinical differential of multifocal conjunctival papilloma was kept, and topical interferon alfa-2b (INFα-2b) was started. No clinical reduction in mass or symptomatology was observed over 6 weeks. Excision biopsy with cryotherapy and subconjunctival injection of INFα-2b was performed over all foci. Conjunctival papilloma was confirmed on histopathology, and topical INFα-2b was continued in postoperative period for 3 months. At 14 months of follow-up, no recurrence, epiphora, or bleeding was noticed. We advocate a possible role of local INF therapy in managing and preventing recurrences of conjunctival papillomatosis.

  7. Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy in adults with Fabry disease

    PubMed Central

    Goláň, Lubor; Goker-Alpan, Ozlem; Holida, Myrl; Kantola, Ikka; Klopotowski, Mariusz; Kuusisto, Johanna; Linhart, Aleš; Musial, Jacek; Nicholls, Kathleen; Gonzalez-Rodriguez, Derlis; Sharma, Reena; Vujkovac, Bojan; Chang, Peter; Wijatyk, Anna

    2015-01-01

    Purpose Efficacy and safety of agalsidase alfa at 0.2 mg/kg weekly were compared with 0.2 mg/kg every other week (EOW). Exploratory analyses were performed for 0.4 mg/kg weekly. Patients and methods This was a 53-week, Phase III/IV, multicenter, open-label study (NCT01124643) in treatment-naïve adults (≥18 years) with Fabry disease. Inclusion criteria were left ventricular hypertrophy at baseline, defined as left ventricular mass indexed to height >50 g/m2.7 for males and >47 g/m2.7 for females. Primary endpoint was reduction of left ventricular mass indexed to height as assessed by echocardiography. Secondary endpoints included cardiac (peak oxygen consumption, 6-minute walk test, Minnesota Living with Heart Failure Questionnaire, New York Heart Association classification), renal (Modification of Diet in Renal Disease, estimated glomerular filtration rate), and biomarker (plasma globotriaosylceramide) assessments. Safety endpoints were adverse events and anti–agalsidase alfa antibodies. Results Twenty patients were randomized to 0.2 mg/kg EOW (mean age, 50.3 years; 70% male), 19 to 0.2 mg/kg weekly (51.8 years; 53% male), and 5 to 0.4 mg/kg weekly (49.4 years; 40% male). The mean change in left ventricular mass indexed to height by Week 53 in the 0.2-mg/kg EOW and weekly groups was 3.2 g/m2.7 and 0.5 g/m2.7, with no significant difference between groups. No clinically meaningful changes by Week 53 were found within or between the 0.2-mg/kg groups for peak oxygen consumption, 6-minute walk test, or Minnesota Living with Heart Failure Questionnaire. Two patients in each group improved by ≥1 New York Heart Association classification. No significant differences were found between 0.2 mg/kg EOW and weekly for mean change in estimated glomerular filtration rate (−1.21 mL/min/1.73 m2 vs −3.32 mL/min/1.73 m2) or plasma globotriaosylceramide (−1.05 nmol/mL vs −2.13 nmol/mL), respectively. Infusion-related adverse events were experienced by 25% and 21% in the

  8. Peginterferon alfa-2b and ribavirin in thalassaemia/chronic hepatitis C virus-co-infected non-responder to standard interferon-based.

    PubMed

    Hamidah, A; Thambidorai, C R; Jamal, R

    2005-10-01

    We describe a patient with HbE-beta thalassaemia and chronic hepatitis C virus infection (genotype 1a) who was treated successfully with peginterferon alfa-2b and ribavirin, following failure to respond to standard interferon and ribavirin therapy. She had sustained virological response for nearly 24 months after completing peginterferon alfa-2b and ribavirin therapy. Transfusion requirements were significantly increased during combination therapy due to ribavirin-induced haemolysis. The adverse effects of interferon were well tolerated. Combination therapy with peginterferon alfa-2b and ribavirin maybe a feasible treatment option for a subset of thalassaemia/HCV infected non-responders to standard interferon-based therapy.

  9. Properties of Cold HI Emission Clouds in the Inner-Galaxy ALFA Survey

    NASA Astrophysics Data System (ADS)

    Hughes, James Marcus; Gibson, Steven J.; Noriega-Crespo, Alberto; Newton, Jonathan; Koo, Bon-Chul; Douglas, Kevin A.; Peek, Joshua Eli Goldston; Park, Geumsook; Kang, Ji-hyun; Korpela, Eric J.; Heiles, Carl E.; Dame, Thomas M.

    2017-01-01

    Star formation, a critical process within galaxies, occurs in the coldest, densest interstellar clouds, whose gas and dust content are observed primarily at radio and infrared wavelengths. The formation of molecular hydrogen (H2) from neutral atomic hydrogen (HI) is an essential early step in the condensation of these clouds from the ambient interstellar medium, but it is not yet completely understood, e.g., what is the predominant trigger? Even more troubling, the abundance of H2 may be severely underestimated by standard tracers like CO, implying significant "dark" H2, and the quantity of HI may also be in error if opacity effects are neglected. We have developed an automated method to account for both HI and H2 in cold, diffuse clouds traced by narrow-line HI 21-cm emission in the Arecibo Inner-Galaxy ALFA (I-GALFA) survey. Our algorithm fits narrow (2-5 km/s), isolated HI line profiles to determine their spin temperature, optical depth, and true column density. We then estimate the "visible" H2 column in the same clouds with CfA and Planck CO data and the total gas column from dust emission measured by Planck, IRAS, and other surveys. Together, these provide constraints on the dark H2 abundance, which we examine in relation to other cloud properties and stages of development. Our aim is to build a database of H2-forming regions with significant dark gas to aid future analyses of coalescing interstellar clouds. We acknowledge support from NSF, NASA, Western Kentucky University, and Williams College. I-GALFA is a GALFA-HI survey observed with the 7-beam ALFA receiver on the 305-meter William E. Gordon Telescope. The Arecibo Observatory is a U.S. National Science Foundation facility operated under sequential cooperative agreements with Cornell University and SRI International, the latter in alliance with the Ana G. Mendez-Universidad Metropolitana and the Universities Space Research Association.

  10. A cost-effectiveness evaluation comparing originator follitropin alfa to the biosimilar for the treatment of infertility

    PubMed Central

    Gizzo, Salvatore; Garcia-Velasco, Juan A; Heiman, Franca; Ripellino, Claudio; Bühler, Klaus

    2016-01-01

    Objectives To perform a cost-effectiveness evaluation comparing the originator follitropin alfa (Gonal-f®) to the biosimilar (Bemfola®) in the Italian and Spanish contexts, with an assessment of the German and UK backgrounds. Methods Starting from the study by Rettenbacher et al, a cost-effectiveness model was developed in the Italian and Spanish contexts. Clinical data on subjects, doses of gonadotropin, pregnancies, live-born children, and ovarian hyperstimulation syndrome were used to feed the model. Costs related to drugs, hospitalizations, specialist visits, and examinations were retrieved from Italian and Spanish tariffs. Gonadotropin acquisition costs for Germany and the UK were also taken into account to expand the economical assessment to the other countries. The evaluation was done based on the National Health Service perspective. Sensitivity analyses, both univariate and probabilistic, as long as scenario analyses, tested the robustness of the model. Results Originator follicle-stimulating hormone (FSH) costs were €3,663 and €6,387 in Italy and Spain, respectively, whereas biosimilar FSH costs were €3,483 and €6,342. The efficacy was found to be 0.52 for the originator and 0.47 for the biosimilar. The average cost per live birth was estimated to be €7,044 and €12,283 for the originator FSH and €7,411 and €13,494 for the biosimilar for Italy and Spain, respectively. Furthermore, the originator FSH generated an incremental cost-effectiveness ratio of €3,600 for Italy and €900 for Spain compared to the biosimilar. Sensitivity analyses confirmed the results of the base case model. Conclusion This analysis indicated that the originator FSH is a cost-efficient treatment strategy for Italian and Spanish health services compared to the biosimilar and it would be worthwhile extending this evaluation to other countries. PMID:27994486

  11. A comparison of menotropin, highly-purified menotropin and follitropin alfa in cycles of intracytoplasmic sperm injection

    PubMed Central

    Esteves, Sandro C; Schertz, Joan C; Verza, Sidney; Schneider, Danielle T; Zabaglia, Silval FC

    2009-01-01

    Background Over the last several decades, as a result of an evolution in manufacturing processes, a marked development has been made in the field of gonadotropins for ovarian stimulation. Initially, therapeutic gonadotropins were produced from a simple process of urine extraction and purification; now they are produced via a complex system involving recombinant technology, which yields gonadotropins with high levels of purity, quality, and consistency. Methods A retrospective analysis of 865 consecutive intracytoplasmic sperm injection (ICSI) cycles of controlled ovarian hyperstimulation (COH) compared the clinical efficacy of three gonadotropins (menotropin [hMG; n = 299], highly-purified hMG [HP-hMG; n = 330] and follitropin alfa [r-hFSH; n = 236]) for ovarian stimulation after pituitary down-regulation. The endpoints were live birth rates and total doses of gonadotropin per cycle and per pregnancy. Results Laboratory and clinical protocols remained unchanged over time, except for the type of gonadotropin used, which was introduced sequentially (hMG, then HP-hMG, and finally r-hFSH). Live birth rates were not significantly different for hMG (24.4%), HP-hMG (32.4%) and r-hFSH (30.1%; p = 0.09) groups. Total dose of gonadotropin per cycle was significantly higher in the hMG (2685 +/- 720 IU) and HP-hMG (2903 +/- 867 IU) groups compared with the r-hFSH-group (2268 +/- 747 IU; p < 0.001). Total dose of gonadotropin required to achieve clinical pregnancy was 15.7% and 11.0% higher for the hMG and HP-hMG groups, respectively, compared with the r-hFSH group, and for live births, the differences observed were 45.3% and 19.8%, respectively. Conclusion Although similar live birth rates were achieved, markedly lower doses of r-hFSH were required compared with hMG or HP-hMG. PMID:19828024

  12. Long-term safety and efficacy of taliglucerase alfa in pediatric Gaucher disease patients who were treatment-naïve or previously treated with imiglucerase.

    PubMed

    Zimran, Ari; Gonzalez-Rodriguez, Derlis Emilio; Abrahamov, Aya; Cooper, Peter A; Varughese, Sheeba; Giraldo, Pilar; Petakov, Milan; Tan, Ee Shien; Chertkoff, Raul

    2016-10-20

    Taliglucerase alfa is an enzyme replacement therapy approved for treatment of Gaucher disease (GD) in children and adults in several countries. This multicenter extension study assessed the efficacy and safety of taliglucerase alfa in pediatric patients with GD who were treatment-naïve (n=10) or switched from imiglucerase (n=5). Patients received taliglucerase alfa 30 or 60U/kg (treatment-naïve) or the same dose as previously treated with imiglucerase every other week. In treatment-naïve patients, taliglucerase alfa 30 and 60U/kg, respectively, reduced mean spleen volume (-18.6 multiples of normal [MN] and -26.0MN), liver volume (-0.8MN and -0.9MN), and chitotriosidase activity (-72.7% and -84.4%), and increased mean Hb concentration (+2.0g/dL and +2.3g/dL) and mean platelet count (+38,200/mm(3) and +138,250/mm(3)) from baseline through 36 total months of treatment. In patients previously treated with imiglucerase, these disease parameters remained stable through 33 total months of treatment with taliglucerase alfa. Most adverse events were mild/moderate; treatment was well tolerated. These findings extend the taliglucerase alfa safety and efficacy profile and demonstrate long-term clinical improvement in treatment-naïve children receiving taliglucerase alfa and maintenance of disease stability in children switched to taliglucerase alfa. Treatment was well-tolerated, with no new safety signals. This study is registered at www.clinicaltrials.gov as NCT01411228.

  13. Clinical improvement of diffuse lymphangiomatosis with pegylated interferon alfa-2b therapy: case report and review of the literature.

    PubMed

    Ozeki, Michio; Funato, Michinori; Kanda, Kaori; Ito, Masahumi; Teramoto, Takahide; Kaneko, Hideo; Fukao, Toshiyuki; Kondo, Naomi

    2007-01-01

    Diffuse lymphangiomatosis is a very rare congenital disease, characterized by diffuse or multifocal lymphangioma in the skeletal tissue, spleen, liver, mediastinum, and/or lung. The prognosis is usually poor, especially for children with thoracic lesion, and treatments for the disease are controversial. The authors report a 9-year-old boy with diffuse lymphangiomatosis involving the thorax with pleural effusions, the spleen, and systemic bone. The patient was treated with pegylated interferon alfa-2b, and achieved good clinical and radiological improvement.

  14. Daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1

    PubMed Central

    Jacobson, Ira; Zeuzem, Stefan; Flisiak, Robert; Knysz, Brygida; Lueth, Stefan; Zarebska-Michaluk, Dorota; Janczewska, Ewa; Ferenci, Peter; Diago, Moises; Zignego, Anna Linda; Safadi, Rifaat; Baruch, Yaacov; Abdurakhmanov, Dzhamal; Shafran, Stephen; Thabut, Dominique; Bruck, Rafael; Gadano, Adrian; Thompson, Alexander James; Kopit, Justin; McPhee, Fiona; Michener, Tracy; Hughes, Eric A; Yin, Philip D; Noviello, Stephanie

    2016-01-01

    AIM: To evaluate daclatasvir vs telaprevir, each combined with peginterferon alfa-2a/ribavirin (pegIFN/RBV), in treatment-naive hepatitis C virus (HCV) genotype (GT) 1-infected patients. METHODS: In this phase 3, randomized, open-label, noninferiority study, 602 patients were randomly assigned (2:1) to daclatasvir vs telaprevir, stratified by IL28B rs12979860 host genotype (CC vs non-CC), cirrhosis status (compensated cirrhosis vs no cirrhosis), and HCV GT1 subtype (GT1a vs GT1b). Patients were selected by study inclusion criteria from a total of 793 enrolled patients. Patients received daclatasvir 60 mg once daily or telaprevir 750 mg 3 times daily plus pegIFN/RBV. Daclatasvir recipients received 24 wk of daclatasvir plus pegIFN/RBV; those without an extended rapid virologic response (eRVR; undetectable HCV-RNA at weeks 4 and 12) received an additional 24 wk of pegIFN/RBV. Telaprevir-treated patients received 12 wk of telaprevir plus pegIFN/RBV followed by 12 (with eRVR) or 36 (no eRVR) wk of pegIFN/RBV. The primary objective was to compare for noninferiority of sustained virologic response rates at posttreatment week 12 (SVR12) in GT1b-infected patients. Key secondary objectives were to demonstrate that the rates of anemia (hemoglobin < 10 g/dL) and rash-related events, through week 12, were lower with daclatasvir + pegIFN/RBV than with telaprevir + pegIFN/RBV among GT1b-infected patients. Resistance testing was performed using population-based sequencing of the NS5A region for all patients at baseline, and for patients with virologic failure or relapse and HCV-RNA ≥ 1000 IU/mL, to investigate any link between NS5A polymorphisms associated with daclatasvir resistance and virologic outcome. RESULTS: Patient demographics and disease characteristics were generally balanced across treatment arms; however, there was a higher proportion of black/African Americans in the daclatasvir groups (6.0% and 8.2% in the GT1b and GT1a groups, respectively) than in the

  15. [Good virological response to pegylated interferon alfa monotherapy of chronic hepatitis C infection in hemodialysis patient].

    PubMed

    Caro, P; Núñez, A; Delgado, R; Dapena, F; Amann, R

    2007-01-01

    Liver disease caused by hepatitis C virus infection is associated to significant morbidity and mortality among patient with end stage renal disease on maintenance hemodialysis (HD). Therapy in these patients consists of Interferon, preferably pegylated Interferon (pIFN), thus Ribavirin (RBV) is not recommended for patients with impaired renal function, outside its use in controlled trials. We report a case of 35 years young woman on HD treatment, renal transplantation candidate with chronic hepatitis C virus infection, HCV RNA positive (by PCR), genotype 3a, moderate viral load, light increase of aminotransferases. Pegylated Interferon alfa-2a (135 mcg/weekly/SC) was initiated. She achieved HVC RNA negative within 12 weeks, following with pINF as monotherapy to complete 24 weeks (6 months). Sustained virologic response persisted to 24 and 48 weeks. Most important side effects were light detriment of anemia, moderate neutropenia and thombocytopenia, transitory elevation of transaminases and "flu-like" syndrome. Adverse events were well tolerated with total compliance with pIFN dose, no requiring reduce or stop the treatment. These findings confirm that hemodialysis patients with chronic hepatitis C respond well to pegylated IFN monotherapy and a long-term sustained virologic response is achieved, appears to be better tolerated with less side effects, so combination therapy with pINF plus ribavirin is not necessary in all cases.

  16. Pharmacokinetics of Novel Plant Cell-Expressed Taliglucerase Alfa in Adult and Pediatric Patients with Gaucher Disease

    PubMed Central

    Abbas, Richat; Park, Glen; Damle, Bharat; Chertkoff, Raul; Alon, Sari

    2015-01-01

    Taliglucerase alfa is a beta-glucocerebrosidase enzyme replacement therapy approved in the United States, Israel, and other countries for treatment of Type 1 Gaucher disease in adults, and is the first approved plant cell—expressed recombinant protein. In this report, taliglucerase alfa pharmacokinetics were assessed in adult and pediatric patients with Gaucher disease from separate multicenter trials of 30 Units/kg and 60 Units/kg doses infused every 2 weeks. Serial blood samples were obtained from adult patients following single-dose administration on day 1 (n = 26) and multiple doses at week 38 (n = 29), and from pediatric patients following administration of multiple doses of taliglucerase alfa for 10–27 months (n = 10). In both adult and pediatric patients, maximum plasma concentration (Cmax), area under the plasma concentration-time curve from time zero to last measureable concentration (AUC0-t), and from time zero to infinity (AUC0-∞) were higher after 60 Units/kg dose than 30 Units/kg dose. No tendency for accumulation or change in taliglucerase alfa pharmacokinetic parameters over time from day 1 to week 38 was observed with repeated doses of 30 or 60 Units/kg in adults. After multiple doses, mean (range) dose-normalized pharmacokinetic parameters were similar for adult versus pediatric patients receiving 60 Units/kg: Cmax expressed in ng/mL/mg was 42.4 (14.5–95.4) in adults and 46.6 (34.4–68.4) in pediatric patients, AUC0 t expressed in ng•h/mL/mg was 63.4 (26.3–156) in adults and 63.9 (39.8–85.1) in pediatric patients, t1/2 expressed in minutes was 34.8 (11.3–104) in adults and 31.5 (18.0–42.9) in pediatric patients and total body clearance expressed in L/h was 19.9 (6.25–37.9) in adults and 17.0 (11.7–24.9) in pediatric patients. These pharmacokinetic data extend the findings of taliglucerase alfa in adult and pediatric patients. Trial Registration ClinicalTrials.gov. NCT00376168 (in adults); NCT01411228 (in children) PMID

  17. HBcrAg Identifies Patients Failing to Achieve HBeAg Seroconversion Treated with Pegylated Interferon Alfa-2b

    PubMed Central

    Ma, Hui; Yang, Rui-Feng; Li, Xiao-He; Jin, Qian; Wei, Lai

    2016-01-01

    Background: We aimed to evaluate the usefulness of serum hepatitis B virus core-related antigens (HBcrAg) for predicting hepatitis B e antigen (HBeAg) seroconversion in HBeAg-positive chronic hepatitis B patients treated with conventional interferon (IFN) alfa-2b or pegylated IFN. Methods: Fifty-eight patients were enrolled: 29 for the training group and 29 for the validating group. HBcrAg was measured at baseline, week 12, end of the treatment, and 12- and 24-week follow-ups. Sixteen patients in the training group were enrolled in the long-term follow-up (LTFU), during which time the dynamics of the HBcrAg was monitored. Results: The serum HBcrAg level gradually declined during treatment among the HBeAg seroconversion patients of the training group (from baseline, week 12, end of the treatment, 12-week follow-up to 24-week follow-up were 110,245 kU/ml, 3760 kU/ml, 7410 kU/ml, 715 kU/ml, 200 kU/ml, respectively). HBcrAg <19,565 kU/ml at week 24, HBcrAg <34,225 kU/ml at 12-week follow-up, and HBcrAg decrease ≥0.565 log10 kU/ml from the baseline to the end of treatment (EOT) had negative predictive values (NPVs) of 100% for HBeAg seroconversion at the end of follow-up, whereas the positive predictive values (PPVs) were 30.77%, 26.67%, and 25.00%, respectively. The patients with HBeAg seroconversion at the end of 24-week follow-up remained in seroconversion during the LTFU, during which time their serum HBcrAg levels steadily declined or even became undetectable, ranging from 0 to 2.1 kU/ml. Conclusions: Effective antiviral treatment can decrease HBcrAg levels in the serum. The NPVs of HBcrAg for predicting HBeAg seroconversion at 24-week follow-up was 100%, but the PPVs were not satisfactory (all <31%). The serum HBcrAg levels of the patients with HBeAg seroconversion at the end of the 24-week follow-up steadily declined or even became undetectable during the LTFU. PMID:27625094

  18. An open-label clinical trial of agalsidase alfa enzyme replacement therapy in children with Fabry disease who are naïve to enzyme replacement therapy

    PubMed Central

    Goker-Alpan, Ozlem; Longo, Nicola; McDonald, Marie; Shankar, Suma P; Schiffmann, Raphael; Chang, Peter; Shen, Yinghua; Pano, Arian

    2016-01-01

    Background Following a drug manufacturing process change, safety/efficacy of agalsidase alfa were evaluated in enzyme replacement therapy (ERT)-naïve children with Fabry disease. Methods In an open-label, multicenter, Phase II study (HGT-REP-084; Shire), 14 children aged ≥7 years received 0.2 mg/kg agalsidase alfa every other week for 55 weeks. Primary endpoints: safety, changes in autonomic function (2-hour Holter monitoring). Secondary endpoints: estimated glomerular filtration rate, left ventricular mass index (LVMI), midwall fractional shortening, pharmacodynamic parameters, and patient-reported quality-of-life. Results Among five boys (median 10.2 [range 6.7, 14.4] years) and nine girls (14.8 [10.1, 15.9] years), eight patients experienced infusion-related adverse events (vomiting, n=4; nausea, n=3; dyspnea, n=3; chest discomfort, n=2; chills, n=2; dizziness, n=2; headache, n=2). One of these had several hypersensitivity episodes. However, no patient discontinued for safety reasons and no serious adverse events occurred. One boy developed immunoglobulin G (IgG) and neutralizing antidrug antibodies. Overall, no deterioration in cardiac function was observed in seven patients with low/abnormal SDNN (standard deviation of all filtered RR intervals; <100 ms) and no left ventricular hypertrophy: mean (SD) baseline SDNN, 81.6 (20.9) ms; mean (95% confidence interval [CI]) change from baseline to week 55, 17.4 (2.9, 31.9) ms. Changes in SDNN correlated with changes in LVMI (r=−0.975). No change occurred in secondary efficacy endpoints: mean (95% CI) change from baseline at week 55 in LVMI, 0.16 (−3.3, 3.7) g/m2.7; midwall fractional shortening, −0.62% (−2.7%, 1.5%); estimated glomerular filtration rate, 0.15 (−11.4, 11.7) mL/min/1.73 m2; urine protein, −1.8 (−6.0, 2.4) mg/dL; urine microalbumin, 0.6 (−0.5, 1.7) mg/dL; plasma globotriaosylceramide (Gb3), −5.71 (−10.8, −0.6) nmol/mL; urinary Gb3, −1,403.3 (−3,714.0, 907.4) nmol/g creatinine

  19. Durability of sustained response shown in paediatric patients with chronic hepatitis C who were treated with interferon alfa-2b plus ribavirin.

    PubMed

    Kelly, D A; Haber, B; González-Peralta, R P; Murray, K F; Jonas, M M; Molleston, J P; Narkewicz, M R; Sinatra, F R; Lang, T; Lachaux, A; Wirth, S; Shelton, M; Te, H S; Pollack, H; Deng, W; Noviello, S; Albrecht, J K

    2012-04-01

    Long-term studies in adults indicate that sustained virologic response (SVR) after combination treatment for chronic hepatitis C (CHC) predicts long-term clearance. Although peginterferon plus ribavirin is now standard care for children with CHC, long-term follow-up studies are not yet available. This study evaluated durability of virologic response over 5 years in children previously treated with interferon alfa-2b plus ribavirin (IFN/R). Ninety-seven of 147 children with CHC, who were treated with IFN/R and completed the 6-month follow-up in two previous clinical trials, participated in this long-term follow-up study. All were assessed annually for up to 5 years; patients with SVR were assessed for durability of virologic response. Children with SVR (n = 56) and those with detectable hepatitis C virus (HCV) RNA 24-week post-treatment (n = 41) were followed for a median of 284 weeks. Overall, 70% (68/97) of patients completed the 5-year follow-up. One patient with genotype 1a CHC had SVR and relapsed at year 1 of follow-up with the same genotype. Kaplan-Meier estimate for sustained response at 5 years was 98% (95% CI: 95%, 100%). Six patients with low-positive HCV RNA levels (n = 4) or missing HCV RNA at the 24-week follow-up visit (n = 2) in the initial treatment studies had virologic response during this long-term follow-up study. Linear growth rate was impaired during treatment with rapid increases in the immediate 6 months post-treatment. Mean height percentile at the end of the 5-year follow-up was slightly less than the mean pretreatment height percentile. Five patients experienced serious adverse events; none related to study drug exposure. SVR after IFN/R predicts long-term clearance of HCV in paediatric patients; growth normalized in the majority of children during the long-term follow-up. Similar long-term results could be expected after peginterferon alfa-2b plus ribavirin treatment.

  20. Development of a high performance size exclusion chromatography method to determine the stability of Human Serum Albumin in a lyophilized formulation of Interferon alfa-2b.

    PubMed

    Qian, Jin; Tang, Qinglin; Cronin, Bart; Markovich, Robert; Rustum, Abu

    2008-06-13

    Intron Powder for Injection is a lyophilized formulation of Interferon alfa-2b marketed for treatment of Hepatitis C and some cancer indications. Human Serum Albumin (HSA) is used as a lyoprotectant and cryoprotectant at 1.0 mg/mL in the product formulation. No stability-indicating method, which can quantitate HSA and its dimer or oligomer aggregates in the formulated product, has been published to date. This paper describes the development and validation of a stability-indicating high performance size exclusion chromatography (HPSEC) method for the assay of HSA and estimation of HSA related compounds in lyophilized Intron Powder for Injection. The method employs a YMC-Pack Diol-200 column (7.8 mm x 30 cm, 5 microm porous particles with 250 A pore size), UV detection at 214 nm, and a mobile phase of 0.1 M phosphate buffer at pH 7.0 with 0.1 M sodium sulfate. The mobiles phase runs in an isocratic mode at 1.0 mL/min and the total chromatographic run time is 30 min. The method was validated for specific, linearity, accuracy, sensitivity, and robustness. It was shown to be specific for HSA and HSA aggregates (dimer and oligomers) with a limit of quantitation of 0.0005 mg/mL or 0.05% of HSA label claim in the presence of active therapeutic protein, Interferon alfa-2b, and the other pharmaceutical excipients, glycine, sodium phosphate dibasic, sodium phosphate monobasic. The method is stability indicating and is suitable for assay of HSA from 0.0005 mg/mL to 1.5mg/mL. (0.05-150% of HSA label claim) and for estimation of HSA related aggregates (dimer, and oligomer) from 0.0005 mg/mL to 0.15 mg/mL (0.05-15% of HSA label claim). The method is robust for routine use in product quality control. The method was applied to the analysis of batches of lyophilized Intron Powder for Injection of low, middle and high strength from the beginning, middle and end of shelf-life. The results indicated that HSA is stable in the product through out its shelf-life.

  1. Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin.

    PubMed

    Poynard, Thierry; McHutchison, John; Manns, Michael; Myers, Rob P; Albrecht, Janice

    2003-08-01

    Liver fibrosis and activity indexes were validated in patients infected by hepatitis C virus (HCV) nontreated and treated by interferon. The aim was to validate their usefulness as surrogate markers of histologic features using the data of a randomized trial of combination peginterferon alfa-2b and ribavirin. Three hundred fifty-two patients who had had 2 interpretable liver biopsies and stored serum sample before and after treatment were selected. Two hundred eight patients received peginterferon alfa-2b 1.5 mcg per kg and ribavirin and 144 patients interferon alfa-2b 3 MU three times a week and ribavirin for 48 weeks. A fibrosis and an activity index combining 5 and 6 biochemical markers were assessed at baseline and at end of follow-up (24 weeks after treatment). The biochemical markers have significant predictive values both for the diagnosis of fibrosis and for activity. For the diagnosis of bridging fibrosis and/or moderate necroinflammatory activity, the area under the receiver operating characteristics curve of the activity index was 0.76 +/- 0.03 at baseline and 0.82 +/- 0.02 at end of follow-up. A cutoff of activity index at 0.30 (range, 0.00-1.00) had 90% sensitivity and 88% positive predictive value for the diagnosis of bridging fibrosis or moderate necroinflammatory activity. Sensitivity analyses with biopsy specimens of size greater than 15 mm suggest that a part of discordances between biochemical markers and histology were due to biopsy specimen sampling error. In conclusion, these biochemical markers of fibrosis and activity could be used as surrogate markers for liver biopsy in patients with chronic hepatitis C, both for the initial evaluation and for follow-up.

  2. Is there a need for recombinant human luteinizing hormone (lutropin alfa) supplementation in ovarian stimulation for assisted reproduction?

    PubMed

    Nawroth, Frank; Ludwig, Michael

    2006-05-01

    Luteinizing hormone is now available as the recombinant product, lutropin alfa for the treatment of female infertility. It is necessary in the natural process of follicular growth and maturation. It is not yet clear which patients really benefit from the addition of this medication to conventional gonadotropin stimulation procedures in infertility treatment. Certainly, it has a proven benefit in patients suffering from hypogonadotropic hypogonadism (WHO I). Others may be older patients, patients with a profound gonadotropin suppression stimulated in long gonadotropin-releasing hormone agonist protocols, or patients with poor ovarian response to conventional stimulation strategies. The available data are reviewed herein.

  3. Extensive Psoriasis Induced by Pegylated Interferon Alfa-2a and Ribavirin in the Treatment of Chronic Hepatitis C

    PubMed Central

    Kim, Gun-Wook; Jwa, Seung-Wook; Song, Margaret; Kim, Hoon-Soo; Kim, Byung-Soo; Kim, Moon-Bum

    2013-01-01

    A 56-year-old man with chronic hepatitis C was treated with pegylated interferon alfa-2a in combination with ribavirin. However, psoriatic lesions appeared and worsened dramatically during therapy. Because of the extensive skin eruptions, he stopped therapy for chronic hepatitis C and subsequently started narrow-band ultraviolet B phototherapy and topical calcipotriol/betamethasone dipropionate ointment. After this, the psoriasis improved in a slow but comprehensive manner. Our case suggests that physicians should keep in mind the possibility of psoriasis as a side effect of interferon treatment for chronic hepatitis C. PMID:24371397

  4. Consensus interferon and ribavirin in patients with chronic hepatitis C who were nonresponders to pegylated interferon alfa-2b and ribavirin.

    PubMed

    Leevy, Carroll B

    2008-07-01

    Recent studies suggest that consensus interferon and ribavirin is effective in retreating patients with chronic hepatitis C who failed therapy with interferon alfa and ribavirin. The objective of the present study was to assess the efficacy, safety, and tolerability of consensus interferon and ribavirin in patients who did not respond to pegylated interferon alfa-2b and ribavirin. We retrospectively identified 137 consecutive nonresponders to pegylated interferon alfa-2b and ribavirin and initiated patients on daily treatment with consensus interferon 15 mug subcutaneously and weight-based ribavirin for 48 weeks. If patients were HCV RNA negative at 12 weeks, the dose was reduced to 15 mug three times weekly for the remaining 36 weeks. The sustained virologic response rate was 37%. Daily consensus interferon therapy was safe and well tolerated in all patients. No dose reductions were required, and no patient discontinued therapy. Further studies of consensus interferon and ribavirin in nonresponders are warranted.

  5. Arecibo pulsar survey using ALFA. III. Precursor survey and population synthesis

    SciTech Connect

    Swiggum, J. K.; Lorimer, D. R.; McLaughlin, M. A.; Bates, S. D.; Senty, T. R.; Champion, D. J.; Lazarus, P.; Ransom, S. M.; Brazier, A.; Chatterjee, S.; Cordes, J. M.; Hessels, J. W. T.; Nice, D. J.; Ellis, J.; Allen, B.; Bhat, N. D. R.; Bogdanov, S.; Camilo, F.; Crawford, F.; Deneva, J. S.; and others

    2014-06-01

    The Pulsar Arecibo L-band Feed Array (PALFA) Survey uses the ALFA 7-beam receiver to search both inner and outer Galactic sectors visible from Arecibo (32° ≲ ℓ ≲ 77° and 168° ≲ ℓ ≲ 214°) close to the Galactic plane (|b| ≲ 5°) for pulsars. The PALFA survey is sensitive to sources fainter and more distant than have previously been seen because of Arecibo's unrivaled sensitivity. In this paper we detail a precursor survey of this region with PALFA, which observed a subset of the full region (slightly more restrictive in ℓ and |b| ≲ 1°) and detected 45 pulsars. Detections included 1 known millisecond pulsar and 11 previously unknown, long-period pulsars. In the surveyed part of the sky that overlaps with the Parkes Multibeam Pulsar Survey (36° ≲ ℓ ≲ 50°), PALFA is probing deeper than the Parkes survey, with four discoveries in this region. For both Galactic millisecond and normal pulsar populations, we compare the survey's detections with simulations to model these populations and, in particular, to estimate the number of observable pulsars in the Galaxy. We place 95% confidence intervals of 82,000 to 143,000 on the number of detectable normal pulsars and 9000 to 100,000 on the number of detectable millisecond pulsars in the Galactic disk. These are consistent with previous estimates. Given the most likely population size in each case (107,000 and 15,000 for normal and millisecond pulsars, respectively), we extend survey detection simulations to predict that, when complete, the full PALFA survey should have detected 1000{sub −230}{sup +330} normal pulsars and 30{sub −20}{sup +200} millisecond pulsars. Identical estimation techniques predict that 490{sub −115}{sup +160} normal pulsars and 12{sub −5}{sup +70} millisecond pulsars would be detected by the beginning of 2014; at the time, the PALFA survey had detected 283 normal pulsars and 31 millisecond pulsars, respectively. We attribute the deficiency in normal pulsar detections

  6. Transient low-dose methotrexate generates B regulatory cells that mediate antigen-specific tolerance to alglucosidase alfa.

    PubMed

    Joly, Marguerite S; Martin, Roderick P; Mitra-Kaushik, Shibani; Phillips, Lucy; D'Angona, Alida; Richards, Susan M; Joseph, Alexandra M

    2014-10-15

    Biologic drugs, including enzyme-replacement therapies, can elicit anti-drug Abs (ADA) that may interfere with drug efficacy and impact patient safety. In an effort to control ADA, we focused on identifying regimens of immune tolerance induction that may be readily available for clinical use. Data generated in both wild-type mice and a Pompe disease mouse model demonstrate that single-cycle, low-dose methotrexate can be as effective as three cycles of methotrexate in providing a long-lived reduction in alglucosidase alfa-specific ADA. In addition, we show that methotrexate induces Ag-specific tolerance as mice generate similar Ab responses to an irrelevant Ag regardless of prior methotrexate treatment. Methotrexate-induced immune tolerance does not seem to involve cell depletion, but rather a specific expansion of IL-10- and TGF-β-secreting B cells that express Foxp3, suggesting an induction of regulatory B cells. The mechanism of immune tolerance induction appears to be IL-10 dependent, as methotrexate does not induce immune tolerance in IL-10 knockout mice. Splenic B cells from animals that have been tolerized to alglucosidase alfa with methotrexate can transfer tolerance to naive hosts. We hypothesize that methotrexate induction treatment concomitant with initial exposure to the biotherapeutic can induce Ag-specific immune tolerance in mice through a mechanism that appears to involve the induction of regulatory B cells.

  7. Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera.

    PubMed

    Gisslinger, Heinz; Zagrijtschuk, Oleh; Buxhofer-Ausch, Veronika; Thaler, Josef; Schloegl, Ernst; Gastl, Guenther A; Wolf, Dominik; Kralovics, Robert; Gisslinger, Bettina; Strecker, Karin; Egle, Alexander; Melchardt, Thomas; Burgstaller, Sonja; Willenbacher, Ella; Schalling, Martin; Them, Nicole C; Kadlecova, Pavla; Klade, Christoph; Greil, Richard

    2015-10-08

    In this prospective, open-label, multicenter phase 1/2 dose escalation study, we used a next-generation, mono-pegylated interferon (IFN) α-2b isoform, ropeginterferon alfa-2b. The unique feature of ropeginterferon alfa-2b is a longer elimination half-life, which allows administration every 2 weeks. We present data from 51 polycythemia vera patients. The main goal was to define the maximum tolerated dose and to assess safety and efficacy. A dose range of 50 to 540 µg was tested without the appearance of dose-limiting toxicities. All drug-related adverse events were known toxicities associated with IFN-α. The cumulative overall response rate was 90%, comprising complete response in 47% and partial response in 43% of patients; the best individual molecular response level was a complete response in 21% of patients and partial response in 47%. Notably, we did not observe any correlation between the dose level and the response rate or response duration, suggesting that already low levels of ropeginterferon alfa-2b are sufficient to induce significant hematologic and molecular responses. These data suggest promising efficacy and safety of ropeginterferon alfa-2b and support the development of the drug in a randomized phase 3 clinical trial. The study was disclosed at www.clinicaltrials.gov as #NCT01193699 before including the first patient.

  8. Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: A Fabry Outcome Survey analysis

    PubMed Central

    Beck, Michael; Hughes, Derralynn; Kampmann, Christoph; Larroque, Sylvain; Mehta, Atul; Pintos-Morell, Guillem; Ramaswami, Uma; West, Michael; Wijatyk, Anna; Giugliani, Roberto

    2015-01-01

    Outcomes from 5 years of treatment with agalsidase alfa enzyme replacement therapy (ERT) for Fabry disease in patients enrolled in the Fabry Outcome Survey (FOS) were compared with published findings for untreated patients with Fabry disease. Data were extracted from FOS, a Shire-sponsored database, for comparison with data from three published studies. Outcomes evaluated were the annualized rate of change in estimated glomerular filtration rate (eGFR) and left ventricular mass indexed to height (LVMI) as well as time to and ages at a composite morbidity endpoint and at death. FOS data were extracted for 740 treated patients who were followed for a median of ~ 5 years. Compared with no treatment, patients treated with agalsidase alfa demonstrated slower decline in renal function and slower progression of left ventricular hypertrophy. Treated male patients with baseline eGFR < 60 mL/min/1.73 m2 had a mean (standard error of the mean [SEM]) annualized change in eGFR of − 2.86 (0.53) mL/min/1.73 m2/y compared with − 6.8 (1.5) in the published untreated cohort. The mean (SEM) rate of LVMI increase with treatment was 0.33 (0.10) g/m2.7/y in males and 0.48 (0.09) in females, compared with 4.07 (1.03) in untreated males and 2.31 (0.81) in untreated females. Morbidity occurred later in treated patients, with ~ 16% risk of a composite morbidity event (26% in males) after 24 months with ERT versus ~ 45% without treatment, with first events and deaths also occurring at older ages in patients administered ERT (e.g., estimated median survival in treated males was 77.5 years versus 60 years in untreated males). Findings from these retrospective comparisons of observational data and published literature support the long-term benefits of ERT with agalsidase alfa for Fabry disease in slowing the progression of renal impairment and cardiomyopathy. Treatment also appeared to delay the onset of morbidity and mortality. Interpretation of these findings should take into

  9. Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: A Fabry Outcome Survey analysis.

    PubMed

    Beck, Michael; Hughes, Derralynn; Kampmann, Christoph; Larroque, Sylvain; Mehta, Atul; Pintos-Morell, Guillem; Ramaswami, Uma; West, Michael; Wijatyk, Anna; Giugliani, Roberto

    2015-06-01

    Outcomes from 5 years of treatment with agalsidase alfa enzyme replacement therapy (ERT) for Fabry disease in patients enrolled in the Fabry Outcome Survey (FOS) were compared with published findings for untreated patients with Fabry disease. Data were extracted from FOS, a Shire-sponsored database, for comparison with data from three published studies. Outcomes evaluated were the annualized rate of change in estimated glomerular filtration rate (eGFR) and left ventricular mass indexed to height (LVMI) as well as time to and ages at a composite morbidity endpoint and at death. FOS data were extracted for 740 treated patients who were followed for a median of ~ 5 years. Compared with no treatment, patients treated with agalsidase alfa demonstrated slower decline in renal function and slower progression of left ventricular hypertrophy. Treated male patients with baseline eGFR < 60 mL/min/1.73 m(2) had a mean (standard error of the mean [SEM]) annualized change in eGFR of - 2.86 (0.53) mL/min/1.73 m(2)/y compared with - 6.8 (1.5) in the published untreated cohort. The mean (SEM) rate of LVMI increase with treatment was 0.33 (0.10) g/m(2.7)/y in males and 0.48 (0.09) in females, compared with 4.07 (1.03) in untreated males and 2.31 (0.81) in untreated females. Morbidity occurred later in treated patients, with ~ 16% risk of a composite morbidity event (26% in males) after 24 months with ERT versus ~ 45% without treatment, with first events and deaths also occurring at older ages in patients administered ERT (e.g., estimated median survival in treated males was 77.5 years versus 60 years in untreated males). Findings from these retrospective comparisons of observational data and published literature support the long-term benefits of ERT with agalsidase alfa for Fabry disease in slowing the progression of renal impairment and cardiomyopathy. Treatment also appeared to delay the onset of morbidity and mortality. Interpretation of these findings should take

  10. [A case of Bell's palsy associated with peginterferon Alfa-2a and ribavirin therapy for chronic hepatitis C virus infection].

    PubMed

    Lee, Moo Yeol; Cho, Hoon; Kim, Yeong Muk; Lee, Joon Sang

    2006-09-01

    Pegylated interferon alfa-2a (PEG-IFN) and ribavirin combination therapy is the first line treatment for chronic HCV infection. There are four reports of Bell's palsy associated with interferon-alpha (IFN-alpha) and ribavirin therapy. We report here a case of Bell's palsy that occurred in a patient with chronic HCV infection during combination PEG-IFN and ribavirin therapy. The patient was 49-year-old man with chronic hepatitis C for 2 years. The liver biopsy showed grade 1 and stage 1. Therapy with PEG-IFN (Pegasys) 180 microgram/week and ribavirin 1200 mg/day was initiated. After 3 weeks of treatment, the patient showed a loss of muscular tone on the left side of his face. A diagnosis of Bell's palsy was made, and the PEG-IFN and ribavirin therapy was stopped. Prednisolone 45 mg/d was given and then tapered for 8 weeks. His palsy improved over 6 weeks.

  11. THE ARECIBO LEGACY FAST ALFA SURVEY. IX. THE LEO REGION H I CATALOG, GROUP MEMBERSHIP, AND THE H I MASS FUNCTION FOR THE LEO I GROUP

    SciTech Connect

    Stierwalt, Sabrina; Haynes, Martha P.; Giovanelli, Riccardo; Martin, Ann M.; Kent, Brian R.; Saintonge, Amelie; Karachentsev, Igor D.; Karachentseva, Valentina E. E-mail: haynes@astro.cornell.edu E-mail: amartin@astro.cornell.edu E-mail: amelie@physik.uzh.ch E-mail: vkarach@observ.univ.kiev.ua

    2009-08-15

    We present the catalog of H I sources extracted from the ongoing Arecibo Legacy Fast ALFA (ALFALFA) extragalactic H I line survey, found within the sky region bounded by 9{sup h}36{sup m} < {alpha} < 11{sup h}36{sup m} and +08{sup 0} < {delta} < +12{sup 0}. The H I catalog presented here for this 118 deg{sup 2} region is combined with the ones derived from surrounding regions also covered by the ALFALFA survey to examine the large-scale structure in the complex Leo region. Because of the combination of wide sky coverage and superior sensitivity, spatial and spectral resolution, the ALFALFA H I catalog of the Leo region improves significantly on the numbers of low H I mass sources as compared with those found in previous H I surveys. The H I mass function of the Leo I group presented here is dominated by low-mass objects: 45 of the 65 Leo I members have M{sub H{sub l}}<10{sup 8} M-odot, yielding tight constraints on the low-mass slope of the Leo I H I mass function. The best-fit slope is {alpha} {approx_equal} -1.41 + 0.2 - 0.1. A direct comparison between the ALFALFA H I line detections and an optical search of the Leo I region proves the advantage of the ALFALFA strategy in finding low-mass, gas-rich dwarfs. These results suggest the existence of a significant population of low surface brightness, gas-rich, yet still very low H I mass galaxies, and may reflect the same type of morphological segregation as is seen in the Local Group. While the low-mass end slope of the Leo I H I mass function is steeper than that determined for luminosity functions of the group, the slope still falls short of the values predicted by simulations of structure formation in the lambda cold dark matter paradigm.

  12. EFFECT OF HCV RNA SUPPRESSION DURING PEGINTERFERON ALFA-2A MAINTENANCE THERAPY ON CLINICAL OUTCOMES IN THE HALT-C TRIAL

    PubMed Central

    Shiffman, Mitchell L; Morishima, Chihiro; Dienstag, Jules L; Lindsay, Karen L; Hoefs, John C; Lee, William M; Wright, Elizabeth C.; Naishadham, Deepa; Everson, Gregory T; Lok, Anna S; Di Bisceglie, Adrian M; Bonkovsky, Herbert L; Ghany, Marc G

    2013-01-01

    Background and Aims The HALT-C trial demonstrated that low-dose peginterferon maintenance therapy was ineffective in preventing clinical outcomes in patients with chronic hepatitis C, advanced fibrosis and failure to achieve a sustained virologic response during lead-in phase treatment with standard dose peginterferon/ribavirin. This analysis was performed to determine if suppressing HCV RNA during the trial was associated with a reduction in clinical outcomes. Methods 764 patients treated during the lead-in phase of HALT-C were randomized to either peginterferon alfa-2a (90 mcg/week) maintenance therapy or no treatment (control) for 3.5 years. Clinical outcomes included an increase in Child-Turcotte-Pugh score, ascites, spontaneous bacterial peritonitis, hepatic encephalopathy, variceal hemorrhage, hepatocellular carcinoma and mortality. Results During the lead-in, ≥4 log10 decline in serum HCV RNA occurred in 178 patients; 82% of whom lost detectable HCV RNA and later broke through or relapsed. These patients had significantly (p=0.003) fewer clinical outcomes whether randomized to maintenance therapy or control. Following randomization serum HCV RNA increased significantly in all 90 control patients and 58/88 receiving maintenance therapy. Only 30 patients had persistent suppression of HCV RNA by ≥4 log10 during maintenance therapy. No significant reduction in clinical outcomes was observed in these patients. Conclusions Viral suppression by ≥4 log10 with full dose peginterferon/ribavirin is associated with a significant reduction in clinical outcomes. Continuing low dose peginterferon maintenance therapy, even in patients with persistent viral suppression, does not lead to a further decline in clinical outcomes. PMID:19747918

  13. A Saudi Gastroenterology Association Position Statement on the Use of Tumor Necrosis Factor-alfa Antagonists for the Treatment of Inflammatory Bowel Disease

    PubMed Central

    Mosli, Mahmoud H.; Al-Harbi, Othman; Feagan, Brian G.; Almadi, Majid A.

    2015-01-01

    The objective of this position statement from the Saudi Gastroenterology Association is to guide gastroenterologists on the use of tumor necrosis factor-alfa (TNF-α) antagonists for the treatment of the idiopathic inflammatory bowel diseases, Crohn's disease, and ulcerative colitis. In this article, we summarize the relevant literature regarding the safety and efficacy of TNF-α antagonists, highlight relevant safety concerns specific to the environment in Saudi Arabia, and provide specific recommendations for the use of these agents. PMID:26228361

  14. Health management program: factors influencing completion of therapy with high-dose interferon alfa-2b for high-risk melanoma

    PubMed Central

    Levesque, N.; Mitchinson, K.; Lawrie, D.; Fedorak, L.; MacDonald, D.; Normand, C.; Pouliot, J.F.

    2008-01-01

    The goal of the 1-year observational, multicentre, open-label study reported here was to identify factors influencing adherence to high-dose interferon alfa-2b adjuvant therapy in patients at high risk of recurrence following surgical excision of malignant melanoma. The study was carried out in 23 tertiary-care centres across Canada. The 225 patients enrolled in the study all had malignant melanoma that was surgically excised and that required adjuvant treatment with interferon alfa-2b. Of these patients, 64% were men. Mean age was 51.7 years. All patients received interferon alfa-2b treatment during a 4-week induction phase (20 MU/m2 intravenously 5 days per week) followed by a 48-week maintenance phase (10 MU/m2 subcutaneously 3 days per week). Oncology nurses reviewed side-effect management with the patients before the induction and maintenance phases. Patients were provided with daily diaries, comprehensive educational materials, and ongoing nursing support. Data on side effects and discontinuations were obtained from patient interviews and diaries. The main outcome measurements were related to treatment discontinuation: rate, timing, reason, and prevention. Of the 225 patients, 75 (33.3%) discontinued interferon during the induction phase, and 58 (25.8%) discontinued during the maintenance phase. The main reasons for discontinuation were adverse events (58%) and disease progression (26%). Patients with a daily fluid intake greater than 1.5 L were more likely to complete therapy than were those with an intake less than 1.5 L (64% vs. 36%, p < 0.0001). Of 225 patients enrolled in the interferon alfa-2b health management program, 41% completed the 1-year treatment course. Higher fluid intake (>1.5 L daily) was associated with increased adherence to therapy. PMID:18317583

  15. Influence of wool and thermo-binder fibers relative fractions on the adhesion of non-woven Alfa fibers reinforced unsaturated polyester hybrid composites

    NASA Astrophysics Data System (ADS)

    Amin Omri, Med; Triki, A.; Ben Hassen, Med; Arous, M.; Bulou, A.

    2016-10-01

    Alfa/wool/thermo-binder fibers hybrid composites were investigated in order to analyze adhesion state. Bearing in mind the chemical structure of wool and thermo-binder fibers, this study revealed a good compatibility between the reinforcement and the matrix. Dielectric measurements revealed the presence of two dielectric relaxations in the composite. The first relaxation was attributed to the α mode relaxation and the second one was associated with the conductivity noted for high temperature. This study allowed the analysis of the interfacial polarization effect using the Havrilliak-Negami model in the electric modulus formalism. The lowness of this relaxation intensity revealed a good adhesion of the fibers in the matrix. Differential Scanning Calorimetry (DSC) showed a slow decrease of the Tg glass transition temperature compared to the matrix, which could be explained by the existence of interactions between the fibers and the matrix. Vibrational analysis, based on FTIR measurements, showed a less hydrophilic character of Alfa fibers owing to a basic dissociation that occurs between the wool fibers and the water molecules associated with Alfa fibers. Furthermore, adhesion mechanism in the composite material was established by covalent and hydrogen bonds. Tensile testing performed on this composite confirmed that such adhesion was improved by increasing the thermo-binder fibers relative fraction.

  16. The Budget of the Atmosphere-Soil Exchange: A Long-term Fluxes Analysis (BASE:ALFA) project.

    NASA Astrophysics Data System (ADS)

    Caporaso, L.; di Giuseppe, F.; Bonafè, G.

    2010-09-01

    A long term measurements of parameters characterizing the energy and water cycle in the Po Valley (Italy) has been carried out between summers 2009 and 2010 to create a data pool of micro-meteorological/soil data to test and validate Surface Vegetation Atmosphere Transfer Scheme (SVATS) and Regional Numerical weather prediction R-NWP with respect to the representation of near-surface processes. The BASE:ALFA project organized in the middle of the Po valley was thought as a prototype experience which tried to fulfill the need highlighted in recent SRNWP program for a network of surface stations which should soon appear in Europe as a spontaneous cooperation of national weather services. We report on our experimental campaigns and on some modeling outcomes. In particular, we will present one targeted application of the collected dataset, which we found of special interest for the area. That is how the wrong PBL mixing height modeling can impact air quality assessment. Most air quality models for pollutant concentrations estimations, in fact, uses R-NWP predicted and or analyzed PBL mixing height to estimate air quality indices, as for example PM10 concentrations.

  17. THE ARECIBO LEGACY FAST ALFA SURVEY. X. THE H I MASS FUNCTION AND {Omega}{sub H{sub i}} FROM THE 40% ALFALFA SURVEY

    SciTech Connect

    Martin, Ann M.; Papastergis, Emmanouil; Giovanelli, Riccardo; Haynes, Martha P.; Springob, Christopher M.; Stierwalt, Sabrina E-mail: papastergis@astro.cornell.ed E-mail: haynes@astro.cornell.ed E-mail: sabrina@ipac.caltech.ed

    2010-11-10

    The Arecibo Legacy Fast ALFA (ALFALFA) survey has completed source extraction for 40% of its total sky area, resulting in the largest sample of H I-selected galaxies to date. We measure the H I mass function from a sample of 10,119 galaxies with 6.2 < log (M{sub H{sub i}}/M{sub sun}) < 11.0 and with well-described mass errors that accurately reflect our knowledge of low-mass systems. We characterize the survey sensitivity and its dependence on profile velocity width, the effect of large-scale structure, and the impact of radio frequency interference in order to calculate the H I mass function with both the 1/V{sub max} and 2DSWML methods. We also assess a flux-limited sample to test the robustness of the methods applied to the full sample. These measurements are in excellent agreement with one another; the derived Schechter function parameters are {phi}{sub *} (h {sup 3}{sub 70} Mpc{sup -3} dex{sup -1}) = 4.8 {+-} 0.3 x 10{sup -3}, log (M{sub *}/M{sub sun}) + 2 log h{sub 70} = 9.96 {+-} 0.02, and {alpha} = -1.33 {+-} 0.02. We find {Omega}{sub H{sub i}}= 4.3 {+-} 0.3 x10{sup -4} h {sup -1}{sub 70}, 16% larger than the 2005 HIPASS result, and our Schechter function fit extrapolated to log (M{sub H{sub i}}/M{sub sun}) = 11.0 predicts an order of magnitude more galaxies than HIPASS. The larger values of {Omega}{sub H{sub i}} and of M{sub *} imply an upward adjustment for estimates of the detection rate of future large-scale H I line surveys with, e.g., the Square Kilometer Array. A comparison with simulated galaxies from the Millennium Run and a treatment of photoheating as a method of baryon removal from H I-selected halos indicate that the disagreement between dark matter mass functions and baryonic mass functions may soon be resolved.

  18. The effectiveness of retreatment with peginterferon alfa and ribavirin in patients with chronic viral hepatitis C genotype 2 and 3: a prospective cohort study in Brazil

    PubMed Central

    2012-01-01

    Background More than 50% of patients infected with chronic hepatitis C virus (HCV) do not respond to treatment with conventional interferon (IFN) combined with ribavirin (RBV). The aim of our study was to evaluate the effectiveness of retreatment with peginterferon alfa-2a or 2b (PEG-IFN 2a or 2b) concomitantly with RBV in patients with HCV genotype 2 and 3, which were non-responders or relapsers to initial treatment with IFN / RBV and to identify possible predictors of sustained virological response (SVR). Methods From September 2003 to March 2009 a cohort of 216 patients who had previously failed therapy with a regimen of standard interferon and ribavirin, were followed in a specialized service implemented in the Brazilian Unified Health System, Rio Grande do Sul. All patients were retreated with PEG-IFN 2a or 2b per week, associated with RBV, through oral route, with doses determined according to weight (1,000 mg if weight ≤ 75 Kg and 1,250 mg if ≥ 75 Kg) per day for 48 weeks. The HCV-RNA was tested by Polymerase Chain Reaction (PCR). Virological Response (VR) within 48 weeks and SVR in the 72 weeks was considered for evaluation of treatment efficacy. Analyses were performed in patients who received at least one dose of PEG-IFN. Results The SVR rate for non-responders to previous treatment was 34.4% and for relapsers was 50% (p = 0.031). As predictive factors that contribute to improve SVR, were identified the age (p = 0.005), to be relapsers to previous treatment (p = 0.023) and present liver biopsy examination Metavir F0-F2 (p = 0.004). In assessing the safety profile, 51 patients (23.6%) discontinued treatment prematurely. Conclusions This alternative retreatment for patients who have failed prior therapies for anti-HCV, has demonstrated promising SVR rate, provided that it includes a careful selection of patients with predictors of response and adverse events monitored. PMID:23270376

  19. Clinical Experience of Interferon Alfa-2a Treatment for Refractory Uveitis in Behçet's Disease.

    PubMed

    Park, Ji-Youn; Chung, Yoo-Ri; Lee, Kihwang; Song, Ji Hun; Lee, Eun-So

    2015-07-01

    Behçet's disease (BD) involves multisystem vasculitis of unknown origin. Ocular manifestations of BD mostly include bilateral panuveitis and retinal vasculitis, which are very challenging to treat. Interferon alfa-2a (IFN) has been recently introduced for treating refractory Behçet uveitis, mainly in Germany and Turkey. Nonetheless, there is so far no consensus about the ideal treatment regimen of IFN for Behçet uveitis. We report our experience of IFN treatment in five Korean BD patients with refractory uveitis. All patients complained of oral ulcers; one patient had a positive pathergy test and 2 showed the presence of HLA-B51. Immunosuppressive agents used prior to IFN treatment included cyclosporine and methotrexate. The IFN treatment was commenced with a dose of 6-9 MIU/day for 7 days, adjusted according to individual ocular manifestations, tapered down to 3 MIU three times in a week, and then discontinued. All patients showed positive response to IFN treatment; 50% of them showed complete response without additional major ocular inflammation during the follow-up period. Other BD symptoms also improved after IFN treatment in most cases. After treatment, the relapse rate and the required dose of oral corticosteroid were decreased in most cases, showing a significant steroid-sparing effect. However, the visual acuity was not improved in most cases due to irreversible macular sequelae. Despite the small sample size of this study, we suggest that, in Korean patients, IFN is an effective treatment modality for BD uveitis as was observed in German and Turkish patients.

  20. Therapeutic and routine prophylactic properties of rFactor VIII Fc (efraloctocog alfa, Eloctate®) in hemophilia A

    PubMed Central

    Chowdary, Pratima; Fosbury, Emma; Riddell, Anne; Mathias, Mary

    2016-01-01

    rFVIIIFc (efraloctocog alfa, Eloctate®) is an extended half-life (EHL) factor VIII licensed for use in patients with hemophilia A for prophylaxis and treatment of bleeding and surgical episodes. Pharmacokinetic studies in adults have shown a mean 1.5-fold increase in half-life compared to full-length factor VIII. When compared to adults, the half-life is decreased by 8% in adolescents between 12 and 17 years, by 18% in children 6 to <12 years, and by 33% in children between the ages of 2 and <6 years. There is a considerable interindividual variation in the prolongation of the half-life particularly in children and across the age groups, the range extending from no increase to a 2.5-fold increase. In addition to age, von willebrand factor (VWF) antigen level has demonstrated a significant impact on rFVIIIFc half-life, with higher VWF levels associated with greater prolongation of half-life. The pivotal and pediatric clinical trials have demonstrated the efficacy and safety of rFVIIIFc for use in regular prophylaxis and in management of bleeds and surgery. In these studies, just under half the participants showed a zero annualized bleed rate (ABR), and the median ABR (1.6 in the pivotal study for the individualized prophylaxis arm) showed a further decrease in the extension study. On average, the patients required fewer infusions (reduced by at least a third), and the mean weekly consumption seems to be in keeping with standard recombinant factor VIII. EHL rFVIIIFc has made decreased infusion frequency a possibility. However, the interindividual variability in dose and infusion frequency highlights the need for a personalized approach based on individual patient’s half-life and/or response to treatment. PMID:27695377

  1. TSAT is a better predictor than ferritin of hemoglobin response to Epoetin alfa in US dialysis patients.

    PubMed

    Gaweda, Adam E; Bhat, Premila; Maglinte, Gregory A; Chang, Chun-Lan; Hill, Jerrold; Park, Grace S; Ashfaq, Akhtar; Gitlin, Matthew

    2014-01-01

    Clinical guidelines recommend concurrent treatment of anemia in end-stage renal disease with erythropoiesis-stimulating agents (ESAs) and iron. However, there are mixed data about optimal iron supplementation. To help address this gap, the relationship between iron markers and hemoglobin (Hb) response to ESA (Epoetin alfa) dose was examined. Electronic medical records of 1902 US chronic hemodialysis patients were analyzed over a 12-month period between June 2009 and June 2010. The analysis included patients who had at least one Hb value during each 4-week interval for four consecutive intervals (k - 2, k - 1, k, and k + 1; k is the index interval), received at least one ESA dose during intervals k - 1 or k, had at least one transferrin saturation (TSAT) value at interval k, and at least one ferritin value during intervals k - 2, k - 1, or k. Effect modification by TSAT and ferritin on Hb response was evaluated using the generalized estimating equations approach. Patients had a mean (standard deviation) age of 62 (15) years; 41% were Caucasian, 34% African American, 65% had hypertension, and 39% diabetes. Transferrin saturation, but not ferritin, had a statistically significant (P < 0.05) modifying effect on Hb response. Maximum Hb response was achieved when TSAT was 34%, with minimal incremental effect beyond these levels. Of the two standard clinical iron markers, TSAT should be used as the primary marker of the modifying effect of iron on Hb response to ESA. Long-term safety of iron use to improve Hb response to ESA warrants further study.

  2. Arecibo Pulsar Survey Using ALFA. IV. Mock Spectrometer Data Analysis, Survey Sensitivity, and the Discovery of 40 Pulsars

    NASA Astrophysics Data System (ADS)

    Lazarus, P.; Brazier, A.; Hessels, J. W. T.; Karako-Argaman, C.; Kaspi, V. M.; Lynch, R.; Madsen, E.; Patel, C.; Ransom, S. M.; Scholz, P.; Swiggum, J.; Zhu, W. W.; Allen, B.; Bogdanov, S.; Camilo, F.; Cardoso, F.; Chatterjee, S.; Cordes, J. M.; Crawford, F.; Deneva, J. S.; Ferdman, R.; Freire, P. C. C.; Jenet, F. A.; Knispel, B.; Lee, K. J.; van Leeuwen, J.; Lorimer, D. R.; Lyne, A. G.; McLaughlin, M. A.; Siemens, X.; Spitler, L. G.; Stairs, I. H.; Stovall, K.; Venkataraman, A.

    2015-10-01

    The on-going Arecibo Pulsar-ALFA (PALFA) survey began in 2004 and is searching for radio pulsars in the Galactic plane at 1.4 GHz. Here we present a comprehensive description of one of its main data reduction pipelines that is based on the PRESTO software and includes new interference-excision algorithms and candidate selection heuristics. This pipeline has been used to discover 40 pulsars, bringing the survey’s discovery total to 144 pulsars. Of the new discoveries, eight are millisecond pulsars (MSPs; P\\lt 10 ms) and one is a Fast Radio Burst (FRB). This pipeline has also re-detected 188 previously known pulsars, 60 of them previously discovered by the other PALFA pipelines. We present a novel method for determining the survey sensitivity that accurately takes into account the effects of interference and red noise: we inject synthetic pulsar signals with various parameters into real survey observations and then attempt to recover them with our pipeline. We find that the PALFA survey achieves the sensitivity to MSPs predicted by theoretical models but suffers a degradation for P≳ 100 ms that gradually becomes up to ˜10 times worse for P\\gt 4 {{s}} at {DM}\\lt 150 pc cm-3. We estimate 33 ± 3% of the slower pulsars are missed, largely due to red noise. A population synthesis analysis using the sensitivity limits we measured suggests the PALFA survey should have found 224 ± 16 un-recycled pulsars in the data set analyzed, in agreement with the 241 actually detected. The reduced sensitivity could have implications on estimates of the number of long-period pulsars in the Galaxy.

  3. Seven‐year safety and efficacy with velaglucerase alfa for treatment‐naïve adult patients with type 1 Gaucher disease

    PubMed Central

    Wang, Nan; Ogg, Carol; Crombez, Eric; Cohn, Gabriel M.; Elstein, Deborah

    2015-01-01

    Velaglucerase alfa is a human β‐glucocerebrosidase approved for Gaucher disease type 1 (GD1) treatment. This report summarizes the 7‐year experience of the now‐completed phase I/II and extension studies of adult GD1 patients who received velaglucerase alfa. Ten patients who completed the 9‐month, phase I/II study entered the extension trial TKT025EXT, of which eight completed this study. Doses were reduced after a cumulative treatment period of 15 to 18 months. Although all patients experienced ≥1 adverse event, no patient withdrew due to a drug‐related adverse event or required premedication. No patient developed anti‐drug antibodies, compliance remained high (median 98%), and seven of eight eligible patients transitioned to home infusions under supervision by healthcare professionals. Statistically significant improvements were observed for efficacy parameters: mean percentage changes from baseline (95% confidence intervals) were 18% (12%, 24%) for hemoglobin concentration, 115% (66%, 164%) for platelet counts, and −42% (−53%, −31%) and −78% (−94%, −62%) for liver and spleen volumes, respectively. Improvements were also observed for secondary endpoints chitotriosidase and CCL18 levels and exploratory endpoints (bone mineral density [BMD], bone marrow burden [BMB] scores). Normalization to near‐normalization of individuals' hemoglobin concentrations, platelet counts, liver volumes, and BMB scores was observed, and there were marked improvements in spleen volumes, biomarkers, and BMD. TKT025EXT represents the longest, prospective clinical trial for GD1 treatment to date and suggests that, despite dose reduction within 18 months of initiating therapy, velaglucerase alfa was generally well tolerated and was associated with marked improvement, including near normalization and/or normalization of key GD1 disease parameters. Am. J. Hematol. 90:577–583, 2015. © 2015 The Authors. American Journal of Hematology published by Wiley Periodicals

  4. CromixSun: un nuovo strumento per osservare il Sole in luce H-alfa

    NASA Astrophysics Data System (ADS)

    Lugli, Marcello

    2005-08-01

    The paper illustrates the possibility to achieve positive and useful results also beyond any imagination and out of any orthodox scheme. More than true what A. Einstein said: "Imagination is more important than knowledge". Only by using and assembling together the simplest filters that actual technology is able to produce it was possible to create a narrow bandpass H-alpha instrument which has nothing to envy other similar devices and probably, it may offer something more than others.

  5. Sustained Virologic Response to a Dual Peginterferon alfa-2a and Ribavirin in Treating Chronic hepatitis C Infection

    PubMed Central

    Naing, Cho; Sitt, Than; Aung, Aye TD; Aung, Kyan

    2015-01-01

    Abstract In Myanmar, hepatitis C virus (HCV) infection prevalence is 2%. A combination therapy of pegylated interferon alfa-2a and ribavirin (PEG-IFNa/RBV) is a standard treatment, but the effect of this antiviral therapy needs evaluation as to determine the efficacy and safety of dual PEG-IFNa/RBV therapy in treating patients infected with HCV in Myanmar. This was a retrospective analysis of data from a single clinic exclusively for gastrointestinal diseases in Yangon, Myanmar. We assessed treatment responses at the defined time points and stratified by genotypes of HCV. We also determined incidences of adverse events (AEs). We investigated independent predictors of sustained virologic response (SVR) in the participants. A total of 362 HCV-infected cases were included in this study. The majority were females (51.7%) with mean age of 47.12 years (±11.6) and noncirrhosis patients (82%). Rapid virologic response (RVR), early virologic response (EVR), end of treatment response (ETR), and SVR 24 weeks after completion of the dual treatment were 50.3% (178/362), 88% (314/357), 80.1% (286/357), and 85.6% (167/195), respectively. The most frequently reported AEs were nausea/anorexia (72.8%) and flu-like symptoms (62.4%). In multivariate analysis, 4 factors were independently associated with SVR; SVR to genotype 3 (odds ratio [OR] 2.4, 95% CI: 1.24–4.62), EVR (OR 0.54, 95% CI: 0.3–0.95), and duration of treatment (OR 1.52, 95% CI: 1.18–1.98). Study limitations were acknowledged. The efficacy and safety of the dual therapy in treating HCV-infected patient in Myanmar was acceptable. We recommend a prospective randomized control trial looking at duration of therapy and rates of achieving SVR, which could significantly impact the care of HCV-infected patients in Myanmar and perhaps other countries as well. PMID:26222859

  6. Benefit of adjuvant interferon alfa-2b (IFN-α) therapy in melanoma patients with high serum MMP-8 levels.

    PubMed

    Vihinen, Pia; Tervahartiala, Taina; Sorsa, Timo; Hansson, Johan; Bastholt, Lars; Aamdal, Steinar; Stierner, Ulrika; Pyrhönen, Seppo; Syrjänen, Kari; Lundin, Johan; Hernberg, Micaela

    2015-02-01

    Matrix metalloproteinases (MMPs) are important enzymes in tissue turnover and various inflammatory processes. In this study, it was evaluated whether serum MMP-8 can predict the response to adjuvant interferon alfa-2b (IFN-α) therapy in patients with operated high-risk cutaneous melanoma. Pre-treatment sera from 460 patients with stage IIB-IIIC melanoma were analyzed for MMP-8. The patients were randomized after surgery to adjuvant IFN-α for 12 or 24 months (n = 313) or observation only (n = 147). The median serum MMP-8 level was used to classify the patients into a low MMP-8 (n = 232) and a high MMP-8 (n = 228) group. In the high MMP-8 subgroup, IFN-α therapy significantly improved relapse-free survival (RFS). RFS was 36.8 months in patients with high MMP-8 levels receiving IFN-α therapy, whereas RFS for those with high MMP-8 levels with observation only was 10.6 months (P = 0.027). Median overall survival for patients with high MMP-8 and observation only was 36.7 versus 71.7 months in those receiving IFN-α (P = 0.13). In a multivariate model, IFN-α therapy was a significant predictor of favorable RFS (HR 0.74; 95 % CI 0.55-0.99; P = 0.048), after adjustment for pre-treatment MMP-8 (HR 1.17; 95 % CI 0.88-1.55; P = 0.28), gender (HR 1.16; 95 % CI 0.86-1.56; P = 0.32), age (HR 1.00; 95 % CI 1.00-1.02; P = 0.12), ulceration (HR 1.09; 95 % CI 0.81-1.46; P = 0.58), and the presence of node metastases (HR 1.36; 95 % CI 1.17-1.58; P < 0.0001). In conclusion, patients with high serum MMP-8 levels may benefit from adjuvant IFN-α therapy, but this observation should be further investigated.

  7. Enhanced anti-melanoma efficacy of interferon alfa-2b via inhibition of Shp2.

    PubMed

    Win-Piazza, Hla; Schneeberger, Valentina E; Chen, Liwei; Pernazza, Daniele; Lawrence, Harshani R; Sebti, Said M; Lawrence, Nicholas J; Wu, Jie

    2012-07-01

    Interferon-α2b (IFN-α2b) is used to treat melanoma but there is a need to improve its efficacy. IFN-α2b signaling requires STAT1/STAT2 tyrosine phosphorylation and is subject to negative regulation by phosphatases. In this study, we determined whether inhibition of the protein tyrosine phosphatase Shp2 could enhance IFN-α2b responses in human melanoma cells. Shp2 knockdown increased IFN-α2b-stimulated STAT1 Tyr-701 phosphorylation and ISRE-luciferase activity even though it did not affect STAT2 Tyr-690 phosphorylation in A375 cells. In A375 tumor xenografts, Shp2 knockdown enhanced the anti-melanoma effect of IFN-α2b. Furthermore, the Shp2 inhibitor SPI-112Me increased the IFN-α2b-induced STAT1 activation and anti-proliferative response in A375 and SK-MEL-2 cells. These results demonstrate that inhibition of Shp2 can enhance the anti-melanoma activity of IFN-α2b.

  8. Pegylated interferon alfa-2b (peg-intron) plus ribavirin (rebetol) in the treatment of chronic hepatitis C: a local experience.

    PubMed

    Seow, E L; Robert Ding, P H

    2005-12-01

    This was an open-label, uncontrolled study with the aim of assessing the efficacy and safety of pegylated interferon alfa-2b plus ribavirin in the treatment of chronic hepatitis C. The study was conducted in Island Hospital, Penang beween January 2002 and December 2003. Thirty-three patients were enrolled in this study with ten defaulters. The overall sustained virological response (SVR) (Intention-To-Treat analysis) in naïve patients was 39.10%. However, when the study was adjusted to only include those who completed treatment and follow-up, overall SVR as 52.9%. Side-effects were tolerable in most patients with anaemia occurring in 22 patients (66.7%), leukopenia 23 patients (69.7%) and thrombocytopenia in 15 patients (45.5%). This study showed that pegylated interferon alfa-2b 1.5 mcg/kg/week plus ribavirin > 10.6 mg/kg/day is efficacious and safe to be used in the treatment of: chronic hepatitis C.

  9. Epoetin alfa 40000 U once weekly and intravenous iron supply in solid tumor patients: early increase of hemoglobin level during chemotherapy.

    PubMed

    Lalle, M; Pistillucci, G; Antimi, M; D'Aprile, M

    2005-06-01

    The objective of this observational study was the early evaluation of the impact, a week after the first administration of epoetin alfa 40000 U once weekly and i.v. dose of 62.5 mg sodium ferric gluconate for seven days in improving hemoglobin levels in cancer patients affected by mild/moderate or severe anemia during chemotherapy. Twenty patients affected by solid tumors who received epoetin alfa 40000 U once weekly and daily i.v. sodium ferric gluconate for one week were evaluated: 90% of the patients showed hemoglobin increase, with a median level of hemoglobin increase of 0.73 g/L from baseline, and 50% of them showing a hemoglobin increase > 1 gr/L. The treatment was well tolerated and no adverse event was observed. The early increase of hemoglobin level from baseline is interesting and suggestive for the possibility of achieving an adequate hemoglobin level with a short-term treatment. It is still necessary to further explore the real need of iron supplementation to maintain adequate erythropoiesis prior and during epoetin therapy.

  10. Reduction of circulating regulatory T cells by intravenous high-dose interferon alfa-2b treatment in melanoma patients.

    PubMed

    Mozzillo, Nicola; Ascierto, Paolo

    2012-10-01

    High-dose interferon alfa-2b (IFNα-2b) is the only approved adjuvant systemic therapy for resected, high risk melanoma in the United States (Fecher and Flaherty, in Natl Compr Cancer Netw 7:295-304, 2009). Recently, two important meta-analyses of randomized trials (Wheatley et al., in J Clin Oncol, 2007; Mocellin et al. in J Natl Cancer Inst, 2010) investigating IFNα-2b versus observation in high risk melanoma patients, showed that adjuvant IFNα-2b has an impact both on relapse-free survival (RFS) and overall survival (OS) independently by dosage, duration and route compared with observation in high risk melanoma patients. Despite of an absolute benefits of 3 % (Wheatley et al., in J Clin Oncol, 2007), this treatment is associated with significant toxicity, which impacts on patient quality of life. A better understanding of the mechanism of action may help to potentiate the clinical efficacy and reduce the toxicity of IFNα-2b/Peg-IFNα-2b. Numerous studies suggest that interferon's mechanism of action in melanoma is primarily immunomodulatory (Table 1) (de La Salmoniere, in Clin Cancer Res 6:4713-4718, 2000; Stuckert, in J Clin Oncol 25:8506, 2007; Gogas et al., in N Engl J Med 354:709-718, 2006; Moschos et al., in J Clin Oncol 24:3164-3171, 2006; Ascierto and Kirkwood, in J Transl Med 6:62, 2008) Recent efforts to elucidate the mechanism of action for interferon have focused upon signal transducers and activators of transcription (STAT) (Simons et al., in J Transl Med 9:52, 2011) signaling and immunoregulatory responses mediated by regulatory T cells (Tregs) (Wang et al., in Clin Cancer Res 13:1523-1531, 2007; Clin Cancer Res 14:8314-8320, 2008). Tregs are a suppressive CD4+ T cell population that is present, along with primed effector T cells, in tumor and tumor-draining lymph nodes (Hiura et al. in J Immunol 175:5058-5066, 2005). Tregs express high levels of surface antigens such as CD25, cytotoxic T lymphocyte associated antigen 4 (CTLA-4), and

  11. Epoetin-associated pure red cell aplasia: past, present, and future considerations

    PubMed Central

    McKoy, June M.; Stonecash, Robin E.; Cournoyer, Denis; Rossert, Jerome; Nissenson, Allen R.; Raisch, Dennis W.; Casadevall, Nicole; Bennett, Charles L.

    2009-01-01

    BACKGROUND Since 1988, millions of patients have received epoetin products intravenously (IV) and subcutaneously. In 1998, epoetin-associated pure red cell aplasia (PRCA) was first reported and causation was attributed to formulations without human serum albumin (HSA), subcutaneous administration, and uncoated rubber stoppers. STUDY DESIGN AND METHODS Data on erythropoietin (EPO)-associated PRCA were obtained from the Food and Drug Administration (FDA), regulatory authorities in other countries, and the manufacturers of epoetin alfa, epoetin beta, and darbepoetin. The data included information on numbers of PRCA cases and estimated exposure-adjusted incidence rates by EPO product, anemia etiology, administration route, country of PRCA identification, and date reported. RESULTS In 1999, academicians in Paris identified 12 EPO-treated patients with antibody-mediated PRCA; 11 of these patients were on hemodialysis and had received subcutaneous Eprex (Johnson & Johnson). In 2002, authorities in Europe, Australia, Singapore, and Canada mandated Eprex by IV route to hemodialysis patients, and the relevant manufacturers added Teflon coating to prefilled syringes of Eprex; PRCA cases subsequently decreased by 90 percent. By 2003, 180 Eprex-associated PRCA cases were identified in Europe, Canada, Australia, and Asia, despite improvements in handling. Since 2002, FDA safety databases include information on 59 new cases of antibody-associated PRCA, primarily associated with subcutaneous epoetin alfa and darbepoetin that does not contain HSA. CONCLUSION Independent actions by regulatory authorities, manufacturers, and academic researchers identified significant numbers of PRCA cases between 1998 and 2003 and characterized the probable etiology. Today, antibody-mediated PRCA is an infrequent class toxicity occurring among some hemodialysis patients on EPOs. PMID:18482185

  12. Impact of Safety-Related Dose Reductions or Discontinuations on Sustained Virologic Response in HCV-Infected Patients: Results from the GUARD-C Cohort

    PubMed Central

    Foster, Graham R.; Coppola, Carmine; Derbala, Moutaz; Ferenci, Peter; Orlandini, Alessandra; Reddy, K. Rajender; Tallarico, Ludovico; Shiffman, Mitchell L.; Ahlers, Silke; Bakalos, Georgios; Hassanein, Tarek

    2016-01-01

    Background Despite the introduction of direct-acting antiviral agents for chronic hepatitis C virus (HCV) infection, peginterferon alfa/ribavirin remains relevant in many resource-constrained settings. The non-randomized GUARD-C cohort investigated baseline predictors of safety-related dose reductions or discontinuations (sr-RD) and their impact on sustained virologic response (SVR) in patients receiving peginterferon alfa/ribavirin in routine practice. Methods A total of 3181 HCV-mono-infected treatment-naive patients were assigned to 24 or 48 weeks of peginterferon alfa/ribavirin by their physician. Patients were categorized by time-to-first sr-RD (Week 4/12). Detailed analyses of the impact of sr-RD on SVR24 (HCV RNA <50 IU/mL) were conducted in 951 Caucasian, noncirrhotic genotype (G)1 patients assigned to peginterferon alfa-2a/ribavirin for 48 weeks. The probability of SVR24 was identified by a baseline scoring system (range: 0–9 points) on which scores of 5 to 9 and <5 represent high and low probability of SVR24, respectively. Results SVR24 rates were 46.1% (754/1634), 77.1% (279/362), 68.0% (514/756), and 51.3% (203/396), respectively, in G1, 2, 3, and 4 patients. Overall, 16.9% and 21.8% patients experienced ≥1 sr-RD for peginterferon alfa and ribavirin, respectively. Among Caucasian noncirrhotic G1 patients: female sex, lower body mass index, pre-existing cardiovascular/pulmonary disease, and low hematological indices were prognostic factors of sr-RD; SVR24 was lower in patients with ≥1 vs. no sr-RD by Week 4 (37.9% vs. 54.4%; P = 0.0046) and Week 12 (41.7% vs. 55.3%; P = 0.0016); sr-RD by Week 4/12 significantly reduced SVR24 in patients with scores <5 but not ≥5. Conclusions In conclusion, sr-RD to peginterferon alfa-2a/ribavirin significantly impacts on SVR24 rates in treatment-naive G1 noncirrhotic Caucasian patients. Baseline characteristics can help select patients with a high probability of SVR24 and a low probability of sr-RD with

  13. Rare Form of Erdheim-Chester Disease Presenting with Isolated Central Skeletal Lesions Treated with a Combination of Alfa-Interferon and Zoledronic Acid

    PubMed Central

    Bulycheva, E. N.; Baykov, V. V.; Zaraĭskiĭ, M. I.; Salogub, G. N.

    2015-01-01

    Erdheim-Chester disease (ECD) represents a clonal non-Langerhans histiocytosis, which manifests under an extensive variety of clinical symptoms. This creates a challenge for the physician, who is required to recognize and diagnose the disease in the early stages. Despite this considerable challenge, in the last decade there has been a dramatic increase in ECD diagnoses, in most part due to an increasing awareness of this rare disorder. Involvement of the axial skeleton is exclusively uncommon with no official recommendations for the treatment of the bone lesions. Here, we present a case report of a young male patient with isolated lesions of the spine, ribs, and pelvis, who was successfully treated with a combination therapy of alfa-interferon and zoledronic acid. PMID:25949835

  14. Epoetin and Darbepoetin Treatment for Adults with Cancer

    MedlinePlus

    ... blood cells (also called low hematocrit), or of hemoglobin, which is the oxygen-carrying part of the ... the levels of red blood cells and/or hemoglobin decrease, the body has to work harder to ...

  15. Mutations selected in the hepatitis C virus NS3 protease domain during sequential treatment with boceprevir with and without pegylated interferon alfa-2b.

    PubMed

    Vermehren, J; Susser, S; Lange, C M; Forestier, N; Karey, U; Hughes, E; Ralston, R; Tong, X; Zeuzem, S; Sarrazin, C

    2012-02-01

    Treatment with hepatitis C virus (HCV)-NS3-protease inhibitors lead to the selection of resistant variants. Viral kinetics and resistance profiles in patients who are re-treated with the same protease inhibitor are unknown. Viral kinetics and NS3-resistance mutations obtained by clonal sequencing of the NS3-protease were analyzed in nine HCV-genotype-1-infected nonresponder patients who were sequentially treated with boceprevir (400 mg t.i.d.) for 1 week, peginterferon-alfa-2b for 2 weeks and combination of the two for 2 weeks in varying order. In addition to predominant wild-type isolates, previously described boceprevir-resistant mutations (V36, T54, R155, A156, V170) were observed. Furthermore, two resistant mutations (Q41, F43) were detected for the first time in vivo. In three patients, mutations selected after initial treatment with boceprevir were re-selected during subsequent boceprevir exposure. However, mutational patterns after the first and second exposure to boceprevir were different in five patients. In one patient, a viral variant (V55A) known to reduce susceptibility to boceprevir was the predominant variant observed at baseline and throughout treatment and was associated with a shallow viral decline. Different resistance mutations were selected during treatment with boceprevir ± peginterferon. Sequential short-term dosing of boceprevir was not associated with accumulation of resistant variants but pre-existing variants may impair virologic response.

  16. THE ARECIBO LEGACY FAST ALFA SURVEY. VIII. H I SOURCE CATALOG OF THE ANTI-VIRGO REGION AT {delta} = +25 DEG

    SciTech Connect

    Martin, Ann M.; Giovanelli, Riccardo; Haynes, Martha P.; Stierwalt, Sabrina; Saintonge, Amelie; Hoffman, G. Lyle; Kent, Brian R. E-mail: riccardo@astro.cornell.edu E-mail: sabrina@astro.cornell.edu E-mail: hoffmang@lafayette.edu

    2009-08-01

    We present a fourth catalog of H I sources from the Arecibo Legacy Fast ALFA (ALFALFA) Survey. We report 541 detections over 136 deg{sup 2}, within the region of the sky having 22{sup h} < {alpha} < 03{sup h} and 24 deg. < {delta} < 26 deg. This complements a previous catalog in the region 26 deg. < {delta} < 28 deg. We present here the detections falling into three classes: (1) extragalactic sources with signal-to-noise ratio (S/N)>6.5, where the reliability of the catalog is better than 95%; (2) extragalactic sources 5.0 < S/N < 6.5 and a previously measured optical redshift that corroborates our detection; or (3) High Velocity Clouds (HVCs), or subcomponents of such clouds, in the periphery of the Milky Way. Of the 541 objects presented here, 90 are associated with HVCs, while the remaining 451 are identified as extragalactic objects. Optical counterparts have been matched with all but one of the extragalactic objects.

  17. Treatment-naïve Gaucher disease patients achieve therapeutic goals and normalization with velaglucerase alfa by 4years in phase 3 trials.

    PubMed

    Zimran, Ari; Elstein, Deborah; Gonzalez, Derlis E; Lukina, Elena A; Qin, Yulin; Dinh, Quinn; Turkia, Hadhami Ben

    2016-10-21

    Gaucher disease is an inherited metabolic disease characterized by β-glucocerebrosidase deficiency and commonly treated with enzyme replacement therapy (ERT). The efficacy of ERT with velaglucerase alfa was assessed based on the achievement of published therapeutic goals and the normalization of disease parameters in 39 treatment-naïve patients with type 1 Gaucher disease, 6 to 62years of age, enrolled in phase 3 clinical trials. After 4years of ERT, therapeutic goals for thrombocytopenia and splenomegaly had been achieved in 100% of patients; goals for anemia and hepatomegaly had been achieved in 95% and 94% of patients, respectively. Consistent with the goal for bone mineral density, lumbar spine bone density improved in 87% of patients ≥18years of age. At year 4, compared with clinical ranges for healthy individuals, 86% of patients with a low baseline hemoglobin concentration had normalized, 60% with a low baseline platelet count had normalized, 67% with baseline splenomegaly had normalized, 58% with hepatomegaly had normalized, and lumbar spine bone density had normalized in 53% of adults. The decade-old therapeutic goals do not reflect the potential for normalization of clinical parameters in ERT-treated patients. Goals consistent with normalization or near-normalization should be considered. ClinicalTrials.gov identifiers: NCT00430625, NCT00553631, NCT00635427.

  18. Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III Italian Melanoma Inter-group trial (IMI – Mel.A.) [ISRCTN75125874

    PubMed Central

    Chiarion-Sileni, Vanna; Del Bianco, Paola; Romanini, Antonella; Guida, Michele; Paccagnella, Adriano; Dalla Palma, Maurizio; Naglieri, Emanuele; Ridolfi, Ruggero; Silvestri, Barbara; Michiara, Maria; De Salvo, Gian Luca

    2006-01-01

    Background High-dose interferon alfa-2b (IFNalfa-2b), according to the ECOG 1684 schedule, is the only approved adjuvant treatment for stage III melanoma patients by the FDA and EMEA. However, the risk/benefit profile has been questioned limiting its world-wide use. In the late nineties, the Italian Melanoma Inter-group started a spontaneous randomized clinical trial (RCT) to verify if a more intense, but shorter than the ECOG 1684 regimen, could improve survival without increasing the toxicity profile. The safety analysis in the first 169 patients who completed the treatment is here described. Methods Stage III melanoma patients were randomized to receive IFNalfa-2b 20 MU/m2/d intravenously (IV) 5 days/week × 4 weeks, repeated for three times on weeks 9 to 12, 17 to 20, 25 to 28 (Dose-Dense/Dose-Intense, DD/DI, arm), or IFNalfa-2b 20 MU/m2/d IV 5 days/week × 4 weeks followed by 10 MU/m2 subcutaneously (SC) three times per week × 48 weeks (High Dose Interferon, HDI, arm). Toxicity was recorded and graded, according to the WHO criteria, as the worst grade that occurred during each cycle. Results The most common toxicities in both arms were flu-like and gastrointestinal symptoms, leukopenia, liver and neuro-psichiatric morbidities; with regard to severe toxicity, only leukopenia was statistically more frequent in DD/DI arm than in HDI arm (24% vs 9%) (p = 0.0074), yet, this did not cause an increase in the infection risk. Discontinuation of treatment, due to toxicity, was observed in 13 and 17% of the patients in the DD/DI and HDI arm, respectively. The median actual dose intensity delivered in the DD/DI arm (36.4 MU/m2/week) was statistically higher than that delivered in the HDI arm (30.7 MU/m2/week) (p = 0.003). Conclusion Four cycles of intravenous high-dose IFNalfa-2b can be safely delivered with an increase in the median dose intensity. Efficacy results from this trial are eagerly awaited. PMID:16504154

  19. THE ARECIBO LEGACY FAST ALFA SURVEY. V. THE H I SOURCE CATALOG OF THE ANTI-VIRGO REGION AT {delta} = +27{sup 0}

    SciTech Connect

    Saintonge, Amelie; Giovanelli, Riccardo; Haynes, Martha P.; Kent, Brian R.; Martin, Ann M.; Stierwalt, Sabrina E-mail: bkentastro@cornell.edu E-mail: sabrina@astro.cornell.edu E-mail: haynes@astro.cornell.edu

    2008-02-15

    We present a second catalog of H I sources detected in the Arecibo Legacy Fast ALFA Survey. We report 488 detections over 135 deg{sup 2}, within the region of the sky having 22 h < {alpha} < 03 h and +26{sup 0} < {delta} < +28{sup 0}. We present here the detections that have either (a) S/N>6.5, where the reliability of the catalog is better than 95% or (b) 5.0 < S/N < 6.5 and a previously measured redshift that corroborates our detection. Of the 488 objects presented here, 49 are high-velocity clouds or clumps thereof with negative heliocentric recession velocities. These clouds are mostly very compact and isolated, while some of them are associated with large features such as Wright's Cloud or the northern extension of the Magellanic Stream. The remaining 439 candidate detections are identified as extragalactic objects and have all been matched with optical counterparts. Five of the six galaxies detected with M{sub Hi}<10{sup 7.5} M{sub sun} are satellites of either the NGC672/IC1727 nearby galaxy pair or their neighboring dwarf irregular galaxy NGC784. The data of this catalog release include a slice through the Pisces-Perseus foreground void, a large nearby underdensity of galaxies. We report no detections within the void, where our catalog is complete for systems with H i masses of 10{sup 8} M{sub sun}. Gas-rich, optically-dark galaxies do not seem to constitute an important void population, and therefore do not suffice for producing a viable solution to the void phenomenon.

  20. Peginterferon alfa-2a plus Weight-Based or Flat-Dose Ribavirin for Treatment-Naïve Hepatitis C Virus Genotype 2 Rapid Responders: A Randomized Trial

    PubMed Central

    Liu, Chen-Hua; Huang, Chung-Feng; Liu, Chun-Jen; Dai, Chia-Yen; Huang, Jee-Fu; Lin, Jou-Wei; Liang, Cheng-Chao; Yang, Sheng-Shun; Lin, Chih-Lin; Su, Tung-Hung; Yang, Hung-Chih; Chen, Pei-Jer; Chen, Ding-Shinn; Chuang, Wan-Long; Kao, Jia-Horng; Yu, Ming-Lung

    2015-01-01

    The impact of ribavirin (RBV) dosage on sustained virologic response (SVR) rates remains elusive in hepatitis C virus genotype 2 (HCV-2) rapid responders receiving 16 weeks of peginterferon (Peg-IFN) plus RBV. Treatment-naïve HCV-2 patients with rapid virologic response (RVR) received Peg-IFN alfa-2a 180 μg/week plus weight-based RBV (1,000 or 1,200 mg/day; cut-off body weight: 75 kg) for 6 weeks, and then randomly received Peg-IFN alfa-2a 180 μg/week plus weight-based (1,000 or 1,200 mg/day; n = 247) or flat-dose (800 mg/day; n = 246) RBV for additional 10 weeks. The primary endpoint was SVR24. Patients receiving weight-based and flat-dose RBV therapies had comparable SVR24 rates (93.5% versus 91.9%, P = 0.49). The risk differences (RDs) of SVR24 receiving weight-based and flat-dose RBV arms were 7.1% [95% CI: 0.7% to 13.6%] in males, and −5.8% [95% CI: −12.1% to 0.5%] in females (interaction P = 0.01). The SVR24 rate was higher in males receiving ≥13 mg/kg/day than those receiving <13 mg/kg/day (96.3% versus 85.1%, P = 0.001). In conclusion, Peg-IFN alfa-2a plus weight-based or flat-dose RBV for 16 weeks provides comparable SVR24 rates in treatment-naïve HCV-2 rapid responders. However, males should receive weight-based RBV to achieve a high SVR24 rate. PMID:26469083

  1. Diffraction and forward physics results of the ATLAS experiment from the Run I

    SciTech Connect

    Taševský, Marek

    2015-04-10

    Various aspects of forward physics have been studied by the ATLAS collaboration using data from Run I at the LHC. In this text, main results of four published analyses are summarized, all based on data from proton-proton collisions at √(s)=7 TeV collected in 2010 or 2011. Two analyses deal with the diffractive signature, one based on single-sided events, the other on large rapidity gaps in soft events. In addition, a recent measurement of the total pp cross section using the ALFA subdetector and a recent study of higher-order QCD effects using a jet veto are discussed.

  2. Risk of Orthopedic Surgical Site Infections in Patients with Rheumatoid Arthritis Treated with Antitumor Necrosis Factor Alfa Therapy

    PubMed Central

    da Cunha, Bernardo Matos; Maria Henrique da Mota, Licia; dos Santos-Neto, Leopoldo Luiz

    2012-01-01

    Introduction. International guidelines recommend interruption of anti-TNF medications in the perioperative period, but there are no randomized trials to support such recommendation. Objectives. To study literature evidence assessing the risk of surgical site infections in orthopedic surgery patients with RA using anti-TNF drugs, compared to untreated patients or those using conventional DMARD. Methods. Systematic review of cohort studies is concerning surgical site infections in orthopedic procedures in patients with RA. Results. Three studies were selected. Only one was considered of high-quality, albeit with low statistical power. The review resulted in inconclusive data, since the best quality study showed no significant differences between groups, while others showed increased risk of infections in patients using anti-TNF medications. Conclusion. It is unclear whether patients with RA using anti-TNF medications are at increased risk of surgical site infections. Randomized controlled trials or new high quality observational studies are needed to clarify the issue. PMID:22500176

  3. Alfa-glucosidase-inhibiting activity of some Mexican plants used in the treatment of type 2 diabetes.

    PubMed

    Andrade-Cetto, Adolfo; Becerra-Jiménez, Jaime; Cárdenas-Vázquez, René

    2008-02-28

    Type 2 diabetes is an endocrine disease, which accounts for 9% of deaths worldwide. The aim of oral therapy is to reach normoglycemia to prevent later complications. Among glucose-lowering medications, alpha-glucosidase inhibitors delay the absorption of ingested carbohydrates, reducing the postprandial glucose and insulin peaks. In the present study, we tested the butanolic extracts of four Mexican plants with respect to their alpha-glucosidase inhibition activity, without excluding other possible mechanisms of action. The plants Cecropia obtusifolia Bertol., Equisetum myriochaetum Schlecht & Cham, Acosmium panamense (Benth.) Yacolev and Malmea depressa (Baill) R.E. Fries are used in traditional medicine to treat type 2 diabetes. In previous studies, we have demonstrated these plants' hypoglycemic activity and determined the phytochemical composition of their extracts. Our results in n-STZ diabetic rats loaded with maltose showed that Malmea and Acosmium extracts decreased plasma glucose significantly from 30 min on resembling the effect of acarbose. Cecropia extract produced the highest reduction of plasma glucose, and at 90 min, the glucose level was lower than the fasting level, which suggests another mechanism of action. Equisetum did not exert any effect. In vitro assays of alpha-glucosidase activity showed an IC(50) of 14 microg/ml for Cecropia, 21 microg/ml for Malmea, and 109 microg/ml for Acosmium, which were lower than that of acarbose (128 microg/ml). Equisetum did not show any significant effect on this assay, either. These results contribute to understand the mechanism of action of these plants on glucose metabolism.

  4. Quantification of hepatitis C virus in patients treated with peginterferon-alfa 2a plus ribavirin treatment by COBAS TaqMan HCV test.

    PubMed

    Kanda, T; Imazeki, F; Yonemitsu, Y; Mikami, S; Takada, N; Nishino, T; Takashi, M; Tsubota, A; Kato, K; Sugiura, N; Tawada, A; Wu, S; Tanaka, T; Nakamoto, S; Mikata, R; Tada, M; Chiba, T; Kurihara, T; Arai, M; Fujiwara, K; Kanai, F; Yokosuka, O

    2011-07-01

    Extremely low levels of serum hepatitis C virus (HCV) RNA can be detected by COBAS TaqMan HCV test. To investigate whether the COBAS TaqMan HCV test is useful for measuring rapid virological response (RVR) and early virological response (EVR) to predict sustained virological response (SVR), we compared the virological response to PEG-IFN-alfa 2a plus RBV in 76 patients infected with HCV genotype 1 when undetectable HCV RNA by the COBAS TaqMan HCV test was used, with those when below 1.7 log IU/mL HCV RNA by COBAS TaqMan HCV test was used, which corresponded to the use of traditional methods. Among the 76 patients, 28 (36.8%) had SVR, 13 (17.1%) relapsed, 19 (25.0%) did not respond, and 16 (21.0%) discontinued the treatment due to side effects. The positive predictive values for SVR based on undetectable HCV RNA by COBAS TaqMan HCV test at 24 weeks after the end of treatment [10/10 (100%) at week 4, 21/23 (91.3%) at week 8 and 26/33 (78.7%) at week 12] were superior to those based on <1.7 log IU/mL HCV RNA [17/19 (89.4%) at week 4, 27/38 (71.0%) at week 8, and 27/43 (62.7%) at week 12]. The negative predictive values for SVR based on <1.7 log IU/mL HCV RNA by COBAS TaqMan HCV test [46/57 (80.7%) at week 4, 37/38 (97.3%) at week 8, and 32/33 (96.9%) at week 12] were superior to those based on undetectable HCV RNA [48/66 (72.7%) at week 4, 46/53 (86.7%) at week 8, and 41/43 (95.3%) at week 12]. The utilization of both undetectable RNA and <1.7 log IU/mL HCV RNA by COBAS TaqMan HCV test is useful and could predict SVR and non-SVR patients with greater accuracy.

  5. Evaluation of prognostic factors for Peg Interferon alfa-2b plus ribavirin treatment on HCV infected patients in Pakistan.

    PubMed

    Aziz, Hafsa; Gil, Muzaffar Latif; Waheed, Yasir; Adeeb, Uzama; Raza, Abida; Bilal, Iram; Athar, Muhammad Amin

    2011-04-01

    The effective standard therapeutic regimen for patients with chronic hepatitis C is pegylated interferon plus ribavirin. The efficacy of treatment in chronic hepatitis C is defined as absence of detectable virus at six months after treatment. Analysis of patient dependent and virus related factors that enable us to predict the response to antiviral treatment is very important. We prospectively studied 403 patients who received PEG-IFN alpha-2b 1.5 μg/kg/body weight plus ribavirin. Treatment was administrated for 24 weeks and 48 weeks for hepatitis C virus (HCV) genotypes 3 and 1, respectively. Out of 403 treated patients, 301 patients (74.7%) showed a sustained virologic response (SVR). Seven variables (age, sex, ethnic group, pretreatment viral load, HCV genotyping and pretreatment ALT) were chosen as possible predictors of SVR and were analysed by means of univariable and multivariable logistic regression analysis. Five variables were statistically significant (p<0.005) on univariable analysis: age, ethnic group, pretreatment viral load, response rate at week 4, and HCV genotype. In multivariable analysis independent factors associated with SVR were low pretreatment viral load (1.97; 95%CI, 1.06-3.66; p=0.03) and attainment of rapid virological response (RVR) (7.19; 95%CI, 4.15-12.45; p<0.001). Our findings support the association between viral load and SVR to PEG-IFN-alpha-2b plus ribavirin therapy. No achievement of RVR is an unfavorable marker for SVR. These findings suggest that all patients considered for treatment should have quantification of serum HCV RNA levels. The result can be used to counsel patients on the likelihood of achieving SVR and may influence the patient's decision on treatment. Future studies should confirm and explore this observation in other ethnic groups and in relation to HCV genotypes 1 and 3.

  6. Recombinant follitropin alfa/lutropin alfa in fertility treatment

    PubMed Central

    Gibreel, Ahmed; Bhattacharya, Siladitya

    2010-01-01

    Recombinant human follicle stimulating hormone (rFSH) and luteinizing hormone (LH), also known as follitropin alpha and lutropin alpha, are manufactured by genetic engineering techniques which ensure high quality and batch to batch consistency. Follitropin alpha can be used for controlled ovarian hyperstimulation in assisted reproduction, ovulation induction for WHO group I and II anovulatory infertility and in men with hypogonadotrophic hypogonadism (HH) or idiopathic oligo-asthenospermia. Current evidence suggests superiority of urinary human menopausal gonadotropin (HMG) over follitropin alpha in controlled ovarian hyperstimulation for IVF in terms of live birth rate per couple. Addition of lutropin to follitropin alpha in an unselected IVF population does not appear to confer any benefit; however, it may have a role in ovulation induction in women with hypothalamic hypogonadism. Urinary HMG preparations (especially currently available highly purified preparations) are more cost effective than rFSH in terms of cost per ongoing pregnancy. However, women using rFSH injection pen devices have higher levels of satisfaction as compared to those using urinary HMG by means of conventional syringes. PMID:20161981

  7. Protective Effect of Infliximab, a Tumor Necrosis Factor-Alfa Inhibitor, on Bleomycin-Induced Lung Fibrosis in Rats.

    PubMed

    Altintas, Nejat; Erboga, Mustafa; Aktas, Cevat; Bilir, Bulent; Aydin, Murat; Sengul, Aysun; Ates, Zehra; Topcu, Birol; Gurel, Ahmet

    2016-02-01

    We aimed to investigate the preventive effect of Infliximab (IFX), a tumor necrosis factor (TNF)-α inhibitor, on bleomycin (BLC)-induced lung fibrosis in rats. Rats were assigned into four groups as follows: I-BLC group, a single intra-tracheal BLC (2.5 mg/kg) was installed; II-control group, a single intra-tracheal saline was installed; III-IFX + BLC group, a single-dose IFX (7 mg/kg) was administered intraperitoneally (i.p.), 72 h before the intra-tracheal BLC installation; IV-IFX group, IFX (7 mg/kg) was administered alone i.p. on the same day with IFX + BLC group. All animals were sacrificed on the 14th day of BLC installation. Levels of tumor necrosis factor (TNF)-α, transforming growth factor (TGF)-β, interleukin (IL)-6, periostin, YKL-40, nitric oxide (NO) in rat serum were measured, as well as, myeloperoxidase (MPO), superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx) activity, and reduced glutathione (GSH), hydroxyproline, malondialdehyde (MDA) content in lung homogenates. Lung tissues were stained with hematoxylin and eosin (H&E) for quantitative histological evaluation. The inducible nitric oxide synthase (iNOS) expression and cell apoptosis in the lung tissues were determined quantitatively by immunohistochemical staining (INOS) and by TUNNEL staining, respectively. BLC installation worsened antioxidant status (such as SOD, CAT, GPx, GSH, MPO), while it increased the serum TNF-α, TGF-β, IL-6, periostin, YKL-40, and lipid peroxidation, and collagen deposition, measured by MDA and hydroxyproline, respectively. IFX pretreatment improved antioxidant status as well as BLC-induced lung pathological changes, while it decreased the TNF-α, TGF-β, IL-6, periostin, YKL-40, lipid peroxidation and collagen deposition. Finally, histological, immunohistochemical, and TUNNEL evidence also supported the ability of IFX to prevent BLC-induced lung fibrosis. The results of the present study indicate that IFX pretreatment can attenuate

  8. Understanding early serum hepatitis D virus and HBsAg kinetics during pegylated interferon-alfa therapy via mathematical modeling

    PubMed Central

    Guedj, Jeremie; Rotman, Yaron; Cotler, Scott J.; Koh, Christopher; Schmid, Peter; Albrecht, Jeff; Haynes-Williams, Vanessa; Liang, Jake T.; Hoofnagle, Jay H.; Heller, Theo; Dahari, Harel

    2014-01-01

    There is little information on the early kinetics of hepatitis delta virus (HDV) and hepatitis B surface antigen (HBsAg) during interferon-α therapy. Here a mathematical model was developed and fitted to frequent HDV and HBsAg kinetic data from 10 patients during the first 28 weeks of pegylated-interferon-α2a (peg-IFN) therapy. Three patients achieved a complete virological response (CVR), defined as undetectable HDV 6 months after treatment stopped with loss of HBsAg and anti-HBsAg seroconversion. After initiation of therapy a median delay of 9 days (interquartile range IQR:[5;15]) was observed with no significant changes in HDV level. Thereafter, HDV declined in a biphasic manner, where a rapid first-phase lasting for 25 days (IQR:[23;58]) was followed by a slower or plateau second-phase. The model predicts that the main effect of peg-IFN is to reduce HDV production/release with a median effectiveness of 96% (IQR:[93;99.8]). Median serum HDV half-life (t1/2) was estimated to 2.9 days (IQR:[1.5;5.3]) with pretreatment production and clearance of about 1010 (IQR:[109.8-1010.8]) virions/day. None of the patients with flat 2nd phase in HDV achieved CVR. HBsAg kinetics of decline paralleled the second-phase of HDV decline consistent with HBsAg-productive-infected cells being the main source of production of HDV, with a median t1/2 of 135 days (IQR:[20-460]. The interferon lambda-3 polymorphism (rs12979860) was not associated with kinetic parameters. Conclusions Modeling results provide insights into HDV-host dynamics, the relationship between serum HBsAg levels and HBsAg-infected cells, IFN's mode of action and its effectiveness. The observation that a flat second phase in HDV and HBsAg kinetics was associated with failure to achieve CVR provides the basis to develop early stopping rules during peg-IFN treatment in HDV-infected patients. PMID:25098971

  9. Interferon Alfa-2b Injection

    MedlinePlus

    ... medication either subcutaneously or intramuscularly three times a week. HBV, inject the medication either subcutaneously or intramuscularly three times a week usually for 16 weeks. hairy cell leukemia, inject ...

  10. Peginterferon Alfa-2a Injection

    MedlinePlus

    ... interferons. Peginterferon is a combination of interferon and polyethylene glycol, which helps the interferon stay active in ... alpha interferons, any other medications, benzyl alcohol, or polyethylene glycol (PEG). Ask your doctor if you are ...

  11. Late results.

    PubMed

    Daly, B D

    1999-08-01

    Pneumonectomy is performed for a number of benign and malignant conditions. It is most commonly performed for lung cancer. Adjuvant and neoadjuvant protocols have increased the number of these operations being performed and the long-term results are improving. Pneumonectomy may also be performed for metastases to lung and for mesothelioma with encouraging results. Some bronchial adenomas require pneumonectomy. Treatment of resistant mycobacteria or the complications of tuberculosis frequently require pneumonectomy. Late bronchopleural fistulae, esophagopleural fistulae, and empyema may occur.

  12. Research Results

    NASA Astrophysics Data System (ADS)

    2011-12-01

    Research on Global Carbon Emission and Sequestration NSFC Funded Project Made Significant Progress in Quantum Dynamics Functional Human Blood Protein Obtained from Rice How Giant Pandas Thrive on a Bamboo Diet New Evidence of Interpersonal Violence from 129,000 Years Ago Found in China Aptamer-Mediated Efficient Capture and Release of T Lymphocytes on Nanostructured Surfaces BGI Study Results on Resequencing 50 Accessions of Rice Cast New Light on Molecular Breeding BGI Reports Study Results on Frequent Mutation of Genes Encoding UMPP Components in Kidney Cancer Research on Habitat Shift Promoting Species Diversification

  13. Tevatron results

    SciTech Connect

    Lefevre, R.; /Barcelona, Autonoma U.

    2005-01-01

    Recent results obtained by the CDF and D0 experiments at the Tevatron Run II are presented. A first part is dedicated to QCD physics where inclusive jet production, dijet azimuthal decorrelations and jet shapes measurements are reported. Electroweak physics is then discussed relating measurements of the W and Z bosons productions, of the forward-backward charge asymmetry in W production, of the W width and of the top quarks mass. The extensive Run II exploration program is finally approached reporting about searches for neutral supersymmetric Higgs bosons in multijet events and for sbottom quark from gluino decays.

  14. Southwest Oncology Group S0008: A Phase III Trial of High-Dose Interferon Alfa-2b Versus Cisplatin, Vinblastine, and Dacarbazine, Plus Interleukin-2 and Interferon in Patients With High-Risk Melanoma—An Intergroup Study of Cancer and Leukemia Group B, Children's Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group

    PubMed Central

    Flaherty, Lawrence E.; Othus, Megan; Atkins, Michael B.; Tuthill, Ralph J.; Thompson, John A.; Vetto, John T.; Haluska, Frank G.; Pappo, Alberto S.; Sosman, Jeffrey A.; Redman, Bruce G.; Moon, James; Ribas, Antoni; Kirkwood, John M.; Sondak, Vernon K.

    2014-01-01

    Purpose High-dose interferon (IFN) for 1 year (HDI) is the US Food and Drug Administration–approved adjuvant therapy for patients with high-risk melanoma. Efforts to modify IFN dose and schedule have not improved efficacy. We sought to determine whether a shorter course of biochemotherapy would be more effective. Patients and Methods S0008 (S0008: Chemotherapy Plus Biological Therapy in Treating Patients With Melanoma) was an Intergroup phase III trial that enrolled high-risk patients (stage IIIA-N2a through IIIC-N3), randomly assigning them to receive either HDI or biochemotherapy consisting of dacarbazine, cisplatin, vinblastine, interleukin-2, IFN alfa-2b (IFN-α-2b) and granulocyte colony-stimulating factor given every 21 days for three cycles. Coprimary end points were relapse-free survival (RFS) and overall survival (OS). Results In all, 432 patients were enrolled. Grade 3 and 4 adverse events occurred in 57% and 7% of HDI patients and 36% and 40% of biochemotherapy patients, respectively. At a median follow-up of 7.2 years, biochemotherapy improved RFS (hazard ratio [HR], 0.75; 95% CI, 0.58 to 0.97; P = .015), with a median RFS of 4.0 years (95% CI, 1.9 years to not reached [NR]) versus 1.9 years for HDI (95% CI, 1.2 to 2.8 years) and a 5-year RFS of 48% versus 39%. Median OS was not different (HR, 0.98; 95% CI, 0.74 to 1.31; P = .55), with a median OS of 9.9 years (95% CI, 4.62 years to NR) for biochemotherapy versus 6.7 years (95% CI, 4.5 years to NR) for HDI and a 5-year OS of 56% for both arms. Conclusion Biochemotherapy is a shorter, alternative adjuvant treatment for patients with high-risk melanoma that provides statistically significant improvement in RFS but no difference in OS and more toxicity compared with HDI. PMID:25332243

  15. Anemia and iron deficiency in heart failure.

    PubMed

    Gunawardena, Shanti; Dunlap, Mark E

    2012-12-01

    Anemia is a common comorbidity in heart failure (HF), and is associated with increased morbidity and mortality. However, it remains unclear whether anemia is merely a marker of poor prognosis or whether anemia itself confers risk. The pathogenesis of anemia in HF is multifactorial. Iron deficiency also confers risk in HF, either with or without associated anemia, and treatment of iron deficiency improves the functional status of patients with HF. An ongoing large clinical trial studying the use of darbepoetin-alfa in patients with anemia and systolic HF is expected to provide information that should improve our understanding of anemia in HF.

  16. Identification of recombinant human EPO variants in greyhound plasma and urine by ELISA, LC-MS/MS and western blotting: a comparative study.

    PubMed

    Timms, Mark; Steel, Rohan; Vine, John

    2016-02-01

    The recombinant human erythropoietins epoetin alfa (Eprex®), darbepoetin (Aranesp®) and methoxy polyethylene glycol-epoetin beta (Mircera®) were administered to greyhounds for 7, 10 and 14 days respectively. Blood and urine samples were collected and analysed for erythropoietin by ELISA, LC-MS/MS and western blotting. Limits of confirmation in plasma for western blotting and LC-MS/MS methods ranged from a low of 2.5mIU/mL, and closely matched the sensitivity of ELISA screening.

  17. [Designing of hybrid human interferon alfa-2 strain-producers and the use of enteropeptidase for obtaining N-terminal methionine-free interferons].

    PubMed

    Shirokov, D A; Riabichenko, V V; Akishina, R I; Ospel'nikova, T P; Glazunov, A V; Chestukhina, G G; Veĭko, V P

    2011-01-01

    A system for production of human interferon-alpha2a (IFN-alpha2a) and IFN-alpha2b lacking N-terminal methionine has been developed. Plasmids containing genes of hybrid IFN-alpha2 under the control of different promoters were constructed; a sequence encoding the enteropeptidase hydrolysis site being introduced in proximal part of the genes. As the result, 4 strains of Escherichia coli producing hybrid IFN-alpha2 have been obtained. The methodology for IFN-alpha2 renaturation, hydrolysis of its N-terminal part, chromatographic purification of N-terminal methionine-free IFN-alpha2 has been developed.

  18. Extended duration versus standard duration of peginterferon alfa-2a in treatment of chronic hepatitis B: A systematic review and meta-analysis.

    PubMed

    Wang, Zhengyan; Sun, Ling; Wu, Yuwan; Xia, Qing

    2016-04-01

    In the last decade, PEG-IFNa-2a has been widely used in the treatment of chronic hepatitis B (CHB). The current standard duration is 48 weeks; however, several studies based on small sample sizes have indicated that treatment extended beyond 48 weeks improved clinical outcomes than standard 48 weeks of therapy. Therefore, we performed a meta-analysis to compare the efficacy and safety of extended duration versus standard duration treatment with PEG-IFNa-2a monotherapy for patients with CHB. Four studies comprising of 350 patients were included in our study. Our analysis showed that extended treatment resulted in a higher HBsAg clearance rate compared with the standard treatment at the end of treatment, 24 and 48 weeks post-treatment [odds ratio (OR)=2.45, 95% confidence intervals (CI) (1.17-5.11), P=0.02; OR=3.17, 95% CI (1.62-6.21), P<0.01; OR=5.02, 95% CI (1.63-15.45), P<0.01, respectively]. Higher HBeAg seroconversion rates were also obtained in the extended treatment group than the standard treatment group at the end of treatment and 48 weeks post-treatment [OR=2.09, 95% CI (1.10-3.98), P=0.02, and OR=2.67, 95% CI (1.39-5.13), P<0.01, respectively]. In addition, extended treatment was superior to standard treatment in HBV-DNA inhibition rate at 48 weeks post-treatment [OR=3.15, 95% CI (1.51-6.57), P<0.01]. Therefore, extended treatment with PEG-IFNa-2a beyond 48 weeks may be a promising strategy to achieve higher rates of sustained HBV-DNA inhibition, HBeAg seroconversion and HBsAg clearance off-therapy for patients with CHB.

  19. The ALFA Roman Pot detectors of ATLAS

    NASA Astrophysics Data System (ADS)

    Abdel Khalek, S.; Allongue, B.; Anghinolfi, F.; Barrillon, P.; Blanchot, G.; Blin-Bondil, S.; Braem, A.; Chytka, L.; Conde Muíño, P.; Düren, M.; Fassnacht, P.; Franz, S.; Gurriana, L.; Grafström, P.; Heller, M.; Haguenauer, M.; Hain, W.; Hamal, P.; Hiller, K.; Iwanski, W.; Jakobsen, S.; Joram, C.; Kötz, U.; Korcyl, K.; Kreutzfeldt, K.; Lohse, T.; Maio, A.; Maneira, M. J. P.; Mapelli, A.; Notz, D.; Nozka, L.; Palma, A.; Petschull, D.; Pons, X.; Puzo, P.; Ravat, S.; Schneider, T.; Seabra, L.; Sykora, T.; Staszewski, R.; Stenzel, H.; Trzebinski, M.; Valkar, S.; Viti, M.; Vorobel, V.; Wemans, A.

    2016-11-01

    The ATLAS Roman Pot system is designed to determine the total proton-proton cross section as well as the luminosity at the Large Hadron Collider (LHC) by measuring elastic proton scattering at very small angles. The system is made of four Roman Pot stations, located in the LHC tunnel in a distance of about 240 m at both sides of the ATLAS interaction point. Each station is equipped with tracking detectors, inserted in Roman Pots which approach the LHC beams vertically. The tracking detectors consist of multi-layer scintillating fibre structures read out by Multi-Anode-Photo-Multipliers.

  20. Peginterferon Alfa-2b (PEG-Intron)

    MedlinePlus

    ... alpha-2b is a combination of interferon and polyethylene glycol, which helps the interferon stay active in ... 2b, other alpha interferons, any other medications, or polyethylene glycol (PEG). Ask your doctor if you are ...

  1. Peginterferon Alfa-2b Injection (Sylatron)

    MedlinePlus

    ... 2b injection is used in people with malignant melanoma (a life-threatening cancer that begins in certain ... is used to reduce the chance that malignant melanoma will come back and must be started within ...

  2. Gateways to clinical trials.

    PubMed

    Bayés, M; Rabasseda, X; Prous, J R

    2007-11-01

    1-Octanol, 9vPnC-MnCc; Abiraterone acetate, Adalimumab, Adefovir dipivoxil, Alemtuzumab, Aliskiren fumarate, Aminolevulinic acid hexyl ester, Amlodipine besylate/atorvastatin calcium, Amrubicin hydrochloride, Anakinra, Aripiprazole, ARRY-520, AS-1404, Asimadoline, Atazanavir sulfate, AVE-0277, Azelnidipine; Bevacizumab, Bimatoprost, Boceprevir, Bortezomib, Bosentan, Botulinum toxin type B; Certolizumab pegol, Cetuximab, Clevudine, Contusugene ladenovec, CP-751871, Crofelemer, Cypher, CYT006-AngQb; Darbepoetin alfa, Desmopressin, Dexlansoprazole, DG-041; E-5555, Ecogramostim, Entecavir, Erlotinib hydrochloride, Escitalopram oxalate, Eszopiclone, Everolimus, Ezetimibe, Ezetimibe/simvastatin; Falecalcitriol, Fampridine, Fesoterodine fumarate, Fingolimod hydrochloride; Gefitinib, Ghrelin (human), GS-7904L, GV-1001; HT-1001; Insulin detemir, ISIS-112989, Istradefylline; Laquinimod sodium, Latanoprost/timolol maleate, Lenalidomide, Levobetaxolol hydrochloride, Liposomal doxorubicin, Liposomal morphine sulfate, Lubiprostone, Lumiracoxib, LY-518674; MEM-1003, Mesna disulfide, Mipomersen sodium, MM-093, Mycophenolic acid sodium salt; Naptumomab estafenatox, Natalizumab; Olmesartan medoxomil, Olmesartan medoxomil/hydrochlorothiazide; Paclitaxel nanoparticles, Paclitaxel poliglumex, Pasireotide, Pazufloxacin mesilate, Pegfilgrastim, Peginterferon alfa-2a, Peginterferon alfa-2b, Peginterferon alfa-2b/ribavirin, Pegvisomant, Pemetrexed disodium, Pimagedine, Pimecrolimus, Pramlintide acetate, Prasterone, Pregabalin, Prulifloxacin; QAE-397; Rec-15/2615, RFB4(dsFv)-PE38, rhGAD65, Roflumilast, Romiplostim, Rosuvastatin calcium, Rotigotine, Rupatadine fumarate; Safinamide mesilate, SIR-Spheres, Sitagliptin phosphate, Sodium phenylacetate, Sodium phenylacetate/Sodium benzoate, Sorafenib, SSR-244738; Taribavirin hydrochloride, Taxus, Teduglutide, Tegaserod maleate, Telaprevir, Telbivudine, Tenofovir disoproxil fumarate, Tigecycline, Tiotropium bromide, Trabectedin, Travoprost

  3. Development of a Fatigue and Functional Impact Scale (FFIS) in Anemic Cancer Patients Receiving Chemotherapy

    PubMed Central

    Cella, David; Viswanathan, Hema N.; Hays, Ron D.; Mendoza, Tito R.; Stein, Kevin D.; Pasta, David J.; Foreman, Aimee J.; Vadhan-Raj, Saroj; Kallich, Joel D.

    2008-01-01

    Purpose To develop a brief measure of fatigue and functional impact in cancer patients with anemia. Patients and Methods Data were obtained from a multi-site, phase 2 study of darbepoetin alfa (n = 1,558). Eligible patients were ≥ 18 years with nonmyeloid malignancies and anemia (hemoglobin ≤11 g/dL) receiving chemotherapy. Items from the Functional Assessment of Cancer Therapy-Fatigue (FACT-F), Brief Fatigue Inventory (BFI), Fatigue Symptom Inventory (FSI) and items adapted from the Medical Outcomes Study SF-36 physical functioning scale were evaluated for inclusion in the measure. Items were selected by identifying the best predictors of total FACT-F scores, hemoglobin, and adjusted VO2Max in regression models. Correlations were examined between scale scores and adjusted VO2Max, hemoglobin, performance, self-reported energy, and productivity. Results Data from 401 patients with complete data were used to identify eight items for the Fatigue and Functional Impact Scale (FFIS), which was then evaluated using 1,355 of the 1,558 patients. The FFIS had an estimated internal consistency reliability of 0.90. The FFIS had large correlations with the FACT-F (r = 0.94), FSI (r = 0.80) and BFI (r = 0.86) from which it was derived. The FFIS also correlated substantially with single item measures of energy (r = 0.75) and productivity (r = 0.72). Conclusion The FFIS is a reliable, brief, and practical tool potentially suitable for identifying fatigue and functional impact in cancer patients. PMID:18642348

  4. Gateways to clinical trials.

    PubMed

    Bayes, M; Rabasseda, X; Prous, J R

    2005-10-01

    Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the following tables have been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity, the drug discovery and development portal, http://integrity.prous.com. This issue focuses on the following selection of drugs: (-)-Epigallocatechin gallate, (Z)-4-hydroxytamoxifen; Ad.muIFN-beta AD-237, adalimumab, adefovir dipivoxil, agalsidase alfa, alemtuzumab, almotriptan, ALVAC vCP1452, alvimopan hydrate, ambrisentan, anakinra, anti-IFN-gamma MAb; Bimatoprost, BMS-188797, BMS-214662, bortezomib, bosentan, bovine lactoferrin; Caffeine, canertinib dihydrochloride, canfosfamide hydrochloride, cannabidiol, caspofungin acetate, cetuximab, cH36, ChimeriVax-JE, ciclesonide, cilansetron, cinacalcet hydrochloride, clopidogrel, CpG-7909, Cypher; Daptomycin, darbepoetin alfa, darifenacin hydrobromide, decitabine, denufosol tetrasodium, Dexamet, diindolemethane, drotrecogin alfa (activated), duloxetine hydrochloride, DX-9065a; E-7010, edaravone, efalizumab, eicosapentaenoic acid/docosahexaenoic acid, elacridar, eletriptan, emtricitabine, epratuzumab, erlotinib hydrochloride, ertapenem sodium, eszopiclone, everolimus, ezetimibe; Fludarabine, fondaparinux sodium; gamma-Hydroxybutyrate sodium, gavestinel sodium, gefitinib, granisetron-Biochronomer; Human Albumin, human insulin; Imatinib mesylate, indiplon, interleukin-2 XL, isatoribine, ISS-1018, i.v. gamma-globulin, ivabradine hydrochloride, ixabepilone; Lanthanum carbonate, L-arginine hydrochloride, liposomal doxorubicin, LY-450139; Magnesium sulfate, melatonin, motexafin gadolinium, mycophenolic acid sodium salt; Natalizumab, nesiritide, niacin/lovastatin; OGX-011, olmesartan medoxomil, omalizumab, ospemifene; PACAP38, panitumumab, parathyroid hormone (human recombinant), parecoxib sodium, patupilone, pegfilgrastim, peginterferon alfa-2a, peginterferon alfa-2b, peginterferon alfa-2b

  5. Cholesterol testing and results

    MedlinePlus

    Cholesterol test results; LDL test results; VLDL test results; HDL test results; Coronary risk profile results; Hyperlipidemia- ... Some cholesterol is considered good and some is considered bad. Different blood tests can be done to measure each ...

  6. Incidence of erythropoietin antibody-mediated pure red cell aplasia: the Prospective Immunogenicity Surveillance Registry (PRIMS)

    PubMed Central

    Macdougall, Iain C.; Casadevall, Nicole; Locatelli, Francesco; Combe, Christian; London, Gerard M.; Di Paolo, Salvatore; Kribben, Andreas; Fliser, Danilo; Messner, Hans; McNeil, John; Stevens, Paul; Santoro, Antonio; De Francisco, Angel L.M.; Percheson, Paul; Potamianou, Anna; Foucher, Arnaud; Fife, Daniel; Mérit, Véronique; Vercammen, Els

    2015-01-01

    Background Subcutaneous administration of Eprex® (epoetin alfa) in patients with chronic kidney disease (CKD) was contraindicated in the European Union between 2002 and 2006 after increased reports of anti-erythropoietin antibody-mediated pure red cell aplasia (PRCA). The Prospective Immunogenicity Surveillance Registry (PRIMS) was conducted to estimate the incidence of antibody-mediated PRCA with subcutaneous administration of a new coated-stopper syringe presentation of Eprex® and to compare this with the PRCA incidence with subcutaneous NeoRecormon® (epoetin beta) and Aranesp® (darbepoetin alfa). Methods PRIMS was a multicentre, multinational, non-interventional, parallel-group, immunogenicity surveillance registry. Adults with CKD receiving or about to initiate subcutaneous Eprex®, NeoRecormon® or Aranesp® for anaemia were enrolled and followed for up to 3 years. Unexplained loss or lack of effect (LOE), including suspected PRCA, was reported, with antibody testing for confirmation of PRCA. Results Of the 15 333 patients enrolled, 5948 received Eprex® (8377 patient-years) and 9356 received NeoRecormon®/Aranesp® (14 286 patient-years). No treatment data were available for 29 patients. Among 23 patients with LOE, five cases of PRCA were confirmed (Eprex®, n = 3; NeoRecormon®, n = 1; Aranesp®, n = 1). Based on exposed time, PRCA incidence was 35.8/100 000 patient-years (95% CI 7.4–104.7) for Eprex® versus 14.0/100 000 patient-years (95% CI 1.7–50.6) for NeoRecormon®/Aranesp®. The incidence of PRCA with Eprex® was not significantly different versus comparator ESAs (rate ratio: 2.56; 95% CI 0.43–15.31). An analysis based on observed time produced similar findings. Conclusion This large, prospective registry demonstrates that PRCA is rare with subcutaneous administration of either the new coated-stopper syringe presentation of Eprex®, or NeoRecormon® or Aranesp®. PMID:25239637

  7. Your Kidney Test Results

    MedlinePlus

    ... blood vessels healthy. Vitamin D is important for bones and heart health. 1 Your Kidney Test Results Other Important Tests, continued A1C (for patients with diabetes) Results Goal: Your Result: Total Cholesterol Normal: Less ...

  8. Autonomous Soaring Flight Results

    NASA Technical Reports Server (NTRS)

    Allen, Michael J.

    2006-01-01

    A viewgraph presentation on autonomous soaring flight results for Unmanned Aerial Vehicles (UAV)'s is shown. The topics include: 1) Background; 2) Thermal Soaring Flight Results; 3) Autonomous Dolphin Soaring; and 4) Future Plans.

  9. Recent results from CDF

    SciTech Connect

    Sally Carol Seidel

    2001-07-16

    During the past year, the CDF Experiment has reported on a variety of results concerning QCD and electroweak studies, studies of the top quark, and searches for new phenomena. A sample of these results is presented here.

  10. Getting Districtwide Results

    ERIC Educational Resources Information Center

    McBeath, Angus

    2006-01-01

    This monograph is based on a keynote presentation by Angus McBeath at the "Getting Districtwide Results" Conference in Long Beach, California, which was co-sponsored by the Cross City Campaign for Urban School Reform and Focus on Results. The author, a former superintendent of the Edmonton Public Schools, how his school district was…

  11. Recent results from TRISTAN

    SciTech Connect

    Enomoto, Ryoji

    1997-01-01

    TRISTAN results on {gamma}{gamma} physics from 1994 to 1995 are reviewed in this report. We have systematically investigated jet production, the {gamma}-structure function, and charm pair production in {gamma}{gamma} processes. The results are discussed, and future prospects are presented.

  12. Diffraction Results from CDF

    SciTech Connect

    Goulianos, Konstantin

    2012-04-01

    We present final results by the CDF II collaboration on diffractive W and Z production, report on the status of ongoing analyses on diffractive dijet production and on rapidity gaps between jets, and briefly summarize results obtained on exclusive production pointing to their relevance to calibrating theoretical models used to predict exclusive Higgs-boson production at the LHC.

  13. Gateways to clinical trials.

    PubMed

    Bayés, M; Rabasseda, X; Prous, J R

    2005-04-01

    Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the following tables has been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity, the drug discovery and development portal, http://integrity. prous.com. This issue focuses on the following selection of drugs: ABX-IL-8, Acclaim, adalimumab, AGI-1067, alagebrium chloride, alemtuzumab, Alequel, Androgel, anti-IL-12 MAb, AOD-9604, aripiprazole, atomoxetine hydrochloride; Biphasic insulin aspart, bosentan, botulinum toxin type B, bovine lactoferrin, brivudine; Cantuzumab mertansine, CB-1954, CDB-4124, CEA-TRICOM, choriogonadotropin alfa, cilansetron, CpG-10101, CpG-7909, CTL-102, CTL-102/CB-1954; DAC:GRF, darbepoetin alfa, davanat-1, decitabine, del-1 Genemedicine, dexanabinol, dextofisopam, dnaJP1, dronedarone hydrochloride, dutasteride; Ecogramostim, eletriptan, emtricitabine, EPI-hNE-4, eplerenone, eplivanserin fumarate, erlotinib hydrochloride, ertapenem sodium, escitalopram oxalate, esomeprazole magnesium, etoricoxib, ezetimibe; Falecalcitriol, fingolimod hydrochloride; Gepirone hydrochloride; HBV-ISS, HSV-2 theracine, human insulin; Imatinib mesylate, Indiplon, insulin glargine, ISAtx-247; L612 HuMAb, levodopa/carbidopa/entacapone, lidocaine/prilocaine, LL-2113AD, lucinactant, LY-156735; Meclinertant, metelimumab, morphine hydrochloride, morphine-6-glucuronide; Natalizumab, nimotuzumab, NX-1207, NYVAC-HIV C; Omalizumab, onercept, osanetant; PABA, palosuran sulfate, parathyroid hormone (human recombinant), parecoxib sodium, PBI-1402, PCK-3145, peginterferon alfa-2a, peginterferon alfa-2b, peginterferon alfa-2b/ribavirin, pemetrexed disodium, pimecrolimus, PINC, pregabalin; Ramelteon, rasagiline mesilate, rasburicase, rimonabant hydrochloride, RO-0098557, rofecoxib, rosiglitazone maleate/metformin hydrochloride; Safinamide mesilate, SHL-749, sitaxsentan sodium, sparfosic acid, SprayGel, squalamine, St. John's Wort

  14. Unfavourable results in hypospadias

    PubMed Central

    Agrawal, Karoon; Misra, Anshumali

    2013-01-01

    Hypospadias urethroplasty is considered difficult as the complications and unfavourable results are not uncommon. At the turn of the century, due to a better understanding of applied anatomy of hypospadias, new techniques were developed which significantly brought down the complication rate. However unfavourable results are still disturbing. An algorithm for selection of surgery has been presented. Forty three secondary surgeries were performed over 3 years for correction of unfavourable results. The urethrocutaneous fistula was the most common (21%) followed by meatal stenosis (14%) and narrow neourethra (14%). Common unfavourable results have been discussed. On the basis of experience with a large number of hypospadias urethroplasty ‘tips to avoid or minimise unfavourable results’ have been presented. However, one should assess the final outcome of urethroplasty using hypospadias objective scoring evaluation. PMID:24501477

  15. Electroweak results from CDF

    SciTech Connect

    D. S. Waters

    2004-06-02

    Inclusive W and Z production cross-sections have been measured by CDF and certain electroweak parameters extracted with high precision from these measurements. New results on diboson production at the Tevatron are also presented.

  16. Results from MAC

    SciTech Connect

    Chadwick, G.B.

    1983-05-01

    The MAC detector has been exposed at PEP to 40 pb/sup -1/ luminosity of e/sup +/e/sup -/ collisions. The detector is described and recent results of a continuing analysis of hadronic cross section, lepton pair charge asymmetry, Bhabha process, two photon final state and radiative ..mu.. pairs are given. New results on flavor tagging of hadronic events with an inclusive ..mu.., and some searches for new particles are presented.

  17. Unfavorable results in replantation.

    PubMed

    Thomas, Abraham G

    2013-05-01

    Reattachment of amputated parts of the body (Replantation) has become a reality since the first arm replant was carried out six decades ago. Failures were not uncommon in the beginning, leading on to the analysis of the problem and refinements in technique. Improvements in sutures, instrumentation and better microscopes further helped the surgeons to do replantation with better finesse and functional results. Evaluation of results and particularly failure and long term results help the younger surgeons to learn from the difficulties faced earlier to do better in the future. An attempt is made to list various aspects of replantation experienced by the author during the past 30 years, particularly in reference to unfavorable results, which had been occasionally total failure, or a partial failure, with poor function and cosmesis due to infection. An insensate limb with poor function is the result of inadequate or improper nerve coaptation or infection destroying the whole repair. It is apt to mention that infection is mostly the result of poor vascularity due to devitalized tissue. Difficulties arise often in identifying the viable tissue, particularly while debriding in the distal amputated part since there is no bleeding. Experience counts in this, specifically to identify the viable muscle. The factors that may lead to complications are listed with remarks to avoid them.

  18. Recent results from CDF

    SciTech Connect

    Takikawa, K.; CDF

    1998-02-15

    We first present recent CDF results on the top quark, covering the measurement of the t{anti t} production cross section and the top quark mass, the observation of hadronic W decays in top events, the measurement of V{sub tb}, the search for flavor changing neutral current decays, and kinematical properties of t{anti t} production. Then we present one topic from CDF exotic physics results, i.e., the search for first-generation leptoquarks, and one topic from CDF B physics results, i.e., the measurement of time-dependent B{sup 0}-{anti B}{sup 0} mixing. Finally we conclude by briefly mentioning the prospects for Run II.

  19. Recent results from PEP

    SciTech Connect

    Hollebeek, R.

    1981-10-01

    Preliminary results are presented for the data taken by the MARK II and MAC collaborations at the PEP storage ring. Results include measurements of QED processes, limits on the weak couplings g/sub V/ and g/sub A/, limits on anomalous lepton production, the measurement of the tau lifetime, scale violation in inclusive hadron production, Monte Carlo independent tests of QCD using energy-energy correlations and single jet energy moments, measurements of the properties of three jet events, and measurements of proton, neutral kaon, lambda and proton pair yields.

  20. Continuous ACL graft, results

    PubMed Central

    Díaz, Jorge Luis; Vega, Marcelo; Matesevach, Ivan

    2017-01-01

    Objectives: describe our technique using hamstring graft that respects the proximal continuity of Semitendinosus and uses the superior biological potential of the distal periosteum., preserving and stressing the ST reinforce the retropulsión and dynamic control of external rotation of the knee. Here the technique, results, difficulties and foundations. Methods: The sample of this research was composed of 229 cases operated between 01/03/97 and 01/03/13 in Arthroscopy Private Center., 166 male and 63 female, the postop follow-up was 86 months. Evaluated with IKDC, Lysholm, Hamstring EMG. Comparative histology study in rabbits. Results: IKDC and Lysholm score showed 93% of very good results. Conclusion: Dynamic ACL reconstruction achieves a static-dynamic stabilization of the knee. Grafts have a plus in their biological potential (proximal continuity - osteo-periosteal insertion of the tendons in the femoral tunnel). The hamstring maintains its functionality (EMG). 93% satisfactory results (IKDC, Lysholm). It is a valid surgical option in ACL injuries.

  1. Sharing Research Results

    ERIC Educational Resources Information Center

    Ashbrook, Peggy

    2011-01-01

    There are many ways to share a collection of data and students' thinking about that data. Explaining the results of science inquiry is important--working scientists and amateurs both contribute information to the body of scientific knowledge. Students can collect data about an activity that is already happening in a classroom (e.g., the qualities…

  2. Reporting Research Results Effectively

    ERIC Educational Resources Information Center

    Volkwein, J. Fredericks

    2010-01-01

    Assessment research is at its best when it packages research results and data so that they can be digested by multiple audiences. Too many assessment researchers spend all their efforts planning and executing the research project with little attention to closing the loop at the end. If assessment findings are not communicated effectively, the…

  3. CPT Results from Ktev

    NASA Astrophysics Data System (ADS)

    Nguyen, Hogan

    2002-02-01

    We present several preliminary measurements from KTeV of the fundamental neutral K parameters, and their implications for CPT violation. A new limit is given on the sidereal time dependence of φ+-. The results are based on data collected in 1996-97.

  4. Results from ARGUS

    NASA Astrophysics Data System (ADS)

    Darden, C.

    1984-10-01

    The ARGUS collaboration reports results bearing on the fragmentation function for D*± mesons, the mass of the F± meson, the decays F±→φπ± and F±→φπ+π-π±, the decay γ'→π+π-γ and the radiative decay γ'→γΥ(3Pj).

  5. Results Are the Reason.

    ERIC Educational Resources Information Center

    Sparks, Dennis

    2000-01-01

    Author Mike Schmoker argues that data should play a crucial role before staff development begins by helping to select the most results-oriented initiatives. Staff development proposals should be based on data that indicate the initiatives have led to higher achievement. This interview discusses barriers to using data and notes the role of…

  6. Recent results from MAC

    SciTech Connect

    MAC Collaboration

    1982-05-01

    Some preliminary results from the MAC detector at PEP are presented. These include measurements of the angular distribution of ..gamma gamma.., ..mu mu.. and tau tau final states, a determination of the tau lifetime, a measurement of R, and a presentation of the inclusive muon p/sub perpendicular/ distribution for hadronic events.

  7. Recent CDF results

    SciTech Connect

    Gomez, Gervasio; /Cantabria Inst. of Phys.

    2007-11-01

    As of November of 2007, the CDF detector has recorded approximately 2.7 fb{sup -1} of data. This contribution describes some of the most recent and most relevant results from the CDF collaboration in all areas of its wide physics program, as well as some insights into the Tevatron reach for Higgs searches within the next few years.

  8. Implementation Challenges and Results

    ERIC Educational Resources Information Center

    Walters, Kirk; Sorensen, Nicholas

    2013-01-01

    This paper describes the implementation of the online and f2f summer algebra courses that were delivered in summers 2011 and 2012. These data will be used to frame the impact results presented in an earlier paper. In particular, the paper will provide a detailed picture of how the online course was structured and the types of supports provided to…

  9. 2008 Election Results

    NASA Astrophysics Data System (ADS)

    McDonough, William; Bamzai, Anjuli; Robinson, Robert

    2008-02-01

    Voting by the membership for Union and Section officers for the 2008-2010 term was completed on 10 January 2008. Voting was conducted electronically through an Internet Web site using commercial surveying software. Paper ballots were available upon request. The tallying and recording of the election was managed by AGU staff using Vovici software. The results of the election are given below.

  10. 2006 Election Results

    NASA Astrophysics Data System (ADS)

    Staudt, Amanda C.; Given, Holly K.; McDonough, William F.

    2006-02-01

    The voting by the membership for Union and Section officers for the 2006-2008 term was completed on 10 January. Voting was conducted electronically through the Internet using commercial surveying software. Paper ballots were available upon request. The tallying and recording of the elections was managed by AGU staff using the Web-Surveyor software. The results of the voting are listed below.

  11. [The applicability of results].

    PubMed

    Marín-León, I

    2015-11-01

    The ultimate aim of the critical reading of medical literature is to use the scientific advances in clinical practice or for innovation. This requires an evaluation of the applicability of the results of the studies that have been published, which begins with a clear understanding of these results. When the studies do not provide sufficient guarantees of rigor in design and analysis, the conditions necessary for the applicability of the results are not met; however, the fact that the results are reliable is not enough to make it worth trying to use their conclusions. This article explains how carrying out studies in experimental or artificial conditions often moves them away from the real conditions in which they claim to apply their conclusions. To evaluate this applicability, the article proposes evaluating a set of items that will enable the reader to determine the likelihood that the benefits and risks reported in the studies will yield the least uncertainty in the clinical arena where they aim to be applied.

  12. QCD results from CDF

    SciTech Connect

    Plunkett, R.; The CDF Collaboration

    1991-10-01

    Results are presented for hadronic jet and direct photon production at {radical}{bar s} = 1800 GeV. The data are compared with next-to-leading QCD calculations. A new limit on the scale of possible composite structure of the quarks is also reported. 12 refs., 4 figs.

  13. Cleanroom energy benchmarking results

    SciTech Connect

    Tschudi, William; Xu, Tengfang

    2001-09-01

    A utility market transformation project studied energy use and identified energy efficiency opportunities in cleanroom HVAC design and operation for fourteen cleanrooms. This paper presents the results of this work and relevant observations. Cleanroom owners and operators know that cleanrooms are energy intensive but have little information to compare their cleanroom's performance over time, or to others. Direct comparison of energy performance by traditional means, such as watts/ft{sup 2}, is not a good indicator with the wide range of industrial processes and cleanliness levels occurring in cleanrooms. In this project, metrics allow direct comparison of the efficiency of HVAC systems and components. Energy and flow measurements were taken to determine actual HVAC system energy efficiency. The results confirm a wide variation in operating efficiency and they identify other non-energy operating problems. Improvement opportunities were identified at each of the benchmarked facilities. Analysis of the best performing systems and components is summarized, as are areas for additional investigation.

  14. Results from SAGE II

    SciTech Connect

    Nico, J.S.

    1994-10-01

    The Russian-American Gallium solar neutrino Experiment (SAGE) began the second phase of operation (SAGE II) in September of 1992. Monthly measurements of the integral flux of solar neutrinos have been made with 55 tonnes of gallium. The K-peak results of the first nine runs of SAGE II give a capture rate of 66{sub -13}{sup +18} (stat) {sub -7}{sup +5} (sys) SNU. Combined with the SAGE I result of 73{sub -16}{sup +18} (stat) {sub -7}{sup 5} (sys) SNU, the capture rate is 69{sub -11}{sup +11} (stat) {sub -7}{sup +5} (sys) SNU. This represents only 52%--56% of the capture rate predicted by different Standard Solar Models.

  15. Early results from ISO

    NASA Astrophysics Data System (ADS)

    1996-01-01

    First findings by Europe's new space telescope ISO (Infrared Space Observatory) will be announced at a press conference to be held at ESA's satellite tracking station in Villafranca, Apartado 50727 - 28080-Madrid, on Wednesday 14 February 1996 Astronomers responsible for ISO's instruments will show results ranging from materials in the planet Saturn, through the birth and death of stars, to the behaviour of colliding galaxies. All instruments are working well and even their preliminary results confirm that ISO is a unique observatory making an unprecedented exploration of the universe by infrared rays. Parallel press conferences will be held at ESA Headquarters in Paris, ESTEC Noordwijk (the Netherlands) and ESOC Darmstadt (Germany) where a live television link will be established with Villafranca and from where the media can participate in the discussion.

  16. Dosimetric results on EURECA

    SciTech Connect

    Reitz, G.

    1995-02-01

    Detector packages were exposed on the European Retrievable Carrier (EURECA) as part of the Biostack experiment inside the Exobiology and Radiation Assembly (ERA) and at several locations around EURECA. The packages consist of different plastic nuclear track detectors, nuclear emulsions and thermoluminescence dosimeters (TLD`s). Evaluation of these detectors yields data on absorbed dose and particle and LET spectra. Preliminary results of absorbed dose measurements in the EURECA dosimeter packages are reported and compared to results of the LDEF experiments. The highest dose rate measured on EURECA is 63.3 plus or minus 0.4 mGy d(exp -1) behind a shielding thickness of 0.09 g cm(exp -2) in front of the detector package.

  17. Titan - Some new results

    NASA Astrophysics Data System (ADS)

    Owen, T.; Gautier, D.

    New analyses of Voyager spectra of Titan have led to improvements in the determination of abundances of minor constituents as a function of latitude and altitude. Ground-based microwave observations have extended the Voyager results for HCN, and have demonstrated that CO is mysteriously deficient in the stratosphere. The origin of the CH4, CO, and N2 in Titan's atmosphere is still unresolved. Both primordial and evolutionary sources are compatible with the available evidence.

  18. Recent results from MAMI

    SciTech Connect

    Arends, Hans-Juergen

    2011-10-24

    The Mainz Microtron MAMI is an ideal facility to study the hadron structure with the electromagnetic probe. With the new accelerator stage (HDSM), which went into operation in 2007, high-intensity polarized electron and photon beams with energies up to 1.6 GeV are delivered to the experiments. Polarized targets and recoil polarimeters in combination with dedicated detectors are available for precision experiments in hadron physics. In this article, an overview over selected recent results is given.

  19. Results from SAGE

    SciTech Connect

    Abdurashitov, J.N.; Gavrin, V.N.; Girin, S.V.

    1996-04-01

    The Russian-American Gallium Solar Neutrino Experiment (SAGE) is described. Beginning in September 1992, SAGE II data were taken with 55 tons of Ga and with significantly reduced backgrounds. The solar neutrino flux measured by 31 extractions through October 1993 is presented. The result of 69 {+-} 10 +5/{minus}7 SNU is to be compared with a Standard Solar Model prediction of 132 SNU.

  20. ICAAS piloted simulation results

    NASA Astrophysics Data System (ADS)

    Landy, R. J.; Halski, P. J.; Meyer, R. P.

    1994-05-01

    This paper reports piloted simulation results from the Integrated Control and Avionics for Air Superiority (ICAAS) piloted simulation evaluations. The program was to develop, integrate, and demonstrate critical technologies which will enable United States Air Force tactical fighter 'blue' aircraft to achieve superiority and survive when outnumbered by as much as four to one by enemy aircraft during air combat engagements. Primary emphasis was placed on beyond visual range (BVR) combat with provisions for effective transition to close-in combat. The ICAAS system was developed and tested in two stages. The first stage, called low risk ICAAS, was defined as employing aircraft and avionics technology with an initial operational date no later than 1995. The second stage, called medium risk ICAAS, was defined as employing aircraft and avionics technology with an initial operational date no later than 1998. Descriptions of the low risk and medium risk simulation configurations are given. Normalized (unclassified) results from both the low risk and medium risk ICAAS simulations are discussed. The results show the ICAAS system provided a significant improvement in air combat performance when compared to a current weapon system. Data are presented for both current generation and advanced fighter aircraft. The ICAAS technologies which are ready for flight testing in order to transition to the fighter fleet are described along with technologies needing additional development.

  1. Certification of computational results

    NASA Technical Reports Server (NTRS)

    Sullivan, Gregory F.; Wilson, Dwight S.; Masson, Gerald M.

    1993-01-01

    A conceptually novel and powerful technique to achieve fault detection and fault tolerance in hardware and software systems is described. When used for software fault detection, this new technique uses time and software redundancy and can be outlined as follows. In the initial phase, a program is run to solve a problem and store the result. In addition, this program leaves behind a trail of data called a certification trail. In the second phase, another program is run which solves the original problem again. This program, however, has access to the certification trail left by the first program. Because of the availability of the certification trail, the second phase can be performed by a less complex program and can execute more quickly. In the final phase, the two results are compared and if they agree the results are accepted as correct; otherwise an error is indicated. An essential aspect of this approach is that the second program must always generate either an error indication or a correct output even when the certification trail it receives from the first program is incorrect. The certification trail approach to fault tolerance is formalized and realizations of it are illustrated by considering algorithms for the following problems: convex hull, sorting, and shortest path. Cases in which the second phase can be run concurrently with the first and act as a monitor are discussed. The certification trail approach are compared to other approaches to fault tolerance.

  2. GIRAFFE test results summary

    SciTech Connect

    Yokobori, S.; Arai, K.; Oikawa, H.

    1996-03-01

    A passive system can provide engineered safety features enhancing safety system reliability and plant simplicity. Toshiba has conducted the test Program to demonstrate the feasibility of the SBWR passive safety system using a full-height, integral system test facility GIRAFFE. The test facility GIRAFFE models the SBWR in full height to correctly present the gravity driving head forces with a 1/400 volume scale. The GIRAFFE test Program includes the certification tests of the passive containment cooling system (PCCS) to remove the post-accident decay heat and the gravity driven cooling system (GDCS) to replenish the reactor coolant inventory during a LOCA. The test results have confirmed the PCCS and GDCS design and in addition, have demonstrated the operation of the pCCS with the presence of a lighter-than-steam noncondensable as well as with the presence of a heavier-than-steam, noncondensable. The GIRAFFE test Program has also provided the database to qualify a best estimate thermal-hydraulic computer code TRAC. The post test analysis results have shown that TRAC can accurately predict the PCCS heat removal Performance and the containment pressure response to a LOCA. This paper summarizes the GIRAFFE test results to investigate post-LOCA PCCS heat removal performance and post-test analysis using TRAC.

  3. The Viking biology results

    NASA Technical Reports Server (NTRS)

    Klein, Harold P.

    1989-01-01

    A brief review of the purposes and the results from the Viking Biology experiments is presented, in the expectation that the lessons learned from this mission will be useful in planning future approaches to the biological exploration of Mars. Since so little was then known about potential micro-environments on Mars, three different experiments were included in the Viking mission, each one based on different assumptions about what Martian organisms might be like. In addition to the Viking Biology Instrument (VBI), important corollary information was obtained from the Viking lander imaging system and from the molecular analysis experiments that were conducted using the gas chromatograph-mass spectrometer (GCMS) instrument. No biological objects were noted by the lander imaging instrument. The GCMS did not detect any organic compounds. A description of the tests conducted by the Gas Exchange Experiment, the Labeled Release experiment, and the Pyrolytic Release experiment is given. Results are discussed. Taken as a whole, the Viking data yielded no unequivocal evidence for a Martian biota at either landing site. The results also revealed the presence of one or more reactive oxidants in the surface material and these need to be further characterized, as does the range of micro-environments, before embarking upon future searches for extant life on Mars.

  4. Explaining embodied cognition results.

    PubMed

    Lakoff, George

    2012-10-01

    From the late 1950s until 1975, cognition was understood mainly as disembodied symbol manipulation in cognitive psychology, linguistics, artificial intelligence, and the nascent field of Cognitive Science. The idea of embodied cognition entered the field of Cognitive Linguistics at its beginning in 1975. Since then, cognitive linguists, working with neuroscientists, computer scientists, and experimental psychologists, have been developing a neural theory of thought and language (NTTL). Central to NTTL are the following ideas: (a) we think with our brains, that is, thought is physical and is carried out by functional neural circuitry; (b) what makes thought meaningful are the ways those neural circuits are connected to the body and characterize embodied experience; (c) so-called abstract ideas are embodied in this way as well, as is language. Experimental results in embodied cognition are seen not only as confirming NTTL but also explained via NTTL, mostly via the neural theory of conceptual metaphor. Left behind more than three decades ago is the old idea that cognition uses the abstract manipulation of disembodied symbols that are meaningless in themselves but that somehow constitute internal "representations of external reality" without serious mediation by the body and brain. This article uniquely explains the connections between embodied cognition results since that time and results from cognitive linguistics, experimental psychology, computational modeling, and neuroscience.

  5. Pressure locking test results

    SciTech Connect

    DeWall, K.G.; Watkins, J.C.; McKellar, M.G.; Bramwell, D.

    1996-12-01

    The U.S. Nuclear Regulatory Commission (NRC), Office of Nuclear Regulatory Research, is funding the Idaho National Engineering Laboratory (INEL) in performing research to provide technical input for their use in evaluating responses to Generic Letter 95-07, {open_quotes}Pressure Locking and Thermal Binding of Safety-Related Power-Operated Gate Valves.{close_quotes} Pressure locking and thermal binding are phenomena that make a closed gate valve difficult to open. This paper discusses only the pressure locking phenomenon in a flexible-wedge gate valve; the authors will publish the results of their thermal binding research at a later date. Pressure locking can occur when operating sequences or temperature changes cause the pressure of the fluid in the bonnet (and, in most valves, between the discs) to be higher than the pressure on the upstream and downstream sides of the disc assembly. This high fluid pressure presses the discs against both seats, making the disc assembly harder to unseat than anticipated by the typical design calculations, which generally consider friction at only one of the two disc/seat interfaces. The high pressure of the bonnet fluid also changes the pressure distribution around the disc in a way that can further contribute to the unseating load. If the combined loads associated with pressure locking are very high, the actuator might not have the capacity to open the valve. The results of the NRC/INEL research discussed in this paper show that the relationship between bonnet pressure and pressure locking stem loads appears linear. The results also show that for this valve, seat leakage affects the bonnet pressurization rate when the valve is subjected to thermally induced pressure locking conditions.

  6. Lithium cell test results

    NASA Technical Reports Server (NTRS)

    Bragg, B. J.

    1977-01-01

    Three lithium SO2 cells, two lithium CF cells, and a vinyl chloride cell, all with crimped seals, and all strictly experimental, were independently discharged on resistors. Three temperatures were used and several different storage temperatures. Discharge rate generally on the nominal discharges were 0.1 amp, 0.5 amp, and 1 amp. Tests results show that the crimp seals are inadequate, especially for the SO2 cells. Normal discharges present no hazards. All cells discharge to zero. The problem of lithium cell explosions, such as occurred during off-limits testing, is discussed.

  7. Recent result from RENO

    NASA Astrophysics Data System (ADS)

    Seo, Hyunkwan; RENO Collaboration

    2016-05-01

    The Reactor Experiment for Neutrino Oscillation (RENO) started data-taking from August, 2011 and has measured the smallest neutrino mixing angle θ13 by observing the disappearance of reactor antineutrinos. Antineutrinos from the six reactors at Hanbit Nuclear Power Plant in Korea are detected and compared by the two identical detectors located in the near and far distances from the reactor array center. We present new results on precisely measured sin 22θ13 value and |Δm2 ee| based on spectral analysis using the 800 days of data sample, which are taken from August, 2011 to Dec., 2013.

  8. Results of railgun experiments

    SciTech Connect

    Hawke, R.S.; Brooks, A.L.; Fowler, C.M.; Peterson, D.R.

    1983-04-01

    During the 1979 Megagauss II conference the hypervelocity potential of railguns and the pulsed power technology needed to power them were discussed. Since then, many laboratories have initiated railgun R and D projects for a variety of potential applications. Los Alamos and Lawrence Livermore National Laboratories initiated a collaborative experimental railgun project which resulted in several successes in accelerating projectiles to high velocities, emphasized the limits on railgun operation, and indicated that the numerical modeling of railgun operation was in good agreement with the experiments.

  9. Planck 2015 Cosmological results

    NASA Astrophysics Data System (ADS)

    Tristram, Matthieu

    2015-08-01

    On behalf of the Planck collaboration, I will present the cosmological results from the 2015 release. The new release now include polarization data from both the LFI and the HFI.I will focus on the impact of the polarization on both the standard LCDM model and its basic extensions. I will compare these constraints with other cosmological probes such as BAO, gravitational lensing and redshift space distortions.LCDM is still a very good fit of the Planck CMB data. The scalar fluctuations are consistent with adiabatic modes.

  10. Recent BABAR Results

    SciTech Connect

    Eigen, Gerald

    2015-04-29

    We present herein the most recent BABAR results on direct CP asymmetry measurements in B → Xsγ, on partial branching fraction and CP asymmetry measurements in B → Xs+-, on a search for B → π/ηℓ+- decays, on a search for lepton number violation in B+ → X-+ℓ'+ modes and a study of B0 →ωω and B0 → ωφ decays.

  11. SPEAR results, 1981

    SciTech Connect

    Scharre, D.L.

    1981-09-01

    New results from SPEAR on the inclusive photon spectrum at the psi' and on J/psi radiative transitions are presented. Evidence for an eta/sub c/' candidate is observed in the psi' inclusive photon spectrum at a mass M = 3592 +- 5 MeV. A new resonance, the theta(1640) which is observed to decay into eta eta, has been seen in radiative transitions from the J/psi. The spin-parity of the l(1440), previously observed in J/psi radiative transitions and originally identified as the E(1420), has been determined to be 0/sup -/.

  12. Recent Results from Borexino

    NASA Astrophysics Data System (ADS)

    Jeschke, D.; Agostini, M.; Altenmüller, K.; Appel, S.; Atroshchenko, V.; Bellini, G.; Benziger, J.; Bick, D.; Bonfini, G.; Bravo, D.; Caccianiga, B.; Calaprice, F.; Caminata, A.; Carlini, M.; Cavalcante, P.; Chepurnov, A.; Choi, K.; D’Angelo, D.; Davini, S.; Derbin, A.; Di Noto, L.; Drachnev, I.; Etenko, A.; Fomenko, K.; Franco, D.; Gabriele, F.; Galbiati, C.; Ghiano, C.; Giammarchi, M.; Goeger-Neff, M.; Goretti, A.; Gromov, M.; Hagner, C.; Hungerford, E.; Ianni, Aldo; Ianni, Andrea; Jany, A.; Jedrzejczak, K.; Jeschke, D.; Kobychev, V.; Korablev, D.; Korga, G.; Kryn, D.; Laubenstein, M.; Lehnert, B.; Litvinovich, E.; Lombardi, F.; Lombardi, P.; Ludhova, L.; Lukyanchenko, G.; Machulin, I.; Manecki, S.; Maneschg, W.; Manuzio, G.; Marcocci, S.; Meroni, E.; Meyer, M.; Miramonti, L.; Misiaszek, M.; Montuschi, M.; Mosteiro, P.; Muratova, V.; Neumair, B.; Oberauer, L.; Obolensky, M.; Ortica, F.; Pallavicini, M.; Papp, L.; Pocar, A.; Ranucci, G.; Razeto, A.; Re, A.; Romani, A.; Roncin, R.; Rossi, N.; Schönert, S.; Semenov, D.; Skorokhvatov, M.; Smirnov, O.; Sotnikov, A.; Sukhotin, S.; Suvorov, Y.; Tartaglia, R.; Testera, G.; Thurn, J.; Toropova, M.; Unzhakov, E.; Vishneva, A.; Vogelaar, R. B.; von Feilitzsch, F.; Wang, H.; Weinz, S.; Winter, J.; Wojcik, M.; Wurm, M.; Yokley, Z.; Zaimidoroga, O.; Zavatarelli, S.; Zuber, K.; Zuzel, G.

    2017-01-01

    The Borexino experiment is taking data since 2007 at the Laboratori Nazionali del Gran Sasso in Italy accomplishing outstanding achievements in the field of neutrino physics. Its success is strongly based on the unprecedented ultra-high radio-purity of the inner scintillator core. The main features of the detector and the impressive results for solar and geo-neutrinos obtained by Borexino so far are summarized. The main focus is laid on the most recent results, i.e. the first real-time measurement of the solar pp neutrino flux and the detection of the signal induced by geo-neutrinos with a significance as high as 5.9σ. The measurement of the pp neutrino flux represents a direct probe of the major mechanism of energy production in the Sun and its observation at a significance of 10σ proves the stability of the Sun over a time of at least 105 years. It further puts Borexino in the unique position of being capable to test the MSW-LMA paradigm across the whole solar energy range. The geo-neutrino data allow to infer information concerning important geophysical properties of the Earth that are also discussed. The perspectives of the final stage of the Borexino solar neutrino program that are centered on the goal of measuring the CNO neutrinos that so far escaped any observation are outlined.

  13. Spacelab Science Results Study

    NASA Technical Reports Server (NTRS)

    Naumann, R. J.; Lundquist, C. A.; Tandberg-Hanssen, E.; Horwitz, J. L.; Germany, G. A.; Cruise, J. F.; Lewis, M. L.; Murphy, K. L.

    2009-01-01

    Beginning with OSTA-1 in November 1981 and ending with Neurolab in March 1998, a total of 36 Shuttle missions carried various Spacelab components such as the Spacelab module, pallet, instrument pointing system, or mission peculiar experiment support structure. The experiments carried out during these flights included astrophysics, solar physics, plasma physics, atmospheric science, Earth observations, and a wide range of microgravity experiments in life sciences, biotechnology, materials science, and fluid physics which includes combustion and critical point phenomena. In all, some 764 experiments were conducted by investigators from the U.S., Europe, and Japan. The purpose of this Spacelab Science Results Study is to document the contributions made in each of the major research areas by giving a brief synopsis of the more significant experiments and an extensive list of the publications that were produced. We have also endeavored to show how these results impacted the existing body of knowledge, where they have spawned new fields, and if appropriate, where the knowledge they produced has been applied.

  14. Unfavourable results in pollicisation

    PubMed Central

    Thatte, Mukund R.; Nehete, Sushil; Garude, Kirti; Mehta, Rujuta

    2013-01-01

    Pollicisation of the index finger is perhaps one of the most complex and most rewarding operations in hand and plastic surgery. It however has a steep learning curve and demands very high skill levels and experience. There are multiple pitfalls and each can result in an unfavourable result. In essence we need to: Shorten the Index, recreate the carpo metacarpal joint from the metacarpo phalangeal (MP) joint, rotate the digit by about 120° for pulp to pulp pinch, palmarly abduct by 40-50° to get a new first web gap, Shorten and readjust the tension of the extensors, re attach the intrinsics to form a thenar eminence capable of positioning the new thumb in various functional positions and finally close the flaps forming a new skin envelope. The author has performed over 75 pollicisations personally and has personal experience of some of the issues raised there. The steps mentioned therefore are an algorithm for helping the uninitiated into these choppy waters. PMID:24501467

  15. Maquet Osteotomy, Results

    PubMed Central

    Díaz, Jorge Luis; Vega, Marcelo; Matesevach, Ivan

    2017-01-01

    Objectives: The objectives are to assess the results and to discuss the indications for Maquet osteotomy in patients with patellofemoral osteoarthritis. Methods: Retrospective study of a series of 32 patients (4 bilateral, that is to say, 36 knees) operated between March 1999 and October 2013 in " Arthroscopy Private Center ", 12 male and 20 female, average age 59 years with an average postoperative surgery outcomes of 53 months. The technique consists of an arthroscopic procedure to treat joint lesions and a tibial tuberosity osteotomy of 5 cm long, by embedding a 1cm subsequent graft taken from the same metaphysis and fixed with 2 screws. Results: All patients had significant improvement, evaluated with Kujala’s score (54 points preop to 86 points postop) and Guillamon Ferguson’s criteria (27.2 very good and 60.7 good). The complication rate was acceptable. Conclusion: The available technics are surgeries on proximal soft structures, osteotomies of tibial tuberosity and patellofemoral arthroplasty. Maquet osteotomy is an excellent procedure when the patient’s selection is right. Obtaining the graft from the same metaphysis simplified the procedure.

  16. CDF results on top

    SciTech Connect

    Beretvas, A.; CDF Collaboration

    1995-08-01

    CDF has established the existence of the top quark. Results from p{anti p} collisions at {radical}s = 1.8 TeV are presented. In the dilepton final state the authors found seven events with a background of 1.3 {+-} 0.3. In the e, {mu} + {nu} + jets channel with a b identified via a secondary vertex detector (SVX), they found twenty one events with a background of 5.5 {+-} 1.8. They measure the top quark mass to be 176 {+-} 8 (stat) {+-} 10 (syst) GeV/c{sup 2}, and the t{anti t} production cross section to be 7.6{sub {minus}2.0}{sup +2.4} pb. The integrated luminosity for the results presented in this talk is 67 pb{sup {minus}1}. The CDF detector needs to be upgraded for the next run. The integrated luminosity for the next run is expected to be more than 1,000 pb{sup {minus}1}.

  17. Organic Separation Test Results

    SciTech Connect

    Russell, Renee L.; Rinehart, Donald E.; Peterson, Reid A.

    2014-09-22

    Separable organics have been defined as “those organic compounds of very limited solubility in the bulk waste and that can form a separate liquid phase or layer” (Smalley and Nguyen 2013), and result from three main solvent extraction processes: U Plant Uranium Recovery Process, B Plant Waste Fractionation Process, and Plutonium Uranium Extraction (PUREX) Process. The primary organic solvents associated with tank solids are TBP, D2EHPA, and NPH. There is concern that, while this organic material is bound to the sludge particles as it is stored in the tanks, waste feed delivery activities, specifically transfer pump and mixer pump operations, could cause the organics to form a separated layer in the tank farms feed tank. Therefore, Washington River Protection Solutions (WRPS) is experimentally evaluating the potential of organic solvents separating from the tank solids (sludge) during waste feed delivery activities, specifically the waste mixing and transfer processes. Given the Hanford Tank Waste Treatment and Immobilization Plant (WTP) waste acceptance criteria per the Waste Feed Acceptance Criteria document (24590-WTP-RPT-MGT-11-014) that there is to be “no visible layer” of separable organics in the waste feed, this would result in the batch being unacceptable to transfer to WTP. This study is of particular importance to WRPS because of these WTP requirements.

  18. First results from CARIBU

    NASA Astrophysics Data System (ADS)

    Savard, Guy

    2011-10-01

    The Californium Rare Ion Breeder Upgrade (CARIBU) of the ATLAS superconducting linac facility aims at providing low energy and reaccelerated neutron-rich radioactive beams to address key nuclear physics, astrophysics and application issues. These beams are obtained from fission fragments of a 1 Ci 252Cf source, thermalized and collected into a low-energy particle beam by a helium gas catcher, mass analyzed by an isobar separator, and charge breed to higher charge states for acceleration in ATLAS. The method described is fast and universal and short-lived isotope yield scale essentially with Californium fission yields. The facility is now commissioned and operating with a 100 mCi source which has yielded extracted low-energy mass separated radioactive beams at intensities in excess of 100000 ions per second. Radioactive beams have been charge bred with an efficiency of up to 12% and reaccelerated to 6 MeV/u. Commissioning results, together with the results from first astrophysics experiments at CARIBU using the beams from the 100 mCi source will be presented. The final 1 Ci source is currently under fabrication and is expected to be installed by the end of the year. This work was supported by the US DOE, Office of Nuclear Physics, under contract DE-AC02-06CH11357.

  19. Recent Results from Phobos

    SciTech Connect

    Garcia, Edmundo; Betts, R. R.; Garcia, E.; Halliwell, C.; Hofman, D. J.; Hollis, R. S.; Iordanova, A.; Sagerer, J.; Smith, C. E.; Back, B. B.; Baker, M. D.; Barton, D. S.; Carroll, A.; Chai, Z.; George, N.; Hauer, M.; Holzman, B.; Pak, R.; Seals, H.; Sedykh, I.

    2007-02-12

    The PHOBOS detector is one of four heavy ion experiments at the Relativistic Heavy Ion Collider at Brookhaven National Laboratory. In this paper we will review some of the results of PHOBOS from the data collected in p+p, d+Au and Au+Au collisions at nucleon-nucleon center-of-mass energies up to 200 GeV. Evidence is found of the formation of a very high energy density and highly interactive system, which can not be described in terms of hadrons, and has a relatively low baryon density. There is evidence that the system formed is thermalized to a certain degree. Scaling with the number of participants and extended longitudinal scaling behavior are also observed in distributions of produced charged particles.

  20. Iron Mountain Electromagnetic Results

    SciTech Connect

    Gail Heath

    2012-07-01

    Iron Mountain Mine is located seventeen miles northwest of Redding, CA. After the completion of mining in early 1960s, the mine workings have been exposed to environmental elements which have resulted in degradation in water quality in the surrounding water sheds. In 1985, the EPA plugged ore stoops in many of the accessible mine drifts in an attempt to restrict water flow through the mine workings. During this process little data was gathered on the orientation of the stoops and construction of the plugs. During the last 25 years, plugs have begun to deteriorate and allow acidic waters from the upper workings to flow out of the mine. A team from Idaho National Laboratory (INL) performed geophysical surveys on a single mine drift and 3 concrete plugs. The project goal was to evaluate several geophysical methods to determine competence of the concrete plugs and orientation of the stopes.

  1. FIRE Science Results 1989

    NASA Technical Reports Server (NTRS)

    Mcdougal, David S. (Editor)

    1990-01-01

    FIRE (First ISCCP Regional Experiment) is a U.S. cloud-radiation research program formed in 1984 to increase the basic understanding of cirrus and marine stratocumulus cloud systems, to develop realistic parameterizations for these systems, and to validate and improve ISCCP cloud product retrievals. Presentations of results culminating the first 5 years of FIRE research activities were highlighted. The 1986 Cirrus Intensive Field Observations (IFO), the 1987 Marine Stratocumulus IFO, the Extended Time Observations (ETO), and modeling activities are described. Collaborative efforts involving the comparison of multiple data sets, incorporation of data measurements into modeling activities, validation of ISCCP cloud parameters, and development of parameterization schemes for General Circulation Models (GCMs) are described.

  2. System results from FRECOPA

    SciTech Connect

    Durin, C.; Berthoud, L.; Mandeville, J.C.

    1995-02-01

    The work carried out over the past three years on FRECOPA and the LDEF has enabled a large quantity of information to be collected, part of which has already been exploited. As far as CNES is concerned, the major spin-offs of this mission mainly focus on the orbital environment and the behavior of materials in such an environment. With respect to the environment, the authors shall develop the lessons learned from expert appraisals on impacts by microparticles, which are the main feature observed in this area. As for the materials, the results show a variety of behavior when subjected to the space environment and even now constitute a wealth of information for the designing and validation of future mechanical systems. Apart from these direct spin-offs, there are repercussions on in-flight and ground testing, the calibration of test benches and improvements to simulation models.

  3. System results from FRECOPA

    NASA Technical Reports Server (NTRS)

    Durin, Christian; Berthoud, Lucinda; Mandeville, Jean-Claude

    1995-01-01

    The work carried out over the past three years on FRECOPA and the LDEF has enabled a large quantity of information to be collected, part of which has already been exploited. As far as CNES is concerned, the major spin-offs of this mission mainly focus on the orbital environment and the behavior of materials in such an environment. With respect to the environment, the authors shall develop the lessons learned from expert appraisals on impacts by microparticles, which are the main feature observed in this area. As for the materials, the results show a variety of behavior when subjected to the space environment and even now constitute a wealth of information for the designing and validation of future mechanical systems. Apart from these direct spin-offs, there are repercussions on in-flight and ground testing, the calibration of test benches and improvements to simulation models.

  4. 2012 election results

    NASA Astrophysics Data System (ADS)

    Robinson, Robert; Tetzlaff, Doerthe

    2012-10-01

    On 4 October 2012, AGU members completed voting for the 2013-2014 leadership term. Union officers, Board members, section and focus group officers, and student and early career representatives to the Council were elected. All members who joined or renewed their membership by 1 July 2012 were eligible to vote in this year's leadership election. The vote was held electronically, and access to voting was provided to all eligible voters for a period of 31 days. The voting was conducted by Survey and Ballot Systems, Inc. (SBS). SBS, which offers election planning and management services, provided unique login credentials and other support services for eligible voters throughout the election. Voting results were certified by SBS on 8 October and by the AGU Tellers Committee on 9 October. The overall participation rate was 21.9%, an increase over previous AGU elections.

  5. Top physics: CDF results

    SciTech Connect

    K. Bloom

    2004-06-23

    The top quark plays an important role in the grand scheme of particle physics, and is also interesting on its own merits. We present recent results from CDF on top-quark physics based on 100-200 pb{sup -1} of p{bar p} collision data. We have measured the t{bar t} cross section in different decay modes using several different techniques, and are beginning our studies of top-quark properties. New analyses for this conference include a measurement of {sigma}{sub t{bar t}} in the lepton-plus-jets channel using a neural net to distinguish signal and background events, and measurements of top-quark branching fractions.

  6. Viscosupplementation: techniques, indications, results.

    PubMed

    Legré-Boyer, V

    2015-02-01

    Viscosupplementation by hyaluronic acid (HA) injections is frequently used for local treatment of osteoarthritis (OA), due to ease of use and good tolerance. A profusion of linear or reticulated HA derivates are marketed, with varied characters and levels of evidence. Viscosupplementation has demonstrated moderate but significant efficacy (20%) versus placebo in terms of pain and function, with a high rate of responders (60-70%) in knee osteoarthritis. It allows reduced administration of opioid analgesics and NSAIDs, with improved risk/benefit ratio, and may delay joint replacement. Cartilage protection remains to be proven. Clinical efficacy shows 1-4 weeks' later onset than corticosteroids, but is maintained for 6 or even 12 months. Systematic association of corticosteroid and HA injection is not justified, and an interval has to be left before undertaking arthroplasty. Intra-articular injection of HA requires a skilled specialist, and may be difficult in a non-swollen joint; some tips and tricks may be helpful. In other joints than the knee, radiologic or ultrasound guidance is recommended. The efficacy of viscosupplementation is a matter of ongoing debate, after discordant findings in some meta-analyses. Some poor results may be due to inappropriate use of HA injections, poorly adapted to the patient's OA phenotype. Viscosupplementation is a treatment for chronic moderate symptomatic OA, and not for flares with joint swelling. Application in sport-related chondropathy has yet to be properly assessed. The optimal response profile remains to be determined. The ideal indication in the knee seems to be moderate femorotibial OA without swelling. Results have been generally disappointing in hip osteoarthritis but promising in OA of the ankle and shoulder (with and without rotator cuff tear). Further studies are needed to determine response profile and optimal treatment schedule, according to the joint.

  7. Recent Dama Results

    NASA Astrophysics Data System (ADS)

    Bernabei, R.; Belli, P.; Montecchia, F.; Nozzoli, F.; Cappella, F.; D'Angelo, A.; Incicchitti, A.; Prosperi, D.; Cerulli, R.; Dai, C. J.; He, H. L.; Kuang, H. H.; Ma, J. M.; Ye, Z. P.

    2006-04-01

    DAMA is an observatory for rare processes and it is operative deep underground at the Gran Sasso National Laboratory of the I.N.F.N. The experiment developes and uses low background scintillator for rare processes investigation. In this paper, after a short presentation of the main DAMA set-ups, the DAMA/NaI apparatus (≃ 100 kg highly radiopure NaI(Tl)) and its main results in the Dark Matter field will be addressed. This experiment, in particular, has effectively investigated the presence of a Dark Matter particle component in the galactic halo by exploiting the model-independent annual modulation signature over seven annual cycles (total exposure of 107731 kg × day), obtaining a 6.3 σ C.L. model-independent evidence for such a presence. In addition, some corollary model-dependent quests to investigate the nature of a candidate particle will be recalled. The new additional analysis for a pseudoscalar and for a scalar bosonic candidate (whose detection only involves electrons and photons/X-rays) will be addressed as well. Some perspectives of the second generation DAMA/LIBRA set-up (≃ 250 kg highly radiopure NaI(Tl)), presently in measurement deep underground, will be mentioned.

  8. Results from SNO

    SciTech Connect

    Chan, Yuen-dat

    2001-10-01

    The Sudbury Neutrino Observatory (SNO) is an underground heavy water Cherenkov detector for studying solar neutrinos. SNO is capable of performing both flavor sensitive and flavor blind measurements of the solar neutrino flux. The first charged current (CC) measurement is found to be: {psi}{sub SNO}{sup CC}({nu}{sub e}) = 1.75 {+-} 0.07(stat.){sub -0.11}{sup +0.12}(sys.) {+-} 0.05 (theor.) x 10{sup 6} cm{sup -2}s{sup -1} and the elastic scattering fluxes (ES) is: {psi}{sub SNO}{sup ES}({nu}{sub x}) = 2.39 {+-} 0.34(stat.){sub -0.14}{sup +0.16} (sys.) x 10{sup 6} cm{sup -2}s{sup -1}. The {psi}{sub SNO}{sup CC}({nu}{sub e}) result, when combined with the high statistics elastic scattering (ES) measurement from Super-Kamiokande, provide a strong evidence for solar neutrino flavor transformation (3.3{sigma}). The deduced total solar neutrino flux is in good agreement with standard solar model predictions. No significant distortion in the energy spectrum is observed.

  9. ALOS-2 initial results

    NASA Astrophysics Data System (ADS)

    Kankaku, Yukihiro; Suzuki, Shinichi; Shimada, Masanobu

    2015-10-01

    The Advanced Land Observing Satellite-2 (ALOS-2) was launched from Tanegashima Space Center by H-IIA rocket successfully on 24th May 2014. ALOS-2 carries the Phased Array type L-band Synthetic Aperture Radar-2 (PALSAR-2) as the state-of-the-art L-band SAR system which succeeds to PALSAR onboard ALOS. PALSAR-2 uses almost whole bandwidth allocated for L-band active sensor of Earth Exploration Satellites Service specified by the Radio Regulation in order to realize the high resolution observation, and also, it transmits more than 6 kW power for lower Noise Equivalent Sigma Zero using 180 TRMs driven by Gallium Nitride (GaN) amplifier which is the first use in space. Furthermore, because ALOS-2 carries the SAR system only, PALSAR-2 antenna can be mounted under the satellite body. It enables to observe right-/left-looking observation by satellite maneuvering. And the high accuracy orbit control to maintain the satellite within 500 m radius tube against the reference orbit enables high coherence for the InSAR processing. Using these new technologies, ALOS-2 has been operating to fulfill the mission requirements such as disaster monitoring and so on. This document introduces the initial result of ALOS-2 from the first year operation.

  10. Simpler images, better results

    NASA Astrophysics Data System (ADS)

    Chance, Britton

    1999-03-01

    The very rapid development of optical technology has followed a pattern similar to that of nuclear magnetic resonance: first, spectroscopy and then imaging. The accomplishments in spectroscopy have been significant--among them, early detection of hematomas and quantitative oximetry (assuming that time and frequency domain instruments are used). Imaging has progressed somewhat later. The first images were obtained in Japan and USA a few years ago, particularly of parietal stimulation of the human brain. Since then, rapid applications to breast and limb, together with higher resolution of the brain now make NIR imaging of functional activation and tumor detection readily available, reliable and affordable devices. The lecture has to do with the applications of imaging to these three areas, particularly to prefrontal imaging of cognitive function, of breast tumor detection, and of localized muscle activation in exercise. The imaging resolution achievable in functional activation appears to be FWHM of 4 mm. The time required for an image is a few seconds or even much less. Breast image detection at 50 microsecond(s) ec/pixel results in images obtainable in a few seconds or shorter times (bandwidths of the kHz are available). Finally, imaging of the body organs is under study in this laboratory, particularly in the in utero fetus. It appears that the photon migration theory now leads to the development of a wide number of images for human subject tissue spectroscopy and imaging.

  11. CTF Challenge: Result Summary

    PubMed Central

    Marabini, Roberto; Carragher, Bridget; Chen, Shaoxia; Chen, James; Cheng, Anchi; Downing, Kenneth H.; Frank, Joachim; Grassucci, Robert A.; Heymann, J. Bernard; Jiang, Wen; Jonic, Slavica; Liao, Hstau Y.; Ludtke, Steven J.; Patwari, Shail; Piotrowski, Angela L.; Quintana, Adrian; Sorzano, Carlos O.S.; Stahlberg, Henning; Vargas, Javier; Voss, Neil R.; Chiu, Wah; Carazo, Jose M.

    2015-01-01

    Image formation in bright field electron microscopy can be described with the help of the contrast transfer function (CTF). In this work the authors describe the “CTF Estimation Challenge”, called by the Madrid Instruct Image Processing Center (I2PC) in collaboration with the National Center for Macromolecular Imaging (NCMI) at Houston. Correcting for the effects of the CTF requires accurate knowledge of the CTF parameters, but these have often been difficult to determine. In this challenge, researchers have had the opportunity to test their ability in estimating some of the key parameters of the electron microscope CTF on a large micrograph data set produced by well-known laboratories on a wide set of experimental conditions. This work presents the first analysis of the results of the CTF Estimation Challenge, including an assessment of the performance of the different software packages under different conditions, so as to identify those areas of research where further developments would be desirable in order to achieve high-resolution structural information. PMID:25913484

  12. SAA drift: Experimental results

    NASA Astrophysics Data System (ADS)

    Grigoryan, O. R.; Romashova, V. V.; Petrov, A. N.

    According to the paleomagnetic analysis there are variations of Earth’s magnetic field connected with magnetic moment changing. These variations affect on the South Atlantic Anomaly (SAA) location. Indeed different observations approved the existence of the SAA westward drift rate (0.1 1.0 deg/year) and northward drift rate (approximately 0.1 deg/year). In this work, we present the analysis of experimental results obtained in Scobeltsyn Institute of Nuclear Physics, Moscow State University (SINP MSU) onboard different Earth’s artificial satellites (1972 2003). The fluxes of protons with energy >50 MeV, gamma quanta with energy >500 keV and neutrons with energy 0.1 1.0 MeV in the SAA region have been analyzed. The mentioned above experimental data were obtained onboard the orbital stations Salut-6 (1979), MIR (1991, 1998) and ISS (2003) by the similar experimental equipment. The comparison of the data obtained during these two decades of investigations confirms the fact that the SAA drifts westward. Moreover the analysis of fluxes of electrons with energy about hundreds keV (Cosmos-484 (1972) and Active (Interkosmos-24, 1991) satellites) verified not only the SAA westward drift but northward drift also.

  13. LSND neutrino oscillation results

    SciTech Connect

    Louis, W.C.; LSND Collaboration

    1996-10-01

    The LSND (Liquid Scintillator Neutrino Detector) experiment at Los Alamos has conducted a search for muon antineutrino {r_arrow} electron antineutrino oscillations using muon neutrinos from antimuon decay at rest. The electron antineutrinos are detected via the reaction electron antineutrino + proton {r_arrow} positron + neutron, correlated with the 2.2-MeV gamma from neutron + proton {r_arrow} deuteron + gamma. The use of tight cuts to identify positron events with correlated gamma rays yields 22 events with positron energy between 36 and 60 MeV and only 4.6 {+-} 0.6 background events. The probability that this excess is due entirely to a statistical fluctuation is 4.1 {times} 10{sup -8}. A chi-squared fit to the entire positron sample results in a total excess of 51.8 {sup +18.7}{sub -16.9} {+-} 8.0 events with positron energy between 20 and 60 MeV. If attributed to muon antineutrino {r_arrow} electron antineutrino oscillations, this corresponds to an oscillation probability (averaged over the experimental energy and spatial acceptance) of (0.31 {+-} 0.12 {+-} 0.05){percent}. 10 refs., 7 figs., 1 tab.

  14. LSND neutrino oscillation results

    SciTech Connect

    White, D.H.; LSND Collaboration

    1997-11-01

    The LSND experiment at Los Alamos has conducted a search for {anti v}{sub {mu}} {yields} {anti v}{sub e} oscillations using {anti v}{sub {mu}} from {mu}{sup +} decay at rest. The {anti v}{sub e} are detected via the reaction {anti v}{sub e} p {yields} e{sup +}n, correlated with the 2.2 MeV {gamma} from n p {yields} d {gamma}. The use of tight cuts to identify e{sup +} events with correlated {gamma} rays yielded 22 events with e{sup +} energy between 36 and 60 MeV and only 4.6 {+-} 0.6 background events. The probability that this excess is due entirely to a statistical fluctuation is 4.1 {times} 10{sup {minus}8}. A {chi}{sup 2} fit to the entire e{sup +} sample results in a total excess of 51.8{sub {minus}16.9}{sup +18.7} {+-} 8.0 events with e{sup +} energy between 20 and 60 MeV. If attributed to {anti v}{sub {mu}} {yields} {anti v}{sub e} oscillations, this corresponds to an oscillation probability (averaged over the experimental energy and spatial acceptance) of 0.31 {+-} 0.12 {+-} 0.05%.

  15. Incidental findings on brain MRI of cognitively normal first-degree descendants of patients with Alzheimer's disease: a cross-sectional analysis from the ALFA (Alzheimer and Families) project

    PubMed Central

    Brugulat-Serrat, Anna; Rojas, Santiago; Bargalló, Nuria; Conesa, Gerardo; Minguillón, Carolina; Fauria, Karine; Gramunt, Nina; Molinuevo, José Luis; Gispert, Juan Domingo

    2017-01-01

    Objectives To describe the prevalence of brain MRI incidental findings (IF) in a cohort of cognitively normal first-degree descendants of patients with Alzheimer's disease (AD). Design Cross-sectional observational study. Setting All scans were obtained with a 3.0 T scanner. Scans were evaluated by a single neuroradiologist and IF recorded and categorised. The presence of white matter hyperintensities (WMH) was determined with the Fazekas scale and reported as relevant if ≥2. Participants 575 participants (45–75 years) underwent high-resolution structural brain MRI. Participants were cognitively normal and scored over the respective cut-off values in all the following neuropsychological tests: Mini-Mental State Examination (≥26), Memory Impairment Screen (≥6), Time Orientation Subtest of the Barcelona Test II (≥68), verbal semantic fluency (naming animals ≥12). Clinical Dementia Rating (CDR) had to be 0. Results 155 participants (27.0%) presented with at least one IF. Relevant WMH were present in 7.8% of the participants, and vascular abnormalities, cyst and brain volume loss in 10.7%, 3.1% and 6.9% of the study volunteers, respectively. Neoplastic brain findings were found in 2.4% of participants and within these, meningiomas were the most common (1.7%) and more frequently found in women. A positive correlation between increasing age and the presence of IF was found. Additionally, brain atrophy greater than that expected by age was significantly more prevalent in participants without a parental history of AD. Conclusions Brain MRIs of healthy middle-aged participants show a relatively high prevalence of IF even when study participants have been screened for subtle cognitive alterations. Most of our participants are first-degree descendants of patients with AD, and therefore these results are of special relevance for novel imaging studies in the context of AD prevention in cognitively healthy middle-aged participants. Trial registration number NCT

  16. Climax granite test results

    SciTech Connect

    Ramspott, L.D.

    1980-01-15

    The Lawrence Livermore Laboratory (LLL), as part of the Nevada Nuclear Waste Storage Investigations (NNWSI) program, is carrying out in situ rock mechanics testing in the Climax granitic stock at the Nevada Test Site (NTS). This summary addresses only those field data taken to date that address thermomechanical modeling for a hard-rock repository. The results to be discussed include thermal measurements in a heater test that was conducted from October 1977 through July 1978, and stress and displacement measurements made during and after excavation of the canister storage drift for the Spent Fuel Test (SFT) in the Climax granite. Associated laboratory and field measurements are summarized. The rock temperature for a given applied heat load at a point in time and space can be adequately modeled with simple analytic calculations involving superposition and integration of numerous point source solutions. The input, for locations beyond about a meter from the source, can be a constant thermal conductivity and diffusivity. The value of thermal conductivity required to match the field data is as much as 25% different from laboratory-measured values. Therefore, unless we come to understand the mechanisms for this difference, a simple in situ test will be required to obtain a value for final repository design. Some sensitivity calculations have shown that the temperature field is about ten times more sensitive to conductivity than to diffusivity under the test conditions. The orthogonal array was designed to detect anisotropy. After considering all error sources, anisotropic efforts in the thermal field were less than 5 to 10%.

  17. [SENTIERI Project: results].

    PubMed

    Crocetti, Emanuele; Pirastu, Roberta; Buzzoni, Carlotta; Minelli, Giada; Manno, Valerio; Bruno, Caterina; Fazzo, Lucia; Iavarone, Ivano; Pasetto, Roberto; Ricci, Paolo; Zona, Amerigo; Conti, Susanna; Comba, Pietro

    2014-01-01

    Of the 18 National Priority Contaminated Sites (NPCSs) analysed in this Report, some have a single source of environmental contamination (such as fluoro-edenite in Biancavilla). In most cases, however, we are looking at multiple heterogeneous sources of contamination. In this respect, the a priori causal evaluation of the association between diseases and environmental exposures in NPCSs, based on epidemiological evidence, can help trace the health impact back to specific types of environmental exposure. There are several cases in which the project's findings have been consistent with a priori evidence: stomach cancer (both genders, excess cancer incidence) in the Fidenza NPCS; stomach cancer (women, excess mortality, cancer incidence and hospital discharges) in the Laguna di Grado e Marano NPCS; excess hospitalisation from respiratory diseases in Brescia-Caffaro, Milazzo and Terni Papigno NPCSs; excesses for non-Hodgkin lymphomas and melanoma (incidence and hospitalisation in men and women) and breast cancer (incidence and hospital discharges, women) in Brescia-Caffaro NPCS. In preorder to properly evaluate the population's health profile, we must also observe whether results remain consistent for all three health outcomes or in both genders. The first is the case of excess mortality, cancer incidence and hospital discharges for bladder cancer (men) in Porto Torres and diseases of the urinary tract in the Basso bacino del fiume Chienti NPCS). Gender consistency is observed, for instance, for all cancer in Bolzano, Porto Torres, Venice, Litorale Domizio Flegreo, Priolo, and Taranto, for all causes in Taranto, Litorale Domizio Flegreo and Trieste. The health impact in the various NPCSs needs to be considered carefully and used as a springboard for further analytical research that could confirm and explain causal links to specific environmental exposures. The observations can, however, already be considered as a basis for mandatory primary prevention measures.

  18. Overview of MAST results

    NASA Astrophysics Data System (ADS)

    Chapman, I. T.; Adamek, J.; Akers, R. J.; Allan, S.; Appel, L.; Asunta, O.; Barnes, M.; Ben Ayed, N.; Bigelow, T.; Boeglin, W.; Bradley, J.; Brünner, J.; Cahyna, P.; Carr, M.; Caughman, J.; Cecconello, M.; Challis, C.; Chapman, S.; Chorley, J.; Colyer, G.; Conway, N.; Cooper, W. A.; Cox, M.; Crocker, N.; Crowley, B.; Cunningham, G.; Danilov, A.; Darrow, D.; Dendy, R.; Diallo, A.; Dickinson, D.; Diem, S.; Dorland, W.; Dudson, B.; Dunai, D.; Easy, L.; Elmore, S.; Field, A.; Fishpool, G.; Fox, M.; Fredrickson, E.; Freethy, S.; Garzotti, L.; Ghim, Y. C.; Gibson, K.; Graves, J.; Gurl, C.; Guttenfelder, W.; Ham, C.; Harrison, J.; Harting, D.; Havlickova, E.; Hawke, J.; Hawkes, N.; Hender, T.; Henderson, S.; Highcock, E.; Hillesheim, J.; Hnat, B.; Holgate, J.; Horacek, J.; Howard, J.; Huang, B.; Imada, K.; Jones, O.; Kaye, S.; Keeling, D.; Kirk, A.; Klimek, I.; Kocan, M.; Leggate, H.; Lilley, M.; Lipschultz, B.; Lisgo, S.; Liu, Y. Q.; Lloyd, B.; Lomanowski, B.; Lupelli, I.; Maddison, G.; Mailloux, J.; Martin, R.; McArdle, G.; McClements, K.; McMillan, B.; Meakins, A.; Meyer, H.; Michael, C.; Militello, F.; Milnes, J.; Morris, A. W.; Motojima, G.; Muir, D.; Nardon, E.; Naulin, V.; Naylor, G.; Nielsen, A.; O'Brien, M.; O'Gorman, T.; Ono, Y.; Oliver, H.; Pamela, S.; Pangione, L.; Parra, F.; Patel, A.; Peebles, W.; Peng, M.; Perez, R.; Pinches, S.; Piron, L.; Podesta, M.; Price, M.; Reinke, M.; Ren, Y.; Roach, C.; Robinson, J.; Romanelli, M.; Rozhansky, V.; Saarelma, S.; Sangaroon, S.; Saveliev, A.; Scannell, R.; Schekochihin, A.; Sharapov, S.; Sharples, R.; Shevchenko, V.; Silburn, S.; Simpson, J.; Storrs, J.; Takase, Y.; Tanabe, H.; Tanaka, H.; Taylor, D.; Taylor, G.; Thomas, D.; Thomas-Davies, N.; Thornton, A.; Turnyanskiy, M.; Valovic, M.; Vann, R.; Walkden, N.; Wilson, H.; van Wyk, F.; Yamada, T.; Zoletnik, S.; MAST; MAST Upgrade Teams

    2015-10-01

    The Mega Ampère Spherical Tokamak (MAST) programme is strongly focused on addressing key physics issues in preparation for operation of ITER as well as providing solutions for DEMO design choices. In this regard, MAST has provided key results in understanding and optimizing H-mode confinement, operating with smaller edge localized modes (ELMs), predicting and handling plasma exhaust and tailoring auxiliary current drive. In all cases, the high-resolution diagnostic capability on MAST is complemented by sophisticated numerical modelling to facilitate a deeper understanding. Mitigation of ELMs with resonant magnetic perturbations (RMPs) with toroidal mode number nRMP = 2, 3, 4, 6 has been demonstrated: at high and low collisionality; for the first ELM following the transition to high confinement operation; during the current ramp-up; and with rotating nRMP = 3 RMPs. nRMP = 4, 6 fields cause less rotation braking whilst the power to access H-mode is less with nRMP = 4 than nRMP = 3, 6. Refuelling with gas or pellets gives plasmas with mitigated ELMs and reduced peak heat flux at the same time as achieving good confinement. A synergy exists between pellet fuelling and RMPs, since mitigated ELMs remove fewer particles. Inter-ELM instabilities observed with Doppler backscattering are consistent with gyrokinetic simulations of micro-tearing modes in the pedestal. Meanwhile, ELM precursors have been strikingly observed with beam emission spectroscopy (BES) measurements. A scan in beta at the L-H transition shows that pedestal height scales strongly with core pressure. Gyro-Bohm normalized turbulent ion heat flux (as estimated from the BES data) is observed to decrease with increasing tilt of the turbulent eddies. Fast ion redistribution by energetic particle modes depends on density, and access to a quiescent domain with ‘classical’ fast ion transport is found above a critical density. Highly efficient electron Bernstein wave current drive (1 A W-1) has been achieved

  19. Recombinant Interferon Alfa-2b in Treating Patients With Melanoma

    ClinicalTrials.gov

    2016-05-17

    Stage IA Skin Melanoma; Stage IB Skin Melanoma; Stage IIA Skin Melanoma; Stage IIB Skin Melanoma; Stage IIC Skin Melanoma; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma

  20. DIC Complicating APL Successfully Treated With Recombinant Thrombomodulin Alfa.

    PubMed

    Saito, Aki; Okamoto, Yasuhiro; Seki, Yuko; Matsunaga, Manaka; Nakagawa, Shunsuke; Kodama, Yuichi; Nishikawa, Takuro; Tanabe, Takayuki; Kawano, Yoshifumi

    2016-08-01

    An 8-year-old boy developed anorexia, fatigue, and fever. Laboratory examination revealed a high white blood cell (WBC) count of 145×10/μL with 97.5% abnormal promyelocytic cells that contained Auer bodies. Faggot cells were seen. He was diagnosed with acute promyelocytic leukemia. Later, a chromosome analysis showed 46,XY,t(15;17)(q22;q12). Promyelocytic Leukemia-retinoic acid receptor α-fused gene and chimeric mRNA were confirmed by fluorescence in situ hybridization and reverse transcriptase polymerase chain reaction, respectively. He was complicated with disseminated intravascular coagulation (DIC) and his fibrin and fibrinogen degradation product at the onset was 37.6 μg/mL. Human recombinant thrombomodulin (rTM) was started for DIC. After dexamethasone was administered at a dose of 8 mg/m to prevent all-trans retinoic acid syndrome on day 1, all-trans retinoic acid was started at a dose of 45 mg/m on day 4. Cytarabine (100 mg/m/d) and daunorubicin (45 mg/m/d) were started on day 9. The WBC count gradually increased to 270×10/μL on day 8, and then decreased beginning on day 9. DIC improved after the initiation of chemotherapy and only minor petechia was noted. DIC did not become worse even after rTM was stopped on day 8. The risk of DIC and bleeding is high in the early stage of treatment for acute promyelocytic leukemia, especially in patients with a high WBC count. In our patient, rTM may have prevented fatal DIC and made it possible to safely administer induction chemotherapy.

  1. [The treatment of chronic myeloleukemia with recombinant alfa-2 interferon].

    PubMed

    Strozha, I; Petukhov, V; Bondare, D; Feldmane, G; Duks, A; Teilane, I; Medne, I; Mauritsas, M; Grinberga, L

    1993-01-01

    A trial has been conducted of recombinant alpha 2-interferon (reaferon) used in 32 patients with Ph'[correction of Rh']-positive chronic myeloid leukemia (CML). A chronic stage was in 3, transient in 3 and blast in 1 patients. 25 CML patients were newly diagnosed. The treatment lasted from 2 months to 3 years. Clinicohematological remission was confirmed conventionally and by the degree of Ph'-positive clone reduction. An attempt is made to clarify the mechanism underlying the resistance to reaferon basing on the immunological data (detection of antireaferon neutralizing antibodies). The authors propose a combined treatment (myelosan plus reaferon) of CML which has obvious advantages over myelosan monotherapy.

  2. Clinical evaluation on porcelain laminate veneers bonded with light-cured composite: results up to 7 years.

    PubMed

    D'Arcangelo, Camillo; De Angelis, Francesco; Vadini, Mirco; D'Amario, Maurizio

    2012-08-01

    The purpose of this study was to evaluate the clinical performance of laminate porcelain veneers bonded with a light-cured composite. Thirty patients were restored with 119 porcelain laminate veneers. The veneers were studied for an observation time of 7 years. Marginal adaptation, marginal discoloration, secondary caries, color match, and anatomic form were clinically examined following modified United States Public Health Service (USPHS) criteria. Each restoration was also examined for cracks, fractures, and debonding. Pulp vitality was verified. In addition, plaque and gingival indexes and increase in gingival recession were recorded. Survival rate evaluating absolute failures and success rate describing relative failures were statistically determined, using both restoration and patient-related analyses. On the basis of the criteria used, most of the veneers rated Alfa. After 7 years, the results of the clinical investigation regarding marginal adaptation and marginal discoloration revealed only 2.5% and 4.2% Bravo ratings, respectively, among the 119 initially placed veneers. Using the restoration as the statistical unit, the survival rate was 97.5%, with a high estimated success probability of 0.843 after 7 years. Using the patient as the statistical unit, the survival rate was 90.0% and the estimated success probability after 7 years was 0.824. Gingival response to the veneers was all in the satisfactory range. Porcelain laminate veneers offer a predictable and successful treatment modality giving a maximum preservation of sound tooth. The preparation, cementation, and finishing procedures adopted are considered key factors for the long-term success and aesthetical result of the veneer restorations.

  3. Gateways to clinical trials.

    PubMed

    Bayés, M; Rabasseda, X; Prous, J R

    2004-04-01

    Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the following tables has been retrieved from the Clinical Studies Knowledge Area of Prous Science Integrity(R), the drug discovery and development portal, http://integrity.prous.com. This issue focuses on the following selection of drugs: ABI-007, adalimumab, adefovir dipivoxil, alefacept, alemtuzumab, 3-AP, AP-12009, APC-8015, L-Arginine hydrochloride, aripiprazole, arundic acid, avasimibe; Bevacizumab, bivatuzumab, BMS-181176, BMS-184476, BMS-188797, bortezomib, bosentan, botulinum toxin type B, BQ-123, BRL-55730, bryostatin 1; CEP-1347, cetuximab, cinacalcet hydrochloride, CP-461, CpG-7909; D-003, dabuzalgron hydrochloride, darbepoetin alfa, desloratadine, desoxyepothilone B, dexmethylphenidate hydrochloride, DHA-paclitaxel, diflomotecan, DN-101, DP-b99, drotrecogin alfa (activated), duloxetine hydrochloride, duramycin; Eculizumab, Efalizumab, EKB-569, elcometrine, enfuvirtide, eplerenone, erlotinib hydrochloride, ertapenem sodium, eszopiclone, everolimus, exatecan mesilate, ezetimibe; Fenretinide, fosamprenavir calcium, frovatriptan; GD2L-KLH conjugate vaccine, gefitinib, glufosfamide, GTI-2040; Hexyl insulin M2, human insulin, hydroquinone, gamma-Hydroxybutyrate sodium; IL-4(38-37)-PE38KDEL, imatinib mesylate, indisulam, inhaled insulin, ixabepilone; KRN-5500; LY-544344; MDX-210, melatonin, mepolizumab, motexafin gadolinium; Natalizumab, NSC-330507, NSC-683864; 1-Octanol, omalizumab, ortataxel; Pagoclone, peginterferon alfa-2a, peginterferon alfa-2b, pemetrexed disodium, phenoxodiol, pimecrolimus, plevitrexed, polyphenon E, pramlintide acetate, prasterone, pregabalin, PX-12; QS-21; Ragaglitazar, ranelic acid distrontium salt, RDP-58, recombinant glucagon-like peptide-1 (7-36) amide, repinotan hydrochloride, rhEndostatin, rh-Lactoferrin, (R)-roscovitine; S-8184, semaxanib, sitafloxacin hydrate, sitaxsentan sodium, sorafenib, synthadotin

  4. Gateways to clinical trials.

    PubMed

    Tomillero, A; Moral, M A

    2009-12-01

    [Methoxy-(11)C]PD-153035, 2-Methoxyestradiol; Adalimumab, Adecatumumab, Adefovir dipivoxil, ADH-1, ADX-10059, Aflibercept, AIR-human growth hormone, Aliskiren fumarate, AMG-221, Amlodipine besylate/olmesartan medoxomil, Aprepitant; Bavituximab, Bevacizumab, Bexarotene, BIBW-2992, BMS-690514, Bortezomib, Bosentan, Briakinumab; Capecitabine, Certolizumab pegol, Cetuximab, Cholecalciferol, Choline fenofibrate, Chorionic gonadotropin (human), Cixutumumab, Clopidogrel, CP-690550 citrate; Dabigatran, Dacetuzumab, Daclizumab, Dapagliflozin, Darbepoetin alfa, Dasatinib, Denosumab; Efavirenz, Elisidepsin, Enoxaparin, Enzastaurin hydrochloride, Eribulin mesilate, Erlotinib hydrochloride, Everolimus, Exenatide; Fenobam, Figitumumab, Filibuvir, Fondaparinux sodium, Fresolimumab; Gefitinib, Golimumab, Golnerminogene pradenovec; Ifosfamide, Imatinib mesylate, Ipilimumab, Ivabradine hydrochloride, Ixabepilone; Lapatinib ditosylate, Lenalidomide, Levocetirizine dihydrochloride, Liposomal vincristine, Liraglutide; M-118, Masitinib mesylate, Metformin hydrochloride, Micafungin sodium, Moxifloxacin hydrochloride; Neratinib; Oblimersen sodium, Ofatumumab, Olmesartan medoxomil; Paclitaxel nanoparticles, Palifosfamide lysine, Panobacumab, Panobinostat, Patupilone, Peginterferon alfa-2a, Pegylated arginine deiminase 20000, Piclozotan hydrochloride hydrate, Pixantrone maleate, Prasterone, Prasugrel, Prednisone, Progesterone, Prucalopride, pVGI.1 (VEGF-2); Retigabine, rhFSH, Rituximab, Rivaroxaban, Rosuvastatin calcium; Salinosporamide A, Selumetinib, Sipuleucel-T, Somatropin, Sorafenib, SSR-244738, Sunitinib malate; Tamoxifen citrate, Teduglutide, Telavancin hydrochloride, Telmisartan, Telmisartan/amlodipine, Telmisartan/hydrochlorothiazide, Temsirolimus, Tenofovir disoproxil fumarate, Tipifarnib, Tolvaptan, Trastuzumab, Trastuzumab-MCC-DM1, Travoprost, Tremelimumab; Valsartan/amlodipine besylate, Valsartan/amlodipine besylate/hydrochlorothiazide, Valsartan/hydrochlorothiazide, Vandetanib

  5. Erythropoiesis stimulating agents: approaches to modulate activity

    PubMed Central

    Sinclair, Angus M

    2013-01-01

    Recombinant human erythropoietin (rHuEPO), such as the approved agents epoetin alfa and epoetin beta, has been used successfully for over 20 years to treat anemia in millions of patients. However, due to the relatively short half-life of the molecule (approximately 8 hours), frequent dosing may be required to achieve required hemoglobin levels. Therefore, a need was identified in some anemic patient populations for erythropoiesis stimulating agents with longer half-lives that required less frequent dosing. This need led to the development of second generation molecules which are modified versions of rHuEPO with improved pharma-cokinetic and pharmacodynamic properties such as darbepoetin alfa, a hyperglycosylated analog of rHuEPO, and pegzyrepoetin, a pegylated rHuEPO. Third generation molecules, such as peginesatide, which are peptide mimetics that have no sequence homology to rHuEPO have also recently been developed. The various molecular, pharmacokinetic, and pharmacodynamic properties of these and other erythropoiesis stimulating agents will be discussed in this review. PMID:23847411

  6. Anti-erythropoietin and anti-thrombopoietin antibodies induced after administration of recombinant human erythropoietin.

    PubMed

    Shin, Sug Kyun; Pack, Seung Pil; Oh, Jin-Gyo; Kang, Nam Kyu; Chang, Myung Hee; Chung, Yoon Hee; Kim, Sung-Jo; Lee, Jong Wook; Heo, Tae-Hwe

    2011-12-01

    Recombinant human erythropoietin (rhEPO) has been successfully used for correcting renal anemia. However, recent studies have raised some concerns about the safety of rhEPO treatment due to its immunogenic side effect - pure red cell aplasia (PRCA). We now report a case of development of anti-EPO neutralizing antibodies (Abs) implicated in thrombocytopenia as well as erythrocytopenia. A 35-year-old man had a history of administering rhEPO (epoetin alfa, epoetin beta and darbepoetin alfa) for 2years to treat renal anemia. The hematological parameters were collected. Anti-EPO, anti-platelet, and anti-thrombopoietin (TPO) Ab assays were performed to test the presence of autoreactive Abs. After performing antibody assays due to severe resistance to rhEPO treatment, a high titer of anti-EPO neutralizing Abs was detected. However, unexpectedly, this patient also showed thrombocytopenia rather than PRCA. We investigated the cause of the marked thrombocytopenia and found anti-TPO Abs in patient serum. To our best knowledge, this is the first report of the development of anti-TPO Abs during rhEPO treatment for anemia.

  7. The non-haematopoietic biological effects of erythropoietin.

    PubMed

    Arcasoy, Murat O

    2008-04-01

    In the haematopoietic system, the principal function of erythropoietin (Epo) is the regulation of red blood cell production, mediated by its specific cell surface receptor (EpoR). Following the cloning of the Epo gene (EPO) and characterization of the selective haematopoietic action of Epo in erythroid lineage cells, recombinant Epo forms (epoetin-alfa, epoetin-beta and the long-acting analogue darbepoetin-alfa) have been widely used for treatment of anaemia in chronic kidney disease and chemotherapy-induced anaemia in cancer patients. Ubiquitous EpoR expression in non-erythroid cells has been associated with the discovery of diverse biological functions for Epo in non-haematopoietic tissues. During development, Epo-EpoR signalling is required not only for fetal liver erythropoiesis, but also for embryonic angiogenesis and brain development. A series of recent studies suggest that endogenous Epo-EpoR signalling contributes to wound healing responses, physiological and pathological angiogenesis, and the body's innate response to injury in the brain and heart. Epo and its novel derivatives have emerged as major tissue-protective cytokines that are being investigated in the first human studies involving neurological and cardiovascular diseases. This review focuses on the scientific evidence documenting the biological effects of Epo in non-haematopoietic tissues and discusses potential future applications of Epo and its derivatives in the clinic.

  8. Paradoxical Results and Item Bundles

    ERIC Educational Resources Information Center

    Hooker, Giles; Finkelman, Matthew

    2010-01-01

    Hooker, Finkelman, and Schwartzman ("Psychometrika," 2009, in press) defined a paradoxical result as the attainment of a higher test score by changing answers from correct to incorrect and demonstrated that such results are unavoidable for maximum likelihood estimates in multidimensional item response theory. The potential for these results to…

  9. Misleading biochemical laboratory test results

    PubMed Central

    Nanji, Amin A.

    1984-01-01

    This article reviews the general and specific factors that interfere with the performance of common biochemical laboratory tests and the interpretation of their results. The clinical status of the patient, drug interactions, and in-vivo and in-vitro biochemical interactions and changes may alter the results obtained from biochemical analysis of blood constituents. Failure to recognize invalid laboratory test results may lead to injudicious and dangerous management of patients. PMID:6375845

  10. MER ARA pyroshock test results

    NASA Technical Reports Server (NTRS)

    Chang, Kurng Y.

    2004-01-01

    This paper presents the shock test results achieved in the MER ARA/brush motor pyroshock qualification. The results of MER flight system pyrofiring tests in comparison with the ARA shock test requirements are discussed herein. Alternate test methods were developed in an effort to qualify the critical MER equipment for adequate performance in the actual flight pyroshock condition.

  11. Latest Electroweak Results from CDF

    SciTech Connect

    Lancaster, Mark

    2010-05-01

    The latest results in electroweak physics from proton anti-proton collisions at the Fermilab Tevatron recorded by the CDF detector are presented. The results provide constraints on parton distribution functions, the mass of the Higgs boson and beyond the Standard Model physics.

  12. Top physics results at CDF

    SciTech Connect

    Vickey, Trevor; /Illinois U., Urbana

    2005-05-01

    The most recent results on top quark physics at CDF are reported. Measurements of cross-section and mass are presented, and the status of single top quark production searches are discussed. The results obtained from probing various top quark properties are also presented.

  13. Results of Neptunium Disposal Testing

    SciTech Connect

    Walker, D.D.

    2003-10-07

    Researchers investigated the neutralization of neptunium solution from H-Canyon Tank 16.4 and the properties of the resulting slurry. This work investigated slurry properties from a single neutralization protocol and limited storage times.

  14. SMART-1/AMIE Camera Results

    NASA Astrophysics Data System (ADS)

    Josset, J.-L.; Beauvivre, S.; Cerroni, P.; de Sanctis, M. C.; Pinet, P.; Chevrel, S.; Langevin, Y.; Barucci, M. A.; Plancke, P.; Koschny, D.; Almeida, M.; Sodnik, Z.; Mancuso, S.; Hofmann, B. A.; Muinonen, K.; Shevchenko, V.; Shkuratov, Yu.; Ehrenfreund

    2007-03-01

    The Advanced Moon micro-Imager Experiment (AMIE), on board ESA SMART-1, the first European mission to the Moon, is an imaging system with scientific, technical and public outreach oriented objectives. This paper presents the first results obtained during

  15. Recent KTeV Results

    SciTech Connect

    Richard Kessler

    2001-11-09

    Preliminary KTEV results are presented based on the 1997 data set, and include an improved measurement of R({epsilon}{prime}/{epsilon}), CPT tests, and precise measurements of {tau}{sub S} and {Delta}{sub m}.

  16. Electroweak results from the tevatron

    SciTech Connect

    Wood, D.

    1997-01-01

    Electroweak results are presented from the CDF and DO experiments based on data collected in recent runs of the Fermilab Tevatron Collider. The measurements include the mass and width of the W boson, the production cross sections of the W and Z bosons, and the W charge asymmetry. Additional results come from studies of events with pairs of electroweak gauge bosons and include limits on anomalous couplings.

  17. Results from experiment PS199

    NASA Astrophysics Data System (ADS)

    Agnello, M.; Ahmidouch, A.; Arvieux, J.; Bertini, R.; Birsa, R.; Bradamante, F.; Bressan, A.; Bressani, T.; Chiavassa, E.; Torre-Colautti, S. Dalla; De Marco, N.; Faivre, J. C.; Giorgi, M.; Heer, E.; Hess, R.; Iazzi, F.; Kunne, R. A.; Lamanna, M.; Luc, C. Lechanoine-Le; Macciotta, M. P.; Martin, A.; Mascarini, C.; Masoni, A.; Minetti, B.; Musso, A.; Penzo, A.; Perrot-Kunne, F.; Piccotti, A.; Puddu, G.; Rapin, D.; Serci, S.; Schiavon, P.; Tessarotto, F.

    1993-06-01

    The aim of the experiment PS199 was to study the spin structure of the charge-exchange overlinepp → overlinenn channel at LEAR. During 1990 we collected data at several energies to measure the analyzing power Aon and the spin depolarization parameter Donon.Results for Aon at all energies and first results for Donon at 905 MeV/c incident antiproton momentum are presented.

  18. QCD results from the Tevatron

    SciTech Connect

    C. Mesropian

    2002-07-12

    The Tevatron hadron collider provides the unique opportunity to study Quantum Chromodynamics, QCD, at the highest energies. The results summarized in this talk, although representing different experimental objects, as hadronic jets and electromagnetic clusters, serve to determine the fundamental input ingredients of QCD as well as to search for new physics. The authors present results from QCD studies at the Tevatron from Run 1 data, including jet and direct photon production, and a measurement of the strong coupling constant.

  19. Analysis of EUVE Experiment Results

    NASA Technical Reports Server (NTRS)

    Horan, Stephen

    1996-01-01

    A series of tests to validate an antenna pointing concept for spin-stabilized satellites using a data relay satellite are described. These tests show that proper antenna pointing on an inertially-stabilized spacecraft can lead to significant access time through the relay satellite even without active antenna pointing. We summarize the test results, the simulations to model the effects of antenna pattern and space loss, and the expected contact times. We also show how antenna beam width affects the results.

  20. The MUNU experiment : preliminary results

    NASA Astrophysics Data System (ADS)

    Busto, J.; MUNU Collaboration

    2000-06-01

    The MUNU collaboration has built a detector to study overlineνe - e - scattering at low energy. From the results we expect to increase the sensitivity to the neutrino magnetic moment. The detector used, a 1 m 3 T.P.C. surrounded by an anti-Compton scintillator, is running at the Bugey nuclear plant. Some preliminary results will be presented in the following.

  1. Planck 2015 results. I. Overview of products and scientific results

    NASA Astrophysics Data System (ADS)

    Planck Collaboration; Adam, R.; Ade, P. A. R.; Aghanim, N.; Akrami, Y.; Alves, M. I. R.; Argüeso, F.; Arnaud, M.; Arroja, F.; Ashdown, M.; Aumont, J.; Baccigalupi, C.; Ballardini, M.; Banday, A. J.; Barreiro, R. B.; Bartlett, J. G.; Bartolo, N.; Basak, S.; Battaglia, P.; Battaner, E.; Battye, R.; Benabed, K.; Benoît, A.; Benoit-Lévy, A.; Bernard, J.-P.; Bersanelli, M.; Bertincourt, B.; Bielewicz, P.; Bikmaev, I.; Bock, J. J.; Böhringer, H.; Bonaldi, A.; Bonavera, L.; Bond, J. R.; Borrill, J.; Bouchet, F. R.; Boulanger, F.; Bucher, M.; Burenin, R.; Burigana, C.; Butler, R. C.; Calabrese, E.; Cardoso, J.-F.; Carvalho, P.; Casaponsa, B.; Castex, G.; Catalano, A.; Challinor, A.; Chamballu, A.; Chary, R.-R.; Chiang, H. C.; Chluba, J.; Chon, G.; Christensen, P. R.; Church, S.; Clemens, M.; Clements, D. L.; Colombi, S.; Colombo, L. P. L.; Combet, C.; Comis, B.; Contreras, D.; Couchot, F.; Coulais, A.; Crill, B. P.; Cruz, M.; Curto, A.; Cuttaia, F.; Danese, L.; Davies, R. D.; Davis, R. J.; de Bernardis, P.; de Rosa, A.; de Zotti, G.; Delabrouille, J.; Delouis, J.-M.; Désert, F.-X.; Di Valentino, E.; Dickinson, C.; Diego, J. M.; Dolag, K.; Dole, H.; Donzelli, S.; Doré, O.; Douspis, M.; Ducout, A.; Dunkley, J.; Dupac, X.; Efstathiou, G.; Eisenhardt, P. R. M.; Elsner, F.; Enßlin, T. A.; Eriksen, H. K.; Falgarone, E.; Fantaye, Y.; Farhang, M.; Feeney, S.; Fergusson, J.; Fernandez-Cobos, R.; Feroz, F.; Finelli, F.; Florido, E.; Forni, O.; Frailis, M.; Fraisse, A. A.; Franceschet, C.; Franceschi, E.; Frejsel, A.; Frolov, A.; Galeotta, S.; Galli, S.; Ganga, K.; Gauthier, C.; Génova-Santos, R. T.; Gerbino, M.; Ghosh, T.; Giard, M.; Giraud-Héraud, Y.; Giusarma, E.; Gjerløw, E.; González-Nuevo, J.; Górski, K. M.; Grainge, K. J. B.; Gratton, S.; Gregorio, A.; Gruppuso, A.; Gudmundsson, J. E.; Hamann, J.; Handley, W.; Hansen, F. K.; Hanson, D.; Harrison, D. L.; Heavens, A.; Helou, G.; Henrot-Versillé, S.; Hernández-Monteagudo, C.; Herranz, D.; Hildebrandt, S. R.; Hivon, E.; Hobson, M.; Holmes, W. A.; Hornstrup, A.; Hovest, W.; Huang, Z.; Huffenberger, K. M.; Hurier, G.; Ilić, S.; Jaffe, A. H.; Jaffe, T. R.; Jin, T.; Jones, W. C.; Juvela, M.; Karakci, A.; Keihänen, E.; Keskitalo, R.; Khamitov, I.; Kiiveri, K.; Kim, J.; Kisner, T. S.; Kneissl, R.; Knoche, J.; Knox, L.; Krachmalnicoff, N.; Kunz, M.; Kurki-Suonio, H.; Lacasa, F.; Lagache, G.; Lähteenmäki, A.; Lamarre, J.-M.; Langer, M.; Lasenby, A.; Lattanzi, M.; Lawrence, C. R.; Le Jeune, M.; Leahy, J. P.; Lellouch, E.; Leonardi, R.; León-Tavares, J.; Lesgourgues, J.; Levrier, F.; Lewis, A.; Liguori, M.; Lilje, P. B.; Lilley, M.; Linden-Vørnle, M.; Lindholm, V.; Liu, H.; López-Caniego, M.; Lubin, P. M.; Ma, Y.-Z.; Macías-Pérez, J. F.; Maggio, G.; Maino, D.; Mak, D. S. Y.; Mandolesi, N.; Mangilli, A.; Marchini, A.; Marcos-Caballero, A.; Marinucci, D.; Maris, M.; Marshall, D. J.; Martin, P. G.; Martinelli, M.; Martínez-González, E.; Masi, S.; Matarrese, S.; Mazzotta, P.; McEwen, J. D.; McGehee, P.; Mei, S.; Meinhold, P. R.; Melchiorri, A.; Melin, J.-B.; Mendes, L.; Mennella, A.; Migliaccio, M.; Mikkelsen, K.; Millea, M.; Mitra, S.; Miville-Deschênes, M.-A.; Molinari, D.; Moneti, A.; Montier, L.; Moreno, R.; Morgante, G.; Mortlock, D.; Moss, A.; Mottet, S.; Münchmeyer, M.; Munshi, D.; Murphy, J. A.; Narimani, A.; Naselsky, P.; Nastasi, A.; Nati, F.; Natoli, P.; Negrello, M.; Netterfield, C. B.; Nørgaard-Nielsen, H. U.; Noviello, F.; Novikov, D.; Novikov, I.; Olamaie, M.; Oppermann, N.; Orlando, E.; Oxborrow, C. A.; Paci, F.; Pagano, L.; Pajot, F.; Paladini, R.; Pandolfi, S.; Paoletti, D.; Partridge, B.; Pasian, F.; Patanchon, G.; Pearson, T. J.; Peel, M.; Peiris, H. V.; Pelkonen, V.-M.; Perdereau, O.; Perotto, L.; Perrott, Y. C.; Perrotta, F.; Pettorino, V.; Piacentini, F.; Piat, M.; Pierpaoli, E.; Pietrobon, D.; Plaszczynski, S.; Pogosyan, D.; Pointecouteau, E.; Polenta, G.; Popa, L.; Pratt, G. W.; Prézeau, G.; Prunet, S.; Puget, J.-L.; Rachen, J. P.; Racine, B.; Reach, W. T.; Rebolo, R.; Reinecke, M.; Remazeilles, M.; Renault, C.; Renzi, A.; Ristorcelli, I.; Rocha, G.; Roman, M.; Romelli, E.; Rosset, C.; Rossetti, M.; Rotti, A.; Roudier, G.; Rouillé d'Orfeuil, B.; Rowan-Robinson, M.; Rubiño-Martín, J. A.; Ruiz-Granados, B.; Rumsey, C.; Rusholme, B.; Said, N.; Salvatelli, V.; Salvati, L.; Sandri, M.; Sanghera, H. S.; Santos, D.; Saunders, R. D. E.; Sauvé, A.; Savelainen, M.; Savini, G.; Schaefer, B. M.; Schammel, M. P.; Scott, D.; Seiffert, M. D.; Serra, P.; Shellard, E. P. S.; Shimwell, T. W.; Shiraishi, M.; Smith, K.; Souradeep, T.; Spencer, L. D.; Spinelli, M.; Stanford, S. A.; Stern, D.; Stolyarov, V.; Stompor, R.; Strong, A. W.; Sudiwala, R.; Sunyaev, R.; Sutter, P.; Sutton, D.; Suur-Uski, A.-S.; Sygnet, J.-F.; Tauber, J. A.; Tavagnacco, D.; Terenzi, L.; Texier, D.; Toffolatti, L.; Tomasi, M.; Tornikoski, M.; Tramonte, D.; Tristram, M.; Troja, A.; Trombetti, T.; Tucci, M.; Tuovinen, J.; Türler, M.; Umana, G.; Valenziano, L.; Valiviita, J.; Van Tent, F.; Vassallo, T.; Vibert, L.; Vidal, M.; Viel, M.; Vielva, P.; Villa, F.; Wade, L. A.; Walter, B.; Wandelt, B. D.; Watson, R.; Wehus, I. K.; Welikala, N.; Weller, J.; White, M.; White, S. D. M.; Wilkinson, A.; Yvon, D.; Zacchei, A.; Zibin, J. P.; Zonca, A.

    2016-09-01

    The European Space Agency's Planck satellite, which is dedicated to studying the early Universe and its subsequent evolution, was launched on 14 May 2009. It scanned the microwave and submillimetre sky continuously between 12 August 2009 and 23 October 2013. In February 2015, ESA and the Planck Collaboration released the second set of cosmology products based ondata from the entire Planck mission, including both temperature and polarization, along with a set of scientific and technical papers and a web-based explanatory supplement. This paper gives an overview of the main characteristics of the data and the data products in the release, as well as the associated cosmological and astrophysical science results and papers. The data products include maps of the cosmic microwave background (CMB), the thermal Sunyaev-Zeldovich effect, diffuse foregrounds in temperature and polarization, catalogues of compact Galactic and extragalactic sources (including separate catalogues of Sunyaev-Zeldovich clusters and Galactic cold clumps), and extensive simulations of signals and noise used in assessing uncertainties and the performance of the analysis methods. The likelihood code used to assess cosmological models against the Planck data is described, along with a CMB lensing likelihood. Scientific results include cosmological parameters derived from CMB power spectra, gravitational lensing, and cluster counts, as well as constraints on inflation, non-Gaussianity, primordial magnetic fields, dark energy, and modified gravity, and new results on low-frequency Galactic foregrounds.

  2. Planck 2013 results. I. Overview of products and scientific results

    NASA Astrophysics Data System (ADS)

    Planck Collaboration; Ade, P. A. R.; Aghanim, N.; Alves, M. I. R.; Armitage-Caplan, C.; Arnaud, M.; Ashdown, M.; Atrio-Barandela, F.; Aumont, J.; Aussel, H.; Baccigalupi, C.; Banday, A. J.; Barreiro, R. B.; Barrena, R.; Bartelmann, M.; Bartlett, J. G.; Bartolo, N.; Basak, S.; Battaner, E.; Battye, R.; Benabed, K.; Benoît, A.; Benoit-Lévy, A.; Bernard, J.-P.; Bersanelli, M.; Bertincourt, B.; Bethermin, M.; Bielewicz, P.; Bikmaev, I.; Blanchard, A.; Bobin, J.; Bock, J. J.; Böhringer, H.; Bonaldi, A.; Bonavera, L.; Bond, J. R.; Borrill, J.; Bouchet, F. R.; Boulanger, F.; Bourdin, H.; Bowyer, J. W.; Bridges, M.; Brown, M. L.; Bucher, M.; Burenin, R.; Burigana, C.; Butler, R. C.; Calabrese, E.; Cappellini, B.; Cardoso, J.-F.; Carr, R.; Carvalho, P.; Casale, M.; Castex, G.; Catalano, A.; Challinor, A.; Chamballu, A.; Chary, R.-R.; Chen, X.; Chiang, H. C.; Chiang, L.-Y.; Chon, G.; Christensen, P. R.; Churazov, E.; Church, S.; Clemens, M.; Clements, D. L.; Colombi, S.; Colombo, L. P. L.; Combet, C.; Comis, B.; Couchot, F.; Coulais, A.; Crill, B. P.; Cruz, M.; Curto, A.; Cuttaia, F.; Da Silva, A.; Dahle, H.; Danese, L.; Davies, R. D.; Davis, R. J.; de Bernardis, P.; de Rosa, A.; de Zotti, G.; Déchelette, T.; Delabrouille, J.; Delouis, J.-M.; Démoclès, J.; Désert, F.-X.; Dick, J.; Dickinson, C.; Diego, J. M.; Dolag, K.; Dole, H.; Donzelli, S.; Doré, O.; Douspis, M.; Ducout, A.; Dunkley, J.; Dupac, X.; Efstathiou, G.; Elsner, F.; Enßlin, T. A.; Eriksen, H. K.; Fabre, O.; Falgarone, E.; Falvella, M. C.; Fantaye, Y.; Fergusson, J.; Filliard, C.; Finelli, F.; Flores-Cacho, I.; Foley, S.; Forni, O.; Fosalba, P.; Frailis, M.; Fraisse, A. A.; Franceschi, E.; Freschi, M.; Fromenteau, S.; Frommert, M.; Gaier, T. C.; Galeotta, S.; Gallegos, J.; Galli, S.; Gandolfo, B.; Ganga, K.; Gauthier, C.; Génova-Santos, R. T.; Ghosh, T.; Giard, M.; Giardino, G.; Gilfanov, M.; Girard, D.; Giraud-Héraud, Y.; Gjerløw, E.; González-Nuevo, J.; Górski, K. M.; Gratton, S.; Gregorio, A.; Gruppuso, A.; Gudmundsson, J. E.; Haissinski, J.; Hamann, J.; Hansen, F. K.; Hansen, M.; Hanson, D.; Harrison, D. L.; Heavens, A.; Helou, G.; Hempel, A.; Henrot-Versillé, S.; Hernández-Monteagudo, C.; Herranz, D.; Hildebrandt, S. R.; Hivon, E.; Ho, S.; Hobson, M.; Holmes, W. A.; Hornstrup, A.; Hou, Z.; Hovest, W.; Huey, G.; Huffenberger, K. M.; Hurier, G.; Ilić, S.; Jaffe, A. H.; Jaffe, T. R.; Jasche, J.; Jewell, J.; Jones, W. C.; Juvela, M.; Kalberla, P.; Kangaslahti, P.; Keihänen, E.; Kerp, J.; Keskitalo, R.; Khamitov, I.; Kiiveri, K.; Kim, J.; Kisner, T. S.; Kneissl, R.; Knoche, J.; Knox, L.; Kunz, M.; Kurki-Suonio, H.; Lacasa, F.; Lagache, G.; Lähteenmäki, A.; Lamarre, J.-M.; Langer, M.; Lasenby, A.; Lattanzi, M.; Laureijs, R. J.; Lavabre, A.; Lawrence, C. R.; Le Jeune, M.; Leach, S.; Leahy, J. P.; Leonardi, R.; León-Tavares, J.; Leroy, C.; Lesgourgues, J.; Lewis, A.; Li, C.; Liddle, A.; Liguori, M.; Lilje, P. B.; Linden-Vørnle, M.; Lindholm, V.; López-Caniego, M.; Lowe, S.; Lubin, P. M.; Macías-Pérez, J. F.; MacTavish, C. J.; Maffei, B.; Maggio, G.; Maino, D.; Mandolesi, N.; Mangilli, A.; Marcos-Caballero, A.; Marinucci, D.; Maris, M.; Marleau, F.; Marshall, D. J.; Martin, P. G.; Martínez-González, E.; Masi, S.; Massardi, M.; Matarrese, S.; Matsumura, T.; Matthai, F.; Maurin, L.; Mazzotta, P.; McDonald, A.; McEwen, J. D.; McGehee, P.; Mei, S.; Meinhold, P. R.; Melchiorri, A.; Melin, J.-B.; Mendes, L.; Menegoni, E.; Mennella, A.; Migliaccio, M.; Mikkelsen, K.; Millea, M.; Miniscalco, R.; Mitra, S.; Miville-Deschênes, M.-A.; Molinari, D.; Moneti, A.; Montier, L.; Morgante, G.; Morisset, N.; Mortlock, D.; Moss, A.; Munshi, D.; Murphy, J. A.; Naselsky, P.; Nati, F.; Natoli, P.; Negrello, M.; Nesvadba, N. P. H.; Netterfield, C. B.; Nørgaard-Nielsen, H. U.; North, C.; Noviello, F.; Novikov, D.; Novikov, I.; O'Dwyer, I. J.; Orieux, F.; Osborne, S.; O'Sullivan, C.; Oxborrow, C. A.; Paci, F.; Pagano, L.; Pajot, F.; Paladini, R.; Pandolfi, S.; Paoletti, D.; Partridge, B.; Pasian, F.; Patanchon, G.; Paykari, P.; Pearson, D.; Pearson, T. J.; Peel, M.; Peiris, H. V.; Perdereau, O.; Perotto, L.; Perrotta, F.; Pettorino, V.; Piacentini, F.; Piat, M.; Pierpaoli, E.; Pietrobon, D.; Plaszczynski, S.; Platania, P.; Pogosyan, D.; Pointecouteau, E.; Polenta, G.; Ponthieu, N.; Popa, L.; Poutanen, T.; Pratt, G. W.; Prézeau, G.; Prunet, S.; Puget, J.-L.; Pullen, A. R.; Rachen, J. P.; Racine, B.; Rahlin, A.; Räth, C.; Reach, W. T.; Rebolo, R.; Reinecke, M.; Remazeilles, M.; Renault, C.; Renzi, A.; Riazuelo, A.; Ricciardi, S.; Riller, T.; Ringeval, C.; Ristorcelli, I.; Robbers, G.; Rocha, G.; Roman, M.; Rosset, C.; Rossetti, M.; Roudier, G.; Rowan-Robinson, M.; Rubiño-Martín, J. A.; Ruiz-Granados, B.; Rusholme, B.; Salerno, E.; Sandri, M.; Sanselme, L.; Santos, D.; Savelainen, M.; Savini, G.; Schaefer, B. M.; Schiavon, F.; Scott, D.; Seiffert, M. D.; Serra, P.; Shellard, E. P. S.; Smith, K.; Smoot, G. F.; Souradeep, T.; Spencer, L. D.; Starck, J.-L.; Stolyarov, V.; Stompor, R.; Sudiwala, R.; Sunyaev, R.; Sureau, F.; Sutter, P.; Sutton, D.; Suur-Uski, A.-S.; Sygnet, J.-F.; Tauber, J. A.; Tavagnacco, D.; Taylor, D.; Terenzi, L.; Texier, D.; Toffolatti, L.; Tomasi, M.; Torre, J.-P.; Tristram, M.; Tucci, M.; Tuovinen, J.; Türler, M.; Tuttlebee, M.; Umana, G.; Valenziano, L.; Valiviita, J.; Van Tent, B.; Varis, J.; Vibert, L.; Viel, M.; Vielva, P.; Villa, F.; Vittorio, N.; Wade, L. A.; Wandelt, B. D.; Watson, C.; Watson, R.; Wehus, I. K.; Welikala, N.; Weller, J.; White, M.; White, S. D. M.; Wilkinson, A.; Winkel, B.; Xia, J.-Q.; Yvon, D.; Zacchei, A.; Zibin, J. P.; Zonca, A.

    2014-11-01

    The European Space Agency's Planck satellite, dedicated to studying the early Universe and its subsequent evolution, was launched 14 May 2009 and has been scanning the microwave and submillimetre sky continuously since 12 August 2009. In March 2013, ESA and the Planck Collaboration released the initial cosmology products based on the first 15.5 months of Planck data, along with a set of scientific and technical papers and a web-based explanatory supplement. This paper gives an overview of the mission and its performance, the processing, analysis, and characteristics of the data, the scientific results, and the science data products and papers in the release. The science products include maps of the cosmic microwave background (CMB) and diffuse extragalactic foregrounds, a catalogue of compact Galactic and extragalactic sources, and a list of sources detected through the Sunyaev-Zeldovich effect. The likelihood code used to assess cosmological models against the Planck data and a lensing likelihood are described. Scientific results include robust support for the standard six-parameter ΛCDM model of cosmology and improved measurements of its parameters, including a highly significant deviation from scale invariance of the primordial power spectrum. The Planck values for these parameters and others derived from them are significantly different from those previously determined. Several large-scale anomalies in the temperature distribution of the CMB, first detected by WMAP, are confirmed with higher confidence. Planck sets new limits on the number and mass of neutrinos, and has measured gravitational lensing of CMB anisotropies at greater than 25σ. Planck finds no evidence for non-Gaussianity in the CMB. Planck's results agree well with results from the measurements of baryon acoustic oscillations. Planck finds a lower Hubble constant than found in some more local measures. Some tension is also present between the amplitude of matter fluctuations (σ8) derived from

  3. Data Mining Citizen Science Results

    NASA Astrophysics Data System (ADS)

    Borne, K. D.

    2012-12-01

    Scientific discovery from big data is enabled through multiple channels, including data mining (through the application of machine learning algorithms) and human computation (commonly implemented through citizen science tasks). We will describe the results of new data mining experiments on the results from citizen science activities. Discovering patterns, trends, and anomalies in data are among the powerful contributions of citizen science. Establishing scientific algorithms that can subsequently re-discover the same types of patterns, trends, and anomalies in automatic data processing pipelines will ultimately result from the transformation of those human algorithms into computer algorithms, which can then be applied to much larger data collections. Scientific discovery from big data is thus greatly amplified through the marriage of data mining with citizen science.

  4. New NAS Parallel Benchmarks Results

    NASA Technical Reports Server (NTRS)

    Yarrow, Maurice; Saphir, William; VanderWijngaart, Rob; Woo, Alex; Kutler, Paul (Technical Monitor)

    1997-01-01

    NPB2 (NAS (NASA Advanced Supercomputing) Parallel Benchmarks 2) is an implementation, based on Fortran and the MPI (message passing interface) message passing standard, of the original NAS Parallel Benchmark specifications. NPB2 programs are run with little or no tuning, in contrast to NPB vendor implementations, which are highly optimized for specific architectures. NPB2 results complement, rather than replace, NPB results. Because they have not been optimized by vendors, NPB2 implementations approximate the performance a typical user can expect for a portable parallel program on distributed memory parallel computers. Together these results provide an insightful comparison of the real-world performance of high-performance computers. New NPB2 features: New implementation (CG), new workstation class problem sizes, new serial sample versions, more performance statistics.

  5. KC-135 winglet flight results

    NASA Technical Reports Server (NTRS)

    Montoya, L. C.

    1981-01-01

    Three KC-135 winglet configurations were flight tested for cant/incidence angles of 15 deg/-4 deg, 15 deg/-2 deg, and 0 deg/-4 deg, as well as the basic wing. The flight results for the 15 deg/-4 deg and basic wing configurations confirm the wind tunnel predicted 7% incremental decrease in total drag at cruise conditions. The 15 deg/-4 configuration flight measured wing and winglet pressure distributions, loads, stability and control, flutter, and buffet also correlate well with predicted values. The only unexpected flight results as compared with analytical predictions is a flutter speed decrease for the 0 deg/-4 deg configuration. The 15 deg/-2 deg configuration results show essentially the same incremental drag reduction as the 15 deg/-4 deg configuration; however, the flight loads are approximately 30% higher for the 15 deg/-2 deg configuration. The drag data for the 0 deg/-4 deg configuration show only a flight drag reduction.

  6. New results from FRECOPA analysis

    NASA Technical Reports Server (NTRS)

    Durin, Christian

    1993-01-01

    New results from the ongoing analysis of the FRECOPA's (FREnch COoperative PAssive payload) system hardware are discussed. FRECOPA (AO138) was one of the 57 experiments flown on the LDEF satellite. The experiment was located on the trailing edge (Tray B3) and was exposed to UV radiation (11,100 equivalent sun hours), approximately equal to 34,000 thermal cycles, higher vacuum levels than the leading edge, a low atomic oxygen flux, and minor doses of protons and electrons. Due to LDEF's extended mission (5.8 years), CNES decided to set up a team to analyze the FRECOPA system. Initial results were presented at the First Post-Retrieval Conference, June, 1991. The results obtained since then are summarized.

  7. Catastrophic disruption experiments: Recent results

    NASA Technical Reports Server (NTRS)

    Martelli, G.; Ryan, E. V.; Nakamura, A. M.; Giblin, I.

    1994-01-01

    This paper presents a review of the progress in the field of catastrophic disruption experiments over the past 4 years, since the publication of the review paper by Fujiwara et al. (1989). We describe the development of new techniques to produce shattering impacts relevant to the study of the collisional evolution of the asteroids, and summarize the results from numerous experiments which have been performed to date, using a variety of materials for both the impactor and the targets. Some of these, such as ice-on-ice, loose aggregates and pressurized targets, are quite new and have provided novel and exciting results. Some of the gaps existing previously in the data on fragment ejection-angle distributions, as well as translational and rotational velocity fields (including fine fragments) have been filled, and these new results will be surveyed.

  8. ACTS: Technology Description and Results

    NASA Technical Reports Server (NTRS)

    Gedney, Richard T.; Schertler, Ronald; Gargione, Frank

    2000-01-01

    The ACTS Project was originated at NASA Glenn Research Center in the early 1980's to sponsor the development and application of technology that was intended to be used by the private sector. The program was formulated with the underlying philosophy of maintaining US leadership in satellite communications while focusing technology development for efficient use of the frequency spectrum. This report chronicles the execution and results of the program from the perspective of its technology managers, from inception through hardware and system development to on-orbit experiments and demonstrations of the technology. The first eight sections of the report discuss programmatic background, the specific satellite and ground terminal technology and the results generated by the program including industry relevance. A federally funded program of this type attracted strong advocates and adversaries and the resulting impact on the project schedule is also discussed. The last two sections are a list of useful acronyms and extensive references.

  9. Supersymmetry results at the Tevatron

    SciTech Connect

    Manca, Giulia; /Liverpool U.

    2005-05-01

    The Run II physics programme of the Tevatron is proceeding with more than 300 pb{sup -1} of analysis quality data, collected at a center-of-mass energy of 1.96 TeV. Searches for supersymmetric particles are starting to set new limits, improving over the LEP and Run I results and exploring new regions of parameter space. They present recent results in Supersymmetry with the upgraded CDF and D0 detectors and give some prospects for the future of these searches.

  10. Improved non-approximability results

    SciTech Connect

    Bellare, M.; Sudan, M.

    1994-12-31

    We indicate strong non-approximability factors for central problems: N{sup 1/4} for Max Clique; N{sup 1/10} for Chromatic Number; and 66/65 for Max 3SAT. Underlying the Max Clique result is a proof system in which the verifier examines only three {open_quotes}free bits{close_quotes} to attain an error of 1/2. Underlying the Chromatic Number result is a reduction from Max Clique which is more efficient than previous ones.

  11. Tau physics results from SLD

    SciTech Connect

    Daoudi, M.; SLD Collaboration

    1996-08-10

    Results on {tau} physics at SLD are presented. They are based on 4,316 {tau}-pair events selected from a 150 k Z{sup 0} data sample collected at the SLC. These results include measurements of the {tau} lifetime ({tau}{sub r} = 288.1 {+-} 6.1 {+-} 3.3 fs), the {tau} Michel parameters ({rho} = 0.71 {+-} 0.09 {+-} 0.04, {zeta} = 1.03 {+-} 0.36 {+-} 0.05, and {zeta}{delta} = 0.84 {+-} 0.27 {+-} 0.05), and the {tau} neutrino helicity (h{sub {nu}} = {minus}0.81 {+-} 0.18 {+-} 0.03).

  12. First results from SAGE II

    SciTech Connect

    Abdurashitov, J.N.; Faizov, E.L.; Gavrin, V.N.

    1994-07-01

    The Russian-American Gallium solar neutrino Experiment (SAGE) began the second phase of operation (SAGE II) in September of 1992. Monthly measurements of the integral flux of solar neutrinos have been made with 55 tonnes of gallium. The K-peak results of the first five runs of SAGE II give a capture rate of 76{sub {minus}18}{sup +21} (stat) {sub {minus}7}{sup +5} (sys) SNU. combined with the SAGE I result, the capture rate is 74{sub {minus}12}{sup +13} (stat) {sub {minus}7}{sup +5} (sys) SNU. This represents only 56%--60% of the capture rate predicted by different Standard Solar Models.

  13. Results from Numerical General Relativity

    NASA Technical Reports Server (NTRS)

    Baker, John G.

    2011-01-01

    For several years numerical simulations have been revealing the details of general relativity's predictions for the dynamical interactions of merging black holes. I will review what has been learned of the rich phenomenology of these mergers and the resulting gravitational wave signatures. These wave forms provide a potentially observable record of the powerful astronomical events, a central target of gravitational wave astronomy. Asymmetric radiation can produce a thrust on the system which may accelerate the single black hole resulting from the merger to high relative velocity.

  14. Spectroscopic commissioning results from MINERVA

    NASA Astrophysics Data System (ADS)

    Eastman, Jason D.; Johnson, Samson; Wang, Sharon; Sliski, David; Wilson, Maurice; Johnson, John A.; McCrady, Nate; Wittenmyer, Robert A.; Wright, Jason; Plavchan, Peter; Blake, Cullen; Beatty, Thomas G.

    2017-01-01

    MINERVA is a robotic observatory with four 0.7 meter telescopes at Mt. Hopkins, Arizona, dedicated to precise photometry and radial velocity observations of bright, nearby stars for the discovery and characterization of small exoplanets. Here we present the first radial velocity results from MINERVA during commissioning at the Fred Lawrence Whipple Observatory in Arizona, demonstrating m/s precision over month-long timescales. These results show that MINERVA is capable of achieving its primary science goal of finding super-Earths around the nearest, brightest stars.

  15. MC-1 Nozzle Testing Results

    NASA Technical Reports Server (NTRS)

    Peters, Warren; Turner, James E. (Technical Monitor)

    2000-01-01

    This document is the presentation graphics which reviews the test results of the MC-1 Nozzle. The MC-1 Nozzle was originally designed for a low cost engine for an expendable booster. It was modified for use in the X-34 propulsion plant. With this design the nozzle and chamber are one piece. The presentation reviews the design goals, the materials and fabrication. The tests and results are reviewed in considerable detail. Included are pictures of the nozzle, and diagrams of the nozzle geometry

  16. Recent results from hadron colliders

    SciTech Connect

    Frisch, H.J. )

    1990-12-10

    This is a summary of some of the many recent results from the CERN and Fermilab colliders, presented for an audience of nuclear, medium-energy, and elementary particle physicists. The topics are jets and QCD at very high energies, precision measurements of electroweak parameters, the remarkably heavy top quark, and new results on the detection of the large flux of B mesons produced at these machines. A summary and some comments on the bright prospects for the future of hadron colliders conclude the talk. 39 refs., 44 figs., 3 tabs.

  17. Photometric commissioning results from MINERVA

    NASA Astrophysics Data System (ADS)

    Eastman, Jason D.; Swift, Jonathan; Beatty, Thomas G.; Bottom, Michael; Johnson, John; Wright, Jason; McCrady, Nate; Wittenmyer, Robert A.; Riddle, Reed L.; Plavchan, Peter; Muirhead, Philip Steven; Blake, Cullen; Zhao, Ming

    2015-01-01

    MINERVA is a robotic observatory with four 0.7 meter telescopes at Mt. Hopkins, Arizona, dedicated to precise photometry and radial velocity observations of bright, nearby stars for the discovery and characterization of small exoplanets. Here we present the first photometric results from MINERVA during commissioning at our test facility in Pasadena, California, demonstrating sub-millimag precision on 3-5 minute timescales over several hours. These results show that MINERVA is well-equipped to address its secondary science goal of searching for transits of known and newly discovered super-Earth exoplanets detected by radial velocity, including potential detections from the MINERVA spectrograph.

  18. CDF results on electroweak physics

    SciTech Connect

    Frisch, H.J.; CDF Collaboration

    1993-11-01

    The second major run of the {bar p}p Fermilab Tevatron collider has just ended on June 1. The CDF detector has accumulated almost five times the data sample of its previous 1988--1989 run. We present new results on the ratio of W to Z boson production cross-sections and on the charge asymmetry in W decay. We give a progress report on the measurement of the W mass. New results from the 1988--1989 data on Drell-Yan production and on W {gamma} production are also presented.

  19. Ensemble Clustering for Result Diversification

    DTIC Science & Technology

    2012-11-01

    different clustering methods for a par- ticular data source. He et al. [8] proposed a framework to combine clusters of external resources to...representations for result diversification. In Proceedings of SIGIR, 2012. [9] D. Hiemstra and C. Hauff. Mapreduce for information retrieval evaluation: ‘let’s

  20. Recent Results from Hera Collider

    NASA Astrophysics Data System (ADS)

    Levonian, Sergey

    2013-11-01

    HERA collaborations H1 and ZEUS are publishing final analyses based on complete e±p statistics of ~ 0.5 fb-1 per experiment and using combinations of their data sets. Here selected recent results are presented from three areas: structure of the proton, searches for new physics and investigations of QCD phenomena at low Bjorken x.

  1. Results of Computer Based Training.

    ERIC Educational Resources Information Center

    1978

    This report compares the projected savings of using computer based training to conduct training for newly hired pilots to the results of that application. New Hire training, one of a number of programs conducted continuously at the United Airline Flight Operations Training Center, is designed to assure that any newly hired pilot will be able to…

  2. Perseids 2006 results in Romania

    NASA Astrophysics Data System (ADS)

    Grigore, Valentin; Berinde, Stefan; Conu, Alexandru

    2007-12-01

    The results of 14th edition of the Perseide (Perseid) project organized by SARM are presented. PERSEIDE 2006 - the national astronomical camp for yought had two distinct parts: a summer astronomical school and a national Perseid network. Over 60 persons attended this event which lasted for four weeks and had both a training and observing component.

  3. HADES results in elementary reactions

    NASA Astrophysics Data System (ADS)

    Ramstein, B.; Adamczewski-Musch, J.; Arnold, O.; Atomssa, E. T.; Behnke, C.; Berger-Chen, J. C.; Biernat, J.; Blanco, A.; Blume, C.; Böhmer, M.; Bordalo, P.; Chernenko, S.; Deveaux, C.; Dybczak, A.; Epple, E.; Fabbietti, L.; Fateev, O.; Fonte, P.; Franco, C.; Friese, J.; Fröhlich, I.; Galatyuk, T.; Garzón, J. A.; Gill, K.; Golubeva, M.; Guber, F.; Gumberidze, M.; Harabasz, S.; Hennino, T.; Hlavac, S.; Höhne, C.; Holzmann, R.; Ierusalimov, A.; Ivashkin, A.; Jurkovic, M.; Kämpfer, B.; Karavicheva, T.; Kardan, K.; Koenig, I.; Koenig, W.; Kolb, B. W.; Korcyl, G.; Kornakov, G.; Kotte, R.; Krása, A.; Krebs, E.; Kuc, H.; Kugler, A.; Kunz, T.; Kurepin, A.; Kurilkin, A.; Kurilkin, P.; Ladygin, V.; Lalik, R.; Lapidus, K.; Lebedev, A.; Lopes, L.; Lorenz, M.; Mahmoud, T.; Maier, L.; Mangiarotti, A.; Markert, J.; Metag, V.; Michel, J.; Müntz, C.; Münzer, R.; Naumann, L.; Palka, M.; Parpottas, Y.; Pechenov, V.; Pechenova, O.; Petousis, V.; Pietraszko, J.; Przygoda, W.; Rehnisch, L.; Reshetin, A.; Rost, A.; Rustamov, A.; Sadovsky, A.; Salabura, P.; Scheib, T.; Schmidt-Sommerfeld, K.; Schuldes, H.; Sellheim, P.; Siebenson, J.; Silva, L.; Sobolev, Yu. G.; Spataro, S.; Ströbele, H.; Stroth, J.; Strzempek, P.; Sturm, C.; Svoboda, O.; Tarantola, A.; Teilab, K.; Tlusty, P.; Traxler, M.; Tsertos, H.; Vasiliev, T.; Wagner, V.; Wendisch, C.; Wirth, J.; Wüstenfeld, J.; Zanevsky, Y.; Zumbruch, P.

    2014-11-01

    Recent results obtained with the HADES experimental set-up at GSI are presented with a focus on dielectron production and strangeness in pp and quasi-free np reactions. Perspectives related to the very recent experiment using the pion beam at GSI are also discussed.

  4. Diffractive physics results at CDF

    SciTech Connect

    Michele Gallinaro

    2003-12-18

    Forward detectors are described together with the first physics results from Run II. Using new data and dedicated diffractive triggers, a measurement of single diffractive dijet production rate, with particular focus on the diffractive structure function of the antiproton, is discussed. Upper limits on the exclusive dijet and {chi}{sub c}{sup 0} production cross sections are also presented.

  5. The Planck Mission: Early Results

    SciTech Connect

    Marco Bersanelli

    2012-03-07

    The ESA Planck space mission, launched on May 14, 2009, is dedicated to high precision measurements of the cosmic microwave background (CMB), the first light of the universe, both in temperature and polarization. The satellite observes the full sky from a far-Earth orbit with two cryogenic instruments in the 30-850 GHz range at the focal plane of a 1.5-meter telescope. The primary objective of Planck is to measure with unprecedented precision the key cosmological parameters and to provide accurate tests of physics in the early universe. Planck has recently completed the fifth full-sky survey. The data analysis is underway. The first cosmology results are expected in early 2013 while a number of astrophysical results have been recently delivered to the community, including galactic and extragalactic astrophysics and a rich catalogue of radio and infrared sources. These results demonstrate the excellent in-orbit performance of the instruments and give excellent prospects for the forthcoming cosmological results.

  6. FFTF startup: status and results

    SciTech Connect

    Noordhoff, B.H.; Moore, C.E.

    1980-03-01

    Startup testing on the Fast Flux Test Facility (FFTF) during the past three years has progressed beyond initial criticality toward the principal goal of power demonstration in 1980. An overview is presented of technical results to date and project plans to achieve power demonstration and complete the startup test program.

  7. Cuesta College School Performance Results.

    ERIC Educational Resources Information Center

    Cuesta Coll., San Luis Obispo, CA.

    This Cuesta College (California) document identifies key institutional effectiveness indicators that are used to assess institutional performance on specified educational processes. The key process of instruction/learning is measured through student performance results such as: (1) transfer rate (University of California/California State…

  8. Recent Results from the Tevatron

    SciTech Connect

    Demorden, L.

    1998-06-01

    We review recent results from fixed-target and collider experiments at the Fermilab Tevatron. Among the topics discussed are jet production rates, {alpha}{sub S} measurements, the {anti d}/{anti u} ratio in the proton sea, diffraction, heavy quark physics and leptoquark searches.

  9. Surveyor 3 Preliminary Science Results

    NASA Technical Reports Server (NTRS)

    1967-01-01

    Surveyor III soft-landed on the Moon at 00:04 GMT on April 20, 1967. Data obtained have significantly increased our knowledge of the Moon. The Surveyor III spacecraft was similar to Surveyor I; the only major change in scientific instrumentation was the addition of a soil mechanics surface sampler. Surveyor III results at this preliminary evaluation of data give valuable information about the relation between the surface skin of under-dense material responsible for the photometric properties and the deeper layers of material whose properties resemble those of ordinary terrestrial soils. In addition, they provide new insight into the relation between the general lunar surface as seen by Surveyor I and the interior of a large subdued crater. The new results have also contributed to our understanding of the mechanism of downhill transport. Many critical questions cannot, however, be answered until final reduction of experimental data.

  10. Forget about data, deliver results

    NASA Astrophysics Data System (ADS)

    Walter, Roland

    2015-12-01

    High-energy astrophysics space missions have pioneered and demonstrated the power of legacy data sets for generating new discoveries, especially when analysed in ways original researchers could not have anticipated. The only way to ensure that the data of present observatories can be effectively used in the future is to allow users to perform on-the-fly data analysis to produce straightforwardly scientific results for any sky position, time and energy intervals without requiring mission specific software or detailed instrumental knowledge. Providing a straightforward interface to complex data and data analysis makes the data and the process of generating science results available to the public and higher education and promotes the visibility of the investment in science to the society. This is a fundamental step to transmit the values of science and to evolve towards a knowledge society.

  11. CMS results on multijet correlations

    SciTech Connect

    Safronov, Grigory

    2015-04-10

    We present recent CMS measurements on multijet correlations using forward and low-p{sub T} jets, focusing on searches for BFKL and saturation phenomena. In pp collisions at √(s)=7 TeV, azimuthal correlations in dijets separated in rapidity by up to 9.4 units were measured. The results are compared to BFKL- and DGLAP-based predictions. In pp collisions at √(s)=8 TeV, cross sections for jets with p{sub T} > 21 GeV and |y| < 4.7, and for track-jets with p{sub T} > 1 GeV (minijets) are presented. The minijet results are sensitive to the bound imposed by the total inelastic cross section, and are compared to various models for taming the growth of the 2 → 2 cross section at low p{sub T}.

  12. Seeds in space experiment results

    NASA Technical Reports Server (NTRS)

    Alston, Jim A.

    1991-01-01

    Two million seeds of 120 different varieties representing 106 species, 97 genera, and 55 plant families were flown aboard the Long Duration Exposure Facility (LDEF). The seeds were housed on the space exposed experiment developed for students (SEEDS) tray in sealed canister number six and in two small vented canisters. The tray was in the F-2 position. The seeds were germinated and the germination rates and development of the resulting plants compared to the control seed that stayed in Park Seed's seed storage facility. The initial results are presented. There was a better survival rate in the sealed canister in space than in the storage facility at Park Seed. At least some of the seeds in each of the vented canisters survived the exposure to vacuum for almost six years. The number of observed apparent mutations was very low.

  13. Top physics results from CDF

    SciTech Connect

    Gomez, Gervasio; /Cantabria Inst. of Phys.

    2005-05-01

    The top quark is by far the most massive fundamental particle observed so far, and the study of its properties is interesting for several reasons ranging from its possible special role in electroweak symmetry breaking to its sensitivity to physics beyond the Standard Model. They present recent top physics results from CDF based on 160-320 pb{sup -1} of p{bar p} collision data at {radical}s = 1.96 TeV. The t{bar t} cross section and the top mass have been measured in different decay channels and using different methods. they have searched for evidence of single top production, setting upper limits on its production rate. Other results shown in this conference include studies of the polarization of W bosons from top decays, a search for charged Higgs decaying from top, and a search for additional heavy t' quarks.

  14. Recent DIII-D results

    SciTech Connect

    Petersen, P.I.

    1994-07-01

    This paper summarizes the recent DIII-D experimental results and the development of the relevant hardware systems. The DIII-D program focuses on divertor solutions for next generation tokamaks such as International Thermo-nuclear Experimental Reactor (ITER) and Tokamak Physics Experiment (TPX), and on developing configurations with enhanced confinement and stability properties that will lead to a more compact and economical fusion reactor. The DIII-D program carries out this research in an integrated fashion.

  15. Cassini Imaging Results at Titan

    NASA Technical Reports Server (NTRS)

    McEwen, A.; Turtle, E.; Perry J.; Fussner, S.; Porco, C.; West, R.; Johnson, T.; Collins, G.; DelGenio, T.; Barbara, J.

    2005-01-01

    The Cassini Imaging Science Subsystem (ISS) images show striking albedo markings on the surface of Titan. In equatorial regions the albedo patterns have high contrast and exhibit prominent lineaments and linear/angular boundaries suggestive of tectonic influences or fracturing of brittle surficial materials. There are intriguing dark curving lines near the south pole. Here we present several working hypotheses to explain these patterns. We also briefly summarize atmospheric science results.

  16. Overview of recent ALICE results

    NASA Astrophysics Data System (ADS)

    Lakomov, Igor

    2016-10-01

    ALICE is one of the four largest LHC experiments. It is dedicated to the study of the properties of the deconfined state of matter formed at large energy densities in heavy-ion collisions — the Quark-Gluon Plasma. The ALICE Collaboration also participated in the pp and p-Pb data-taking periods at the LHC. An overview of recent ALICE results is presented for three collision systems: pp, p-Pb and Pb-Pb.

  17. Electroweak results from D0

    SciTech Connect

    Demarteau, M.; D0 Collaboration

    1993-05-01

    Preliminary results from D0 are presented on properties of the W{sup {plus_minus}} and Z{sup 0} electroweak gauge bosons, using final states containing electrons and muons. In particular, preliminary measurements of the W{sup {plus_minus}} and Z{sup 0} production cross sections with decay into final states containing electrons are shown and a status report on the determination of M{sub w}/M{sub z} is given.

  18. B0s Oscillation Results

    SciTech Connect

    Willocq, Stephane

    2002-08-09

    The authors review new studies of the time dependence of B{sub s}{sup 0}-{bar B}{sub s}{sup 0} mixing by the ALEPH, DELPHI and SLD Collaborations, with an emphasis on the different analysis methods used. Combining all available results yields a preliminary lower limit on the oscillation frequency of {Delta}m{sub s} > 14.4 ps{sup -1} at the 95% C.L.

  19. SPQR -- Spectroscopy: Prospects, Questions & Results

    SciTech Connect

    Pennington, Michael R.

    2014-06-01

    Tremendous progress has been made in mapping out the spectrum of hadrons over the past decade with plans to make further advances in the decade ahead. Baryons and mesons, both expected and unexpected, have been found, the results of precision experiments often with polarized beams, polarized targets and sometimes polarization of the final states. All these hadrons generate poles in the complex energy plane that are consequences of strong coupling QCD. They reveal how this works.

  20. Top quark results at CDF

    SciTech Connect

    Leone, S.; CDF Collaboration

    1996-08-01

    We present the latest results on the top quark obtained by the CDF experiment using a data sample of about 110 {ital pb}{sup -1} collected at the Fermilab Tevatron collider. We briefly describe the candidate events selection and then discuss the production cross section determination and the mass measurement. The study of two new decay channels (all hadronic and ``tau dilepton``) is also reported.

  1. Recent results from Daya Bay

    NASA Astrophysics Data System (ADS)

    Chua, Ming-chung

    2016-11-01

    Utilizing powerful nuclear reactors as antineutrino sources, high mountains to provide ample shielding from cosmic rays in the vicinity, and functionally identical detectors with large target volume for near-far relative measurement, the Daya Bay Reactor Neutrino Experiment has achieved unprecedented precision in measuring the neutrino mixing angle θ13 and the neutrino mass squared difference |Δm2ee|. I will report the latest Daya Bay results on neutrino oscillations and light sterile neutrino search.

  2. [Results of routine intraoperative cholangiography].

    PubMed

    Klima, S; Schyra, B

    1999-01-01

    Most bile duct injuries result from an incorrect interpretation of bile duct anatomy. In 500 laparoscopic cholecystectomies we used a modified technique of cholecystcholangiography. This method is very easy and needs only 5 minutes. We found variants of bile duct anatomy in 74 cases and occult bile duct stones in 20 patients. We recommend this method which decreases the risk of bile duct injuries and gives the opportunity to approximate the golden standard of conventional cholecystectomy.

  3. Open cherry picker simulation results

    NASA Technical Reports Server (NTRS)

    Nathan, C. A.

    1982-01-01

    The simulation program associated with a key piece of support equipment to be used to service satellites directly from the Shuttle is assessed. The Open Cherry Picker (OCP) is a manned platform mounted at the end of the remote manipulator system (RMS) and is used to enhance extra vehicular activities (EVA). The results of simulations performed on the Grumman Large Amplitude Space Simulator (LASS) and at the JSC Water Immersion Facility are summarized.

  4. Results from the B Factories

    SciTech Connect

    Bevan, A.; /Queen Mary, U. of London

    2009-01-08

    These proceedings are based on lectures given at the Helmholtz International Summer School Heavy Quark Physics at the Bogoliubov Laboratory of Theoretical Physics, Dubna, Russia, during August 2008. I review the current status of CP violation in B meson decays from the B factories. These results can be used, along with measurements of the sides of the Unitarity Triangle, to test the CKM mechanism. In addition I discuss experimental studies of B decays to final states with 'spin-one' particles.

  5. Digital coincidence counting - initial results

    NASA Astrophysics Data System (ADS)

    Butcher, K. S. A.; Watt, G. C.; Alexiev, D.; van der Gaast, H.; Davies, J.; Mo, Li; Wyllie, H. A.; Keightley, J. D.; Smith, D.; Woods, M. J.

    2000-08-01

    Digital Coincidence Counting (DCC) is a new technique in radiation metrology, based on the older method of analogue coincidence counting. It has been developed by the Australian Nuclear Science and Technology Organisation (ANSTO), in collaboration with the National Physical Laboratory (NPL) of the United Kingdom, as a faster more reliable means of determining the activity of ionising radiation samples. The technique employs a dual channel analogue-to-digital converter acquisition system for collecting pulse information from a 4π beta detector and an NaI(Tl) gamma detector. The digitised pulse information is stored on a high-speed hard disk and timing information for both channels is also stored. The data may subsequently be recalled and analysed using software-based algorithms. In this letter we describe some recent results obtained with the new acquistion hardware being tested at ANSTO. The system is fully operational and is now in routine use. Results for 60Co and 22Na radiation activity calibrations are presented, initial results with 153Sm are also briefly mentioned.

  6. PACOSS program status and results

    NASA Technical Reports Server (NTRS)

    Richards, K. E., Jr.

    1989-01-01

    Future large space systems (LSS), both civilian and military, will have performance objectives which require stringent pointing accuracies, relatively fast retargeting times, short settling times, accurate dynamic shape requirements, or combinations thereof. Many of these structures will be large but lightweight and will exhibit a dense, low-frequency modal spectrum with significant content within the control bandwidth. Although it is possible in principle to achieve structural vibration control with purely active means, experience with complex structures has shown that the realities of plant model inaccuracies and real sensor and actuator dynamics frequently combine to produce disappointing results. It was shown that a combination of passive and active control will result in a simpler system which can be expected to be more reliable and less expensive than a corresponding system utilizing active control exclusively. The goals of the Passive and Active Control of Space Structures (PACOSS) program consist of a thorough investigation of the relative roles of passive active vibration control, and the development of validated means of vibration control. The program approach, representative system article, dynamic test article, and test status and results are outlined.

  7. ISO: highlights of recent results

    NASA Astrophysics Data System (ADS)

    Metcalfe, L.; Salama, A.

    ESA's Infrared Space Observatory (ISO) mission, operating in the wavelength range from 2.5 to 240 microns, made over 26000 scientific observations during its 2.5 year operational lifetime. ISO's results broke new ground on all scales. New asteroid counts and improved asteroid thermophysical models augmented important advances in Solar System chemistry to comprise a striking body of results addressing our planetary system. In turn, parallels between the chemical composition of Solar System dust and dust around other stars revealed by the comparison of stellar spectra with cometary spectra, together with results on the incidence and stability of stellar disks, recall the birth of our Solar System and point to fundamental similarities with other star systems. Numerous important facts concerning the chemistry of the ISM have unfolded, such as the ubiquity of water and of the probably-organic carriers of the Unidentified Infrared Bands (UIBs). The large systematic body of data on galactic stars has permitted fascinating advances in the characterisation of important aspects of stellar evolution. Investigations of nearby normal galaxies complement template specimens of interacting galaxies. These in turn exemplify galaxy evolutionary processes in the early Universe associated with a huge burst of dust-obscured star formation at redshifts of just below one. This global surge of star formation has vital implications for the interpretation and explanation of major components of the Extragalactic Background Light (EBL) and for charting the global history of star formation and the relative importance of sources which derive their energy from accretion processes. Representative examples of key aspects of ISO's recent scientific output will be presented, once again affirming ISO's place at the forefront of successful space-borne astronomy missions.

  8. Results from the HARP Experiment

    SciTech Connect

    Catanesi, M. G.

    2008-02-21

    Hadron production is a key ingredient in many aspects of {nu} physics. Precise prediction of atmospheric {nu} fluxes, characterization of accelerator {nu} beams, quantification of {pi} production and capture for {nu}-factory designs, all of these would profit from hadron production measurements. HARP at the CERN PS was the first hadron production experiment designed on purpose to match all these requirements. It combines a large, full phase space acceptance with low systematic errors and high statistics. HARP was operated in the range from 3 GeV to 15 GeV. We briefly describe here the most recent results.

  9. Lightcurve Results for Eleven Asteroids

    NASA Astrophysics Data System (ADS)

    Gartrelle, Gordon M.

    2012-04-01

    Differential photometry techniques were used to develop lightcurves, rotation periods and amplitudes for eleven main-belt asteroids: 833 Monica, 962 Aslog, 1020 Arcadia, 1082 Pirola, 1097 Vicia, 1122 Lugduna, 1145 Robelmonte, 1253 Frisia, 1256 Normannia, 1525 Savolinna, and 2324 Janice. Ground-based observations from Badlands Observatory (BLO) in Quinn, SD, as well as the University of North Dakota Observatory (UND) in Grand Forks, ND, provided the data for the project. A search of the asteroid lightcurve database (LCDB) did not reveal any previously reported results for seven of the eleven targets in this study.

  10. Some Recent Results with CLAS

    SciTech Connect

    Maurik Holtrop

    2010-10-01

    The CLAS is a multipurpose, large acceptance magnetic spectrometer, instrumented with detector systems sensitive to charged and neutral particles. The experimental program at CLAS is aimed at furthering our understanding of hadronic and nuclear physics, through electron and photon scattering experiments, which cover a large range of topics, including meson and baryon spectroscopy, nucleon structure through elastic and deep inelastic scattering, nuclear transparency, nuclear correlations and nuclear structure. This talk will briefly describe the detector and the collaboration that uses it and will highlight some recent results.

  11. Results from the EDGES Survey

    NASA Astrophysics Data System (ADS)

    van Zee, Liese; EDGES Team

    2017-03-01

    Results are presented from a deep imaging survey with the Spitzer Space Telescope which was designed to identify and measure the faint stellar populations around nearby galaxies. The Extended Disk Galaxy Exploration Science (EDGES) Survey includes a sample of 92 nearby galaxies with a range of morphological types and environments. The observations include a field-of-view of at least 5 times the optical size and are deep enough to detect stellar mass surface densities of several hundredths of a solar mass per square parsec. The observations reveal extended stellar features, such as stellar disks and stellar streams, around many of the target galaxies, as expected from hierarchical galaxy formation scenarios.

  12. Results from the MSSTA III

    NASA Astrophysics Data System (ADS)

    Boerner, P. F. X.; Martinez-Galarce, D. S.; Bay, T. J.; Barbee, T. W.; Talasaz, A. A.; Kumar, R.; Jain, P.; Hakim, N.

    2002-12-01

    The Multi-Spectral Solar Telescope Array was launched on April 30th, 2002 on a Terrier-boosted Black Brant at White Sands Missile Range. It used an array of multilayer-coated Ritchey-Chretien telescopes to image the solar corona at 150 Å, 171 Å, 180 Å, 195 Å and 211 Å. High-resolution chromospheric spectroheliograms at 1216 Å and 1550 Å were also obtained. We present the results of the mission and report on the status of the image calibration, as well as early analysis of active region loops using MSSTA data.

  13. RSG Deployment Case Testing Results

    SciTech Connect

    Owsley, Stanley L.; Dodson, Michael G.; Hatchell, Brian K.; Seim, Thomas A.; Alexander, David L.; Hawthorne, Woodrow T.

    2005-09-01

    The RSG deployment case design is centered on taking the RSG system and producing a transport case that houses the RSG in a safe and controlled manner for transport. The transport case was driven by two conflicting constraints, first that the case be as light as possible, and second that it meet a stringent list of Military Specified requirements. The design team worked to extract every bit of weight from the design while striving to meet the rigorous Mil-Spec constraints. In the end compromises were made primarily on the specification side to control the overall weight of the transport case. This report outlines the case testing results.

  14. Recent QCD results from CDF

    SciTech Connect

    I. Gorelov

    2001-12-28

    Experimental results on QCD measurements obtained in recent analyses and based on data collected with CDF Detector from the Run 1b Tevatron running cycle are presented. The scope of the talk includes major QCD topics: a measurement of the strong coupling constant {alpha}{sub s}, extracted from inclusive jet spectra and the underlying event energy contribution to a jet cone. Another experimental object of QCD interest, prompt photon production, is also discussed and the updated measurements by CDF of the inclusive photon cross section at 630 GeV and 1800 GeV, and the comparison with NLO QCD predictions is presented.

  15. Overview of recent ALICE results

    NASA Astrophysics Data System (ADS)

    Gunji, Taku

    2016-12-01

    The ALICE experiment explores the properties of strongly interacting QCD matter at extremely high temperatures created in Pb-Pb collisions at LHC and provides further insight into small-system physics in (high-multiplicity) pp and p-Pb collisions. The ALICE collaboration presented 27 parallel talks, 50 posters, and 1 flash talk at Quark Matter 2015 and covered various topics including collective dynamics, correlations and fluctuations, heavy flavors, quarkonia, jets and high pT hadrons, electromagnetic probes, small system physics, and the upgrade program. This paper highlights some of the selected results.

  16. Electroweak results from the Tevatron

    SciTech Connect

    Demarteau, M.

    1995-10-01

    Results from the CDF and D{O} experiments are presented on properties of the W{plus_minus} and Z{sup 0} gauge bosons using final states containing electrons and muons based on large integrated luminosities. In particular, measurements of the W{plus_minus} and Z{sup 0} production cross sections, the W-charge asymmetry and the CDF measurement of the W-mass are summarized. Gauge boson self interactions axe measured by studying di-gauge boson production and limits on anomalous gauge boson couplings axe discussed.

  17. APS undulator radiation: First results

    SciTech Connect

    Cai, Z.; Dejus, R.J.; Hartog, P.D.

    1995-12-31

    The first undulator radiation has been extracted from the Advanced Photon Source (APS). The results from the characterization of this radiation are very satisfactory. With the undulator set at a gap of 15.8 mm (K=1.61), harmonics as high as the 17th were observed using a crystal spectrometer. The angular distribution of the third-harmonic radiation was measured, and the source was imaged using a zone plate to determine the particle beam emittance. The horizontal beam emittance was found to be 6.9 {plus_minus} 1.0 nm-rad, and the vertical emittance coupling was found to be less than 3%. The absolute spectral flux was measured over a wide range of photon energies, and it agrees remarkably well with the theoretical calculations based on the measured undulator magnetic field profile and the measured beam emittance. These results indicate that both the emittance of the electron beam and the undulator magnetic field quality exceed the original specifications.

  18. Unfavourable results in thumb reconstruction

    PubMed Central

    Kumta, Samir M.

    2013-01-01

    The history of thumb reconstruction parallels the history of hand surgery. The attributes that make the thumb unique, and that the reconstructive surgeon must assess and try to restore when reconstructing a thumb, are: Position, stability, strength, length, motion, sensibility and appearance. Deficiency in any of these attributes can reduce the utility of the reconstructed thumb. A detailed assessment of the patient and his requirements needs to be performed before embarking on a thumb reconstruction. Most unsatisfactory results can be attributed to wrong choice of procedure. Component defects of the thumb are commonly treated by tissue from adjacent fingers, hand or forearm. With refinements in microsurgery, the foot has become a major source of tissue for component replacement in the thumb. Bone lengthening, osteoplastic reconstruction, pollicisation, and toe to hand transfers are the commonest methods of thumb reconstruction. Unfavourable results can be classified as functional and aesthetic. Some are common to all types of procedures. However each type of reconstruction has its own unique set of problems. Meticulous planning and execution is essential to give an aesthetic and functionally useful thumb. Secondary surgeries like tendon transfers, bone grafting, debulking, arthrodesis, may be required to correct deficiencies in the reconstruction. Attention needs to be paid to the donor site as well. PMID:24501466

  19. Latest results from Double Chooz

    NASA Astrophysics Data System (ADS)

    Minotti, A.

    2017-01-01

    Double Chooz is a short-baseline neutrino disappearance experiment. It detects ν¯ e produced in the power plant of Chooz, France, where is located. The main goal of the experiment is the measurement of θ13 mixing angle and in 2011 for the first time the experiment observed an indication for a non zero value of such an oscillation parameter. The mixing angle was successively measured using only the far detector finding the best fit value of sin2(2θ13) = 0.090 -0.029 +0.032 . The near detector is under construction and will start data taking by the middle of 2014 allowing the reduction of the systematic errors. In this paper I make a review of the Double Chooz experiment, focusing in particular on the latest results of the measurement of the mixing angle θ13 relying on the neutron absorption on Gadolinium. I also present results proving the capability of Double Chooz to identify the ortho-positronium. This has been done in an event-by-event basis for the first time in a large liquid scintillator experiments, and can be an additional handle for the electron/positron discrimination in future detectors based on such technology.

  20. REMS Wind Sensor Preliminary Results

    NASA Astrophysics Data System (ADS)

    De La Torre Juarez, M.; Gomez-Elvira, J.; Navarro, S.; Marin, M.; Torres, J.; Rafkin, S. C.; Newman, C. E.; Pla-García, J.

    2015-12-01

    The REMS instrument is part of the Mars Science Laboratory payload. It is a sensor suite distributed over several parts of the rover. The wind sensor, which is composed of two booms equipped with a set of hot plate anemometers, is installed on the Rover Sensing Mast (RSM). During landing most of the hot plates of one boom were damaged, most likely by the pebbles lifted by the Sky Crane thruster. The loss of one wind boom necessitated a full review of the data processing strategy. Different algorithms have been tested on the readings of the first Mars year, and these results are now archived in the Planetary Data System (PDS), The presentation will include a description of the data processing methods and of the resulting products, including the typical evolution of wind speed and direction session-by-session, hour-by-hour and other kinds of statistics . A review of the wind readings over the first Mars year will also be presented.

  1. Wave results from OEDIPUS A

    NASA Astrophysics Data System (ADS)

    James, H. G.

    1993-10-01

    Active wave experiments in the 0-5 MHz range were carried out using a synchronized transmitter-receiver pair on the tethered sounding rocket payload OEDIPUS A. At full tether extension, the transmitter-receiver separation was 958 m. Although the transmitter power was modest (2.5 W), the receiver recorded strong propagation in tether-guided sheath-wave and plane-wave electromagnetic modes. After a summary of two principal wave results from the OEDIPUS experiment, these results are compared with related phenomena from the topside sounder spacecraft. The sheath-wave spectra clearly suggest that sheath waves are damped by electrostatic cyclotron waves. This is consistent with ideas in the topside-sounder literature that discuss how electrostatic waves transfer energy to the surrounding plasma. The transmission efficiency of slow Z-mode plane waves between the plasma and upper-hybrid resonance frequencies depends on guiding by density irregularities, which have produced related signatures in the monostatic sounder records.

  2. Gateways to clinical trials.

    PubMed

    Tomillero, A; Moral, M A

    2008-09-01

    Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data in the following tables has been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity, the drug discovery and development portal, http://integrity.prous.com.This issue focuses on the following selection of drugs: ABT-263, AC-2307, Aclidinium bromide, Adefovir dipivoxil, ADH-1, Agatolimod sodium, Alefacept, Aliskiren fumarate, Aminolevulinic acid methyl ester, Anakinra, Apaziquone, Aprepitant, Aripiprazole, ASM-8, Atiprimod hydrochloride, AVE-0277, AVE-1642, AVE-8062, Axitinib, Azacitidine, AZD-0530; Bazedoxifene acetate, Bevacizumab, Bexarotene, BI-2536, Biphasic insulin aspart, BMS-387032, BMS-663513, Bortezomib, BQ-123, Brivanib alaninate, BSI-201; Caspofungin acetate, CDX-110, Cetuximab, Ciclesonide, CR-011, Cypher; Daptomycin, Darbepoetin alfa, Dasatinib, Decitabine, Deferasirox, Denosumab, Dexlansoprazole, Dexmethylphenidate hydrochloride, DNA-Hsp65 vaccine, Dovitinib, Drotrecogin alfa (activated), DTaP-HBV-IPV/Hibvaccine, DTaP-IPV-HB-PRP-T, Duloxetine hydrochloride, Dutasteride; Ecogramostim, Elacytarabine, Emtricitabine, Endothelin, Entecavir, Eplivanserin fumarate, Escitalopram oxalate, Everolimus, Ezetimibe, Ezetimibe/simvastatin; Farletuzumab, Fesoterodine fumarate, Fibrin sealant (human), Fulvestrant; Gefitinib, Gemtuzumab ozogamicin, Glufosfamide, GSK-1562902A; Hib-TT; Imatinib mesylate, IMC-11F8, Imidazoacridinone, IMP-321, INCB-18424, Indiplon, Indisulam, INNO-406, Irinotecan hydrochloride/Floxuridine, ITF-2357, Ixabepilone; KRN-951; Lasofoxifene tartrate; Lenalidomide, LGD-4665, Lonafarnib, Lubiprostone, Lumiliximab; MDX-1100, Melan-A/MART-1/gp100/IFN-alfa, Methyl-CDDO, Metreleptin, MLN-2704, Mycophenolic acid sodium salt; Na-ASP-2, Naproxcinod, Nilotinib hydrochloride monohydrate, NPI-2358; Oblimersen sodium, Odanacatib; Paclitaxel nanoparticles, PAN-811, Panobinostat, PBI-1402, PC-515, Peginterferon alfa

  3. Gateways to clinical trials.

    PubMed

    Bayes, M; Rabasseda, X; Prous, J R

    2005-01-01

    Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data in the following tables have been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity, the drug discovery and development portal, http://integrity.prous.com. This issue focuses on the following selection of drugs: (-)-Epigallocatechin gallate; ACP-103, Ad.Egr.TNF.11 D, adalimumab, AF-IL 12, AIDSVAX gp120 B/B, alefacept, alemtuzumab, a-Galactosylceramide, ALVAC vCP 1452, alvimopan hydrate, alvocidib hydrochloride, aminolevulinic acid hydrochloride, aminolevulinic acid methyl ester, anakinra, anidulafungin, antarelix, aprepitant, aripiprazole, arsenic sulfide, asoprisnil, atazanavir sulfate, atomoxetine hydrochloride; Bevacizumab, bimatoprost, BMS-184476, bortezomib, bosentan, botulinum toxin type B, BrachySil, brivudine; Caffeine, calcipotriol/betamethasone dipropionate, cannabidiol, capsaicin for injection, caspofungin acetate, CC-4047, cetuximab, CGP-36742, clofazimine, CpG-7909, Cypher; Darbepoetin alfa, dextromethorphan/quinidine sulfate, dimethylfumarate, dronabinol/cannabidiol, drotrecogin alfa (activated), duloxetine hydrochloride, dutasteride; Ecogramostim, efalizumab, eletriptan, emtricitabine, enfuvirtide, eplerenone, esomeprazole magnesium, estradiol acetate, eszopiclone, etoricoxib, exenatide, ezetimibe, ezetimibe/simvastatin; Fampridine, fondaparinux sodium, fosamprenavir calcium; Gefitinib, GPI-0100; hA 20, HTU-PA, human insulin, HuOKT 3 gamma 1(Ala 234-Ala 235), hyaluronic acid; Icatibant, imatinib mesylate, Indiplon, INKP-100, INKP-102, iodine (I131) tositumomab, istradefylline, IV gamma-globulin, ivabradine hydrochloride, ixabepilone; Lacosamide, landiolol, lanthanum carbonate, lasofoxifene tartrate, LB-80380, lenalidomide, lidocaine/tetracaine, linezolid, liposomal doxorubicin, liposomal vincristine sulfate, lopinavir, lopinavir/ritonavir, lumiracoxib, lurtotecan; Maribavir, morphine glucuronide, MVA-5 T

  4. Airfreight forecasting methodology and results

    NASA Technical Reports Server (NTRS)

    1978-01-01

    A series of econometric behavioral equations was developed to explain and forecast the evolution of airfreight traffic demand for the total U.S. domestic airfreight system, the total U.S. international airfreight system, and the total scheduled international cargo traffic carried by the top 44 foreign airlines. The basic explanatory variables used in these macromodels were the real gross national products of the countries involved and a measure of relative transportation costs. The results of the econometric analysis reveal that the models explain more than 99 percent of the historical evolution of freight traffic. The long term traffic forecasts generated with these models are based on scenarios of the likely economic outlook in the United States and 31 major foreign countries.

  5. First year results from LOTIS

    NASA Astrophysics Data System (ADS)

    Williams, G. G.; Parks, H. S.; Ables, E.

    1997-11-01

    LOTIS (Livermore Optical Transient Imaging System) is a gamma-ray burst optical couterpart search experiment located near Lawrence Livermore National Laboratory in California. The system is linked to the GCN (GRB Coordinates Network) real-time coordinate distribution network and can respond to a burst trigger in 6-15 seconds. LOTIS has a total field-of-view of 17.4 degrees x 17.4 degrees with a completeness sensitivity of mv approximately 11 for a 10 second integration time. Since operations began in October 1996, LOTIS has responded to over 30 GCN/BATSE GRB triggers. Seven of these triggers are considered good events subject to the criteria of clear weather conditions, (lt) 60 S RESPONSE TIME, AND (gt)50% coverage of the final BATSE 3(sigma) error circle. We discuss results from the first year of LOTIS operations with an emphasis on the observations and analysis of GRB 971006 (BATSE trigger 6414) .

  6. Data Assimilation Results from PLASMON

    NASA Astrophysics Data System (ADS)

    Jorgensen, A. M.; Lichtenberger, J.; Duffy, J.; Friedel, R. H.; Clilverd, M.; Heilig, B.; Vellante, M.; Manninen, J. K.; Raita, T.; Rodger, C. J.; Collier, A.; Reda, J.; Holzworth, R. H.; Ober, D. M.; Boudouridis, A.; Zesta, E.; Chi, P. J.

    2013-12-01

    VLF and magnetometer observations can be used to remotely sense the plasmasphere. VLF whistler waves can be used to measure the electron density and magnetic Field Line Resonance (FLR) measurements can be used to measure the mass density. In principle it is then possible to remotely map the plasmasphere with a network of ground-based stations which are also less expensive and more permanent than satellites. The PLASMON project, funded by the EU FP-7 program, is in the process of doing just this. A large number of ground-based observations will be input into a data assimilative framework which models the plasmasphere structure and dynamics. The data assimilation framework combines the Ensemble Kalman Filter with the Dynamic Global Core Plasma Model. In this presentation we will describe the plasmasphere model, the data assimilation approach that we have taken, PLASMON data and data assimilation results for specific events.

  7. GRAVITY acquisition camera: characterization results

    NASA Astrophysics Data System (ADS)

    Anugu, Narsireddy; Garcia, Paulo; Amorim, Antonio; Wiezorrek, Erich; Wieprecht, Ekkehard; Eisenhauer, Frank; Ott, Thomas; Pfuhl, Oliver; Gordo, Paulo; Perrin, Guy; Brandner, Wolfgang; Straubmeier, Christian; Perraut, Karine

    2016-08-01

    GRAVITY acquisition camera implements four optical functions to track multiple beams of Very Large Telescope Interferometer (VLTI): a) pupil tracker: a 2×2 lenslet images four pupil reference lasers mounted on the spiders of telescope secondary mirror; b) field tracker: images science object; c) pupil imager: reimages telescope pupil; d) aberration tracker: images a Shack-Hartmann. The estimation of beam stabilization parameters from the acquisition camera detector image is carried out, for every 0.7 s, with a dedicated data reduction software. The measured parameters are used in: a) alignment of GRAVITY with the VLTI; b) active pupil and field stabilization; c) defocus correction and engineering purposes. The instrument is now successfully operational on-sky in closed loop. The relevant data reduction and on-sky characterization results are reported.

  8. Preliminary results of UCN τ

    NASA Astrophysics Data System (ADS)

    Pattie, Robert; UCNtau Collaboration

    2017-01-01

    There is currently a 4 σ discrepancy between measurements of the neutron lifetime performed using cold neutron beams and those performed with ultracold neutron (UCN) storage vessels. The UCN τ experiment uses an asymmetric magneto-gravitational UCN trap with in situ counting of surviving neutrons to measure the neutron lifetime. This design eliminates a major systematic of previous bottle experiments related to the loss of UCN on material trap walls and with unloading neutrons from the storage vessel. A new in situ detection system was used in the 2015-2016 run that was able to measure the population of surviving UCN at different heights in the trap, providing important information on spectral evolution. Understanding the behavior of quasi-bound UCN in a bottle experiment is essential to achieving a subsecond precision measurement of τn. We will present the preliminary results from the 2015-2016 data set and an update on the UCN τ experiment.

  9. Results from the Magsat mission

    NASA Technical Reports Server (NTRS)

    Langel, R. A.

    1982-01-01

    The results of analyses of the data gathered by Magsat on the geomagnetic field, crustal magnetic anomalies, fields arising from external current systems, and in investigations of the earth's core, mantle, and core-mantle boundary are presented. A least squares potential function showed that the geomagnetic field was 30,000-50,000 nanoteslas at the Magsat altitude, while fields from external sources were 0-1000 nanoteslas and those from crustal sources 0-50 nanoteslas. Long-wavelength magnetic anomalies were correlated with tectonic features, sometimes reflecting undulations in the Curie isotherm at other times changes in the structure of the lower crust. Detailed anomaly maps from regional data analyses are provided, and possible future spacecraft missions for improving the resolution of contours and strengths of the anomalies are described.

  10. Wake Vortex Algorithm Scoring Results

    NASA Technical Reports Server (NTRS)

    Robins, R. E.; Delisi, D. P.; Hinton, David (Technical Monitor)

    2002-01-01

    This report compares the performance of two models of trailing vortex evolution for which interaction with the ground is not a significant factor. One model uses eddy dissipation rate (EDR) and the other uses the kinetic energy of turbulence fluctuations (TKE) to represent the effect of turbulence. In other respects, the models are nearly identical. The models are evaluated by comparing their predictions of circulation decay, vertical descent, and lateral transport to observations for over four hundred cases from Memphis and Dallas/Fort Worth International Airports. These observations were obtained during deployments in support of NASA's Aircraft Vortex Spacing System (AVOSS). The results of the comparisons show that the EDR model usually performs slightly better than the TKE model.

  11. The Recent Results from CMS

    NASA Astrophysics Data System (ADS)

    Kim, Tae Jeong

    The Large Hadron Collider (LHC) at CERN sitting astride the Franco-Swiss border near Geneva has accumulated the proton and proton collision data corresponding to an integrated luminosity of around 5 fb-1 at the center of mass energy 7 TeV in 2011 and around 20 fb-1 at 8 TeV in 2012 with the Compact Muon Solenoid (CMS) detector. The CMS detector is designed to investigate the wide range of particle physics including testing perturbative QCD and searching for Brout-Englert-Higgs (BEH) boson as well as new physics phenomena beyond the Standard Model. Observation of a new boson has moved the phase from hunting for the SM BEH boson to evaluating the consistency of this new particle with the SM expectation. The latest results from the CMS collaboration will be presented.

  12. [The Subretinal Implant - Clinical Results].

    PubMed

    Sachs, H G

    2016-11-01

    Since the end of the last century, subretinal electronic chips have been used to restore vision in patients blinded by degenerative retinal diseases such as retinitis pigmentosa. Various procedures have been suggested by different international scientific groups. The promising were the retinal-based concepts, for which there are now human data. The two distinct retina-based concepts not only differ in the site of stimulation (epi- or subretinal), but in their physiological concept. Whereas in camera-based systems (epiretinal, transchoroidal), eye movements cannot be used to detect objects, this is possible with subretinal access. It is as yet unclear as to whether this is relevant to restoring some kind of useful visual perception. This and other questions can only be answered by carefully designed human studies with sufficient patient numbers. Comparison of the visual results of the different groups is neither simple nor trivial. The implantations in each project need well trained and skilled retinal surgeons.

  13. Cryogenic Brush Seal Test Results

    NASA Technical Reports Server (NTRS)

    Proctor, Margaret P.; Walker, James F.

    1996-01-01

    Brush seals are compliant, contact seals that have long-life, low-leakage characteristics desirable for use in rocket engine turbopumps. 50.8-mm (2.0 inch) diameter brush seals with a nominal initial radial interference of 0.127-mm (0.005 inch) were tested in liquid nitrogen at shaft speeds up to 35,000 rpm and differential pressure loads up to 1.21 MPa (175 psi) per brush. The measured leakage rate of a single brush was 2-3 times less than that measured for a 12-tooth, 0.127-mm (0.005 inch) radial clearance labyrinth seal used as a baseline. Stage effects were studied and it was found that two brush seals with a large separation distance leaked less than two brushes tightly packed together. The maximum measured groove depth on the Inconel 718 rotor was 25.4 (mu)m (0.001 inch) after 4.31 hours of shaft rotation. The Haynes-25 bristles wore approximately 25.4-76.2 (mu)m (0.001-0.003 inch) under the same conditions. Three seal runner coatings, chromium carbide, Teflon impregnated chromium, and zirconium oxide, were tested in liquid hydrogen at 35,000 and 65,000 rpm with separate 50.8 mm diameter brush seals made of Haynes-25 bristles and having a nominal initial radial interference of 129 rpm. Two bare Inconel-718 rotors were also tested as a baseline. The test results revealed significant differences between the wear characteristics of the uncoated and coated seal runners. At both speeds the brush seal with the bare Inconel-718 seal runner exhibited significant bristle wear with excessive material transferring to the runner surface. In contrast, the coated seal runners inhibited the transfer and deposit of bristle material. The chromium carbide coating showed only small quantities of bristle material transferring to its surface. The Teflon impregnated chromium coating also inhibited material transfer and provided some lubrication. This coating, however, is self-sacrificing. The Teflon remained present on the low speed runner, but it was completely removed from the

  14. Monsoon '90 - Preliminary SAR results

    NASA Technical Reports Server (NTRS)

    Dubois, Pascale C.; Van Zyl, Jakob J.; Guerra, Abel G.

    1992-01-01

    Multifrequency polarimetric synthetic aperture radar (SAR) images of the Walnut Gulch watershed near Tombstone, Arizona were acquired on 28 Mar. 1990 and on 1 Aug. 1990. Trihedral corner reflectors were deployed prior to both overflights to allow calibration of the two SAR data sets. During both overflights, gravimetric soil moisture and dielectric constant measurements were made. Detailed vegetation height, density, and water content measurements were made as part of the Monsoon 1990 Experiment. Preliminary results based on analysis of the multitemporal polarimetric SAR data are presented. Only the C-band data (5.7-cm wavelength) radar images show significant difference between Mar. and Aug., with the strongest difference observed in the HV images. Based on the radar data analysis and the in situ measurements, we conclude that these differences are mainly due to changes in the vegetation and not due to the soil moisture changes.

  15. Monsoon 1990: Preliminary SAR results

    NASA Technical Reports Server (NTRS)

    Vanzyl, Jakob J.; Dubois, Pascale; Guerra, Abel

    1991-01-01

    Multifrequency polarimetric synthetic aperture radar (SAR) images of the Walnut Gulch watershed near Tombstone, Arizona were acquired on 28 Mar. 1990 and on 1 Aug. 1990. Trihedral corner reflectors were deployed prior to both overflights to allow calibration of the two SAR data sets. During both overflights, gravimetric soil moisture and dielectric constant measurements were made. Detailed vegetation height, density, and water content measurements were made as part of the Monsoon 1990 Experiment. Preliminary results based on analysis of the multitemporal polarimetric SAR data are presented. Only the C-band data (5.7-cm wavelength) radar images show significant difference between Mar. and Aug., with the strongest difference observed in the HV images. Based on the radar data analysis and the in situ measurements, we conclude that these differences are mainly due to changes in the vegetation and not due to the soil moisture changes.

  16. PLACES Aircraft Experiment Test Results

    DTIC Science & Technology

    1982-05-01

    7 7 -7 II’ DNA-TR-81-223 ~ PLACES AIRCRAFT EXPERIMENT TEST RESULTS ESL, Incorporated 495 Java Drive...Incorporated AREA , WORK UNIT NUMBERS 495 Java Drive Task S99QAXHB-00007 Sunnyvale, California 94086 II. CONTROLLING OFFICE NAME AND ADDRESS 12...a, . C . . . ’. . ’’ " ’ ’ " ’ " ." "" " " "S """" " ", " " "" :""’" " ’ ,.U I p.00 I’. (v cu C. 2Sso7 012 22S 7571 linq ~ STR IE 0i aA 0 Fiue1-16 A

  17. Gravitational microlensing searches and results

    SciTech Connect

    Alcock, C.

    1997-05-08

    Baryonic matter, in the form of Machos (MAssive Compact Halo Objects), might be a significant constituent of the dark matter that dominates the Milky Way. This article describes how surveys for Machos exploit the gravitational microlens magnification of extragalactic stars. The experimental searches for this effect monitor millions of stars, in some cases every night, looking for magnification events. The early results of these surveys indicate that Machos make up a significant fraction of the dark matter in the Milky Way, and that these objects have stellar masses. Truly substellar objects do not contribute much to the total. Additionally, the relatively high event rate towards the Galactic bulge seems to require that the bulge be elongated, and massive.

  18. Initial Blackbeard power survey results

    SciTech Connect

    Murphy, T.; Devenport, J.; Holden, D.

    1996-06-01

    The Blackbeard broadband VHF radio receiver is in low-earth orbit aboard the ALEXIS satellite. The receiver has been used to measure the transmitted power in four VHF bands (55.2-75.8, 28.0-94.8, 132.3-152.2, and 107.7-166.0 MHz) over quiet and noisy parts of the earth. The authors present the results of the survey and discuss their implications. They find that there are remote ocean areas over which the observed spectrum is largely free of man-made interference, but that the spectrum over most of the earth is dominated by broadcast VHF signals. The signal characteristics observed over a given area are quite constant when observed at different times of day and at intervals of several weeks to months. It appears that in many cases the bulk of the signal power is coming from a small number of sources.

  19. Research Results and Information Update

    NASA Astrophysics Data System (ADS)

    2011-01-01

    Research Results Monsoon behavior balanced by glaciers Research Discovers Frequent Mutations of Chromatin Significant Progress in Water Photochemistry Research Structural signature in amorphous alloy formation and plastic deformation The neural basis of Drosophila larval light/darkness preference Important roles of brain-specific carnitine palmitoyltransferase and ceramide metabolism in leptin hypothalamic control of feeding Integrin activation and internalization on soft ECM as a mechanism of induction of stem cell differentiation by ECM elasticity Determination of electron pairing symmetry of iron-based superconductor FeSe Long-Range Topological Order in Metallic Glass Information Update List of Projects Jointly Funded by NSFC and CNRS in 2011 List of Projects Jointly Funded by NSFC and ESRC in 2011 List of Projects Jointly Funded by NSFC and RS in 2011 List of Projects Jointly Funded by NSFC and RSE in 2011 Funding of Major Program Projects in 2010 Funding of Key Program Projects in 2010

  20. SOFIS FTS EM test results

    NASA Astrophysics Data System (ADS)

    Soucy, Marc-Andre A.; Levesque, Luc E.; Tanii, Jun; Kawashima, Takahiro; Nakajima, Hideaki

    2003-04-01

    The Solar Occultation FTS for Inclined-orbit Satellite (SOFIS) is a solar occultation Fourier transform spectrometer developed by the Ministry of the Environment (MOE) in Japan for the Global Change Observation Mission-A1 (GCOM-A1) satellite. GCOM-A1 will be placed in a 650 km non-sun-synchronous orbit, with an inclination angle of 69 degrees. ABB-Bomem is a sub-contractor of NTSpace (NEC-Toshiba Space) for the design and manufacturing of the FTS Engineering Model of SOFIS. SOFIS measures the vertical profile of the atmospheric constituents with 0.2 cm-1 spectral resolution for the spectral range covering 3-13 μm. The atmospheric vertical resolution of SOFIS is 1 km. The target of SOFIS measurements is a global distribution of O3, HNO3, NO2, N2O, CH4, H2O, CO2, CFC-11, CFC-12, ClONO2, aerosol extinction, atmospheric pressure and temperature. NTSpace in Japan is the prime contractor of SOFIS. The spectrometer is an adapted version of the classical Michelson interferometer using an optimized optical layout and moving retro-reflectors. A solid-state laser diode operating at 1550 nm is used as metrology source of the interferometer. Its highly folded optical design results in a high performance instrument with a compact size. SOFIS FTS implements high performance control techniques to achieve outstanding speed stability of the moving mechanism. This paper describes the test activities of the SOFIS-FTS Engineering Model (EM) and preliminary results. The performances of the FTS are presented in terms of key parameters like signal-to-noise ratio, modulation efficiency and stability. Spectra acquired are shown and test methodology and analyses are presented. Lessons learned during assembly, integration and testing are described as well as improvements planned to be implemented in the Flight Model.

  1. Huygens GCMS Results from Titan

    NASA Technical Reports Server (NTRS)

    Niemann, Hasso B.; Demick, Jaime; Kasprzak, Wayne; Atreya, Sushil; Owen, Tobias

    2007-01-01

    The Huygens Probe executed a successful entry, descent and impact on the Saturnian moon of Titan on January 14, 2005. The Gas Chromatograph Mass Spectrometer (GCMS) instrument conducted isotopic and compositional measurements throughout the two and one half hour descent from 146 km altitude, and on the surface for 69 minutes until loss of signal from the orbiting Cassini spacecraft. The GCMS incorporated a quadrupole mass filter with a secondary electron multiplier detection system. The gas sampling system provided continuous direct atmospheric composition measurements and batch sampling through three gas chromatographic (GC) columns, a chemical scrubber and a hydrocarbon enrichment cell. The GCMS gas inlet was heated to prevent condensation, and to evaporate volatiles from the surface after impact. Data products from the GCMS included altitude profiles of the major atmospheric constituents dinitrogen (N2) and methane (CH4), isotope ratios of 14N/15N, 12C/13C, and D/H, mole fractions of radiogenic argon (40Ar) and primordial argon (36Ar), and upper limits on the mole fractions of neon, krypton and xenon, which were found to be absent. Surface measurements confirmed the presence of ethane (C2H6) and cyanogen (C2N2). Later data products expanded atmospheric profiles to include the surface response of C2N2. C2H6, acetylene (C2H2), and carbon dioxide (CO2). More recent results include the profiles of benzene (C6H6) and molecular hydrogen (H2). The GCMS data are being further analyzed to obtain higher precision results and to identify other trace species ion the atmosphere and evaporating from the surface.

  2. SMART-1 Payload First Results

    NASA Astrophysics Data System (ADS)

    Foing, B. H.; SMART-1 Science Technology Working Team

    We present first results from SMART-1's science and technology payload, with a total mass of some 19 kg, featuring many innovative instruments and advanced technologies. A miniaturised high-resolution camera (AMIE) for lunar surface imaging, a near-infrared point-spectrometer (SIR) for lunar mineralogy investigation, and a very compact X-ray spectrometer (D-CIXS) with a new type of detector and micro-collimator which will provide fluorescence spectroscopy and imagery of the Moon's surface elemental composition. The payload also includes an experiment (KaTE) aimed at demonstrating deep-space telemetry and telecommand communications in the X and Ka-bands, a radio-science experiment (RSIS), a deep space optical link (Laser-Link Experiment), using the ESA Optical Ground station in Tenerife, and the validation of a system of autonomous navigation (OBAN) based on image processing. SMART-1 lunar science investigations include studies of the chemical composition of the Moon, of geophysical processes (volcanism, tectonics, cratering, erosion, deposition of ices and volatiles) for comparative planetology, and high resolution studies in preparation for future steps of lunar exploration. The mission could address several topics such as the accretional processes that led to the formation of rocky planets, and the origin and evolution of the Earth-Moon system. The SMART-1 observations will be coordinated with Japanese missions Lunar-A and SELENE, to answer open questions about comparative planetology, the origin of the Earth --Moon system, the early evolution of life, the planetary environment and the existence of in-situ resources necessary to support human presence (e.g. water, oxygen). With their science and technology results, these missions can be considered as preparatory missions for future robotic and human exploration of the solar system.

  3. Results of arthroscopic meniscal repair

    PubMed Central

    Orlowski, María Belén; Arroquy, Damián; Chahla, Jorge; Guiñazú, Jorge; Bisso, Martín Carboni; Vilaseca, Tomás

    2017-01-01

    Objectives: Currently the arthroscopic treatment of meniscal pathology has become one of the most common procedures in orthopedic practice and although in most cases meniscectomy is done, meniscal sutures are the treatment of choice when a reparable lesion is diagnosed, especially in young patients. It has been reported that the meniscal repair leads to a lower incidence of developing degenerative changes in the long-term when compared with meniscectomy and nonsurgical treatment of meniscal injuries. The aim of this study was to determine the success rate of meniscal repair achieved in our sports medicine practice. Methods: Between 2006 and 2015, 62 meniscal tears in 58 patients with a mean age of 31 years (range 15-58) were repaired. Mean follow-up was 52 months (range 6-120 months). In 16 patients (28%) was associated with arthroscopic ACL reconstruction. The repair techniques used included outside-in sutures, inside-out sutures, all-inside sutures and a combination of techniques. Failure of the repair was defined by the requirement for repeat knee arthroscopy and partial or subtotal meniscectomy. The indication of arthroscopic revision was based on the presence of mechanical symptoms, after the suture. Results: Failure of meniscus repair occurred in four patients (failure rate: 6.45%), one case was associated with ACL reconstruction (failure rate: 6.25%) and 3 had undergone isolated meniscal suture (failure rate: 8%). The average time for the reoperation was 15 months (4-24). We had no intraoperative complications. Conclusion: The reported failure rate of meniscal repair in stable knees varies between 12% and 43%, with reports that demonstrate a clinical success rate of 100%. In this study, we obtained a success rate of 93.5%. These results are slightly higher than those in the literature, which can be attributed to careful selection of patients and the fact that clinical success tends to be better than the assessed arthroscopically. In summary, we consider the

  4. Geophysical Model Research and Results

    SciTech Connect

    Pasyanos, M; Walter, W; Tkalcic, H; Franz, G; Flanagan, M

    2004-07-07

    Geophysical models constitute an important component of calibration for nuclear explosion monitoring. We will focus on four major topics: (1) a priori geophysical models, (2) surface wave models, (3) receiver function derived profiles, and (4) stochastic geophysical models. The first, a priori models, can be used to predict a host of geophysical measurements, such as body wave travel times, and can be derived from direct regional studies or even by geophysical analogy. Use of these models is particularly important in aseismic regions or regions without seismic stations, where data of direct measurements might not exist. Lawrence Livermore National Laboratory (LLNL) has developed the Western Eurasia and North Africa (WENA) model which has been evaluated using a number of data sets, including travel times, surface waves, receiver functions, and waveform analysis (Pasyanos et al., 2004). We have joined this model with our Yellow Sea - Korean Peninsula (YSKP) model and the Los Alamos National Laboratory (LANL) East Asia model to construct a model for all of Eurasia and North Africa. Secondly, we continue to improve upon our surface wave model by adding more paths. This has allowed us to expand the region to all of Eurasia and into Africa, increase the resolution of our model, and extend results to even shorter periods (7 sec). High-resolution models exist for the Middle East and the YSKP region. The surface wave results can be inverted either alone, or in conjunction with other data, to derive models of the crust and upper mantle structure. We are also using receiver functions, in joint inversions with the surface waves, to produce profiles directly under seismic stations throughout the region. In a collaborative project with Ammon, et al., they have been focusing on stations throughout western Eurasia and North Africa, while we have been focusing on LLNL deployments in the Middle East, including Kuwait, Jordan, and the United Arab Emirates. Finally, we have been

  5. Cassini ISS Satellite Orbit Results

    NASA Astrophysics Data System (ADS)

    Spitale, J. N.; Jacobson, R. A.; Porco, C. C.; Owen, W. M.; Charnoz, S.; Murray, C. D.; Brahic, A.; Evans, M. W.; Beurle, K.; Cooper, N.; Cassini Imaging

    2004-11-01

    We report on the orbits of several small Saturnian satellites, either recovered or newly-discovered in recent Cassini imaging observations. The mean motions of Pan and Atlas have been corrected based on recent Cassini imaging combined with Voyager observations. Two small satellites, S/2004 S 1 and S/2004 S 2, have been discovered between the orbits of Mimas and Enceladus on orbits that are nearly circular and uninclined. Both bodies were observed for a fraction of one orbit on June 1, 2004 and S/2004 S 1 was subsequently detected in images shuttered three weeks earlier. Those bodies may be recovered in late October in imaging sequences designed for that purpose. A third new object was detected in images from June 21, 2004, orbiting just outside the F ring. However, a search for additional detections revealed something orbiting interior to the F ring near the longitude at which the new object would be expected 5 hours later. A low-residual orbit that crosses the F ring has been found to explain all of the observations, but it is not yet clear whether the two sequences imaged the same object or two different objects that coincidentally were found orbiting at the same longitude but at different orbital semimajor axes. These issues make its nature -- solid satellite or F ring clump -- unclear. The data, fitting procedures, and results will be discussed.

  6. Results from the NEXT Protogypes

    SciTech Connect

    Oliveira, C A.B.

    2013-10-04

    NEXT-100 is an electroluminescent high pressure Time Projection Chamber currently under construction. It will search for the neutrino-less double beta decay in 136Xe at the Canfranc Underground Laboratory. NEXT-100 aims to achieve nearly intrinsic energy resolution and to highly suppress background events by taking advantage of the unique properties of xenon in the gaseous phase as the detection medium. In order to prove the principle of operation and to study which are the best operational conditions, two prototypes were constructed: NEXT-DEMO and NEXT-DBDM. In this study we present the latest results from both prototypes. We report the improvement in terms of light collection (~ 3x) achieved by coating the walls of NEXT-DEMO with tetraphenyl butadiene (TPB), the outstanding energy resolution of 1% (Full Width Half Maximum) from NEXT-DBDM as well as the tracking capabilities of this prototype (2.1 mm RMS error for point-like depositions) achieved by using a square array of 8 x 8 SiPMs.

  7. Cosmic radioactivity and INTEGRAL results

    SciTech Connect

    Diehl, Roland

    2014-05-02

    Gamma-ray lines from radioactive decay of unstable isotopes co-produced by nucleosynthesis in massive stars and supernova have been measured since more than thirty years. Over the past ten years, INTEGRAL complemented the first sky survey made by COMPTEL. The {sup 26}A1 isotope with 1 My decay time had been first direct proof of currently-ongoing nucleosynthesis in our Galaxy. This has now become a tool to study the ∼My history of specific source regions, such as massive-star groups and associations in nearby regions which can be discriminated from the galactic-plane background, and the inner Galaxy, where Doppler shifted lines add to the astronomical information about bar and spiral structure. Recent findings suggest that superbubbles show a remarkable asymmetry, on average, in the spiral arms of our galaxy. {sup 60}Fe is co-produced by the sources of {sup 26}A1, and the isotopic ratio from their nucleosynthesis encodes stellar-structure information. Annihilation gamma-rays from positrons in interstellar space show a puzzling bright and extended source region central to our Galaxy, but also may be partly related to nucleosynthesis. {sup 56}Ni and {sup 44}Ti isotope gamma-rays have been used to constrain supernova explosion mechanisms. Here we report latest results using the accumulated multi-year database of INTEGRAL observations, and discuss their astrophysical interpretations, connecting to other traces of cosmic radioactivity and to other cosmic messengers.

  8. Experimental results on evaporation waves

    NASA Astrophysics Data System (ADS)

    Grana Otero, Jose; Parra Fabian, Ignacio

    2010-11-01

    A liquid contained in a vertical glass tube is suddenly depressurized from a high initial pressure down to one for which the stable state is vapour, so vaporization sets off at the free surface. For large enough evaporation rates, the planar vapour-liquid interface is Darrieus-Landau unstable [1], leading to the interface surface rippling close to the instability threshold. Further increasing the initial to final pressure ratio brings about evaporation waves [2,3], in which a highly corrugated front propagates downwards into the liquid. A new experimental method is presented as well as some experimental results obtained by tracking the evolution of the front with a high speed camera. In addition, a number of new phenomena related to the dynamics of bubbles growth at the walls has been uncovered. In particular, a new mode of propagation of the evaporation front is found. In this mode the front originates from below the interface, so the propagation is upwards against gravity with a curved but smooth front.[4pt] [1] F. J. Higuera, Phys. Fluids, V. 30, 679 (1987).[0pt] [2] J.E.Shepherd and B.Sturtevant, J.Fluid Mech., V.121,379 (1982).[0pt] [3] P.Reinke and G.Yadigaroglu, Int.J.Multiph. Flow, V.27,1487 (2001).

  9. Results of the PALADIN experiment

    NASA Astrophysics Data System (ADS)

    Weir, J. T.; Orzechowski, T. J.; Miller, J. L.; Chong, Y. P.; Chambers, F.; Deis, G. A.; Paul, C.; Prosnitz, D.; Scharlemann, E. T.; Halbach, K.

    1989-03-01

    PALADIN is a single pass, free laser amplifier located at the Lawrence Livermore National Laboratory. This free electron laser (FEL) is designed to run at 10.6 micrometers. The 1-kA, 45-MeV electron beam is provided by the Advanced Test Accelerator. The wiggler is 25 m long with an 8 cm period. The input optical signal to the amplifier is provided by a conventional CO2 laser, which can produce a peak input power of either 18 kW or 3.6 MW. We have demonstrated 31 dB of gain with the 18-kW input and 12.9 dB of gain for the 3.6-MW input, producing over 70 MW of optical power. Using the 18-kW input, the gain saturated at about 12 m into the wiggler; with the 3.6-MW input, the gain saturated at about 8 m. Modeling results are shown.

  10. Latest results from jet measurements

    NASA Astrophysics Data System (ADS)

    Bruna, Elena

    2009-10-01

    A first stage in understanding the phenomenon of jet quenching in the hot and dense nuclear matter has been successfully reached at RHIC through measurements of inclusive hadron suppression and di-hadron azimuthal correlations. A significant step forward in this field is being obtained by full jet reconstruction in heavy-ion collisions, that in principle should give access to the energy of the hard scattering independent of the presence of the medium and should enable the study of jet quenching at the partonic level. Due to the intrinsic difficulties of such a measurement in the high multiplicity environment, this is an innovative analysis and the first results of full jet reconstruction were obtained only over the last year thanks to the recently developed jet-finding techniques. We discuss the current methods to treat the large background, which is the main critical aspect that makes full jet reconstruction a challenge at RHIC. New measurements directed to address the mechanisms of partonic energy loss in hot QCD matter are presented. These measurements include the ratio of inclusive jet cross sections in Au+Au and p+p and the comparison of jet fragmentation functions in Au+Au and p+p.

  11. Visible Nulling Coronagraph Testbed Results

    NASA Technical Reports Server (NTRS)

    Lyon, Richard G.; Clampin, Mark; Melnick, Gary; Tolls, Volker; Woodruff, Robert; Vasudevan, Gopal; Rizzo, Maxime; Thompson, Patrick

    2009-01-01

    The Extrasolar Planetary Imaging Coronagraph (EPIC) is a NASA Astrophysics Strategic Mission Concept study and a proposed NASA Discovery mission to image and characterize extrasolar giant planets in orbits with semi-major axes between 2 and 10 AU. EPIC would provide insights into the physical nature of a variety of planets in other solar systems complimenting radial velocity (RV) and astrometric planet searches. It will detect and characterize the atmospheres of planets identified by radial velocity surveys, determine orbital inclinations and masses, characterize the atmospheres around A and F stars, observed the inner spatial structure and colors of inner Spitzer selected debris disks. EPIC would be launched to heliocentric Earth trailing drift-away orbit, with a 5-year mission lifetime. The starlight suppression approach consists of a visible nulling coronagraph (VNC) that enables starlight suppression in broadband light from 480-960 nm. To demonstrate the VNC approach and advance it's technology readiness we have developed a laboratory VNC and have demonstrated white light nulling. We will discuss our ongoing VNC work and show the latest results from the VNC testbed.

  12. Solar neutrinos: Interpretation of results

    NASA Astrophysics Data System (ADS)

    Smirnov, A. Yu.

    2003-04-01

    Recent SNO results give strong evidence that the solar neutrinos undergo flavor conversion. The main issue now is the identification of the mechanism of conversion. The LMA MSW solution with Δm2 = (5-7)·10 -5 eV 2, tan 2≡ = 0.35-0.45 looks rather plausible: it fits well the experimental data and our new theoretical prejudices. In the LMA case, KamLAND should see (0.5 - 0.7) reduced signal. VAC-QVO and LOW are accepted at about 3δ-level. The SMA solution is practically excluded. No sub-leading effects produced by Ue3 and admixture of sterile neutrino have been found. The fit becomes worse with an increase of Ue3 (for LMA) and a νs admixture. Still a (30 - 50)% presence of the sterile neutrino is allowed. Solutions based on the neutrino spin-flip in the magnetic fields of the Sun as well as on non-standard neutrino interactions give a good fit of the data. If KamLAND confirms LMA MSW, the spin-flip and non-standard interactions can be considered (and will be searched for) as sub-leading effects.

  13. Results from the PAMELA experiment.

    NASA Astrophysics Data System (ADS)

    Mori, Nicola

    2014-08-01

    PAMELA is a satellite-borne experiment, aimed at precision measurements of the charged, light component of the cosmic-ray spectrum. It consists of a magnetic spectrometer, a time-of-flight system, an electromagnetic calorimeter, an anticoincidence system and a neutron detector. The main focus of the experiment is on antimatter; other components of the spectrum that can be investigated include electrons and light nuclei up to oxygen. Thanks to its placement out of the terrestrial atmosphere and the long exposure time, PAMELA is able to provide data with low systematic effects and high statistical significance. Its semi-polar orbit allows to detect particles of solar origin and to investigate the effects of the solar activity on the low-energy part of the galactic component of the spectrum (solar modulation). The redundancy of its detectors allows to monitor the detector performance and to measure the data selection efficiency directly from flight data. The instrument has been launched in 2006 and it is continuously taking data since then. The most important and recent results from the experiment will be presented.

  14. Mark III results from SPEAR

    SciTech Connect

    Toki, W.

    1983-11-01

    First results from the MARK III detector at SPEAR are presented based on 2.7 million J/psi decays. The eta/sub c/ is observed in three modes, J/psi ..-->.. ..gamma..eta/sub c/, (eta/sub c/ ..-->.. rho anti rho, eta..pi../sup +/..pi../sup -/, and phi phi). Using the phi phi mode, the eta/sub c/ spin-parity is determined to be 0/sup -/. The known radiative J/psi decays J/psi ..-->.. ..gamma..f(f ..-->.. ..pi../sup +/..pi../sup -/), ..gamma..eta'(eta' ..-->.. ..gamma..rho/sup 0/, eta..pi../sup +/..pi../sup -/), ..gamma..f'(f' ..-->.. kappa/sup +/kappa/sup -/), ..gamma..theta(theta ..-->.. kappa anti kappa), and ..gamma..iota(iota ..-->.. ..pi..kappa anti kappa) are observed and their branching ratios found to be in agreement with previous measurements. In the J/psi ..-->.. ..gamma..kappa/sup +/kappa/sup -/ mode a new state is observed at 2.22 GeV and in the J/psi ..-->.. ..gamma gamma..rho/sup 0/ and ..gamma..eta..pi../sup +/..pi../sup -/ modes evidence for new structures near 1.4 GeV is presented. 29 references.

  15. EUPORIAS: plans and preliminary results

    NASA Astrophysics Data System (ADS)

    Buontempo, C.

    2013-12-01

    Recent advances in our understanding and ability to forecast climate variability have meant that skilful predictions are beginning to be routinely made on seasonal to decadal (s2d) timescales. Such forecasts have the potential to be of great value to a wide range of decision-making, where outcomes are strongly influenced by variations in the climate. In 2012 the European Commission funded EUPORIAS, a four year long project to develop prototype end-to-end climate impact prediction services operating on a seasonal to decadal timescale, and assess their value in informing decision-making. EUPORIAS commenced on 1 November 2012, coordinated by the UK Met Office leading a consortium of 24 organisations representing world-class European climate research and climate service centres, expertise in impacts assessments and seasonal predictions, two United Nations agencies, specialists in new media, and commercial companies in climate-vulnerable sectors such as energy, water and tourism. The poster describes the setup of the project, its main outcome and some of the very preliminary results.

  16. First photometry results from Gaia

    NASA Astrophysics Data System (ADS)

    Brown, Anthony

    2015-08-01

    An overview of the Gaia Photometric Processing is presented. The Gaia photometry consists of the white light (330-1050 nm) G-band, and low resolution spectrophotometry realized by two prisms dispersing all the light entering the field of view. One disperser - called BP for Blue Photometer- operates in the wavelength range 330-680 nm; the other - called RP for Red Photometer - covers the wavelength range 640-1050 nm. The light collected by BP and RP can also be integrated into two broad bands, G_BP and G_RP.This photometric data reduction is based on the overall principle of a self-calibrating system improved by iteration. The input data includes flux (G, G_BP, G_RP) and the low-resolution spectral data. The calibration models and algorithms used are described. Initial validation results are shown which indicate the photometric quality of the preliminary calibrated data. Expectations for the quality of the photometric data to be included in the first public data release (mid-2016) are discussed.

  17. Results from the NEXT Protogypes

    DOE PAGES

    Oliveira, C A.B.

    2013-10-04

    NEXT-100 is an electroluminescent high pressure Time Projection Chamber currently under construction. It will search for the neutrino-less double beta decay in 136Xe at the Canfranc Underground Laboratory. NEXT-100 aims to achieve nearly intrinsic energy resolution and to highly suppress background events by taking advantage of the unique properties of xenon in the gaseous phase as the detection medium. In order to prove the principle of operation and to study which are the best operational conditions, two prototypes were constructed: NEXT-DEMO and NEXT-DBDM. In this study we present the latest results from both prototypes. We report the improvement in termsmore » of light collection (~ 3x) achieved by coating the walls of NEXT-DEMO with tetraphenyl butadiene (TPB), the outstanding energy resolution of 1% (Full Width Half Maximum) from NEXT-DBDM as well as the tracking capabilities of this prototype (2.1 mm RMS error for point-like depositions) achieved by using a square array of 8 x 8 SiPMs.« less

  18. Results from p p colliders

    SciTech Connect

    Huth, J.

    1991-08-01

    Recent results {bar p}p colliders are presented. From elastic scattering experiments at the Tevatron, an average value of {sigma}{sub tot} = 72.1{plus minus}2 mb is reported, along with a new measurement of {rho} = 0.13 {plus minus} 0.7. New measurements of jet direct photon and high p{sub t} W and Z production are compared to more precise, higher order predictions from perturbative QCD. Recently available data on the W mass and width give combined values for M{sub W} = 80.14{plus minus}0.27 GeV/c{sup 2}, and {Gamma}(W) =2. 14 {plus minus} 0.08 GeV. From electroweak radiative corrections and M{sub W}, one finds M{sub top} = 130{plus minus}40 GeV/c{sup 2}, with a 95% C.L. upper limit at 210 GeV/c{sup 2}. Current limits on M{sub top} are presented, along with a review of the prospects for top discovery. From jet data there is no evidence of quark substructure down to the distance scale of 1.4 {times} 10{sup {minus}17} cm, nor is there evidence for supersymmetry or heavy gauge bosons at {bar p}p colliders, allowing lower limits on M{sub W}, > 520 GeV/c{sup 2} and M{sub Z} 412 GeV/c{sup 2}. 66 refs., 26 figs.

  19. SAA drift:experimental results

    NASA Astrophysics Data System (ADS)

    Grigoryan, O. R.; Kudela, K.; Romashova, V. V.; Drozdov, A. Yu.

    According to the paleomagnetic analysis there are variations of Earth's magnetic field connected with magnetic momentum changing. Besides these variations affects on the trapped belt South Atlantic Anomaly (SAA) location. Indeed different observations including Space Shuttle short-time flights approved the existence SAA westward drift with speed 0.1-1.0 (deg/year) and northward drift with speed approximately 0.1 (deg/year). In this work we present the analysis of experimental results obtained in SINP MSU in 1972-2003 from different satellites. There were analyzed the fluxes of protons with energy > 50 MeV, gamma quanta with energy > 500 keV and neutrons with energy 0.1-1.0 MeV in SAA area and their maxima location. The data about fluxes were obtained onboard the orbital stations ``Salut-6'' (1979), MIR (1991, 1998) and ISS (2003) by the identical experimental equipment. The comparison of the data obtained during these two decades of investigations confirms the fact of the SAA westward drift. Moreover the same analysis of maximum flux location of electrons with hundreds keV energy (satellites ``Kosmos-484'' (1972), ``Interkosmos-17'' (1977) and ``Activny'' (``Interkosmos-24'', 1991)) confirmed not only the SAA westward drift but northward drift also.

  20. Preliminary results of ANAIS-25

    NASA Astrophysics Data System (ADS)

    Amaré, J.; Cebrián, S.; Cuesta, C.; García, E.; Ginestra, C.; Martínez, M.; Oliván, M. A.; Ortigoza, Y.; Ortiz de Solórzano, A.; Pobes, C.; Puimedón, J.; Sarsa, M. L.; Villar, J. A.; Villar, P.

    2014-04-01

    The ANAIS (Annual Modulation with NaI(Tl) Scintillators) experiment aims at the confirmation of the DAMA/LIBRA signal using the same target and technique at the Canfranc Underground Laboratory. 250 kg of ultrapure NaI(Tl) crystals will be used as a target, divided into 20 modules, each coupled to two photomultipliers. Two NaI(Tl) crystals of 12.5 kg each, grown by Alpha Spectra from a powder having a potassium level under the limit of our analytical techniques, form the ANAIS-25 set-up. The background contributions are being carefully studied and preliminary results are presented: their natural potassium content in the bulk has been quantified, as well as the uranium and thorium radioactive chains presence in the bulk through the discrimination of the corresponding alpha events by PSA, and due to the fast commissioning, the contribution from cosmogenic activated isotopes is clearly identified and their decay observed along the first months of data taking. Following the procedures established with ANAIS-0 and previous prototypes, bulk NaI(Tl) scintillation events selection and light collection efficiency have been also studied in ANAIS-25.

  1. Mobile evaporator corrosion test results

    SciTech Connect

    Rozeveld, A.; Chamberlain, D.B.

    1997-05-01

    Laboratory corrosion tests were conducted on eight candidates to select a durable and cost-effective alloy for use in mobile evaporators to process radioactive waste solutions. Based on an extensive literature survey of corrosion data, three stainless steel alloys (304L, 316L, AL-6XN), four nickel-based alloys (825, 625, 690, G-30), and titanium were selected for testing. The corrosion tests included vapor phase, liquid junction (interface), liquid immersion, and crevice corrosion tests on plain and welded samples of candidate materials. Tests were conducted at 80{degrees}C for 45 days in two different test solutions: a nitric acid solution. to simulate evaporator conditions during the processing of the cesium ion-exchange eluant and a highly alkaline sodium hydroxide solution to simulate the composition of Tank 241-AW-101 during evaporation. All of the alloys exhibited excellent corrosion resistance in the alkaline test solution. Corrosion rates were very low and localized corrosion was not observed. Results from the nitric acid tests showed that only 316L stainless steel did not meet our performance criteria. The 316L welded interface and crevice specimens had rates of 22.2 mpy and 21.8 mpy, respectively, which exceeds the maximum corrosion rate of 20 mpy. The other welded samples had about the same corrosion resistance as the plain samples. None of the welded samples showed preferential weld or heat-affected zone (HAZ) attack. Vapor corrosion was negligible for all alloys. All of the alloys except 316L exhibited either {open_quotes}satisfactory{close_quotes} (2-20 mpy) or {open_quotes}excellent{close_quotes} (<2 mpy) corrosion resistance as defined by National Association of Corrosion Engineers. However, many of the alloys experienced intergranular corrosion in the nitric acid test solution, which could indicate a susceptibility to stress corrosion cracking (SCC) in this environment.

  2. Corral Monitoring System assessment results

    SciTech Connect

    Filby, E.E.; Haskel, K.J.

    1998-03-01

    This report describes the results of a functional and operational assessment of the Corral Monitoring Systems (CMS), which was designed to detect and document accountable items entering or leaving a monitored site. Its development was motivated by the possibility that multiple sites in the nuclear weapons states of the former Soviet Union might be opened to such monitoring under the provisions of the Strategic Arms Reduction Treaty. The assessment was performed at three levels. One level evaluated how well the planned approach addressed the target application, and which involved tracking sensitive items moving into and around a site being monitored as part of an international treaty or other agreement. The second level examined the overall design and development approach, while the third focused on individual subsystems within the total package. Unfortunately, the system was delivered as disassembled parts and pieces, with very poor documentation. Thus, the assessment was based on fragmentary operating data coupled with an analysis of what documents were provided with the system. The system design seemed to be a reasonable match to the requirements of the target application; however, important questions about site manning and top level administrative control were left unanswered. Four weaknesses in the overall design and development approach were detected: (1) poor configuration control and management, (2) inadequate adherence to a well defined architectural standard, (3) no apparent provision for improving top level error tolerance, and (4) weaknesses in the object oriented programming approach. The individual subsystems were found to offer few features or capabilities that were new or unique, even at the conceptual level. The CMS might possibly have offered a unique combination of features, but this level of integration was never realized, and it had no unique capabilities that could be readily extracted for use in another system.

  3. An overview of FTU results

    NASA Astrophysics Data System (ADS)

    Buratti, P.; Alessi, E.; Amicucci, L.; Angelini, B.; Apicella, M. L.; Apruzzese, G.; Artaserse, G.; Barbato, E.; Belli, F.; Bertocchi, A.; Bin, W.; Boncagni, L.; Botrugno, A.; Briguglio, S.; Bruschi, A.; Calabrò, G.; Cardinali, A.; Castaldo, C.; Ceccuzzi, S.; Centioli, C.; Cesario, R.; Cianfarani, C.; Cirant, S.; Crisanti, F.; D'Arcangelo, O.; De Angeli, M.; De Angelis, R.; Di Matteo, L.; Di Troia, C.; Esposito, B.; Farina, D.; Figini, L.; Fogaccia, G.; Frigione, D.; Fusco, V.; Gabellieri, L.; Galperti, C.; Garavaglia, S.; Giovannozzi, E.; Granucci, G.; Grossetti, G.; Grosso, G.; Guimarães-Filho, Z. O.; Iannone, F.; Krivska, A.; Kroegler, H.; Lazzaro, E.; Lontano, M.; Maddaluno, G.; Marchetto, C.; Marinucci, M.; Marocco, D.; Mazzitelli, G.; Mazzotta, C.; Milovanov, A.; Minelli, D.; Mirizzi, F. C.; Moro, G. A.; Napoli, F.; Nowak, S.; Orsitto, F. P.; Pacella, D.; Panaccione, L.; Panella, M.; Pericoli-Ridolfini, V.; Podda, S.; Pizzuto, A.; Pucella, G.; Ramogida, G.; Ravera, G.; Romano, A.; Sozzi, C.; Tuccillo, A. A.; Tudisco, O.; Viola, B.; Vitale, V.; Vlad, G.; Zanza, V.; Zerbini, M.; Zonca, F.; Aquilini, M.; Cefali, P.; Di Ferdinando, E.; Di Giovenale, S.; Giacomi, G.; Gravanti, F.; Grosso, A.; Mellera, V.; Mezzacappa, M.; Pensa, A.; Petrolini, P.; Piergotti, V.; Raspante, B.; Rocchi, G.; Sibio, A.; Tilia, B.; Torelli, C.; Tulli, R.; Vellucci, M.; Zannetti, D.

    2013-10-01

    Since the 2010 IAEA-FEC Conference, FTU has exploited improvements in cleaning procedures and in the density control system to complete a systematic exploration of access to high-density conditions in a wide range of plasma currents and magnetic fields. The line-averaged densities at the disruptive limit increased more than linearly with the toroidal field, while no dependence on plasma current was found; in fact, the maximum density of 4.3 × 1020 m-3 was reached at B = 8 T even at the minimum current of 0.5 MA, corresponding to twice the Greenwald limit. The lack of plasma current dependence was due to the increase in density peaking with the safety factor. Experiments with the 140 GHz electron cyclotron resonance heating (ECRH) system were focused on the sawtooth (ST) period control and on the commissioning of a new launcher with real-time steering capability that will act as the front-end actuator of a real-time system for ST period control and tearing mode stabilization. Various ECRH and electron cyclotron current-drive modulation schemes were used; with the fastest one, the ST period synchronized with an 8 ms modulation period. The observed period variations were simulated using the JETTO code with a critical shear model for the crash trigger. The new launcher was of the plug-in type, allowing quick insertion and connection to the transmission line. Both beam characteristics and steering speed were in line with design expectation. Experimental results on the connection between improved coupling of lower hybrid waves in high-density plasmas and reduced wave spectral broadening were interpreted by fully kinetic, non-linear model calculations. A dual-frequency, time-of-flight diagnostic for the measurement of density profiles was developed and successfully tested. Fishbone-like instabilities driven by energetic electrons were simulated by the hybrid MHD-gyrokinetic XHMGC code.

  4. Introduction and Summary of Results

    NASA Astrophysics Data System (ADS)

    Yaghjian, Arthur D.

    The primary purpose of this work is to determine an equation of motion for the classical Lorentz model of the electron that is consistent with causal solutions to the Maxwell-Lorentz equations, the relativistic generalization of Newton's second law of motion, and Einstein's mass-energy relation. (The latter two laws of physics were not discovered until after the original works of Lorentz, Abraham, and Poincaré. The hope of Lorentz and Abraham for deriving the equation of motion of an electron from the self force determined by the Maxwell-Lorentz equations alone was not fully realized.) The work begins by reviewing the contributions of Lorentz, Abraham, Poincaré, and Schott to this century-old problem of finding the equation of motion of an extended electron. Their original derivations, which were based on the Maxwell-Lorentz equations and assumed a zero bare mass, are modified and generalized to obtain a nonzero bare mass and consistent force and power equations of motion. By looking at the Lorentz model of the electron as a charged insulator, general expressions are derived for the binding forces that Poincaré postulated to hold the charge distribution together. A careful examination of the classic Lorentz-Abraham derivation reveals that the self electromagnetic force must be modified during a short time interval after the external force is first applied and after all other nonanalytic points in time of the external force. The resulting modification to the equation of motion, although slight, eliminates the noncausal pre-acceleration (and pre-deceleration) that has plagued the solution to the Lorentz-Abraham equation of motion. As part of the analysis, general momentum and energy relations are derived and interpreted physically for the solutions to the equation of motion, including “hyperbolic” and “runaway” solutions. Also, a stress-momentum-energy tensor that includes the binding, bare-mass, and electromagnetic momentum-energy densities is derived for

  5. Overview of ASDEX Upgrade results

    NASA Astrophysics Data System (ADS)

    Stroth, U.; Adamek, J.; Aho-Mantila, L.; Äkäslompolo, S.; Amdor, C.; Angioni, C.; Balden, M.; Bardin, S.; Barrera Orte, L.; Behler, K.; Belonohy, E.; Bergmann, A.; Bernert, M.; Bilato, R.; Birkenmeier, G.; Bobkov, V.; Boom, J.; Bottereau, C.; Bottino, A.; Braun, F.; Brezinsek, S.; Brochard, T.; Brüdgam, M.; Buhler, A.; Burckhart, A.; Casson, F. J.; Chankin, A.; Chapman, I.; Clairet, F.; Classen, I. G. J.; Coenen, J. W.; Conway, G. D.; Coster, D. P.; Curran, D.; da Silva, F.; de Marné, P.; D'Inca, R.; Douai, D.; Drube, R.; Dunne, M.; Dux, R.; Eich, T.; Eixenberger, H.; Endstrasser, N.; Engelhardt, K.; Esposito, B.; Fable, E.; Fischer, R.; Fünfgelder, H.; Fuchs, J. C.; Gál, K.; García Muñoz, M.; Geiger, B.; Giannone, L.; Görler, T.; da Graca, S.; Greuner, H.; Gruber, O.; Gude, A.; Guimarais, L.; Günter, S.; Haas, G.; Hakola, A. H.; Hangan, D.; Happel, T.; Härtl, T.; Hauff, T.; Heinemann, B.; Herrmann, A.; Hobirk, J.; Höhnle, H.; Hölzl, M.; Hopf, C.; Houben, A.; Igochine, V.; Ionita, C.; Janzer, A.; Jenko, F.; Kantor, M.; Käsemann, C.-P.; Kallenbach, A.; Kálvin, S.; Kantor, M.; Kappatou, A.; Kardaun, O.; Kasparek, W.; Kaufmann, M.; Kirk, A.; Klingshirn, H.-J.; Kocan, M.; Kocsis, G.; Konz, C.; Koslowski, R.; Krieger, K.; Kubic, M.; Kurki-Suonio, T.; Kurzan, B.; Lackner, K.; Lang, P. T.; Lauber, P.; Laux, M.; Lazaros, A.; Leipold, F.; Leuterer, F.; Lindig, S.; Lisgo, S.; Lohs, A.; Lunt, T.; Maier, H.; Makkonen, T.; Mank, K.; Manso, M.-E.; Maraschek, M.; Mayer, M.; McCarthy, P. J.; McDermott, R.; Mehlmann, F.; Meister, H.; Menchero, L.; Meo, F.; Merkel, P.; Merkel, R.; Mertens, V.; Merz, F.; Mlynek, A.; Monaco, F.; Müller, S.; Müller, H. W.; Münich, M.; Neu, G.; Neu, R.; Neuwirth, D.; Nocente, M.; Nold, B.; Noterdaeme, J.-M.; Pautasso, G.; Pereverzev, G.; Plöckl, B.; Podoba, Y.; Pompon, F.; Poli, E.; Polozhiy, K.; Potzel, S.; Püschel, M. J.; Pütterich, T.; Rathgeber, S. K.; Raupp, G.; Reich, M.; Reimold, F.; Ribeiro, T.; Riedl, R.; Rohde, V.; Rooij, G. v.; Roth, J.; Rott, M.; Ryter, F.; Salewski, M.; Santos, J.; Sauter, P.; Scarabosio, A.; Schall, G.; Schmid, K.; Schneider, P. A.; Schneider, W.; Schrittwieser, R.; Schubert, M.; Schweinzer, J.; Scott, B.; Sempf, M.; Sertoli, M.; Siccinio, M.; Sieglin, B.; Sigalov, A.; Silva, A.; Sommer, F.; Stäbler, A.; Stober, J.; Streibl, B.; Strumberger, E.; Sugiyama, K.; Suttrop, W.; Tala, T.; Tardini, G.; Teschke, M.; Tichmann, C.; Told, D.; Treutterer, W.; Tsalas, M.; Van Zeeland, M. A.; Varela, P.; Veres, G.; Vicente, J.; Vianello, N.; Vierle, T.; Viezzer, E.; Viola, B.; Vorpahl, C.; Wachowski, M.; Wagner, D.; Wauters, T.; Weller, A.; Wenninger, R.; Wieland, B.; Willensdorfer, M.; Wischmeier, M.; Wolfrum, E.; Würsching, E.; Yu, Q.; Zammuto, I.; Zasche, D.; Zehetbauer, T.; Zhang, Y.; Zilker, M.; Zohm, H.

    2013-10-01

    The medium size divertor tokamak ASDEX Upgrade (major and minor radii 1.65 m and 0.5 m, respectively, magnetic-field strength 2.5 T) possesses flexible shaping and versatile heating and current drive systems. Recently the technical capabilities were extended by increasing the electron cyclotron resonance heating (ECRH) power, by installing 2 × 8 internal magnetic perturbation coils, and by improving the ion cyclotron range of frequency compatibility with the tungsten wall. With the perturbation coils, reliable suppression of large type-I edge localized modes (ELMs) could be demonstrated in a wide operational window, which opens up above a critical plasma pedestal density. The pellet fuelling efficiency was observed to increase which gives access to H-mode discharges with peaked density profiles at line densities clearly exceeding the empirical Greenwald limit. Owing to the increased ECRH power of 4 MW, H-mode discharges could be studied in regimes with dominant electron heating and low plasma rotation velocities, i.e. under conditions particularly relevant for ITER. The ion-pressure gradient and the neoclassical radial electric field emerge as key parameters for the transition. Using the total simultaneously available heating power of 23 MW, high performance discharges have been carried out where feed-back controlled radiative cooling in the core and the divertor allowed the divertor peak power loads to be maintained below 5 MW m-2. Under attached divertor conditions, a multi-device scaling expression for the power-decay length was obtained which is independent of major radius and decreases with magnetic field resulting in a decay length of 1 mm for ITER. At higher densities and under partially detached conditions, however, a broadening of the decay length is observed. In discharges with density ramps up to the density limit, the divertor plasma shows a complex behaviour with a localized high-density region in the inner divertor before the outer divertor detaches

  6. Overview of ASDEX Upgrade results

    NASA Astrophysics Data System (ADS)

    Gruber, O.; Bosch, H.-S.; Günter, S.; Herrmann, A.; Kallenbach, A.; Kaufmann, M.; Krieger, K.; Lackner, K.; Mertens, V.; Neu, R.; Ryter, F.; Schweinzer, J.; Stäbler, A.; Suttrop, W.; Wolf, R.; Asmussen, K.; Bard, A.; Becker, G.; Behler, K.; Behringer, K.; Bergmann, A.; Bessenrodt-Weberpals, M.; Borrass, K.; Braams, B.; Brambilla, M.; Brandenburg, R.; Braun, F.; Brinkschulte, H.; Brückner, R.; Brüsehaber, B.; Büchl, K.; Buhler, A.; Callaghan, H. P.; Carlson, A.; Coster, D. P.; Cupido, L.; de Peña Hempel, S.; Dorn, C.; Drube, R.; Dux, R.; Egorov, S.; Engelhardt, W.; Fahrbach, H.-U.; Fantz, U.; Feist, H.-U.; Franzen, P.; Fuchs, J. C.; Fussmann, G.; Gafert, J.; Gantenbein, G.; Gehre, O.; Geier, A.; Gernhardt, J.; Gubanka, E.; Gude, A.; Haas, G.; Hallatschek, K.; Hartmann, D.; Heinemann, B.; Herppich, G.; Herrmann, W.; Hofmeister, F.; Holzhauer, E.; Jacobi, D.; Kakoulidis, M.; Karakatsanis, N.; Kardaun, O.; Khutoretski, A.; Kollotzek, H.; Kötterl, S.; Kraus, W.; Kurzan, B.; Kyriakakis, G.; Lang, P. T.; Lang, R. S.; Laux, M.; Lengyel, L. L.; Leuterer, F.; Lorenz, A.; Maier, H.; Manso, M.; Maraschek, M.; Markoulaki, M.; Mast, K.-F.; McCarthy, P. J.; Meisel, D.; Meister, H.; Merkel, R.; Meskat, J. P.; Müller, H. W.; Münich, M.; Murmann, H.; Napiontek, B.; Neu, G.; Neuhauser, J.; Niethammer, M.; Noterdaeme, J.-M.; Pautasso, G.; Peeters, A. G.; Pereverzev, G.; Pinches, S.; Raupp, G.; Reinmüller, K.; Riedl, R.; Rohde, V.; Röhr, H.; Roth, J.; Salzmann, H.; Sandmann, W.; Schilling, H.-B.; Schlögl, D.; Schmidtmann, K.; Schneider, H.; Schneider, R.; Schneider, W.; Schramm, G.; Schweizer, S.; Schwörer, R. R.; Scott, B. D.; Seidel, U.; Serra, F.; Sesnic, S.; Sihler, C.; Silva, A.; Speth, E.; Steuer, K.-H.; Stober, J.; Streibl, B.; Thoma, A.; Treutterer, W.; Troppmann, M.; Tsois, N.; Ullrich, W.; Ulrich, M.; Varela, P.; Verbeek, H.; Vollmer, O.; Wedler, H.; Weinlich, M.; Wenzel, U.; Wesner, F.; Wunderlich, R.; Xantopoulos, N.; Yu, Q.; Zasche, D.; Zehetbauer, T.; Zehrfeld, H.-P.; Zohm, H.; Zouhar, M.

    1999-09-01

    The closed ASDEX Upgrade Divertor II, `LYRA', is capable of handling heating powers of up to 20 MW or P/R of 12 MW/m, owing to a reduction of the maximum heat flux to the target plates by more than a factor of 2 compared with the open Divertor I. This reduction is caused by high radiative losses from carbon and hydrogen inside the divertor region and is in agreement with B2-EIRENE modelling predictions. At medium densities in the H mode, the type I ELM behaviour shows no dependence on the heating method (NBI, ICRH). ASDEX Upgrade-JET dimensionless identity experiments showed compatibility of the L-H transition with core physics constraints, while in the H mode confinement, inconsistencies with the invariance principle were established. At high densities close to the Greenwald density, the MHD limited edge pressures, the influence of divertor detachment on separatrix parameters and increasing edge transport lead to limited edge densities and finally to temperatures below the critical edge temperatures for H mode. This results in a drastic increase of the H mode threshold power and an upper H mode density limit with gas puff refuelling. The H mode confinement degradation approaching this density limit is caused by the ballooning mode limited edge pressures and `stiff' temperature profiles relating core and edge temperatures. Repetitive high field side pellet injection allows for H mode operation well above the Greenwald density; moreover, higher confinement than with gas fuelling is found up to the highest densities. Neoclassical tearing modes limit the achievable β depending on the collisionality at the resonant surface. In agreement with the polarization current model, the onset β is found to be proportional to the ion gyroradius in the collisionless regime, while higher collisionalities are stabilizing. The fractional energy loss connected with saturated modes at high pressures is about 25%. A reduction of neoclassical mode amplitude and an increase of β have

  7. [Results for SHEBA/FIRE

    NASA Technical Reports Server (NTRS)

    Valero, Francisco P. J.

    2003-01-01

    The Atmospheric Research Laboratory's Radiation Measurement System (RAMS) was on the NCAR C-130 aircraft in May and July 1998, collecting radiometric data on the science flights conducted in the vicinity of the Surface Heat Budget of the Arctic Ocean (SHEBA) ship. These measurements were part of the FIRE Arctic Cloud Experiment (FIRE ACE). Analysis of some of the data focused on the absorption, reflection, and transmittance of Arctic clouds, especially compared to model results. In order to assess the absorption of solar radiation by the clear and cloudy atmosphere in the Arctic the measurements from the radiometers were combined in pairs of above-cloud segments and below-cloud segments. To get these pairs, the data for all sixteen of the flights (8 in May and 8 in July) were examined for occurrences of low-altitude segments in proximity to high-altitude segments. The low-altitude data are then treated as measurements of the bottom of a layer and the high-altitude data are taken as measurements of the top of the layer. With measurements of the upwelling and downwelling irradiances above and below a layer one can determine the reflectance, transmittance, and absorptance of the layer. Attachment: Doelling, D.R., P. Minnis, D.A. Spangenberg, V. Chakrapani, A. Mahesh, S.K. Pope, and F.P.J. Valero, Cloud radiative forcing at the top of the atmosphere during FIRE ACE derived from AVHRR data, J. Geophys. Res. 106, 15,279-15,296,2001. Minnis, P., D.R. Doelling, D.A. Spangenberg, A. Mahesh, S.K. Pope, and F.P.J. Valero, AVHRR-derived cloud radiative forcing over the ARM NSA and SHEBA site during FIRE ACE, abstract submitted to the ARM Science Team Meeting, San Antonio, TX, M a . 13-17,2000. Pope, S.K., and F.P.J. Valero, Measured and modeled radiometric fluxes in the Arctic during FIRE-ACE, presented as a poster at the American Geophysical Union meeting, San Francisco, CA, Dec. 13-17, 1999. Pope, S.K., and F.P.J. Valero, Measured and modeled radiometric fluxes in the Arctic

  8. Overview of ASDEX Upgrade results

    NASA Astrophysics Data System (ADS)

    Gruber, O.; Arslanbekov, R.; Atanasiu, C.; Bard, A.; Becker, G.; Becker, W.; Beckmann, M.; Behler, K.; Behringer, K.; Bergmann, A.; Bilato, R.; Bolshukin, D.; Borrass, K.; Bosch, H.-S.; Braams, B.; Brambilla, M.; Brandenburg, R.; Braun, F.; Brinkschulte, H.; Brückner, R.; Brüsehaber, B.; Büchl, K.; Buhler, A.; Bürbaumer, H.; Carlson, A.; Ciric, M.; Conway, G.; Coster, D. P.; Dorn, C.; Drube, R.; Dux, R.; Egorov, S.; Engelhardt, W.; Fahrbach, H.-U.; Fantz, U.; Faugel, H.; Foley, M.; Franzen, P.; Fu, P.; Fuchs, J. C.; Gafert, J.; Gantenbein, G.; Gehre, O.; Geier, A.; Gernhardt, J.; Gubanka, E.; Gude, A.; Günter, S.; Haas, G.; Hartmann, D.; Heinemann, B.; Herrmann, A.; Hobirk, J.; Hofmeister, F.; Hohenöcker, H.; Horton, L.; Hu, L.; Jacobi, D.; Jakobi, M.; Jenko, F.; Kallenbach, A.; Kardaun, O.; Kaufmann, M.; Kendl, A.; Kim, J.-W.; Kirov, K.; Kochergov, R.; Kollotzek, H.; Kraus, W.; Krieger, K.; Kurzan, B.; Kyriakakis, G.; Lackner, K.; Lang, P. T.; Lang, R. S.; Laux, M.; Lengyel, L.; Leuterer, F.; Lorenz, A.; Maier, H.; Mank, K.; Manso, M.-E.; Maraschek, M.; Mast, K.-F.; McCarthy, P. J.; Meisel, D.; Meister, H.; Meo, F.; Merkel, R.; Mertens, V.; Meskat, J. P.; Monk, R.; Müller, H. W.; Münich, M.; Murmann, H.; Neu, G.; Neu, R.; Neuhauser, J.; Noterdaeme, J.-M.; Nunes, I.; Pautasso, G.; Peeters, A. G.; Pereverzev, G.; Pinches, S.; Poli, E.; Pugno, R.; Raupp, G.; Ribeiro, T.; Riedl, R.; Riondato, S.; Rohde, V.; Röhr, H.; Roth, J.; Ryter, F.; Salzmann, H.; Sandmann, W.; Sarelma, S.; Schade, S.; Schilling, H.-B.; Schlögl, D.; Schmidtmann, K.; Schneider, R.; Schneider, W.; Schramm, G.; Schweinzer, J.; Schweizer, S.; Scott, B. D.; Seidel, U.; Serra, F.; Sesnic, S.; Sihler, C.; Silva, A.; Sips, A.; Speth, E.; Stäbler, A.; Steuer, K.-H.; Stober, J.; Streibl, B.; Strumberger, E.; Suttrop, W.; Tabasso, A.; Tanga, A.; Tardini, G.; Tichmann, C.; Treutterer, W.; Troppmann, M.; Tsois, N.; Ullrich, W.; Ulrich, M.; Varela, P.; Vollmer, O.; Wenzel, U.; Wesner, F.; Wolf, R.; Wolfrum, E.; Wunderlich, R.; Xantopoulos, N.; Yu, Q.; Zarrabian, M.; Zasche, D.; Zehetbauer, T.; Zehrfeld, H.-P.; Zeiler, A.; Zohm, H.

    2001-10-01

    Ion and electron temperature profiles in conventional L and H mode on ASDEX Upgrade are generally stiff and limited by a critical temperature gradient length ∇T/T as given by ion temperature gradient (ITG) driven turbulence. ECRH experiments indicate that electron temperature (Te) profiles are also stiff, as predicted by electron temperature gradient turbulence with streamers. Accordingly, the core and edge temperatures are proportional to each other and the plasma energy is proportional to the pedestal pressure for fixed density profiles. Density profiles are not stiff, and confinement improves with density peaking. Medium triangularity shapes (δ<0.45) show strongly improved confinement up to the Greenwald density nGW and therefore higher βvalues, owing to increasing pedestal pressure, and H mode density operation extends above nGW. Density profile peaking at nGW was achieved with controlled gas puffing rates, and first results from a new high field side pellet launcher allowing higher pellet velocities are promising. At these high densities, small type II ELMs provide good confinement with low divertor power loading. In advanced scenarios the highest performance was achieved in the improved H mode with HL-89PβN approx 7.2 at δ = 0.3 for five confinement times, limited by neoclassical tearing modes (NTMs) at low central magnetic shear (qmin approx 1). The T profiles are still governed by ITG and trapped electron mode (TEM) turbulence, and confinement is improved by density peaking connected with low magnetic shear. Ion internal transport barrier (ITB) discharges - mostly with reversed shear (qmin>1) and L mode edge - achieved HL-89P <= 2.1 and are limited to βN <= 1.7 by internal and external ideal MHD modes. Turbulence driven transport is suppressed, in agreement with the E × B shear flow paradigm, and core transport coefficients are at the neoclassical ion transport level, where the latter was established by Monte Carlo simulations. Reactor relevant ion

  9. Recent Opportunity Microscopic Imager Results

    NASA Astrophysics Data System (ADS)

    Herkenhoff, K. E.; Arvidson, R. E.; Jolliff, B. L.; Yingst, R.; Team, A.

    2013-12-01

    Opportunity. The extremely soft bedrock exposed at a Whitewater Lake outcrop target dubbed 'Azilda' is mostly fine-grained, with dispersed 2-5 mm-diameter spherules and resistant veins. This target was easily abraded by the RAT, exposing a sandstone-like texture, but the sorting of grains is difficult to determine at MI resolution. Darker, erosion-resistant veneers, similar to desert varnishes on Earth, appear to record aqueous alteration that post-dates the formation of the Ca sulfate veins; they likely contain the nontronite that is observed by CRISM in this area. The inferred neutral pH and relatively low temperature of the fluids involved in these phases of alteration would have provided a habitable environment for life if it existed on Mars at that time. Because Opportunity can no longer directly sense phyllosilicate mineralogy with the MiniTES or Mössbauer spectrometers, it is focusing on characterizing the chemistry with the APXS and texture with the MI of potential phyllosilicate host rocks. The Athena MI continues to return useful images of Mars that are being used to study the textures of rocks and soils at Endeavour crater. Exploration by Opportunity continues, with the rover approaching 'Solander Point' and more exposures of phyllosilicates detected from orbit; the latest MI results will be presented at the conference.

  10. An overview of KSTAR results

    NASA Astrophysics Data System (ADS)

    Kwak, Jong-Gu; Oh, Y. K.; Yang, H. L.; Park, K. R.; Kim, Y. S.; Kim, W. C.; Kim, J. Y.; Lee, S. G.; Na, H. K.; Kwon, M.; Lee, G. S.; Ahn, H. S.; Ahn, J.-W.; Bae, Y. S.; Bak, J. G.; Bang, E. N.; Chang, C. S.; Chang, D. H.; Chen, Z. Y.; Cho, K. W.; Cho, M. H.; Choi, M.; Choe, W.; Choi, J. H.; Chu, Y.; Chung, K. S.; Diamond, P.; Delpech, L.; Do, H. J.; Eidietis, N.; England, A. C.; Ellis, R.; Evans, T.; Choe, G.; Grisham, L.; Gorelov, Y.; Hahn, H. S.; Hahn, S. H.; Han, W. S.; Hatae, T.; Hillis, D.; Hoang, T.; Hong, J. S.; Hong, S. H.; Hong, S. R.; Hosea, J.; Humphreys, D.; Hwang, Y. S.; Hyatt, A.; Ida, K.; In, Y. K.; Ide, S.; Jang, Y. B.; Jeon, Y. M.; Jeong, J. I.; Jeong, N. Y.; Jeong, S. H.; Jin, J. K.; Joung, M.; Ju, J.; Kawahata, K.; Kim, C. H.; Kim, Hee-Su; Kim, H. S.; Kim, H. J.; Kim, H. K.; Kim, H. T.; Kim, J. H.; Kim, J.; Kim, J. C.; Kim, Jong-Su; Kim, Jung-Su; Kim, J. H.; Kim, Kyung-Min; Kim, K. J.; Kim, K. P.; Kim, M. K.; Kim, S. T.; Kim, S. W.; Kim, Y. J.; Kim, Y. K.; Kim, Y. O.; Ko, J. S.; Ko, W. H.; Kogi, Y.; Kolemen, E.; Kong, J. D.; Kwak, S. W.; Kwon, J. M.; Kwon, O. J.; Lee, D. G.; Lee, D. R.; Lee, D. S.; Lee, H. J.; Lee, J.; Lee, J. H.; Lee, K. D.; Lee, K. S.; Lee, S. H.; Lee, S. I.; Lee, S. M.; Lee, T. G.; Lee, W.; Lee, W. L.; Lim, D. S.; Litaudon, X.; Lohr, J.; Mueller, D.; Moon, K. M.; Na, D. H.; Na, Y. S.; Nam, Y. U.; Namkung, W.; Narihara, K.; Oh, S. T.; Oh, D. G.; Ono, T.; Park, B. H.; Park, D. S.; Park, G. Y.; Park, H.; Park, H. T.; Park, J. K.; Park, J. S.; Park, M. K.; Park, S. H.; Park, S.; Park, Y. M.; Park, Y. S.; Parker, R.; Rhee, D. R.; Sabbagh, S. A.; Sakamoto, K.; Shiraiwa, S.; Seo, D. C.; Seo, S. H.; Seol, J. C.; Shi, Y. J.; Son, S. H.; Song, N. H.; Suzuki, T.; Terzolo, L.; Walker, M.; Wallace, G.; Watanabe, K.; Wang, S. J.; Woo, H. J.; Woo, I. S.; Yagi, M.; Yu, Y. W.; Yamada, I.; Yonekawa, Y.; Yoo, C. M.; You, K. I.; Yoo, J. W.; Yun, G. S.; Yu, M. G.; Yoon, S. W.; Xiao, W.; Zoletnik, S.; the KSTAR Team

    2013-10-01

    Since the first H-mode discharges in 2010, the duration of the H-mode state has been extended and a significantly wider operational window of plasma parameters has been attained. Using a second neutral beam (NB) source and improved tuning of equilibrium configuration with real-time plasma control, a stored energy of Wtot ˜ 450 kJ has been achieved with a corresponding energy confinement time of τE ˜ 163 ms. Recent discharges, produced in the fall of 2012, have reached plasma βN up to 2.9 and surpassed the n = 1 ideal no-wall stability limit computed for H-mode pressure profiles, which is one of the key threshold parameters defining advanced tokamak operation. Typical H-mode discharges were operated with a plasma current of 600 kA at a toroidal magnetic field BT = 2 T. L-H transitions were obtained with 0.8-3.0 MW of NB injection power in both single- and double-null configurations, with H-mode durations up to ˜15 s at 600 kA of plasma current. The measured power threshold as a function of line-averaged density showed a roll-over with a minimum value of ˜0.8 MW at \\bar{n}_e\\sim 2\\times 10^{19}\\,m^{-3} . Several edge-localized mode (ELM) control techniques during H-mode were examined with successful results including resonant magnetic perturbation, supersonic molecular beam injection (SMBI), vertical jogging and electron cyclotron current drive injection into the pedestal region. We observed various ELM responses, i.e. suppression or mitigation, depending on the relative phase of in-vessel control coil currents. In particular, with the 90° phase of the n = 1 RMP as the most resonant configuration, a complete suppression of type-I ELMs was demonstrated. In addition, fast vertical jogging of the plasma column was also observed to be effective in ELM pace-making. SMBI-mitigated ELMs, a state of mitigated ELMs, were sustained for a few tens of ELM periods. A simple cellular automata (‘sand-pile’) model predicted that shallow deposition near the pedestal

  11. SMOS first results over land

    NASA Astrophysics Data System (ADS)

    Kerr, Yann; Waldteufel, Philippe; Cabot, François; Richaume, Philippe; Jacquette, Elsa; Bitar, Ahmad Al; Mamhoodi, Ali; Delwart, Steven; Wigneron, Jean-Pierre

    2010-05-01

    retrieve soil moisture over fairly large and thus inhomogeneous areas. The retrieval is carried out at nodes of a fixed Earth surface grid. To achieve this purpose, after checking input data quality and ingesting auxiliary data, the retrieval process per se can be initiated. This cannot be done blindly as the direct model will be dependent upon surface characteristics. It is thus necessary to first assess what is the dominant land use of a node. For this, an average weighing function (MEAN_WEF) which takes into account the "antenna"pattern is run over the high resolution land use map to assess the dominant cover type. This is used to drive the decision tree which, step by step, selects the type of model to be used as per surface conditions. All this being said and done the retrieval procedure starts if all the conditions are satisfied, ideally to retrieve 3 parameters over the dominant class (the so-called rich retrieval). If the algorithm does not converge satisfactorily, a new trial is made with less floating parameters ("poorer retrieval") until either results are satisfactory or the algorithm is considered to fail. The retrieval algorithm also delivers whenever possible a dielectric constant parameter (using the-so called cardioid approach). Finally, once the retrieval converged, it is possible to compute the brightness temperature at a given fixed angle (42.5°) using the selected forward models applied to the set of parameters obtained at the end of the retrieval process. So the output product of the level 2 soil moisture algorithm should be node position, soil moisture, dielectric constants, computed brightness temperature at 42.5°, flags and quality indices. During the presentation we will describe in more details the algorithm and accompanying work in particular decision tree principle and characteristics, the auxiliary data used and the special and "exotic"cases. We will also be more explicit on the algorithm validation and verification through the data

  12. New results of paleomagnetic investigations of Llanvirn sequences, Leningrad area: Was 465 Ma ago the East-European platform located much closer to equator, than it was supposed before?

    NASA Astrophysics Data System (ADS)

    Lubnina, N. V.; Rodionov, V. P.; Pavlov, V. E.

    2003-04-01

    Although first paleomagnetic investigations of the Ordovician rocks at the Leningrad area were begun more than 40 years ago (A.N. Khramov, 1958), number of palepmagnetic data for the Ordovician pole of the East-European platform (EEP)is limited enough till now. Exept paleomagnetic poles obtained by Smethurst et al. (1998), all others paleomagnetic results based on ivestigations of Swedish Ordovician limestones (Torsvik and Trench, 1991; Trench and Torsvik, 1991; Claesson, 1998; Torsvik et al., 2000; Perroud et al., 1992). These data suggest that northwest margin of East-European platform located at 40S at Llanvirn time. However paleomagnetic data for Lower Ordovician red-colored sandstones and aleurolites (Didenko, Lubnina, 1998) testify for more low-latitude location of the EEP at that time. For solution of this difficulty and also for increasing of paleomagnetic database we sampled carbonaceous sections of Volkhov and Kunda stages (Llanvirn) not far from village Shirokovo and in Lomashka river valley. The other important task of our researches was receive new magnitostratigraphy information about polarity of Llanvirn geomagnetic field. Thermal demagnetization of these rocks yield two monopolar components.The first one component A is allocated as characteristic, has unblocking temperatures about 400-450° and is typical for low-magnetic samples (magnetization less than 1-2.10-4 ). Another - component B removed maximum at 500-560C and is typical for high-magnetic samples (magnetization more than 2-3.10-4). Mean direction of component B (D= 36.8; I = 58.3; N = 33; K = 31.8; alfa95 = 4.5) is close to the direction of Mezozic magnetization reversal (Smethurst et al., 1998). Sometimes components A and B occur together and component B is less stability. However there are also took place return cases. Mean direction of components A (D = 156.4; I = 38.8; N = 29; K = 31.8; alfa95 = 11.3) is close to Ordovician direction (Torsvik and Trench, 1991; Trench and Torsvik, 1991

  13. Addition of Nitazoxanide to PEG-IFN and Ribavirin to Improve HCV Treatment Response in HIV-1 and HCV Genotype 1 Coinfected Persons Naïve to HCV Therapy: Results of the ACTG A5269 Trial

    PubMed Central

    Amorosa, Valerianna K.; Luetkemeyer, Anne; Kang, Minhee; Johnson, Victoria A.; Umbleja, Triin; Haas, David W.; Yesmin, Suria; Bardin, Matthew C.; Chung, Ray T.; Alston-Smith, Beverly; Tebas, Pablo; Peters, Marion G.

    2014-01-01

    Background We hypothesized that nitazoxanide (NTZ) added to pegylated inter-feron alfa-2a (PEG-IFN) and weight-based ribavirin (WBR) would improve hepatitis C virus (HCV) virologic responses in HCV treatment-naïve HIV-1/HCV genotype 1 coin-fected persons. Methods Prospective, single-arm study in which subjects received 4-week lead-in (NTZ 500 mg twice daily) followed by 48 weeks of NTZ, PEG-IFN, and WBR. We compared the HCV virologic responses of these subjects to his­torical controls from the completed ACTG study A5178 who received PEG-IFN and WBR and had similar subject characteristics. Primary endpoints were early virologic response and complete early virologic response (EVR and cEVR). Results Among 67 subjects (78% male; 48% Black; median age, 50 years), EVR was achieved in 65.7% (90% CI, 55.0%–75.3%), cEVR in 38.8% (28.8%–49.6%). and SVR in 32.8% (23.4%–43.5%). EVR was higher with NTZ (51.4% in A5178; P = .03), but the sustained virologic response (SVR) proportion was similar (27.3% in A5178; P = .24). In contrast to A5178, SVR was similar across IL28B genotypes. Overall, NTZ was safe and well-tolerated. Conclusion Whereas EVR proportion improved significantly in this pilot study, the addition of NTZ to PEG-IFN/WBR did not significantly improve SVR compared to historical controls. NTZ may be associated with an attenuation of the effect of IL28B on HCV treatment response. PMID:24334180

  14. Evaluation of a Novel Rapid Test System for the Detection of Specific IgE to Hymenoptera Venoms

    PubMed Central

    Pfender, Nikolai; Lucassen, Ralf; Offermann, Nadine; Schulte-Pelkum, Johannes; Fooke, Margrit; Jakob, Thilo

    2012-01-01

    Background. The Allergy Lateral Flow Assay (ALFA) is a novel rapid assay for the detection of sIgE to allergens. The objective of this study is the evaluation of ALFA for the detection of sIgE to bee venom (BV) and wasp venom (WV) in insect venom allergic patients. Methods. Specific IgE to BV and WV was analyzed by ALFA, ALLERG-O-LIQ, and ImmunoCAP in 80 insect venom allergic patients and 60 control sera. Sensitivity and specificity of ALFA and correlation of ALFA and ImmunoCAP results were calculated. Results. The sensitivity/specificity of ALFA to the diagnosis was 100%/83% for BV and 82%/97% for WV. For insect venom allergic patients, the Spearman correlation coefficient for ALFA versus ImmunoCAP was 0.79 for BV and 0.80 for WV. However, significant differences in the negative control groups were observed. Conclusion. ALFA represents a simple, robust, and reliable tool for the rapid detection of sIgE to insect venoms. PMID:22500188

  15. Gateways to clinical trials.

    PubMed

    Bayes, M; Rabasseda, X; Prous, J R

    2006-03-01

    Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data in the following tables have been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity, the drug discovery and development portal, http://integrity.prous.com. This issue focuses on the following selection of drugs: 131I-labetuzumab; Abacavir sulfate, abatacept, adalimumab, ademetionine, adjuvanted influenza vaccine, alefacept, alemtuzumab, amlodipine, amphotericin B, anakinra, aripiprazole, aspirin, axitinib; Betamethasone dipropionate, bevacizumab, biphasic insulin aspart, bortezomib, bosentan, botulinum toxin type B, BQ-123; Calcium folinate, canertinib dihydrochloride, carboplatin, carmustine, cetirizine hydrochloride, cetuximab, cholecalciferol, ciclesonide, ciclosporin, cinacalcet hydrochloride, cisplatin, clarithromycin, clofazimine, cold-adapted influenza vaccine trivalent, CpG-7909; Darbepoetin alfa, darifenacin hydrobromide, DB-289, desloratadine, Dexamet, dicycloverine hydrochloride, dimethyl fumarate, docetaxel, dolastatin 10, drospirenone, drospirenone/estradiol, duloxetine hydrochloride; Ecogramostim, edotecarin, efaproxiral sodium, enalapril maleate, epoetin beta, epoprostenol sodium, epratuzumab, erlotinib hydrochloride, escitalopram oxalate, estradiol, etanercept; Fluconazole, fludarabine phosphate, fluorouracil; Gefitinib, gemcitabine, Ghrelin (human), glibenclamide, glimepiride, GTI-2040; Haloperidol, human insulin, hydrocortisone probutate; Imatinib mesylate, indisulam, influenza vaccine, inhaled insulin, insulin aspart, insulin glulisine, insulin lispro, irinotecan, ispronicline; Lamivudine, lamivudine/zidovudine/abacavir sulfate, lapatinib, letrozole, levocetirizine, lomustine, lonafarnib, lumiracoxib;Magnesium sulfate, MD-1100, melphalan, metformin hydrochloride, methotrexate, metoclopramide hydrochloride, mitiglinide calcium hydrate, monophosphoryl lipid A, montelukast sodium, motexafin gadolinium

  16. Gateways to Clinical Trials.

    PubMed

    Bayes, M; Rabasseda, X; Prous, J R

    2002-04-01

    Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the following tables has been retrieved from the Clinical Studies knowledge area of Prous Science Integrity, the world's first drug discovery and development portal, and provides information on study design, treatments, conclusions and references. This issue focuses on the following selection of drugs: Abiciximab, acetylcholine chloride, acetylcysteine, alefacept, alemtuzumab, alicaforsen, alteplase, aminopterin, amoxicillin sodium, amphotericin B, anastrozole, argatroban monohydrate, arsenic trioxide, aspirin, atazanavir, atorvastatin, augmerosen, azathioprine; Benzylpenicillin, BMS-284756, botulinum toxin type A, botulinum toxin type B, BQ-123, budesonide, BXT-51072; Calcium folinate, carbamazepine, carboplatin, carmustine, ceftriaxone sodium, cefuroxime axetil, chorionic gonadotropin (human), cimetidine, ciprofloxacin hydrochloride, cisplatin, citalopram hydrobromide, cladribine, clarithromycin, clavulanic acid, clofarabine, clopidogrel hydrogensulfate, clotrimazole, CNI-1493, colesevelam hydrochloride, cyclophosphamide, cytarabine; Dalteparin sodium, daptomycin, darbepoetin alfa, debrisoquine sulfate, dexrazoxane, diaziquone, didanosine, docetaxel, donezepil, doxorubicin hydrochloride liposome injection, DX-9065a; Eberconazole, ecogramostim, eletriptan, enoxaparin sodium, epoetin, epoprostenol sodium, erlizumab, ertapenem sodium, ezetimibe; Fampridine, fenofibrate, filgrastim, fluconazole, fludarabine phosphate, fluorouracil, 5-fluorouracil/epinephrine, fondaparinux sodium, formoterol fumarate; Gabapentin, gemcitabine, gemfibrozil, glatiramer; Heparin sodium, homoharringtonine; Ibuprofen, iloprost, imatinib mesilate, imiquimod, interferon alpha-2b, interferon alpha-2c, interferon-beta; KW-6002; Lamotrigine, lanoteplase, metoprolol tartrate, mitoxantrone hydrochloride; Naproxen sodium, naratriptan, Natalizumab, nelfinavir mesilate

  17. Gateways to clinical trials.

    PubMed

    Bayes, M; Rabasseda, X; Prous, J R

    2004-01-01

    Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the following tables has been retrieved from the Clinical Trials Know- ledge Area of Prous Science Integrity, the drug discovery and development portal, http://integrity.prous.com. This issue focuses on the following selection of drugs: ABI-007, Ad.Egr.TNF.11D, adefovir dipivoxil, AdPEDF.11, AES-14, albumex, alefacept, alemtuzumab, aliskiren fumarate, alvimopan hydrate, aAminolevulinic acid hydrochloride, aminolevulinic acid methyl ester, anakinra, anti-IL-12 MAb, aprepitant, atazanavir sulfate, atrasentan, avanafil; Banoxantrone, BG-12, bimatoprost, bortezomib, bosentan; Calcipotriol/betamethasone dipropionate, caspofungin acetate, CBT-1, ciclesonide, clofarabine, conivaptan hydrochloride, CpG-7909, C-Vax, Cypher; DA-8159, DAC:GLP-1, darbepoetin alfa, darifenacin, duloxetine hydrochloride; Eculizumab, efalizumab, efaproxiral sodium, EGF vaccine, eletriptan, epratuzumab, erlotinib hydrochloride, escitalopram oxalate, ETC-642, etoricoxib, everolimus, exenatide; Gefitinib, IV gamma-globulin; Human insulin, gamma-hydroxybutyrate sodium; IDN-6556, iguratimod, imatinib mesylate, indiplon, ixabepilone; Laquinimod, LB-80380, lidocaine/prilocaineliraglutide, lopinavir, lopinavir/ritonavir, lucinactant; MAb-14.18, melatonin, MLN-591-DM1; NC-531, neridronic acid, nesiritide, neutrophil-inhibitory factor, niacin/lovastatin; Oblimersen sodium, olcegepant, oral Insulin, ORV-105; Palonosetron hydrochloride, PAmAb, pegaptanib sodium, peginterferon alfa-2a, pegvisomant, perifosine, pexelizumab, phenoxodiol, phenserine tartrate, pimecrolimus, pramlintide acetate, pregabalin, PRO-542, prostate cancer vaccine, PT-141; Ramelteon, rasagiline mesilate, rDNA insulin, reslizumab, rh-Lactoferrin, ribamidine hydrochloride, rosuvastatin calcium; S-8184l, SC-1, sorafenib, St. John's Wort extract, SU-11248; Taxus, telbivudine, tenofovir disoproxil fumarate, teriparatide

  18. Novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia of chronic disease associated with cancer

    PubMed Central

    Smith, R E; Jaiyesimi, I A; Meza, L A; Tchekmedyian, N S; Chan, D; Griffith, H; Brosman, S; Bukowski, R; Murdoch, M; Rarick, M; Saven, A; Colowick, A B; Fleishman, A; Gayko, U; Glaspy, J

    2001-01-01

    Anaemia is a common haematologic disorder in patients with cancer and has a multifactorial aetiology, including the effects of the malignancy itself and residual effects from previous therapy. Novel erythropoiesis stimulating protein (NESP, darbepoetin alfa), a protein with additional sialic acid compared with erythropoietin (EPO), stimulates erythropoiesis by the same mechanism as recombinant human erythropoietin (rHuEPO) but it is biochemically distinct. NESP, with its approximately 3-fold greater serum half-life, can maintain haemoglobin levels as effectively as rHuEPO in anaemic patients with chronic renal failure and do so with less frequent dosing. We investigated the ability of NESP to safely increase haemoglobin levels of anaemic patients with non-myeloid malignancies not receiving chemotherapy. NESP was administered under the supervision of a physician at doses of 0.5, 1.0, 2.25 or 4.5 mcg kg−1wk−1for a maximum of 12 weeks. This report includes 89 patients completing the study by November 2000. NESP was well tolerated, with no reported dose-limiting toxicities or treatment-related severe adverse events. Increasing doses of NESP corresponded with increased efficacy. The percentage (95% confidence interval) of patients responding ranged from 61% (42%, 77%) in the 1.0 mcg kg−1wk−1group to 83% (65%, 94%) in the 4.5 mcg kg−1wk−1group. © 2001 Cance Cancer Research Campaign PMID:11308271

  19. 16 CFR 1610.8 - Reporting results.

    Code of Federal Regulations, 2011 CFR

    2011-01-01

    ... FLAMMABILITY OF CLOTHING TEXTILES The Standard § 1610.8 Reporting results. (a) The reported result shall be the... following are the definitions for the test result codes, which shall be used for recording...

  20. 16 CFR 1610.8 - Reporting results.

    Code of Federal Regulations, 2010 CFR

    2010-01-01

    ... FLAMMABILITY OF CLOTHING TEXTILES The Standard § 1610.8 Reporting results. (a) The reported result shall be the... following are the definitions for the test result codes, which shall be used for recording...

  1. FY 2011 Pollution Prevention Grant Results Summary

    EPA Pesticide Factsheets

    The Pollution Prevention Program reports the environmental results of grants. These grants produce annual environmental results in pounds of hazardous materials reduced, BTUs of energy, water and dollars saved.

  2. FY 2012 Pollution Prevention Grant Results Summary

    EPA Pesticide Factsheets

    The Pollution Prevention Program reports the environmental results of grants. These grants produce annual environmental results in pounds of hazardous materials reduced, BTUs of energy, water and dollars saved.

  3. Ideas for Effective Communication of Statistical Results

    DOE PAGES

    Anderson-Cook, Christine M.

    2015-03-01

    Effective presentation of statistical results to those with less statistical training, including managers and decision-makers requires planning, anticipation and thoughtful delivery. Here are several recommendations for effectively presenting statistical results.

  4. Accuracy of results with NASTRAN modal synthesis

    NASA Technical Reports Server (NTRS)

    Herting, D. N.

    1978-01-01

    A new method for component mode synthesis was developed for installation in NASTRAN level 17.5. Results obtained from the new method are presented, and these results are compared with existing modal synthesis methods.

  5. FY 2013 Pollution Prevention Grant Results Summary

    EPA Pesticide Factsheets

    The Pollution Prevention Program reports the environmental results of grants. These grants produce annual environmental results in pounds of hazardous materials reduced, BTUs of energy, water and dollars saved.

  6. Notification: EPA Benefits from STAR Grant Results

    EPA Pesticide Factsheets

    Project #OPE-FY15-0017, January 15, 2015. The Office of Inspector General (OIG) for the U.S. Environmental Protection Agency (EPA) plans to begin preliminary research on results from Science to Achieve Results (STAR) grants.

  7. Symposium on Recent Results in Infrared Astrophysics

    NASA Technical Reports Server (NTRS)

    Dyal, P. (Editor)

    1977-01-01

    Abstracts of papers presented at a symposium titled Recent Results in Infrared Astrophysics are set forth. The abstracts emphasize photometric, spectroscopic, polarization, and theoretical results on a broad range of current topics in infrared astrophysics.

  8. Earth Radiation Budget Experiment - Preliminary seasonal results

    NASA Technical Reports Server (NTRS)

    Barkstrom, Bruce R.; Harrison, Edwin F.; Lee, Robert B., III

    1990-01-01

    Data from the Earth Radiation Budget Satellite (ERBS) and from the operational NOAA-9 satellite being placed in the archive of the earth Radiation Budget Experiment (ERBE) are discussed. The results of the ERBE data validation effort are reviewed along with ERBE solar constant observations and earth-viewing results. The latter include monthly average results for July 1985, annual average clear-sky fluxes, and annual average, zonal, and global results.

  9. Innovation Impact: Breakthrough Research Results (Brochure)

    SciTech Connect

    Not Available

    2013-07-01

    The Innovation Impact brochure captures key breakthrough results across NREL's primary areas of renewable energy and energy efficiency research: solar, wind, bioenergy, transportation, buildings, analysis, and manufacturing technologies.

  10. Biosparging results: How clean is the site?

    SciTech Connect

    Billings, J.F.; Griswold, J.E.; Billings, B.G.

    1995-12-31

    Biosparging, a technique similar to air sparging but with the design intent of plume discretization with low to moderate flows per sparge point and operational patience to allow for bioremediation, is producing remediation results distancing itself from air sparging in general. While some debate the efficacy of sparging, this paper discusses results at biosparging sites that are by design and operation significantly different than results from air sparging sites. The authors have participated in biosparging projects across the country for a number of years that have resulted in a range of applications with a large database of results. To provide insight into recent debate concerning the use of water quality results at sparging sites, data from permanent monitoring wells, located 50 to 200 feet beyond the direct influence of air movement, are provided. Water quality results from wells where systems have been off from weeks to more than a year also are provided, as well as confirmation borings of soil concentrations above, at, and below the water table. Additionally, results from new borings and monitoring wells are provided for systems after shutdown. Wells undergoing active sparging/agitation can provide results indicating clean water. Attention is focused on BTEX analytes.

  11. Getting to Results. Closing the Achievement Gap

    ERIC Educational Resources Information Center

    Read, Tory

    2008-01-01

    The "Closing the Achievement Gap" series explores the Casey Foundation's education investments and presents stories, results, and lessons learned. This publication describes efforts to develop a flexible but rigorous results measurements system that enables the Foundation and its grantees to reflect on practice and course-correct as…

  12. Injuries resulting from bungee-cord jumping.

    PubMed

    Hite, P R; Greene, K A; Levy, D I; Jackimczyk, K

    1993-06-01

    A 19-year-old woman sustained a nonfatal hanging injury and a 28-year-old man sustained a unilateral locked facet with resultant quadriplegia as a result of bungee jumping. Injuries due to this sport have not been reported previously.

  13. Zero Result Searches. . . How to Minimize Them.

    ERIC Educational Resources Information Center

    Atkinson, Steve

    1986-01-01

    Based on manual observation of 187 zero result online searches at a university library, this article addresses three types of problems that can produce such search results: multiple database searching, topic negotiation, and database availability. A summary of conceptual and practical recommendations for searchers are provided. (6 references) (EJS)

  14. Supporting Public Access to Research Results

    ERIC Educational Resources Information Center

    Lapinski, P. Scott; Osterbur, David; Parker, Joshua; McCray, Alexa T.

    2014-01-01

    We posed the question of what services an academic library can best provide to support the NIH Public Access Policy. We approached the answer to this question through education, collaboration, and tool-building. As a result, over the last four years we have engaged over 1,500 participants in discussions of public access to research results, forged…

  15. Pluto results on jets and QCD

    SciTech Connect

    Pluto collaboration

    1981-02-01

    Results obtained with the PLUTO detector at PETRA are presented. Multihadron final states have been analysed with respect to clustering, energy-energy correlations and transverse momenta in jets. QCD predictions for hard gluon emission and soft gluon-quark cascades are discussed. Results on ..cap alpha../sub s/ and the gluon spin are given.

  16. 40 CFR 799.12 - Test results.

    Code of Federal Regulations, 2014 CFR

    2014-07-01

    ... 40 Protection of Environment 32 2014-07-01 2014-07-01 false Test results. 799.12 Section 799.12...) IDENTIFICATION OF SPECIFIC CHEMICAL SUBSTANCE AND MIXTURE TESTING REQUIREMENTS General Provisions § 799.12 Test results. Except as set forth in specific chemical test rules in subpart B of this part, a positive...

  17. 40 CFR 799.12 - Test results.

    Code of Federal Regulations, 2011 CFR

    2011-07-01

    ... 40 Protection of Environment 32 2011-07-01 2011-07-01 false Test results. 799.12 Section 799.12...) IDENTIFICATION OF SPECIFIC CHEMICAL SUBSTANCE AND MIXTURE TESTING REQUIREMENTS General Provisions § 799.12 Test results. Except as set forth in specific chemical test rules in subpart B of this part, a positive...

  18. Zbrowse: An interactive GWAS results browser

    Technology Transfer Automated Retrieval System (TEKTRAN)

    The growing number of genotyped populations, the advent of high-throughput phenotyping techniques and the development of GWAS analysis software has rapidly accelerated the number of GWAS experimental results. Candidate gene discovery from these results files is often tedious, involving many manual s...

  19. A Westerner's Thoughts on the Referendum Results.

    ERIC Educational Resources Information Center

    Kilgour, David

    1993-01-01

    Reviews the results of the October 26, 1992, national referendum on the Canadian constitution. Describes the impact of the results on the provinces of western Canada. Concludes that a new national election should be called to resolve further the constitutional issues. (CFR)

  20. Croatian survey on critical results reporting

    PubMed Central

    Trifunović, Jasenka; Pavosevic, Tihana; Nikolac, Nora

    2015-01-01

    Introduction Poor harmonization of critical results management is present in various laboratories and countries, including Croatia. We aimed to investigate procedures used in critical results reporting in Croatian medical biochemistry laboratories (MBLs). Materials and methods An anonymous questionnaire, consisting of 24 questions/statements, related to critical results reporting procedures, was send to managers of MBLs in Croatia. Participants were asked to declare the frequency of performing procedures and degree of agreement with statements about critical values reporting using a Likert scale. Total score and mean scores for corresponding separate statements divided according to health care setting were calculated and compared. Results Responses from 111 Croatian laboratories (48%) were analyzed. General practice laboratories (GPLs) more often re-analyzed the sample before reporting the critical result in comparison with the hospital laboratories (HLs) (score: 4.86 (4.75-4.96) vs. 4.49 (4.25-4.72); P = 0.001) and more often reported the critical value exclusively to the responsible physician compared to HLs (4.46 (4.29-4.64) vs. 3.76 (3.48-4.03), P < 0.001). High total score (4.69 (4.56-4.82)) was observed for selection of the critical results list issued by the Croatian Chamber of Medical Biochemistry (CCMB) indicating a high harmonization level for this aspect of critical result management. Low total scores were observed for the statements regarding data recording and documentation of critical result notification. Conclusions Differences in practices about critical results reporting between HLs and GPLs were found. The homogeneity of least favorable responses detected for data recording and documentation of critical results notification reflects the lack of specific national recommendations. PMID:26110031

  1. Alglucosidase alfa treatment alleviates liver disease in a mouse model of glycogen storage disease type IV.

    PubMed

    Yi, Haiqing; Gao, Fengqin; Austin, Stephanie; Kishnani, Priya S; Sun, Baodong

    2016-12-01

    Patients with progressive hepatic form of GSD IV often die of liver failure in early childhood. We tested the feasibility of using recombinant human acid-α glucosidase (rhGAA) for treating GSD IV. Weekly intravenously injection of rhGAA at 40 mg/kg for 4 weeks significantly reduced hepatic glycogen accumulation, lowered liver/body weight ratio, and reduced plasma ALP and ALT activities in GSD IV mice. Our data suggests that rhGAA is a potential therapy for GSD IV.

  2. Interleukin-2 Plus Interferon Alfa in Treating Adults With Metastatic Cancer

    ClinicalTrials.gov

    2011-05-10

    Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Precancerous/Nonmalignant Condition; Unspecified Adult Solid Tumor, Protocol Specific

  3. Interleukin-12 Followed by Interferon Alfa in Treating Patients With Advanced Cancer

    ClinicalTrials.gov

    2013-01-31

    Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Precancerous Condition; Unspecified Adult Solid Tumor, Protocol Specific

  4. Differential Dynamics of CALR Mutant Allele Burden in Myeloproliferative Neoplasms during Interferon Alfa Treatment

    PubMed Central

    Holmström, Morten O.; Thomassen, Mads; Kruse, Torben A; Pallisgaard, Niels; Larsen, Thomas S.; de Stricker, Karin; Skov, Vibe; Hasselbalch, Hans C.

    2016-01-01

    Discovery of somatic mutations in the calreticulin gene (CALR) has identified a subgroup of Philadelphia-negative chronic myeloproliferative neoplasms (MPN) with separate haematological characteristics and prognosis. CALR mutations serve as novel markers both of diagnostic value and as targets for monitoring molecular responses during therapy. Interferon-α (IFN) selectively targets the malignant clone in a subset of MPN patients and can induce both haematological and molecular remissions in CALR mutated essential thrombocythemia (ET) patients. We investigated the response to IFN in a cohort of 21 CALR mutated MPN patients including ET, prefibrotic primary myelofibrosis (pre-PMF), and primary myelofibrosis (PMF) with a median follow-up of 31 months. For evaluation of a molecular response, we developed highly sensitive quantitative PCR (qPCR) assays for monitoring the mutant allele burden of the two most prevalent CALR mutations (type 1 and type 2). Thirteen patients (62%) experienced a decrease in the mutant allele burden with a median decline of 29% from baseline. However, only four patients, including patients with ET, pre-PMF, and PMF diagnosis, achieved molecular responder (MR) status with >50% reduction in mutant allele burden according to European LeukemiaNet (ELN) guidelines. MR patients displayed significant differences in the dynamics of the CALR mutant load with regard to time to response and dynamics in mutant allele burden after discontinuation of IFN treatment. Furthermore, we highlight the prognostic value of the CALR mutant allele burden by showing a close association with leucocyte- and platelet counts, hemoglobin concentration, in addition to plasma lactate dehydrogenase (LDH) irrespective of molecular response and treatment status. PMID:27764253

  5. [Alfa and beta diversity of reptilian assemblages in Zapatosa wetland complex, Colombia].

    PubMed

    Medina-Rangel, Guido Fabián

    2011-06-01

    Diversity is a property of community that can described, characterized, and understood according to the functioning of ecosystems. To study the richness and local abundance and species replacement between habitats around the Zapatosa's wetland complex (El Cesar Department), I carried out four field trips between November of 2006 and October of 2007. A total of 640 sampling hours/man analyzed five habitat types chasmophyte forest, dry forest, riparian forest, palm-grove and tree-lined savanna; with the exception of the palm-grove sampled at its 75%, the others were sampled up to their 80%. I found 847 reptiles that were distributed in 48 species. The group with the highest number of species was Colubridae with 14, followed by Gekkonidae with five. Five endemic species and eight with some conservation threat grade at a national level are reported. The riparian forest was the richest and most abundant habitat with 34 species and 196 individuals. For each habitat, Colubridae had the highest number of species, followed by the families Polychrotidae, Gekkonidae and Teiidae, in that order. The reptile species composition was not different between the tree-lined savanna and the chasmophyte forest, but differed among the tree-lined savanna and the riparian forest, palm-grove and dry forest habitats. The most important differences in the species composition among almost all the habitats were influenced by the species Anolis tropidogaster and Gonatodes albogularis, and the higher occurrence of Stenocercus erythrogaster in the chasmophyte forest. The species replacement had an average value of 50%; the biggest amounts of shared species were the lizards, while the snake Leptodeira septentrionalis was the only one present in all habitat types. The forest grows-among-rocks showed the biggest complementarity and number of unique species compared to the other habitats. The wetland complex provides two thirds of the reptile's species reported until now for the Caribbean region, and more than 80% of those reported for the El Cesar department. This wetland complex seems to behave as a center for low land species concentration as it hosts a high proportion of species from those places.

  6. Bell's palsy associated with chronic HCV infection before and during peginterferon alfa and ribavirin therapy.

    PubMed

    Jabbari, Hossain; Fakharzadeh, Elham; Merat, Shahin; Zamini, Hedyeh; Sharifi, Amir Houshang

    2011-05-01

    Neuropsychiatric side effects of peg interferon-α (PEG-IFN-α) therapy consist of a large spectrum of symptoms. Organic personality syndrome, organic affective syndrome, psychotic manifestations and seizures are more common side effects of PEG-IFN-α whereas cranial neuropathy and movement disorders are less common. Bell's palsy is often idiopathic, but has been linked to some viral infections, particularly with herpes viruses. Other infections, such as human immunodeficiency virus infection and Lyme disease, may also lead to idiopathic facial paralysis. Neither acute nor chronic Hepatitis C infection has been implicated previously in Bell's palsy, but PEG-IFN-α may play a role. Two patients with CHC who developed Bell's palsy before and during treatment with PEG-IFN-α and Ribavirin are presented here.

  7. Storage and treatment of SNF of Alfa class nuclear submarines: current status and problems

    SciTech Connect

    Ignatiev, Sviatoslav; Zabudko, Alexey; Pankratov, Dmitry; Somov, Ivan; Suvorov, Gennady

    2007-07-01

    Available in abstract form only. Full text of publication follows: The current status and main problems associated with storage, defueling and following treatment of spent nuclear fuel (SNF) of Nuclear Submarines (NS) with heavy liquid metal cooled reactors are considered. In the final analysis these solutions could be realized in the form of separate projects to be funded through national and bi- and multilateral funding in the framework of the international collaboration of the Russian Federation on complex utilization of NS and rehabilitation of contaminated objects allocated in the North-West region of Russia. (authors)

  8. [Tumor necrosis factor alfa in cardiovascular diseases: molecular biology and genetics].

    PubMed

    Fragoso Lona, José Manuel; Sierra Martínez, Mónica; Vargas Alarcón, Gilberto; Barrios Rodas, Angélica; Ramírez Bello, Julián

    2013-01-01

    Cardiovascular diseases are a major public health problem globally. In 1997, cardiovascular disease caused 41% of deaths in the United States. It has been reported that about 60 million people in the United States have some form of cardiovascular disease. These entities are chronic conditions initiated by a dysregulation of the immune response. One gene and its protein product -tumor necrosis factor a (TNF-α)- a powerful pleiotropic cytokine with multiple cellular functions, plays a role in the inflammation, initiation, development, susceptibility, severity, and response to treatment, etc. of coronary artery disease (CAD). The focus of the present review is to summarize recent evidence showing the biological role of TNF-α in the initiation and progression of endothelial dysfunction and complications of atherosclerosis, and as a genetic variation of TNF-α confer susceptibility, severity, and treatment response in CAD: ST-segment elevation myocardial infarction and non-ST segment elevation myocardial infarction, unstable angina, and coronary restenosis.

  9. The Arecibo Legacy Fast ALFA Survey: The Galaxy Population Detected by ALFALFA

    NASA Astrophysics Data System (ADS)

    Huang, Shan; Haynes, Martha P.; Giovanelli, Riccardo; Brinchmann, Jarle

    2012-09-01

    Making use of H I 21 cm line measurements from the ALFALFA survey (α.40) and photometry from the Sloan Digital Sky Survey (SDSS) and Galaxy Evolution Explorer (GALEX), we investigate the global scaling relations and fundamental planes linking stars and gas for a sample of 9417 common galaxies: the α.40-SDSS-GALEX sample. In addition to their H I properties derived from the ALFALFA data set, stellar masses (M *) and star formation rates (SFRs) are derived from fitting the UV-optical spectral energy distributions. 96% of the α.40-SDSS-GALEX galaxies belong to the blue cloud, with the average gas fraction f H I ≡ M H I /M * ~ 1.5. A transition in star formation (SF) properties is found whereby below M * ~ 109.5 M ⊙, the slope of the star-forming sequence changes, the dispersion in the specific star formation rate (SSFR) distribution increases, and the star formation efficiency (SFE) mildly increases with M *. The evolutionary track in the SSFR-M * diagram, as well as that in the color-magnitude diagram, is linked to the H I content; below this transition mass, the SF is regulated strongly by the H I. Comparison of H I and optically selected samples over the same restricted volume shows that the H I-selected population is less evolved and has overall higher SFR and SSFR at a given stellar mass, but lower SFE and extinction, suggesting either that a bottleneck exists in the H I-to-H2 conversion or that the process of SF in the very H I-dominated galaxies obeys an unusual, low-efficiency SF law. A trend is found that, for a given stellar mass, high gas fraction galaxies reside preferentially in dark matter halos with high spin parameters. Because it represents a full census of H I-bearing galaxies at z ~ 0, the scaling relations and fundamental planes derived for the ALFALFA population can be used to assess the H I detection rate by future blind H I surveys and intensity mapping experiments at higher redshift. Based on observations made with the Arecibo Observatory. The Arecibo Observatory is operated by SRI International under a cooperative agreement with the National Science Foundation (AST-1100968) and in alliance with Ana G. Méndez-Universidad Metropolitana and the Universities Space Research Association.

  10. Scheduling periodic jobs using imprecise results

    NASA Technical Reports Server (NTRS)

    Chung, Jen-Yao; Liu, Jane W. S.; Lin, Kwei-Jay

    1987-01-01

    One approach to avoid timing faults in hard, real-time systems is to make available intermediate, imprecise results produced by real-time processes. When a result of the desired quality cannot be produced in time, an imprecise result of acceptable quality produced before the deadline can be used. The problem of scheduling periodic jobs to meet deadlines on a system that provides the necessary programming language primitives and run-time support for processes to return imprecise results is discussed. Since the scheduler may choose to terminate a task before it is completed, causing it to produce an acceptable but imprecise result, the amount of processor time assigned to any task in a valid schedule can be less than the amount of time required to complete the task. A meaningful formulation of the scheduling problem must take into account the overall quality of the results. Depending on the different types of undesirable effects caused by errors, jobs are classified as type N or type C. For type N jobs, the effects of errors in results produced in different periods are not cumulative. A reasonable performance measure is the average error over all jobs. Three heuristic algorithms that lead to feasible schedules with small average errors are described. For type C jobs, the undesirable effects of errors produced in different periods are cumulative. Schedulability criteria of type C jobs are discussed.

  11. Semantic Clustering of Search Engine Results

    PubMed Central

    Soliman, Sara Saad; El-Sayed, Maged F.; Hassan, Yasser F.

    2015-01-01

    This paper presents a novel approach for search engine results clustering that relies on the semantics of the retrieved documents rather than the terms in those documents. The proposed approach takes into consideration both lexical and semantics similarities among documents and applies activation spreading technique in order to generate semantically meaningful clusters. This approach allows documents that are semantically similar to be clustered together rather than clustering documents based on similar terms. A prototype is implemented and several experiments are conducted to test the prospered solution. The result of the experiment confirmed that the proposed solution achieves remarkable results in terms of precision. PMID:26933673

  12. Review of Physics Results from the Tevatron

    SciTech Connect

    Bandurin, D.; Bernardi, G.; Gerber, C.; Junk, T.; Juste, A.; Kotwal, A.; Lewis, J.; Mesropian, C.; Schellman, H.; Sekaric, J.; Toback, D.; Van Kooten, R.; Vellidis, C.; Zivkovic, L.

    2015-02-27

    We present a comprehensive review of the physics results obtained by the CDF and D0 collaborations up to summer 2014, with emphasis on those achieved in the Run II of the Tevatron collider which delivered a total integrated luminosity of ~10 fb$^{-1}$ at $\\sqrt{s} = 1.96~{\\rm TeV}$. The results are presented in six main physics topics: QCD, Heavy Flavor, Electroweak, Top quark, Higgs boson and searches for New Particles and Interactions. The characteristics of the accelerator, detectors, and the techniques used to achieve these results are also briefly summarized.

  13. Livermore Big Trees Park: 1998 Results

    SciTech Connect

    Mac Queen, D; Gallegos, G; Surano, K

    2002-04-18

    This report is an in-depth study of results from environmental sampling conducted in 1998 by the Lawrence Livermore National Laboratory (LLNL) at Big Trees Park in the city of Livermore. The purpose of the sampling was to determine the extent and origin of plutonium found in soil at concentrations above fallout-background levels in the park. This report describes the sampling that was conducted, the chemical and radio-chemical analyses of the samples, the quality control assessments and statistical analyses of the analytical results, and LLNL's interpretations of the results. It includes a number of data analyses not presented in LLNL's previous reports on Big Trees Park.

  14. New results on the tau lepton

    SciTech Connect

    Gan, K.K.

    1987-11-01

    This is a review of new results on the tau lepton. The results include precise measurements of the lifetime, measurements of the decay tau/sup -/ ..-->.. ..pi../sup -/2..pi../sup 0/nu/sub tau/ with much improved precision, and limits on decay modes containing eta mesons, including the second-class-current decay tau/sup -/ ..-->.. ..pi../sup -/eta nu/sub tau/. The implications of these new results on the discrepancy in the one-charged-particle decay modes are discussed. 52 refs., 6 figs., 2 tabs.

  15. Experimental rotordynamic coefficient results for honeycomb seals

    NASA Technical Reports Server (NTRS)

    Elrod, David A.; Childs, Dara W.

    1988-01-01

    Test results (leakage and rotordynamic coefficients) are presented for seven honeycomb-stator smooth-rotor seals. Tests were carried out with air at rotor speeds up to 16,000 cpm and supply pressures up to 8.2 bars. Test results for the seven seals are compared, and the most stable configuration is identified based on the whirl frequency ratio. Results from tests of a smooth-rotor/smooth-stator seal, a teeth-on-stator labyrinth seal, and the most stable honeycomb seal are compared.

  16. Optimization and qualification of capillary zone electrophoresis method for glycoprotein isoform distribution of erythropoietin for quality control laboratory.

    PubMed

    Zhang, Junge; Chakraborty, Utpal; Villalobos, Annabelle P; Brown, John M; Foley, Joe P

    2009-10-15

    The European Pharmacopoeia (Ph. Eur.) monograph for Erythropoietin Concentrated Solution describes a capillary zone electrophoresis method for identification of recombinant human erythropoietin. However, this method has shown poor reproducibility due to inadequate capillary conditioning. We have modified the Ph. Eur. method to make it more robust and suitable for the quality control laboratory for the analysis of epoetin alfa and epoetin alfa after formulation with polysorbate 80. This study qualified the modified method by showing improved robustness and reproducibility. The study also characterized and qualified a secondary standard of epoetin alfa as a substitute for the primary standard, Ph. Eur. erythropoietin Biological Reference Preparation, which is available in limited supply. Four sets of analyses were performed to assess repeatability, intermediate precision, and the secondary standard. The results showed that the modified method is suitable for its intended purpose to test epoetin alfa and formulated epoetin alfa samples. The epoetin alfa secondary standard is a suitable substitute for the primary standard. Further, we developed a procedure for the removal of polysorbate 80 from formulated epoetin alfa, allowing the material to be analyzed by the modified Ph. Eur. method.

  17. Evaluation metric of an image understanding result

    NASA Astrophysics Data System (ADS)

    Hemery, Baptiste; Laurent, Helene; Emile, Bruno; Rosenberger, Christophe

    2015-01-01

    Image processing algorithms include methods that process images from their acquisition to the extraction of useful information for a given application. Among interpretation algorithms, some are designed to detect, localize, and identify one or several objects in an image. The problem addressed is the evaluation of the interpretation results of an image or a video given an associated ground truth. Challenges are multiple, such as the comparison of algorithms, evaluation of an algorithm during its development, or the definition of its optimal settings. We propose a new metric for evaluating the interpretation result of an image. The advantage of the proposed metric is to evaluate a result by taking into account the quality of the localization, recognition, and detection of objects of interest in the image. Several parameters allow us to change the behavior of this metric for a given application. Its behavior has been tested on a large database and showed interesting results.

  18. 7 CFR 1205.29 - Reporting results.

    Code of Federal Regulations, 2010 CFR

    2010-01-01

    ... Procedures for Conduct of Sign-up Period Procedures § 1205.29 Reporting results. (a) Each county FSA office... that requested a continuance referendum, through the sign-up period, to the Deputy...

  19. 7 CFR 1205.29 - Reporting results.

    Code of Federal Regulations, 2011 CFR

    2011-01-01

    ... Procedures for Conduct of Sign-up Period Procedures § 1205.29 Reporting results. (a) Each county FSA office... that requested a continuance referendum, through the sign-up period, to the Deputy...

  20. 7 CFR 1205.29 - Reporting results.

    Code of Federal Regulations, 2013 CFR

    2013-01-01

    ... Procedures for Conduct of Sign-up Period Procedures § 1205.29 Reporting results. (a) Each county FSA office... that requested a continuance referendum, through the sign-up period, to the Deputy...

  1. 7 CFR 1205.29 - Reporting results.

    Code of Federal Regulations, 2014 CFR

    2014-01-01

    ... Procedures for Conduct of Sign-up Period Procedures § 1205.29 Reporting results. (a) Each county FSA office... that requested a continuance referendum, through the sign-up period, to the Deputy...

  2. 7 CFR 1205.29 - Reporting results.

    Code of Federal Regulations, 2012 CFR

    2012-01-01

    ... Procedures for Conduct of Sign-up Period Procedures § 1205.29 Reporting results. (a) Each county FSA office... that requested a continuance referendum, through the sign-up period, to the Deputy...

  3. Manual and Automatic Lineament Mapping: Comparing Results

    NASA Astrophysics Data System (ADS)

    Vaz, D. A.; di Achille, G.; Barata, M. T.; Alves, E. I.

    2008-03-01

    A method for automatic lineament extraction using topographic data is applied on the Thaumasia plateau. A comparison is made between the results that are obtained from the automatic mapping approach and from a traditional tectonic lineament mapping.

  4. Scaling results for the liquid sheet radiator

    NASA Technical Reports Server (NTRS)

    Chubb, Donald L.; Calfo, Frederick D.

    1989-01-01

    Surface tension forces at the edges of a thin liquid (approx 100 micrometers) sheet flow result in a triangularly shaped sheet. Such a geometry is ideal for an external flow radiator. The experimental investigation of such sheet flows was extended to large sheets (width = 23.5 cm, length = 3.5 m). Experimental L/W results are greater than the calculated results. However, more experimental results are necessary for a complete comparison. The calculated emissivity of a sheet of Dow-Corning 705 silicone oil, which is low temperature (300-400 K) candidate for a liquid sheet radiator (LSR), is greater than 0.8 for sheet thicknesses greater than 100 micrometers.

  5. Scaling results for the liquid sheet radiator

    NASA Astrophysics Data System (ADS)

    Chubb, Donald L.; Calfo, Frederick D.

    Surface tension forces at the edges of a thin liquid (approx 100 micrometers) sheet flow result in a triangularly shaped sheet. Such a geometry is ideal for an external flow radiator. The experimental investigation of such sheet flows was extended to large sheets (width = 23.5 cm, length = 3.5 m). Experimental L/W results are greater than the calculated results. However, more experimental results are necessary for a complete comparison. The calculated emissivity of a sheet of Dow-Corning 705 silicone oil, which is low temperature (300-400 K) candidate for a liquid sheet radiator (LSR), is greater than 0.8 for sheet thicknesses greater than 100 micrometers.

  6. Three electroweak results from lattice QCD

    SciTech Connect

    Kronfeld, A.S., FERMI

    1998-08-01

    Quantum chromodynamics is needed to understand quarks and, hence, to determine the quarks` Yukawa couplings from experimental measurements. As a short illustration, the results of three lattice calculations are given.

  7. Focus on Communication: NIH Research to Results

    MedlinePlus

    ... Current Issue Past Issues Special Section: Focus on Communication NIH Research to Results Past Issues / Fall 2008 ... grew new hair cells. Read More "Focus on Communication" Articles Living with Hearing Loss / Anatomy of the ...

  8. EPA Announces 2015 Annual Environmental Enforcement Results

    EPA Pesticide Factsheets

    WASHINGTON - The U.S. Environmental Protection Agency (EPA) today released its annual enforcement and compliance results highlighted by large cases that reduce pollution, level the playing field for responsible companies, and protect public health i

  9. Skin Cancer: NIH Research to Results

    MedlinePlus

    ... of this page please turn Javascript on. Feature: Skin Cancer NIH Research to Results Past Issues / Summer 2013 ... making a person immune to his or her skin cancer cells. Another method is to train a person's ...

  10. Cone Penetrometer N Factor Determination Testing Results

    SciTech Connect

    Follett, Jordan R.

    2014-03-05

    This document contains the results of testing activities to determine the empirical 'N Factor' for the cone penetrometer in kaolin clay simulant. The N Factor is used to releate resistance measurements taken with the cone penetrometer to shear strength.

  11. Results of coronal hole research: An overview

    NASA Technical Reports Server (NTRS)

    Wilson, R. M.

    1976-01-01

    An overview of the last 10 years of coronal hole research, in particular since 1970, is presented. The findings of the early investigations and the more recent results obtained with Skylab/Apollo Telescope Mount instrumentation are discussed.

  12. Recent Radiation Test Results for Power MOSFETs

    NASA Technical Reports Server (NTRS)

    Lauenstein, Jean-Marie; Topper, Alyson D.; Casey, Megan C.; Wilcox, Edward P.; Phan, Anthony M.; Kim, Hak S.; LaBel, Kenneth A.

    2013-01-01

    Single-event effect (SEE) and total ionizing dose (TID) test results are presented for various hardened and commercial power metal-oxide-semiconductor field effect transistors (MOSFETs), including vertical planar, trench, superjunction, and lateral process designs.

  13. [Results of ethmoidectomy in children with mucoviscidosis].

    PubMed

    Clement, P A; Brihaye, P

    1994-01-01

    Eighteen children with cystic fibrosis who underwent in total 30 sinus interventions were examined in a retrospective study. There was 44% of recurrence. A review of the literature shows that sphenoethmoidectomy gives better results than nasal polypectomy.

  14. Norcal Prototype LNG Truck Fleet: Final Results

    SciTech Connect

    Not Available

    2004-07-01

    U.S. DOE and National Renewable Energy Laboratory evaluated Norcal Waste Systems liquefied natural gas (LNG) waste transfer trucks. Trucks had prototype Cummins Westport ISXG engines. Report gives final evaluation results.

  15. CTEPP NC DATA QA/QC RESULTS

    EPA Science Inventory

    This data set contains the method performance results. This includes field blanks, method blanks, duplicate samples, analytical duplicates, matrix spikes, and surrogate recovery standards.

    The Children’s Total Exposure to Persistent Pesticides and Other Persistent Pollutant (...

  16. Heavy quark results at D0

    SciTech Connect

    Fein, D.K.; D0 Collaboration

    1997-01-01

    Recent results in heavy quark physics from the D0 experiment at the Fermilab Tevatron Collider are reported. Topics included are top quark production and mass determination, bottom production and correlations, and charmonium production. 20 refs., 10 figs., 2 tabs.

  17. Recent QCD results from the Tevatron

    SciTech Connect

    Pickarz, Henryk; CDF and DO collaboration

    1997-02-01

    Recent QCD results from the CDF and D0 detectors at the Tevatron proton-antiproton collider are presented. An outlook for future QCD tests at the Tevatron collider is also breifly discussed. 27 refs., 11 figs.

  18. Recent results from COMPASS muon scattering measurements

    NASA Astrophysics Data System (ADS)

    Capozza, Luigi; Compass Collaboration

    2012-10-01

    A sample of recent results in muon scattering measurements from the COMPASS experiment at CERN will be reviewed. These include high energy processes with longitudinally polarised proton and deuteron targets. High energy polarised measurements provide important constraints for studying the nucleon spin structure and thus permit to test the applicability of the theoretical framework of factorisation theorems and perturbative QCD. Specifically, latest results on longitudinal quark polarisation, quark helicity densities and gluon polarisation will be reviewed.

  19. Pulmonary hemorrhage resulting from bungee jumping.

    PubMed

    Manos, Daria; Hamer, Okka; Müller, Nestor L

    2007-11-01

    Pulmonary hemorrhage is a relatively common complication of blunt chest trauma. Occasionally, it may result from pulmonary barotrauma after scuba diving or from sports activities not associated with barotrauma such as long breath-hold diving. We report a case of symmetric diffuse upper lobe hemorrhage resulting from a bungee jump in a previously healthy man. Bungee jumping is an increasingly popular sport with relatively few reported injuries. To our knowledge pulmonary hemorrhage in this setting has not yet been described.

  20. NASA JSC neural network survey results

    NASA Technical Reports Server (NTRS)

    Greenwood, Dan

    1987-01-01

    A survey of Artificial Neural Systems in support of NASA's (Johnson Space Center) Automatic Perception for Mission Planning and Flight Control Research Program was conducted. Several of the world's leading researchers contributed papers containing their most recent results on artificial neural systems. These papers were broken into categories and descriptive accounts of the results make up a large part of this report. Also included is material on sources of information on artificial neural systems such as books, technical reports, software tools, etc.

  1. Random walk through recent CDF QCD results

    SciTech Connect

    C. Mesropian

    2003-04-09

    We present recent results on jet fragmentation, jet evolution in jet and minimum bias events, and underlying event studies. The results presented in this talk address significant questions relevant to QCD and, in particular, to jet studies. One topic discussed is jet fragmentation and the possibility of describing it down to very small momentum scales in terms of pQCD. Another topic is the studies of underlying event energy originating from fragmentation of partons not associated with the hard scattering.

  2. Results on CP violation from CDF

    SciTech Connect

    S. Giagu

    2003-12-11

    The CDF experiment at the Tevatron collider is collecting a large sample of fully hadronic decays of Bottom and Charm mesons. First CP Violation measurements have been performed using the initial data, achieving results which clearly state the CDF ability in extracting significant CKM information from p{bar p} collisions. The first results on direct CP asymmetries on Charm and Bottom decays and future plans from the CDF experiment are discussed in this paper.

  3. Pancreatic carcinoma: results with fast neutron therapy

    SciTech Connect

    Kaul, R.; Cohen, L.; Hendrickson, F.; Awschalom, M.; Hrejsa, A.F.; Rosenberg, I.

    1981-02-01

    Results of therapy in 31 of 50 patients who were treated for advanced pancreatic carcinoma at Fermi National Accelerator Laboratory are presented here. To date, six patients are alive and four are free of disease. Since the main reason for failure was lack of control of primary tumor, the tumor dose has been increased by 15%. Based on our results, a nationwide study has been launched to assess the effectiveness of neutrons vs photons in the treatment of locally advanced pancreatic carcinoma.

  4. Abdominal apoplexy resulting in small bowel obstruction

    PubMed Central

    Le, Don; Guileyardo, Joseph; Casanova, Mark

    2016-01-01

    Abdominal apoplexy is a rare hemorrhagic condition involving the small arteries or veins within the abdominal cavity. A high degree of clinical suspicion, followed by appropriate diagnostic workup and therapeutic intervention, is critical, as nonoperative mortality approaches 100%. Contrary to most previously reported cases, which were associated with hemoperitoneum, we present a patient in which gastroduodenal artery dissection resulted in an organized retroperitoneal hematoma with local compression of the duodenum and subsequent bowel obstruction, resulting in vomiting, aspiration, and death. PMID:27695177

  5. Log(s) physics results from CDF

    SciTech Connect

    Not Available

    1989-11-08

    The Collider Detector at Fermilab (CDF) is a large, azimuthally symmetric detector designed to study {bar p}p interactions at the Fermilab Tevatron Collider. Results are presented from data taken with a minimum bias trigger at {radical}s = 630 and 1800 GeV during the 1987 run. The topics include the current analysis of dn/d{eta} and some very preliminary results on short range pseudorapidity correlations and Bose-Einstein correlations. 7 refs., 5 figs., 2 tabs.

  6. Implications of the Qweak Commissioning Result

    NASA Astrophysics Data System (ADS)

    Smith, Greg; Qweak Collaboration

    2014-09-01

    The commissioning results of the Qweak experiment at Jefferson Lab, which constituted approximately 4% of the total results obtained in that experiment, were recently published. After a brief review of the experiment, new, unpublished results derived from that publication will be presented. The sensitivity of the fit used to extract the proton's weak charge to the choice of electromagnetic form factors, to the proton radius puzzle, and to the dipole mass used for the Q2 evolution will be examined. The running of sin2 (θw) and the experiment's mass reach will be discussed. The status of the ongoing effort to complete the analysis of the full experiment will also be shown. The commissioning results of the Qweak experiment at Jefferson Lab, which constituted approximately 4% of the total results obtained in that experiment, were recently published. After a brief review of the experiment, new, unpublished results derived from that publication will be presented. The sensitivity of the fit used to extract the proton's weak charge to the choice of electromagnetic form factors, to the proton radius puzzle, and to the dipole mass used for the Q2 evolution will be examined. The running of sin2 (θw) and the experiment's mass reach will be discussed. The status of the ongoing effort to complete the analysis of the full experiment will also be shown. This work was supported by DOE Contract No. DE-AC05-06OR23177, under which Jefferson Science Associates, LLC operates Thomas Jefferson National Accelerator Facility.

  7. Test result management in global health settings.

    PubMed

    Palazuelos, Daniel; Payne, Jonathan D; Dalal, Anuj K

    2012-09-01

    Across the globe, the ways in which patients' test results are managed are as varied as the many different types of healthcare systems that manage these data. The outcomes, however, are often not too dissimilar: too many clinically significant test results fall through the cracks. The consequences of not following up test results in a timely manner are serious and often devastating to patients: diagnoses are delayed, treatments are not initiated or altered in time, and diseases progress. In resource-poor settings, test results too commonly get filed away within the paper chart in ways that isolate them and prevent passage to future providers caring for a patient. To make matters worse, the onus to act upon these test results often rests on patients who need to return to the clinic within a specified timeframe in order to obtain their results but who may not have the means or are too ill to do so. Even in more developed healthcare settings that use electronic records, clinical data residing in the electronic medical record (EMR) are often stubbornly "static"-key pieces of clinical information are frequently not recognized, retrieved, or shared easily. In this way, EMRs are not unlike paper record systems, and therefore, EMRs alone will not solve this problem. To illustrate this problem, consider the case of a patient newly diagnosed with HIV in 3 different healthcare delivery settings.

  8. Critical international normalized ratio results after hours

    PubMed Central

    Korn, Darlene; Sean McMurtry, M.; George-Phillips, Kirsten; Bungard, Tammy J.

    2017-01-01

    Abstract Objective To determine whether the timing of notification of critical international normalized ratio (INR) results (during or after clinic hours) altered the clinician’s ability to affect same-day patient care. Design Retrospective chart review. Setting The Anticoagulation Management Service at the University of Alberta Hospital in Edmonton. Participants A total of 276 patients with critical INR results (> 5.0) separated by at least 30 days were identified to have 200 critical INR results reported during clinic hours and 200 reported after hours. Main outcome measures Differences in the proportion of patients with critical INR results having same-day care altered (by changing warfarin dose, administering vitamin K, or referring for assessment) between those with results reported during clinic hours compared with those with results reported after clinic hours. Differences by highly critical INR results (> 9.0 vs ≤ 9.0) and whether patients experienced thromboembolism or bleeding within 30 days were also assessed. Results Same-day patient care was affected for 174 out of 200 (87.0%) critical INR results reported during clinic hours compared with 101 out of 200 (50.5%) reported after clinic hours (P < .001). The most common reason for not being able to intervene was that warfarin had already been taken. Warfarin dose alteration was the most frequent change (97.1% during clinic hours and 96.0% after hours). When patients with INRs greater than 9.0 were assessed separately, the ability to affect care increased for INRs reported both during and after clinic hours (92.9% and 63.6%, respectively), largely attributable to oral vitamin K use. Overall, thromboembolic and major bleeding event rates were low and were similar in both groups. Conclusion Same-day care was less likely to be affected by critical INR results communicated after hours, most commonly because the patient had already taken their daily warfarin dose. However, after-hours care was still

  9. Scheduling periodic jobs that allow imprecise results

    NASA Technical Reports Server (NTRS)

    Chung, Jen-Yao; Liu, Jane W. S.; Lin, Kwei-Jay

    1990-01-01

    The problem of scheduling periodic jobs in hard real-time systems that support imprecise computations is discussed. Two workload models of imprecise computations are presented. These models differ from traditional models in that a task may be terminated any time after it has produced an acceptable result. Each task is logically decomposed into a mandatory part followed by an optional part. In a feasible schedule, the mandatory part of every task is completed before the deadline of the task. The optional part refines the result produced by the mandatory part to reduce the error in the result. Applications are classified as type N and type C, according to undesirable effects of errors. The two workload models characterize the two types of applications. The optional parts of the tasks in an N job need not ever be completed. The resulting quality of each type-N job is measured in terms of the average error in the results over several consecutive periods. A class of preemptive, priority-driven algorithms that leads to feasible schedules with small average error is described and evaluated.

  10. Quasi-normal frequencies: key analytic results

    NASA Astrophysics Data System (ADS)

    Boonserm, Petarpa; Visser, Matt

    2011-03-01

    The study of exact quasi-normal modes [QNMs], and their associated quasi-normal frequencies [QNFs], has had a long and convoluted history — replete with many rediscoveries of previously known results. In this article we shall collect and survey a number of known analytic results, and develop several new analytic results — specifically we shall provide several new QNF results and estimates, in a form amenable for comparison with the extant literature. Apart from their intrinsic interest, these exact and approximate results serve as a backdrop and a consistency check on ongoing efforts to find general model-independent estimates for QNFs, and general model-independent bounds on transmission probabilities. Our calculations also provide yet another physics application of the Lambert W function. These ideas have relevance to fields as diverse as black hole physics, (where they are related to the damped oscillations of astrophysical black holes, to greybody factors for the Hawking radiation, and to more speculative state-counting models for the Bekenstein entropy), to quantum field theory (where they are related to Casimir energies in unbounded systems), through to condensed matter physics, (where one may literally be interested in an electron tunnelling through a physical barrier).

  11. Results from the Double Chooz experiment

    NASA Astrophysics Data System (ADS)

    Kaneda, Michiru

    2016-11-01

    Recent results from the Double Chooz experiment on the neutrino mixing angle θ13 are presented. Two detectors are located at distances of 400m and 1050m from the reactor cores of the Chooz nuclear power plant, to measure the original neutrino flux from the reactor cores and the disappearance of neutrinos, respectively. The Far Detector has taken data since 2011 while the Near Detector started the data taking in 2014. The latest far detector only result with gadolinium capture events is sin2 2θ13=0.090+0.032.-0.029. Studies using hydrogen capture events also have been improved and the combined result of gadolinium and hydrogen capture events is obtained as sin2 2θ13 = 0.088 ± 0.033.

  12. Convergence results for elliptic quasivariational inequalities

    NASA Astrophysics Data System (ADS)

    Sofonea, Mircea; Benraouda, Ahlem

    2017-02-01

    In this paper, we state and prove various convergence results for a general class of elliptic quasivariational inequalities with constraints. Thus, we prove the convergence of the solution of a class of penalized problems to the solution of the original inequality, as the penalty parameter converges to zero. We also prove a continuous dependence result of the solution with respect the convex set of constraints. Then, we consider a mathematical model which describes the equilibrium of an elastic rod attached to a nonlinear spring. We derive the variational formulation of the model which is in a form of an elliptic quasivariational inequality for the displacement field. We prove the unique weak solvability of the model, and then we state and prove two convergence results and provide their corresponding mechanical interpretation.

  13. On the reliability of reverse engineering results.

    PubMed

    Amotchkina, Tatiana V; Trubetskov, Michael K; Pervak, Vladimir; Romanov, Boris; Tikhonravov, Alexander V

    2012-08-01

    Determination of actual parameters of manufactured optical coatings (reverse engineering of optical coatings) provides feedback to the design-production chain and thus plays an important role in raising the quality of optical coatings production. In this paper, the reliability of reverse engineering results obtained using different types of experimental data is investigated. Considered experimental data include offline normal incidence transmittance data, offline ellipsometric data, and online transmittance monitoring data recorded during depositions of all coating layers. Experimental data are obtained for special test quarter-wave mirrors with intentional errors in some layers. These mirrors were produced by a well-calibrated magnetron-sputtering process. The intentional errors are several times higher than estimated errors of layer thickness monitoring, and the reliability of their detection is used as a measure of reliability of reverse engineering results. It is demonstrated that the most reliable results are provided by online transmittance data.

  14. East Mountain Area 1995 air sampling results

    SciTech Connect

    Deola, R.A.

    1996-09-01

    Ambient air samples were taken at two locations in the East Mountain Area in conjunction with thermal testing at the Lurance Canyon Burn Site (LCBS). The samples were taken to provide measurements of particulate matter with a diameter less than or equal to 10 micrometers (PM{sub 10}) and volatile organic compounds (VOCs). This report summarizes the results of the sampling performed in 1995. The results from small-scale testing performed to determine the potentially produced air pollutants in the thermal tests are included in this report. Analytical results indicate few samples produced measurable concentrations of pollutants believed to be produced by thermal testing. Recommendations for future air sampling in the East Mountain Area are also noted.

  15. Adaptive structures - Test hardware and experimental results

    NASA Technical Reports Server (NTRS)

    Wada, Ben K.; Fanson, James L.; Chen, Gun-Shing; Kuo, Chin-Po

    1990-01-01

    The facilities and procedures used at JPL to test adaptive structures such as the large deployable reflector (LDR) are described and preliminary results are reported. The applications of adaptive structures in future NASA missions are outlined, and the techniques which are employed to modify damping, stiffness, and isolation characteristics, as well as geometric changes, are listed. The development of adaptive structures is shown to be effective as a result of new actuators and sensors, and examples are listed for categories such as fiber optics, shape-memory materials, piezoelectrics, and electrorheological fluids. Some ground test results are described for laboratory truss structures and truss test beds, which are shown to be efficient and easy to assemble in space. Adaptive structures are shown to be important for precision space structures such as the LDR, and can alleviate ground test requirements.

  16. CEBAF'S New RF Separator Structure Test Results

    SciTech Connect

    Reza Kazimi; Jock Fugitt; A. Krycuk; Charles Sinclair; Larry Turlington

    1993-05-01

    Prototypes of the rf separator for CEBAF have been made and successfully beam tested. The structure is a new design which has a high transverse shunt impedance together with a small transverse dimension compared to more conventional rf deflecting structures. Five rf separators will be used at CEBAF to allow beam from any one of the five recirculation passes to be delivered to any of the three experimental halls. The authors have already described the basic design of the structure and theoretical calculations. They have also reported some results from rf measurements and beam tests. In this paper they present more beam test results, their final design parameters, and test results of coupling two 1/2 wavelength cavities together.

  17. Nebraska wind resource assessment first year results

    SciTech Connect

    Hurley, P.J.F.; Vilhauer, R.; Stooksbury, D.

    1996-12-31

    This paper presents the preliminary results from a wind resource assessment program in Nebraska sponsored by the Nebraska Power Association. During the first year the measured annual wind speed at 40 meters ranged from 6.5 - 7.5 m/s (14.6 - 16.8 mph) at eight stations across the state. The site selection process is discussed as well as an overview of the site characteristics at the monitoring locations. Results from the first year monitoring period including data recovery rate, directionality, average wind speeds, wind shear, and turbulence intensity are presented. Results from the eight sites are qualitatively compared with other midwest and west coast locations. 5 figs., 2 tabs.

  18. Diffraction at the Tevatron: CDF results

    SciTech Connect

    Goulianos, Konstantin; /Rockefeller U.

    2006-11-01

    The diffractive program of the CDF Collaboration at the Fermilab Tevatron p{bar p} Collider is reviewed with emphasis on recent results from Run II at {radical}s = 1.96 TeV. Updated results on the x{sub B{sub j}} and Q{sup 2} dependence of the diffractive structure function obtained from dijet production, and on the slope parameter of the t-distribution of diffractive events as a function of Q{sup 2} in the range 1 GeV{sup 2} < Q{sup 2} < 10{sup 4} GeV{sup 2}, are presented and compared with theoretical expectations. Results on cross sections for exclusive dijet and diphoton production are also presented and used to calibrate theoretical estimates for exclusive Higgs production at the Large Hadron Collider.

  19. MiniBooNE Oscillation Results 2011

    SciTech Connect

    Djurcic, Zelimir

    2012-01-01

    The MiniBooNE neutrino oscillation search experiment at Fermilab has recently updated results from a search for {bar {nu}}{sub {mu}} {yields} {bar {nu}}{sub e} oscillations, using a data sample corresponding to 8.58 x 10{sup 20} protons on target in anti-neutrino mode. This high statistics result represent an increase in statistics of 52% compared to result published in 2010. An excess of 57.7 {+-} 28.5 events is observed in the energy range 200 MeV < E{sub {nu}} < 3000 MeV. The data favor LSND-like {bar {nu}}{sub {mu}} {yields} {bar {nu}}{sub e} oscillations over a background only hypothesis at 91.1% confidence level in the energy range 475 < E{sub {nu}} < 3000 MeV.

  20. Annotating images by mining image search results.

    PubMed

    Wang, Xin-Jing; Zhang, Lei; Li, Xirong; Ma, Wei-Ying

    2008-11-01

    Although it has been studied for years by the computer vision and machine learning communities, image annotation is still far from practical. In this paper, we propose a novel attempt at model-free image annotation, which is a data-driven approach that annotates images by mining their search results. Some 2.4 million images with their surrounding text are collected from a few photo forums to support this approach. The entire process is formulated in a divide-and-conquer framework where a query keyword is provided along with the uncaptioned image to improve both the effectiveness and efficiency. This is helpful when the collected data set is not dense everywhere. In this sense, our approach contains three steps: 1) the search process to discover visually and semantically similar search results, 2) the mining process to identify salient terms from textual descriptions of the search results, and 3) the annotation rejection process to filter out noisy terms yielded by Step 2. To ensure real-time annotation, two key techniques are leveraged-one is to map the high-dimensional image visual features into hash codes, the other is to implement it as a distributed system, of which the search and mining processes are provided as Web services. As a typical result, the entire process finishes in less than 1 second. Since no training data set is required, our approach enables annotating with unlimited vocabulary and is highly scalable and robust to outliers. Experimental results on both real Web images and a benchmark image data set show the effectiveness and efficiency of the proposed algorithm. It is also worth noting that, although the entire approach is illustrated within the divide-and conquer framework, a query keyword is not crucial to our current implementation. We provide experimental results to prove this.